The preparation and characterisation of cells and their scaffolds suitable for tissue repair applications. by Pittarello, L.
The preparation and characterisation of ceils and their 
scaffolds suitable for tissue repair applications
Thesis submitted for the degree of 
Doctor of Philosophy 
in
Biochemical Engineering
by
Leda Pittarello
BS MSc
The Advanced Centre for Biochemical Engineering 
Department of Biochemical Engineering 
University College London
September 2007
1
UMI Number: U592557
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a complete manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
Dissertation Publishing
UMI U592557
Published by ProQuest LLC 2013. Copyright in the Dissertation held by the Author.
Microform Edition © ProQuest LLC.
All rights reserved. This work is protected against 
unauthorized copying under Title 17, United States Code.
ProQuest LLC 
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml 48106-1346
To my parents, Maria and Adelmo
Acknowledgments
First of all I would like to thank Prof. Anthony Hollander, who put trust in me and 
instilled me the idea of a PhD for the very first time.
I would like to thank also my supervisor Frank Baganz for his kind support and help, and 
my advisor Chris Mason for his encouragement during the writing of this thesis. I certainly 
could not have brought this hard work to completion without their input and kind help.
I wish also to thank Prof. Nigel Titchener-Hooker and Prof. Gary Lye for their special 
help in making all of this possible; Alethea Tabor for her comments on my data; Prof. Peter 
Dunnill for his extraordinary guidance during the first year of my PhD and for taking care of 
reviewing my data and part of this thesis. Special thanks also to Prof. Mike Hoare for giving 
me the possibility to work and study in the Department of Biochemical Engineering during 
the three years of my experimental work.
My thanks also to my colleagues for the great time I had in working with them in the lab: 
Julia Markusen and Emily Culme-Seymour, for the great collaboration on the alginate 
derivatisation work, and Spyros Gerontas for being always happy to help and discuss about 
our works. Many thanks also to my friend Anna Cariboni, who helped me with the staining 
and the photographs of my samples during the last stages of my experimental work.
I want to express my gratitude also to Prof. Tom Byers, who taught me most of all to 
“make no little plans”. Thanks to him I will always make of my aspirations true possibilities.
I thank Elena and Joseph as well as Samuela, Marta and Jim, Roberta, Anna, Kuna and 
Adrian for real friendship, and Duncan for being always so much fun and such a good 
mentor, anytime I need. I thank also my other best friends, who I have left in Italy a while 
ago, but always remain by my side: the “Pink Ladies” Dommi, Silvia and Stefania.
I thank my ex-flatmates Fabio Sormani, John Baker and Bruno Garcia for their incredible 
patience and for cheering me up during the most difficult moments of this journey.
Last but not least, I wish to thank my parents Maria and Adelmo, to whom I dedicate this 
work, for accepting my choice of doing a PhD and bearing with both my physical and 
psychological absence during these past years. To them as well as to my sister Sara and my 
lovely niece Ludovica (and to Brian!) I will always feel close even being far away.
I guess I cannot avoid thanking also the one and only person that was responsible for my 
moving to London five years ago -  with all that much this has meant for both my career and 
personal life. Despite all, he opened up my view on the world and extended my horizon.
This PhD has been supported by the Department of Biochemical Engineering and the 
Engineering and Physical Sciences Research Council (EPSRC), and their support is gratefully 
acknowledged.
3
Abstract
In this research, a tissue engineering approach was investigated for the 
fabrication of homogeneous polymer/cells scaffolds suitable for applications in the 
clinic, in particular for the treatment of coronary disease and atherosclerosis.
Sodium alginate chemically modified with an RGD-containing peptide promoting 
cell attachment was chosen as the natural polymer for the preparation of 
matrix/cells constructs. Several conditions were investigated to optimise the 
derivatisation of the biomaterial, and no major dissimilarities were identified 
among alginates with different guluronic/mannuronic acid compositions and 
viscosities during the derivatisation process. Successful incorporation of the 
GRGDY-pentapeptide onto the alginate was achieved. Amino acid analysis, which 
allowed a reliable quantification of the degree of peptide attached, demonstrated 
that the complete pentapeptidic sequence was present in the alginate after 
completion of the derivatisation procedure. However, a significant loss of the 
peptide’s final tyrosine residue was consistently observed during derivatisation.
Studies were also performed using multipotent fibroblast-like plastic-adherent 
cells recovered from frozen bone marrow samples of adult patients, here defined as 
human “mesenchymal stem cells” (hMSCs). Prior to the cell immobilisation in the 
alginate matrix, the optimal conditions for cell expansion in monolayer culture 
were identified. Cell samples were assessed according to their percent viability at 
each expansion passage, doubling time, cell growth rate and specific glucose 
consumption rate. Overall, the highest cell growth kinetics, highest cell viabilities 
and lowest doubling times were observed for the combined use of serum-/bFGF- 
supplemented low-glucose DMEM medium and non-coated culture vessels in a 
21% dissolved oxygen tension atmosphere. hMSCs expanded for four subsequent 
passages under these monolayer conditions proved to retain their undifferentiated 
state and their ability to differentiate toward multiple phenotypes.
Finally, alginate/cells beads were prepared and maintained in the optimal 
culture conditions identified in the monolayer studies. Constructs prepared with 
either hMSCs or human foreskin fibroblasts in either unmodified alginate or 
alginate coupled with the GRGDY-pentapeptide were analysed. After 
immobilisation, both cell types failed to adhere to the matrix and to acquire their 
characteristic elongated, spindle-shaped morphology. Lack of cell proliferation and
4
cell death were also observed over time for both cell types in constructs prepared 
with either the unmodified or the derivatised alginates.
Further studies are required to understand whether tyrosine loss is responsible 
for the lack of matrix-cells interactions, and to develop strategies to prevent this 
phenomenon.
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1 Introduction
1.1 Tissue Engineering
1.1.1 Tissue Engineering: a new discipline
The loss or failure of an organ or tissue is one of the most frequent, devastating, 
and costly problems in healthcare [Langer and Vacanti, 1993]. Until very recently, 
most scientists and clinicians believed that damaged or diseased human tissue could 
only be replaced by donor transplants or with totally artificial parts. The main 
drawback of organ transplantation is that the need for donor organs far exceeds the 
supply. The need for substitutes to replace or repair tissues or organs because of 
disease, trauma, or congenital problems is indeed overwhelming, and the organ 
shortages for transplantation continue to worsen [Nasseri et al., 2001; Tie, 2001] 
(figure 1.1) [UNOS, 2001]. This trend persists, as demonstrated by the fact that, in the 
United States alone, approximately only 23,500 people received transplants from July 
2000 to July 2001, while approximately 80,000 registrations were left on the waiting 
list for an organ during the same period [http://ustransplant.org., 2002; UNOS, 2002 
and UNOS, 2001].
The necessity of alternative therapies is illustrated by this ever-widening supply 
and demand mismatch of organs and tissues for transplantation [2000 Annual Report 
of the US Scientific Registry for Transplant Recipients and the Organ Procurement 
and Transplantation Network: Transplantation Data: 1990-1999.]. The overwhelming 
organ shortage has resulted in new surgical techniques, such as transplanting whole 
organs (e.g. kidneys) from living, related donors and splitting adult organs for 
transplant (e.g. a part of a liver or a lung from a parent to a child). Despite excellent 
results with these transplant techniques, the problem of donor scarcity remains. 
Alternative current treatment modalities include surgical reconstruction, use of 
mechanical devices, or supplementation of metabolic products. While these strategies 
incorporate significant advances in the field of medicine, they have a number of 
inherent limitations, replacing the diseased organ or tissue only imperfectly, or 
displaying lack of compliance of the artificial prostheses to allow growth and/or 
requiring immunosuppressive treatment.
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A new multidisciplinary research field, tissue engineering, aims to provide vital 
tissues with the abilities to function, grow, repair and remodel. Langer and Vacanti 
(1993) defined tissue engineering as “an interdisciplinary field that applies the 
principles and methods of engineering and the life sciences toward the development 
of biological substitutes that restore, maintain, or improve tissue function” [Langer 
and Vacanti, 1993]. This new promising solution to tissue loss requires an 
interdisciplinary cooperation among developmental and cellular molecular biologists, 
engineers, material scientists, and physicians.
The hope is that tissue-engineered products deliver superior treatments, improving 
the speed, extent and duration of healing compared to conventional treatments. The 
most important expected outcomes are enhanced quality of life of patients and the 
ability to overcome organ shortage for transplantation in the long run.
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Figure 1.1: UNOS organ transplant statistics for 1990 to 1999 documenting the 
wait-listed patients (O) and transplants ( • )  [www.unos.org.].
1.1.2 Different approaches in Regenerative Medicine
One approach to regenerative medicine is simple in that it just involves injecting a 
bioactive substance, such as a growth factor, into the damaged tissue or organ. That
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substance recruits the patient’s own cells to migrate into the desired area and to 
encourage proliferation or differentiation to re-form new healthy tissue.
A second avenue explored in creating new tissues is the re-introduction into the 
body of individual cells or clusters to reproduce a specific -  often enzymatic -  
function. It has been used successfully in pancreatic islet transplantation [White et al., 
2001]. A non-enzymatic example is the transplantation of myoblast cells into the area 
of myocardial infarction to limit the area of fibrotic scarring and restore contractile 
function [Menasche’ et al., 2001].
Another approach originally described for similar applications is the implantation 
of an acellular biomaterial which acts as a template for tissue regeneration and which 
is repopulated by native cells from adjacent uninjured tissue.
The more complex and challenging approach involves the patient receiving a 
three-dimensional construct that contain all of the following components -  cells, 
scaffold or support material, and sometimes bioactive substances. The cells could be 
obtained from the patient or from a donor. The scaffold could be natural, artificial, 
biodegradable or non-biodegradable. The bioactive substances could be growth 
factors, hormones, peptide sequences or protein coatings to promote cell attachment. 
The entire 3D structure is transplanted into the damaged site where the cells 
proliferate and/or the patient’s cells are recruited and organized into new tissue. As 
the tissue matures, the scaffold material could degrade, leaving only tissue [Mooney 
and Mikos, 1997]. Figure 1.2 illustrates the main different tissue engineering 
approaches explored so far.
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Figure 1.2 Different approaches in Regenerative Medicine. (Picture adapted from 
biolab -  laboratory for bioimages & bioengineering, available at 
http://www.bio.dist.unige.it).
1.1.3 The development and the current status of Tissue 
Engineering
The idea behind tissue regeneration and transplantation is not a new one. 
Rudimentary attempts of transplantations were already performed in the Middle 
Ages. Even the science itself is not brand new. The first accepted example of tissue 
engineering dates back 70 years to when Bisceglie (1933) wrapped mouse tumour 
cells in a polymer membrane and successfully transplanted them into the chick 
embryo peritoneum [Bisceglie, 1993]. Thirty years ago Chick et al. reported their 
results of encapsulated pancreatic islet cells in semipermeable membranes to aid 
glucose control in patients with diabetes [Chick et al., 1975]. A few years later, 
Yannas et al. [Yannas et al., 1980] designed a collagen, glucosaminoglycan scaffold, 
which aided in regenerating dermis for the bum patient. Later, Bell et al. added
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fibroblasts to a contracted collagen gel to replace skin [Bell et al., 1981]. Recent 
advances in cellular and molecular biology have provided the means to more 
precisely manipulate, and perhaps duplicate, tissue function. In the 1990s, tissue 
engineering evolved tremendously and so far no tissue or organ has been excluded 
from active research.
It has been projected that tissue engineering will be one of the most significant 
health/science employment fields of the next few centuries. In 2000, Tissue Engineer 
has been listed as the number one career and, interestingly, three of the other top five 
careers involve technologies that readily overlap with the field of tissue engineering 
[TIME Magazine, 2000]. However, this novel biotechnology is still in its infancy: 
despite the huge breadth of interest in and immense potential of this rapidly growing 
field, to date tissue-engineered products are available only for a few specific clinical 
applications. The first tissue-engineered product (cartilage-ACT product Carticel) 
was approved for marketing in 1996 in the USA. Since then, progress in tissue 
engineering has resulted in several commercialised products for skin substitution, 
knee cartilage repair and a few bone repair products from several companies in 
Europe and the USA. These products yet have to gain broad acceptance in clinical 
practice [JRCEC, 2003].
The table in figure 1.3 gives an overview of current research projects in tissue 
engineering [Vacanti, 2001].
There are also new products in the pipeline, addressing diseases for which no 
treatment is available today, for example in the cardiovascular area (tissue-engineered 
heart valves, vessel grafts and heart muscle tissue) or concerning neurodegenerative 
diseases (e.g. Alzheimer’s and Parkinson’s). These applications may also constitute 
future business opportunities.
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Figure 1.3: Current research projects in tissue engineering [modified from 
Vacanti, 2001].
1.1.4 The emerging industry of Tissue Engineering
In a little over a decade, more than $3.5 billion has been invested in worldwide 
research and development in tissue engineering. Over 90% of this financial 
investment has been from the private sector [Lysaght and Reyes; 2001]. A recent 
study identified a total of 113 companies active in the field of tissue engineering in 
Europe, 54 companies belonging to the core tissue-engineering category [JRCEC, 
2003]. From this study emerged that the European market is characterised by young, 
small, research-based and technology-oriented companies, most of them SMEs with 
less than 50 employees. Comparable results have been obtained for the USA market 
from a survey made in 2001 [Lysaght and Reyes, 2001]. The United States gave birth 
to the field of tissue engineering through pioneering efforts in cell therapy and 
biomaterials engineering, aided by the presence of a strong private and 
entrepreneurial spirit. Growth in the U.S. biotechnology industry led to establishment
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of several of the first cellular tissue engineering and cell therapy companies around 
mid- to late-1980s [Mclntire et al., 2002]. According to both the European and the 
USA surveys, tissue-engineering firms have increased spending at a compound 
annual rate of 16% since 1990 [JRCEC, 2003; Lysaght and Reyes, 2001]. About two 
dozens of the companies are listed on the stock exchanges (representing 35% of the 
workforce employed) [JRCEC, 2003]. However, as stated earlier (previous section) 
no profitable tissue-engineered product seems to be yet on the market.
At the end of 2002, ten tissue-engineered products were in various stages of 
clinical trials; however, six products had failed or were abandoned [Lysaght and 
Hazlehurst, 2004]. The industry leaders, Organogenesis and Advanced Tissue 
Sciences, filed for Chapter 11 and reorganised under new organisations (Novartis and 
Smith and Nephew, respectively) in late 2002 due to financial challenges of 
development, manufacture, testing distribution and poor market acceptance 
[www.yahoo.com, 2002]. Both Organogenesis and Advanced Tissue Sciences faced 
significant difficulties including slow regulatory approval, competitors entering the 
market, and highly laborious and expensive manufacturing processes prone to 
introduction of microbial contaminations [Stone, 2003].
1.1.5 The challenges and the way forward
Important scientific and technical problems still need to be solved for the 
development of more complex tissues (e.g. comprehensive understanding of cell and 
tissue growth and behaviour, large-scale production and storage). The lack of a 
specific European regulatory framework for tissue-engineered products is currently 
hampering market growth in Europe. Only products that respond to large, long-term 
clinical trials testing their quality, safety and efficacy can gain approval from the 
regulatory bodies and ensure profits to the manufacturing firms. The small biotech 
companies involved in the manufacturing of tissue-engineering products do not have 
the resources for such trials to provide information on the cost-effectiveness of their 
products compared to conventional alternatives. In the USA, the Food and Drug 
Administration has been working toward a comprehensive regulatory scheme for 
tissue-engineered products since early 1997, and only very recently it has developed a
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guideline covering the rules requirements for human cells, tissues, and cellular and 
tissue-based products [Federal Register, November 24, 2004].
Certainly tissue engineering is “a new commercial biotechnology sector in 
Europe” [“European Commission focuses on human tissue engineering potential”, 
Brussels, 22 January 2004, IP/04/85]. Even though still in its infant phase, tissue 
engineering is expanding very quickly and, by providing the health sector with new 
opportunities and challenges, it is initiating a revolution in health care and biomedical 
research, and it is setting the stage for a new era in transplantation.
The next 5 to 10 year will be critical for the maturation of tissue engineering and 
its pivotal role in clinical medicine [Mclntire et al., 2002]. Filling the gap areas in 
basic science and engineering will be crucial for the development of actual products. 
The free movement of tissue-engineered products will be aided by the establishment 
of a uniform regulatory framework, and the creation of important alliances as well as 
mergers and acquisitions will help in reaching critical mass, rendering the companies 
more effective in both the discovery and the commercialisation processes [Pangarkar 
et al, 2003]. In addition, a highly automated development of new tissue-engineering 
products will permit biotech companies to utilize their existing equipment and GMP 
facilities, and this may ultimately decrease time to market, facilitating success of the 
resulting products [Mason, 2003a, Mason, 2003b; Naughton, 2002].
Ultimately, the perceived potential of stem cells to impact this area has already 
dramatically stimulated research activity in cellular tissue-engineering and cell 
therapy. The recent advances in these fields have created a window of opportunity for 
the successful application of tissue-engineering products in clinical practice. The use 
of autologous stem cells (isolated from the same patient) promise to overcome the 
ethical concerns surrounding embryonic stem cells, together with the immunological 
and safety considerations encountered when using allogeneic (derived from a donor 
of the same species) or xenogeneic (animal-derived) cells.
30
1.1.6 Vascular tissue engineering for the treatment of 
atherosclerosis and coronary artery disease
Among all the possible tissue engineering applications, cardiovascular tissue 
engineering has two key advantages in that it is both a life-saving or limb-saving 
treatment and targets a very large patient population [L’Heureux et al., 2007]. The 
need for arterial substitutes in the clinic is unfortunately increasing, due to the ever­
growing occurrence of vascular disease and atherosclerosis in recent years. 
Atherosclerotic vascular disease, including peripheral vascular and coronary artery 
disease, is the major cause of mortality and morbidity in the United States, Europe, 
and other western nations [Niklason et al., 1999]. The development of arterial 
atherosclerosis occurs when deposits of cholesterol and plaque accumulate at a tear in 
the inner lining of an artery. As the deposits harden and occlude the arterial lumen, 
blood flow to distant tissues decreases and a clot may become lodged, completely 
blocking the artery. Current surgical therapy for diseased vessels less than 6 mm in 
diameter involves bypass grafting with autologous blood vessels such as saphenous 
vein or, for coronary artery grafting, the internal mammary artery [Niklason et al., 
1999; Darling et al., 1972]. Coronary artery bypass grafting procedures are performed 
approximately 600,000 times annually in the United States alone [Edelman, 1999; 
www.americanheart.org]. Figure 1.4 illustrates the vessels involved in the coronary 
artery bypass grafting surgical procedure. Although common surgical practice, 
vascular grafting is usually associated with disfunction or inflammatory responses 
and thrombotic complications. Allografts are problematic because of a high rate of 
rejection. Synthetic materials are excessively thrombotic when used to by-pass 
arteries less than 6 mm in diameter, with thrombosis rates higher than 40% after 6 
months [Edelman, 1999]. As a result, the need for a tissue-engineered vessel of small 
calibre composed of biological materials and autologous cells has arisen and has been 
an area of active investigation for more than 15 years [Edelman, 1999].
31
Aorta
internal 
'rm n im  -tr,
arlerjCholostercifcjlld-VD
Saphenous 
vein bypass
£> Yc
Figure 1.4: Typical location for a coronary artery bypass graft. The most 
commonly used bypass vessel is the saphenous vein from the leg. Bypass grafting 
involves sewing the graft vessels to the coronary arteries beyond the narrowing or 
blockage. The other end of this vein is attached to the aorta. Over the past 10 to 15 
years, chest wall arteries, particularly the left internal mammary artery, have been 
increasingly used as bypass grafts. (The picture was sourced from MedicineNet, 
available at: http://intensivecare.hsnet.nsw.gov.au).
1.1.6.1 The artery wall: anatomy and function
The wall structure of the blood vessels is composed of three distinct and well- 
defined layers: the tunica intima, tunica media, and tunica adventitia (figure 1.5).
The innermost layer or intima, directly bordering the vessel lumen, typically 
consists of a monolayer of endothelial cells and an underlying thin (approx. 80 nm) 
basal lamina. Endothelial cells are usually flat and elongated in the direction of blood 
flow. The internal elastic lamina, which separates the intima and media, is essentially 
a fenestrated “sheet” of elastin that allows the transport of H2 O, nutrients, and 
electrolytes across the wall. An important role of the endothelium is to act as a non- 
thrombogenic lining that separates the wall contents from the flowing blood. It allows 
transport of substances to and from the bloodstream, and it must be considered as a 
selective barrier.
The media layer contains spindle-shaped smooth muscle cells that are embedded 
in an extracellular plexus of elastin and collagen (primarily types I, III, and V), as
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well as an aequous ground substance matrix containing proteoglycans. The primary 
roles of the contraction of vascular smooth muscle are to modify the distensibility of 
the large arteries or to regulate the luminal diameter in medium and small arteries 
[Milnor, 1990], The connective tissue augments the structural integrity of the wall 
and its ability to generate force, and acts as a scaffolding on which the cells can 
adhere or move on.
Finally, the adventitia, or outermost layer of the wall, consists primarily of a 
dense network of type I collagen fibers with admixed elastin and fibroblasts. The 
collagenous adventitia is thought to limit acute overdistension in the vessel and may 
serve primarily as a protective sheath, similar to the epicardium of the heart. 
Morevoer, the presence of nerves within the adventitia also allows innervation of 
smooth muscle in the outer media, while the vasa vasorum, an intramural network of 
arterioles, capillaries, and venules allows sufficient transport of O2 , CO2 , nutrients, 
and metabolites to the outer portion of the wall in thick arteries.
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Figure 1.5: The composition of a medium-size mature muscular artery in side 
view and cross section view. Pictures adapted from Hansen and Jain, 2003.
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1.1.6.2 Ideal mechanical and haemodynamic properties of 
vascular grafts
Tissue-engineering techniques may employ different types of materials, often 
after colonization by the selected cell type, to achieve a live prosthesis with the 
capacity to take part in the tissue-repair process. This represents a promising 
experimental approach to the in vitro creation of live autologous vascular substitutes 
with an ability for growth, repair and remodelling [Bujan et al., 2004].
The physical and mechanical properties of commercially available grafts vary
widely, but a number of characteristics common to all successful vascular prostheses
may be identified. These include [Greenwald and Berry, 2000]:
• biocompatibility;
• lack of chemical reactivity;
• very low thrombogenicity;
• porosity;
• sterility.
Moreover, to guarantee simple insertion and long-term success of a graft, the 
following properties are also essential [Greenwald and Berry, 2000]:
• flexibility;
• the ability to resist kinking and squashing;
• the ability to stretch/elasticity;
• availability in a range of sizes to match the dimensions of the native 
vessels;
• tensile stiffness sufficient to resist fraying at cut edges and tearing out of
sutures;
• circumferential strength sufficient to withstand arterial pressures.
In general, the physical and mechanical properties of successful vascular grafts 
should approximate those of the native vessels to which they are attached.
In the last 40 years, as techniques and materials have improved, the success rate 
of vascular prostheses with diameter greater than 6 mm has risen steadily, 5-year 
survival rates exceeding 95% in most centres [Nugent and Edelman, 2003]. Modem 
materials meet many of the above-listed requirements, permitting high success rates 
of the implantation procedure and long-term patency of large grafts. However, with 
smaller grafts no comparable improvement has occurred, the majority failing within 5
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years [Pevec et al., 1992]. This is mainly caused by intimal hyperplasia and, 
ultimately, atherosclerosis, developing in and around the downstream anastomosis 
[Bos et al., 1998]. Thus, in most cases the long-term success rate of grafts with a 
diameter of less than 6 mm is far from satisfactory and falls steadily as the diameter 
becomes smaller [Greenwald and Berry, 2000]. Recently, a variety of materials 
including Nylon, Teflon, Orion, Dacron, polyurethane and PTFE have been tested, 
and other materials are currently being investigated. However, these biomaterials lack 
the ability to grow and consequently do not achieve adequate remodelling, giving rise 
to post-implant complications such as thrombosis, stenosis or aneurismal dilation. 
More research is needed to determine the effectiveness of possible successful 
approaches in the treatment of compromised small vessels.
1.1.6.3 Tissue engineering of arterial vessel substitutes
The vascular wall, with its complicated architecture and distinctive mechanical 
properties, presents an enormous challenge to tissue engineering. The search for a 
perfect model, and perhaps the birth of vascular tissue engineering, can be tracked 
back to 1986 when Weinberg and Bell constructed an in vitro tissue-engineered blood 
vessel composed of natural materials [Weinberg and Bell, 1986]. They mimicked the 
adventitial and medial layers of native artery using culture derived collagen/fibroblast 
gel sheets and a similar collagen/smooth muscle cell (SMC) sheet wrapped over each 
other to form a tubular construct. These were then lined by an endothelial cell 
monolayer. This artificial artery represented a major advance in conduit technology. 
The endothelial lining of this blood vessel model functioned like a normal 
endothelium in several respects. To maximize the burst strength, Winberg and Bell 
optimized several parameters including the collagen concentration, initial cell density, 
and time elapsed after casting, and thus they produced a model with a burst strength 
of 323 +/- 31 mmHg. However, the tensile strength of such constructs was woefully 
inadequate for physiological use and required external support from a Dacron™ 
framework, which inevitably introduced limitations to the biological adaptation 
and/or vasoactivity. Additional limitations of this model were lack of elastin in the 
matrix mixture and incorrect orientation and low density of the smooth muscle cells 
and collagen fibers.
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A vascular graft formed without the use of a scaffold support was later developed 
by L’Heureux and colleagues [L’Heureux et al., 1998]. Human vascular smooth 
muscle cells were used to mimic the media layer in this system, and fibroblasts were 
then wrapped around the media to serve as the adventitia. This tissue-engineered 
vessel exhibited a well-defined organisation and had a burst strength of more than 
2000 mmHg, comparable to human vessels. One week after implantation into canine 
femoral arteries these structures remained patent in 50% of cases. However, it was 
unclear whether the material exhibited the normal viscoelastic response under 
physiological loading, or whether it would experience compliance mismatch on 
implantation.
Another interesting approach was followed by Niklason et al., who used a 
scaffold made of a biodegradable polyglycolic acid (PGA) mesh and seeded it with 
porcine aortic smooth muscle cells [Niklason et al., 1999]. The constructs were 
cultured for several weeks under pulsatile radial stresses in a parallel flow system. 
Following an 8-week period of in vitro maturation, porcine endothelial cells were 
seeded onto the lumen of the constructs to form a confluent monolayer. Culture 
medium containing growth factors and supplements (e.g. 20% fetal bovine serum, 
ascorbic acid, copper sulphate, and amino acids) was used to ensure that the proper 
biochemical signalling was available for cells to produce and cross-link matrix 
proteins. The resulting constructs exhibited burst pressures greater than 2000 mmHg 
and desiderable histological characteristics. When cultured under pulsatile conditions, 
these engineered vessels were also able to contract in response to known vasoactive 
substances, such as serotonin and endothelin-1. However, the engineered vessels did 
not demonstrate a full vasoactive response when compared with native blood vessels.
More recently, in the first clinical use of a vascular construct produced in vitro, 
Shin’oka et al. were able to regenerate a low-pressure pulmonary outflow tract in 
pediatric patients with cyanotic congenital defects [Shin’oka et al., 2001; Shin’oka et 
al., 2005]. Shin’oka seeded autologous bone marrow cells into tubes of a copolymer 
of L-lactide and e-caprolactone reinforced with a polyglycolic acid sleeve. 
Unfortunately, following implantation, these grafts were not suitable for the high- 
pressure nonpulmonary circulation.
Interestingly, L’Heureux and colleagues have recently developed a completely 
autologous approach whereby dermal fibroblasts obtained from skin biopsies were 
grown in conditions that promote the production of extracellular matrix proteins
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[L’Heureux et a l, 2006]. Following 6-10 weeks in culture, sheets of dermal 
fibroblasts were detached from the culture substrate and fused into a homogeneous 
tissue, which resulted in multilayer vessels with burst pressures in excess of 3000 
mmHg. Prior to implantation these vessels were seeded with autologous endothelial 
cells taken from the patients. Despite being time-consuming, this approach is showing 
encouraging results from the follow-up on ongoing clinical trials. With this approach 
graft failure appears unlikely to be life or limb-threatening, and all grafts seem to 
demonstrate excellent surgical handling characteristics [L’Heureux et a l, 2007].
In conclusions, over the past twenty years several approaches to creating tissue 
engineered blood vessels have been investigated, and research has moved toward 
engineering a completely natural vessel composed of smooth muscle cells and 
endothelial cells that is grown under biological conditions [Riha et al, 2005]. 
However, so far only two techniques (i.e. Shin’oka’s and L’Heureux’s) have been 
translated to clinical use. Early clinical trials results for both techniques seem 
encouraging; however, significant clinical (i.e. long production time) and regulatory 
challenges (i.e. lack of a harmonised European regulatory framework for advanced 
medicinal therapeutics) remain to be overcome before vascular tissue engineering can 
develop satisfactory small arthery prosthesis for clinical use [L’Heureux et al, 2007].
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1.2 Selection of a cell source for a bio-engineered tissue 
substitute
The source of the cells is a key element enabling or prohibiting potential tissue- 
engineering application. There are a variety of choices, depending on the clinical 
procedure:
1. autologous cells
2. allogeneic cells
3. xenogeneic cells
4. stem cells, either autologous (adult derived) or allogeneic (embryonic, 
fetal or adult derived).
The urgency or lack of urgency of the clinical application will determine how the 
cells will be selected, obtained, cultivated, and manipulated. For instance, cells 
required for blood vessel repair could be isolated from the patient’s own body, if the 
cell cultivation procedure is performed in advance. In contrast, nerve repair must 
occur within several hours/days from the initial damage in order to be successful, and 
therefore in this case the use of pre-cultivated cells and cells that can be expanded in 
vitro in sufficient quantity in culture are required. The source of the cells influences 
the culture requirements, delivery strategies and many other design parameters 
[Young et al, 1997].
1.2.1 Autologous cells
Autologous cells are derived from the specific individual into which they will be 
later reimplanted. The use of autologous cells obviates the problem of host’s immune 
rejection and, due to the reduced safety and regulatory requirements compared to the 
use of allogeneic and xenogeneic cells, they are often seen as the most obvious route 
to clinical application of tissue-engineered products. Cultured autologous cells were 
in fact the first to be used in clinical application of cellular tissue engineering: Gallico 
and colleagues cultured in vitro autologous keratinocytes and employed the resulting 
grafts in bum patients [Gallico et al., 1984]. Due to the long time required to harvest 
the cells, expand them in culture, and construct the implant, autologous cells are not
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the best choice for implants to be used in emergency clinical procedures. Moreover, 
the use of autologous cells does not necessarily imply minimal manipulation and 
maximum safety for the host, as culture protocols and reagents, if  not screened and 
validated, can introduce adventitious agents and alter cell populations regardless of 
their origin.
Tissue availability, inherent variability and limitations on expansion in culture are 
the major drawbacks to the use of autologous cells.
1.2.2 Allogeneic cells
Allogeneic cells are derived from an individual of the same species other than the 
recipient. Unlike autologus cells, allogeneic cells can be cultured and cryopreserved 
in sufficient quantity ready for immediate use. However, the use of allogeneic sources 
presents unique immunological and safety considerations. Allograft rejection is 
primarily a T cell mediated immune response. Endothelial cells, leukocytes and other 
cell populations are strongly allostimulatory. By contrast, there is now substantial 
accumulated clinical experience regarding the lack of immunogenicity of other cell 
types such as keratinocytes, fibroblasts, and smooth muscle cells [Falanga et al., 
1998; Laning et al., 1999; Young et al, 1997]. The inability of these cells to stimulate 
naive T cells presents the possibility of using allogeneic skin constructs containing 
only human epidermal keratinocytes and dermal fibroblasts for tissue engineering 
applications [Wilkins et al., 1994]. In summary, allogeneic cells may represent a valid 
alternative to the use of autologous cells when the degree of immunoreactivity of the 
resulting graft is reasonably low.
1.2.3 Xenogeneic cells
Xenogeneic cells are derived from a species different to that of the recipient. The 
use of xenogeneic cells obviously requires additional safety assessment in order to 
ensure that pathogenic viruses and prions are not introduced into the human 
population. Gel encapsulation of cell aggregates, cell microencapsuation, 
conformational coating of cell clusters, genetic manipulation and other technologies
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are currently being developed to block rejection and enable the use of xenogeneic 
tissue [Uludag et al., 2000].
1.2.4 Stem cells
Stem cells have the potential to revolutionize cell therapy and tissue engineering. 
The peculiar biological properties of these cells make their clinical exploitation both 
feasible and attractive. Human embryonic stem cells, which are isolated from a 
blastocyst, are pluripotent and can give rise to virtually any cell type in the body 
[Department of Health and Human Services, June 2001]. Adult stem cells, existing in 
most, if  not all, tissues, have also been shown to differentiate into numerous 
specialized, functional cells [Pittenger et al., 1999]. For this reason the use of stem 
cells has opened the door to the possible generation of almost limitless cell sources 
for a variety of tissues, and stem cells are considered an attractive “raw material” for 
multiple biotechnological applications. However, stem cells’ potential is limited, to 
date, by researchers’ rudimentary ability to control their proliferation and 
differentiation. The stability of Mesenchymal Stem Cells’ phenotype remains a 
concern and the ability to control or direct cell response is still one of the most 
limiting but important aspects of cellular tissue engineering. Aside from scientific and 
technical hurdles, the use of embryonic stem cells can provoke strong ethical 
reactions. This field is just beginning to be understood and obviously there are several 
significant scientific challenges and ethical issues to overcome prior to the feasibility 
of use for a repair aid. Stem cells’ properties, their potential applications and the 
obstacles hampering their use in clinic are briefly described in the next sections.
1.2.4.1 Stem cells: an alternative cell source for vascular 
grafts
The source of cells to be seeded onto or into synthetic grafts for blood vessel 
repair is not yet unequivocally established [Nerem, 2004]. With regard to clinical 
applications, several vascular human cell sources have been investigated [Schnell et 
al., 2001]. However, the proliferative capacity of many adult tissue-specific cells is 
very limited, making their expansion in vitro difficult in the preparation for scaffold
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seeding. Long-term in vitro cultivation also reduces their functional quality. As far as 
the engineering of small-calibre arteries for bypass surgery is concerned, smooth 
muscle cells -which are the main cellular component of these vessels- divide a finite 
number of times before undergoing growth arrest in a state known as senescence. 
This is largely due to the progressive erosion of chromosome-capping telomeres with 
each cell division, which ultimately leads to a critically short telomere length that 
signals senescence [Bierman E.L., 1978]. Smooth muscle cells must proliferate for at 
least 45-60 population doublings (PDs) to produce a mechanically robust artery in 
vitro. Bovine, porcine and human fetal and neonatal cells have long telomeres, and 
correspondingly divide extensively in culture [Kozik et al., 1998]; long enough, in 
fact, to form arteries in vitro. However, non-neonatal human smooth muscle cells that 
would be used clinically for tissue engineering can proliferate in vitro for only 10-30 
PDs before undergoing senescence [Bierman, 1978]. The limited life-span of non- 
neonatal smooth muscle cells may therefore be the rate-limiting step in constructing 
autologous human arteries in vitro. An important attempt at extending the life-span of 
non-neonatal human smooth muscle cells by inducing telomerase expression in these 
cells has been recently investigated [McKee et al., 2003].
However, as an alternative to this approach, attention has started shifting from 
seeding scaffolds with tissue-specific cells to the use of stem cells or progenitor cells. 
Recent in vitro studies conducted by Kadner and colleagues have shown that 
constructs seeded with bone marrow stromal progenitors cells develope a matrix 
composition similar to that of constructs seeded with vascular cells [Kadner et al., 
2002]. In contrast to vascular cells, these cells can be obtained without the need to 
disrupt intact vessels, representing an easy-to-access cell source in a possible routine 
clinical scenario. Due to their good proliferation and progenitor potential, these cells 
are expected to be an attractive alternative for cardiovascular tissue engineering 
application. Moreover, adult bone marrow cells (including mesenchymal stem cells), 
endothelial cells, vascular smooth muscle cells and fibroblasts all derive from the 
mesodermal germ layer. This close embryonic relationship further justifies studies 
focused on guiding differentiation of adult mesenchymal stem cells into vascular cells 
[Department of Health and Human Services, June 2001].
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1.2.4.2 Stem cells: a brief history
Mesenchymal Stem Cells (MSCs) were first identified in the pioneering studies of 
Friedenstein, who isolated bone-forming progenitor cells from rat marrow 
[Friedenstein et al., 1966]. However, the new stem cell biology era began only in 
1998, when James Thomson and his colleagues reported methods for deriving and 
maintaining human embryonic stem cells from the inner cell mass of human 
blastocysts that were produced through in vitro fertilization (IVF) and donated for 
research purposes [Thomson et al., 1995]. Since then, several research teams have 
tried to characterize many of the molecular characteristics of these cells and to 
improve the methods for culturing them.
1.2.4.3 The unique properties of stem cells
It is nowadays generally accepted that all stem cells -regardless of their source- 
exhibit three general and unique properties: they are capable of dividing and renewing 
themselves for long periods; they are unspecialized; and they can give rise to 
specialized cell types [Department of Health and Human Services, June 2001]. 
Furthermore, a stem cell can be considered totipotent, pluripotent, or multipotent 
[Vats et al., 2002]. A totipotent stem cell can form all cells/tissues that contribute to 
the formation of an organism (e.g. the fertilized egg or zygote); a pluripotent stem cell 
can form most (but not all) cells/tissues of an organism (e.g. embryonic stem cells and 
embryonic germ layers); and a multipotent stem cell can form a small number of 
cells/tissues that are usually restricted to a particular germ layer origin (e.g. bone 
marrow stromal or mesenchymal stem cells) [Kuo and Tuan, 2003]. Stem cells’ long­
term self-renewal and their pluri/multi-potentiality are what make them particularly 
attractive for clinical applications in the innovative field of tissue engineering.
1.2.4.4 Human stem cells and cell-based therapies
Perhaps the most important potential application of human stem cells is the 
generation of cells and tissues that could be used for cell-based therapies. Today, 
donated organs and tissues are often used to replace ailing or destroyed tissue, but the 
need for transplantable tissues and organs far outweighs the available supply. Stem 
cells, directed to differentiate into specific cell types, offer the possibility of a
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renewable cell source for the replacement of compromised tissues and organs. Among 
the disorders that might benefit from stem cell-based therapy are brain damages and 
disorders, acute liver and heart failures, vision disorders, arthritis, skin disorders and 
diabetes (see figure 1.8) [Orlic et al., 2001; Soria et al., 2000; Guettier, 2005; 
Lindvall et al., 2004].
STEM CELL-BASED THERAPIES
Figure 1.6. Scheme showing the tissues/organs constituting the potent targets for 
tissue regeneration by stem cell-based therapies. The localization of tissue-specific 
stem cells and their niches is shown. The tissue-specific degenerating disorders and 
diseases that might be treated by the transplantation of stem cell progenitors derived 
from embryonic stem cells, fetal stem cells, umbilical cord blood, and adult 
tissues/organs, including bone marrow (BM), are also indicated. The possibility of the 
mobilization of BM stem cells and their progenitors in the bloodstream by using the 
mobilizing agents is also shown. Abbreviations: bESC, bulge epithelial stem cell; 
CESC, comeal epithelial stem cell; CNS, central nervous system; CSC, cardiac stem 
cell; CXCR, CXC-chemokine receptor; eNCSC, epidermal neural crest stem cell; G- 
CSF, granulocyte colony-stimulating factor; HOC, hepatic oval cell; HSC, 
hematopoietic stem cell; KSC, keratinocyte stem cell; MPC, mesodermal progenitor 
cell; MSC, mechenchymal stem cell; NSC, neural stem cell; PSC, pancreatic stem 
cell; RSC, retinal stem cell; SDF, stromal-derived factor; SKP, skin-derived precursor 
[Mimeault and Batra, 2006].
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However, to realize the promise of novel cell-based therapies for such pervasive 
and debilitating diseases, it will be essential to find a way to easily and reproducibly 
manipulate stem cells so that they possess the necessary characteristics for successful 
differentiation, transplantation and engraftment. The following is a list of steps in 
successful cell-based treatments that will be necessary to learn to precisely control to 
bring such treatments to the clinic.
To be useful for transplant purposes, stem cells must be reproducibly made to:
• Proliferate extensively and generate sufficient quantities of tissue.
• Differentiate into the desired cell type(s).
• Survive in the recipient after transplantation.
• Integrate into the surrounding tissue after transplantation.
• Function appropriately for the duration of the recipient’s life.
• Avoid harming the recipient in any way.
1.2.4.5 Obstacles limiting the promise of stem cell-based
therapies
Despite the recent advances in stem cell research, the clinical utility of these cells 
is still limited, because to date, no effective technological methodologies exist to 
cultivate these cells in vitro, and scientists are just beginning to direct the 
differentiation of the human pluripotent stem cells and to identify the functional 
capabilities of the resulting specialized cells. In addition, the defining parameters 
required to maintain and expand the stem cell pool in vitro, and the mechanisms 
regulating their differentiation are still poorly defined [Zandstra and Nagy, 2001].
Mesenchymal stem cells’ definition itself is still unclear. Mesenchymal stem cell 
(MSC) is the designation commonly applied to the plastic-adherent cells isolated 
from the bone marrow; however, this heterogeneous population is recognized, among 
leading investigators, to be too “crude” to be considered all mesenchymal stem cells, 
and there are no convincing data to support the “sternness” of these cells [Horwitz 
and Keating, 2000]. In order to address the inconsistency between nomenclature and 
biological properties, it has been recently proposed to term multipotent 
“mesenchymal stromal cells” the fibroblast-like plastic-adherent cells, regardless of 
the tissue from which they are isolated, while reserving the term “mesenchymal stem
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cells” (for which the acronym MSC remains unchanged) for cells that meet specified 
stem cell criteria [Horwitz et al., 2005]. This proposed solution is still the object of 
debate among scientists worldwide, and clearly the confusion over stem cells’ 
terminology is a reflection of the need for thorough characterization of these cells 
[Kuo and Tuan, 2003].
In order to avoid this issue, the mixed population of bone marrow derived 
progenitor cells used in this research will be referred to as multipotent “mesenchymal 
stem cells”, as this was the accepted term at the beginning of this research.
1.2.4.6 Embryonic and adult mesenchymal stem cells
The embryonic stem cell is defined by its origin -that is from one of the earliest 
stages of the development of the embryo, called the blastocyst. Human embryonic 
stem cells can be cultured by isolating a blastocyst, removing the outer cell wall, 
placing into culture with a layer of mouse feeder cells, and adding selected 
differentiation factors after colonies of embryonic stem cells have been formed 
[Pedersen, 1997]. Pluripotency -that is the ability to give rise to differentiated cell 
types that are derived from all three primary germ layers of the embryo, endoderm, 
mesoderm, and ectoderm- is what makes ES cells unique. Despite the potential of ES 
cells, legal and ethical issues surrounding their use have turned much attention to the 
use of adult stem cells. Relative to embryonic stem cells, adult stem cells have also 
reduced tumorigenicity and thus are preferable for therapeutic purposes because they 
are considered safer for implantation. Besides, the use of autologous adult stem cells 
avoids triggering of immune rejection.
Adult stem cells are undifferentiated (unspecialized) cells that reside in small 
numbers among differentiated (specialized) cells in many adult mammalian normal 
tissues/organs, including bone marrow, heart, kidneys, brain, skin, eyes, 
gastrointestinal tract, liver, pancreas, lungs, breast, ovaries, prostate, and testis 
[Department of Health and Human Services, June 2001; Muschler et al., 2003; 
Muschler et al., 2002]. Bone marrow-derived MSCs for example, represent a very 
small fraction, 0.001-0.01%, of the total population of nucleated cells in marrow 
[Pittenger et al., 1999]. Numerous studies have revealed that a population of adult 
stem cells resides within specific areas designated as niches in most of the above- 
mentioned tissues or organs [Heissig et al., 2005]. Adult stem cells appear to persist
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in their specialized niches where they remain quiescent (resting or not actively 
proliferating/dividing) for many years until they are activated by disease or tissue 
injury. Although adult stem cells share with embryonic stem cells the ability to renew 
themselves and to generate differentiated cell progenitors of different lineages 
[Caplan, 1991; Pittenger et al., 1999], they generally show a more restricted 
differentiation potential and give rise to a more limited number of distinct cell 
progenitors. However, due to the potential advantages listed above, adult stem cells 
are the object of intense and active investigations in the emerging fields of cell-based 
therapy and tissue engineering.
1.2.4.7 Bone marrow-derived MSCs
Adult bone marrow is one of the most widely used sources of adult stem cells. 
Bone marrow contains at least two, and likely more discemable stem cell populations 
[Jiang et al., 2002; Mazurier et al., 2003]. Besides the hematopoietic stem cell (HSC), 
which renew circulating blood elements, a cell type termed mesenchymal or marrow 
stromal (MSC) also exists in marrow [Majumdar et a l, 1998]. This cell provides 
support for hematopoietic and other cells within the marrow, and contribute to the 
regeneration of mesenchymal tissues such as bone, cartilage, muscle, ligament, 
tendon, adipose, and stroma [Kuznetsov et a l  1997; Friedenstein et al., 1987; 
Haynesworth et' al., 1992]. Both HSCs and MSCs can be isolated from the 
mononuclear fraction of bone marrow aspirates. Unlike hematopoietic stem cells, 
which can be identified and isolated on the basis of characteristic surface markers, 
there is not currently a well-established, unique profile of surface markers to identify 
MSCs [Minguell et al., 2001; Fibbe, 2002]. As a result, mesenchymal stem cells are 
most commonly identified by their tendency to adhere to tissue culture plastic. In fact, 
one of the most common techniques used to isolate and culture expand in vitro the 
multipotent human MSCs is aspiration from bone marrow followed by density 
gradient fractionation and direct plating [Pittenger et a l  1999]. Other techniques 
utilized for MSCs’ identification are based on their expansion potential and their 
capacity to undergo all three differentiation pathways of osteogenesis, 
chondrogenesis, and adipogenesis in culture with appropriate combination of growth 
factors and supplements [Pittenger et al., 1999].
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Recent studies have demonstrated the existence of bone marrow-derived 
endothelial progenitor cells that contribute to vasculogenesis and angiogenesis 
[Takahashi et al., 1999] and experiments have proved endothelialization of artificial 
grafts using bone marrow cells (BMCs) [Noishiki et al., 1996]. Bone marrow cells 
(BMCs) have also been seeded onto a biodegradable scaffold to establish tissue- 
engineered vascular autografts successfully implanted in vivo both in animal and 
human models [Matsumura et al., 2003a; Matsumura et al., 2003b]. More recently, a 
specific subpopulation of human bone marrow-derived MSCs has demonstrated the 
potential to differentiate into endothelial-like cells in vitro [Oswald et al., 2004] 
making it an attractive candidate for the development of engineered vessels as well as 
for the vascularization of engineered tissues. These findings may support the 
development of tissue-engineered vascular grafts based on autologous bone marrow- 
derived MSCs, although clinical studies will have to establish whether these cells 
have enough potential for expansion to be practically useful and to display significant 
positive effects in patients with small vessel diseases.
To summarise, the promise of stem cell therapies is an exciting one, but 
significant technical hurdles remain that will only be overcome through years of 
intensive research. Like many expanding fields of scientific inquiry, research on stem 
cells raises scientific questions as rapidly as it generates new discoveries. However, 
stem cells remain one of the most fascinating areas of biology today, and research in 
this emerging field of science is showing the first promising results, indicating that 
Regenerative or Reparative Medicine, that is treatment of disease through cell-based 
therapies, is most likely to become a real possibility in the near future.
1.3 Selection of a three-dimensional matrix suitable for the 
preparation of an engineered tissue
Most tissue-derived cells are anchorage dependent and require attachment to a 
solid surface for viability and growth. Biomaterials are used to promote cell adhesion, 
spreading and migration, to guide the organization, growth and differentiation of cells 
in the process of forming functional tissue and provide both physical and chemical 
cues.
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Scaffold materials for tissue engineering applications must at minimum satisfy a 
number of design criteria to function appropriately and promote new tissue formation. 
These criteria include classical parameters such as structural and mechanical 
properties as well as biological performance parameters like biocompatibility and 
suitability for cell adhesion [Chen et al., 2002].
Both synthetic and natural materials have been designed to meet nutritional and 
biological needs for the specific cell population involved and to guide the 
development of new tissues. A list of some materials used as bioengineered scaffolds 
is presented in the table in figure 1.7.
Synthetic polymers used os scaffolds in tissue 
engineering 
Poly beta-hydroxybutrate 
Polyglycolic acid 
Poly lactic acid
Polyglycolic acid poly L lactic acid co polymer 
Polyethylene 
Polyethylene oxide 
Carrier materials of natural origin used as scaffolds in 
tissue engineering 
Collagen sponges 
Collagen gel 
Alginate 
Fibrin
1 lyaluronic acid 
Gelatin
Ctillagen-glycosaminoglycan matrices
Figure 1.7: Examples of some materials used in bioengineered scaffolds [adapted 
from Sarraf et al., 2002].
1.3.1 Synthetic materials
A variety of synthetic materials, both degradable and non-degradable, have been 
used to fabricate tissue engineering matrices. Two main structural types are fiber- 
based and sponge-based scaffolds. Currently, polyglycolic acid and poly-L-lactic 
acid, which are biodegradable materials, are mainly used in this field, and the 
hydrolytically degradable poly(lactide-co-glycolide) PLG polymers have been 
approved by the FDA for use in the body [Thomson et al., 1995; Wong and Mooney,
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1997]. Such synthetic polymers are well suited for the delivery of a large number of 
cells because of their high porosity and extensive surface area. Their porosity also 
allows for the vascularization and structural integration of the new tissue with 
surrounding native tissue after implantation. Synthetic polymers can be readily 
processed into the devices of varying sizes and shapes and have chemical and 
mechanical properties that can be accurately controlled and manipulated.
1.3.2 Natural polymers
Natural polymers include both extracellular matrix (ECM) proteins and 
derivatives (including collagen, fibrin, gelatin, hyaluronic acid) and materials derived 
from plants and seaweed (such as alginate). A variety of naturally derived hydrogel 
forming polymers, a class of highly hydrated polymer materials (water content > 30% 
by weight) [Park and Lakes, 1992] are being employed as scaffold materials because 
they are either components of or have macromolecular properties similar to the 
natural ECM. These materials have been shown to interact in a favourable manner in 
vivo and thus have been utilized as hydrogel scaffold materials for tissue engineering 
[Lee and Mooney, 2001].
1.3.3 Activation of inert supports
In order to promote cell attachment and cell growth, polymers can be modified at 
their surface.
Tissue-culture vessels, for example, are usually made of polystyrene, which can 
be treated by radioffequency plasma deposition or exposure to sulphuric acid in order 
to increase the number of charged groups at its surface. Alternatively, polymer 
surfaces can be treated with purified protein solutions (such as fibronectin, laminin, 
collagen and other extracellular matrix proteins) that permit cell adhesion. The 
optimal surface for cell adhesion has an intermediate wettability and high surface free 
energy, which allows cell adhesion proteins to adsorb to the surface.
With the exception of collagen, which is a natural ECM protein, most hydrogel 
forming polymers do not normally permit cell adhesion. Furthermore, because of the 
hydrophilic nature of hydrogels, ECM proteins such as laminin, fibronectin and 
vitronectin typically do not readily absorb to the gel surface [West and Hubbell,
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1997]. A common approach to design a highly specific adhesive surface requires 
covalently bonding synthetic peptides or incorporating small biologically active 
functional groups of the ECM to the graft polymer [West and Hubbell, 1997]. These 
peptidic sequences and functional groups are based on the receptor-binding domains 
of cell adhesion proteins. Most cell types synthesize and express on their surface 
specific proteins, known as integrins, which are able to recognize these cell binding 
peptidic sequences. The most common peptide used in this approach is the amino acid 
sequence arginine-glycine-aspartic acid (RGD) derived from numerous ECM proteins 
including fibronectin, laminin, vitronectin and collagen [West and Hubbell, 1997]. 
The proteins that contain the RGD sequence, together with their specific integrin cell 
receptors, constitute a major recognition system for cell adhesion. The RGD peptide, 
the major cell binding sequence, is critical for the interaction of the ECM proteins 
with the adhesion receptors [Ruoslahti and Pierschbacher, 1987; Ruoslahti, 1996]. 
Other common peptides used in this approach include arginine-glutamic acid-aspartic 
acid-valine (REDV) (from fibronectin), tyrosine-isoleucine-glycine-serine-arginine 
(YIGSR) (from laminin) and isoleucine-lysine-valine-alanine-valine (IKVAV) (from 
laminin) [West and Hubbell, 1997].
Mooney and colleagues at the University of Michigan, for example, have been 
tailoring and modifying alginate with the RGD peptide to promote cellular adhesion 
[Alsberg et al., 2001; Rowley et al., 1999], ultimately permitting optimal 
performance of the alginate in tissue-engineering applications (see also section 
1.4.4.2).
1.3.4 Sodium alginate
Alginate is a naturally derived polysaccharide and one of the most versatile 
biopolymers with a wide range of pharmaceutical and biomedical applications.
Alginate is a common term for a family of natural non-branched binary 
copolymers of 1 -4 glycosidically linked (3-D-mannuronic acid (M) and a-L-guluronic 
acid residues (G).
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Figure 1.8: Chemical block structures of alginate. Picture adapted from Mulder, 
2002.
All current industrial manufacture of alginate is based on extraction of the 
polymer from brown algae. The seaweed grows naturally mainly in the temperate 
zone, but large amounts are also cultivated in the Far East, on the coast of China and 
Japan in particular. The ratio of the M and G subunits and their sequential 
arrangement will vary from one species of brown algae to another. Similar variations 
are also found in the seaweed during the growth season, and between different parts 
of the plant.
The functional properties of alginate mostly utilized are the viscoelastic ones, as a 
gelling agent through cross-linking with calcium, and as a viscosifier in aqueous 
solutions. Solubility, swellability and film-forming properties are other capabilities 
utilized in biomedical and pharmaceutical applications. The gelling properties of 
alginate are a function of the M/G composition and the sequential structure of M and 
G along the alginate chain. Divalent cations cooperatively bind between the G-blocks 
of adjacent alginate chains, creating ionic interchain bridges which cause gelling of 
aequous alginate solutions. A solution of calcium chloride is most commonly used to 
donate the calcium ions, which compete for the sodium ion position on the hydroxyl 
groups of adjacent blocks of G subunits. The gel formation can be reversed by 
addition of excess sodium ions [Martinsen et al., 1989] (Figure 1.9).
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M-ricIi network G-rich network
represents M-firacdons 
^  represents cross-linked G-fractions
Figure 1.9: Cross-linking of alginate G-blocks with calcium [Melvik et al., 
Pronova Biomedical].
Injectable, in vivo gelling forms of alginate [Marler et al., 2000; Alsberg et al., 
2001] have been successfully combined with cells and/or bioactive molecules and 
delivered in a minimally invasive manner.
1.3.4.1 Quality of alginate
In order to be used for transplantation, matrix components of a tissue engineered 
product must be non-toxic, non-immunogenic and pyrogen free (not contain 
components such as proteins, complex carbohydrates, and nucleotides from micro­
organisms) [Skjak-Braek et al., 1989]. Natural, non-animal derived matrices are the 
most desirable from a regulatory standpoint. Plant derived materials, such as alginate, 
are ideal because they do not contain human pathogens. However, potential 
contaminants typically found in alginate include hazardous and cytotoxic 
components, like endotoxins, heavy metals and polyphenols, which need to be 
removed [Zimmermann et al., 2001]. These are present in alginates in various 
amounts according to their source and type. The phenolyc compounds can be detected 
by fluorescence spectroscopy in concentrations lower than 1 ppm [Skjak-Braek et al., 
1987]. The contaminants can be reduced by selection of the original alginate material 
with low initial polyphenols. Alternatively, various purification protocols can be 
employed to remove mitogenic and cytotoxic impurities and other contaminants from 
the alginate. These include treatment with specific enzymes, or with bleaching agents
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such as H2O2 or sodium hyper chlorite (NaC1 0 2 ); followed by a dialysis step to 
remove low molecular weight constituents; extraction with organic solvents, such as 
acetone or ethanol; adsorption chromatography through polyamide beads or 
granulated activated carbon; and filtration through a 0.45 pm membrane filter [Skjak- 
Braek et al., 1987].
Following increasing popularity of alginate as an immobilization matrix, Pronova 
Biomedical (Norway) now commercially manufactures ultra-pure alginates that are 
low in pyrogens and highly compatible with mammalian biological systems. These 
alginates have been shown to support tissue and vascular in-growth with minimal 
inflammatory response and capsule formation in in vivo animal models [Halberstadt 
et al., 2002].
1.3.4.2 Alginate’s biomedical and biotechnology
applications
Alginates have been used for decades as helping agents in various human-health 
applications, including in traditional wound dressings, in dental impression material, 
and in some formulations preventing gastric reflux. However, due to its increasing 
popularity as an immobilization matrix in various biotechnological processes, 
alginate’s applications now include other and more advanced technical domains in 
addition to its traditional uses. Alginate hydrogels are for example currently 
extensively used in enzyme and cell encapsulation and in tissue engineering 
applications.
Perhaps the most exciting prospect for alginate gel immobilized cells remains 
their potential use in cell transplantation. Here, the main purpose of the gel is to act as 
a barrier between the transplant and the immune system of the host [Draget et al., 
2005]. Different cells have been suggested for gel immobilization, including 
dopamine-producing adrenal chromaffin cells for treatment of Parkinson’s disease 
[Aebisher et al, 1993]. However, major interest has been focused on insulin- 
producing cells for treatment of Type I diabetes. Alginate/poly-L-lysine capsules 
containing pancreatic Langerhans islets have been shown to reverse diabetes in large 
animals and currently are being clinically tested in humans [Soon-Shiong et al., 1993; 
Soon-Shiong et al., 1994].
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Entrapment of cells within calcium-alginate spheres has also become the most 
widely used technique for the immobilization of living cells [Smidsrod and Skjak- 
Braek, 1990].
Mooney and co-workers have studied alginate that contain covalently bound the 
adhesion RGD peptide sequence as a substrate for growth of a variety of cell types in 
vitro [Rowley and Mooney, 2002]. Mooney’s group also successfully transplanted 
calvarial osteoblasts [Alsberg et al., 2001], pre-adipocytes [Halberstadt et al., 2002], 
fibroblasts [Marler et al., 2000] and cotransplants of calvarial osteoblasts and 
chondrocytes [Alsberg et al., 2002] immobilised within the modified gel in vivo using 
modified alginate scaffolds. Other studies reported data retention of cell function and 
differentiation using alginate as a matrix. In addition, chondrocytes have been shown 
to maintain a stable differentiated phenotype when cultured in alginate as compared 
to 2-D cultures [Hauselmann et al., 1994].
Peptide modified alginates have been also employed as potential scaffolds for 
skeletal muscle engineering [Rowley and Mooney, 2002]. Alginate hydrogels have 
also shown potential as Schwann cell matrices in the area of nerve grafting [Mosahebi 
et al., 2001] and as scaffolds to promote hepatocyte function and synthesis of liver 
specific proteins [Glicklis et al., 2000]. A recent study [Wang et al., 2003] has 
demonstrated that purified, unmodified alginate gels with a high guluronic acid 
content are able to support proliferation of rat marrow cells and their differentiation 
along the osteoblastic lineage. However, in two separate studies, both rat neonatal 
cardiac cells and human MSCs were shown not to proliferate after immobilization in 
unmodified alginate scaffolds [Dar et al., 2002; Ma et al., 2003].
There are still several important issues that need to be addressed prior to the 
feasibility o f using alginate scaffold materials for tissue engineering applications in a 
clinical setting. These include tailoring the alginate’s micro-architecture in a way that 
permits vascularization of the newly formed tissue; controlling the alginate’s 
decomposition and degradation and its clearance from the body, and ensuring its 
biocompatibility through purification techniques that remove immune response 
invoking impurities.
However, in many cases, alginate has already demonstrated the potential to act as 
an optimal scaffold material for different cell transplantation and tissue-engineering 
applications, in particular for structural tissues such as soft tissue, cartilage,
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myocardium, bone and liver. These encouraging results, together with the lack of 
studies demonstrating the suitability of the alginate as scaffold material for the 
preparation of tissue engineered vascular grafts, justify and drive interest on studies 
investigating alginate in this particular field.
1.4 The role of bioactive molecules and oxygen tension in 
the in vitro environment
As already mentioned (see section 1.1.2), tissue engineering principles are based 
on the utilization of three primary components: the biomaterial, the cells and the 
biomolecules, which serve to integrate and to functionally regulate the behaviour of 
the first two. Biomolecules are regulatory molecules that function as mediators of cell 
communication and can exert multiple biological functions by interaction with 
specific cell surface receptors. Bioactive molecules include agents with a large 
diversity of functions that are key to either the assembly and structural integrity of 
tissue engineered constructs or to the functional parameters of these constructs.
This chapter describes the roles of the animal serum and the soluble growth 
factors that are normally added to the basal medium in which the cells are grown in 
routine culture techniques. In addition, a brief description of the role of some 
insoluble ECM macromolecules that can be used as additional supplements in the 
medium formulation or can be coated to the surface of the culture vessels or added to 
the scaffold material in cell culture applications is provided. Finally, the effects of the 
oxygen tension and oxidative stress on cell proliferation potential are presented.
1.4.1 Growth medium
All isolated cells cultured in vitro need an artificial environment that allows 
growth and proliferation. Cell cultures must be maintained regularly to prevent 
overgrowth, accelerated cell death from exhausted medium, and to promote the 
growth of the next generation of cells [Palsson and Bhatia, 2004]. The liquid or 
“medium” in which cells are grown and expanded in culture provides inorganic salts, 
amino acids, carbohydrates, vitamins and other nutrients important for cell
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maintenance in vitro. Table 1.1 lists major components found in commercially 
available tissue-culture media. Medium formulation is typically tailored for each cell 
type -  some aspects mimic the physiological environment (pH, osmolarity), others 
are supra-physiologic (hormones, nutrients), and some are non-physiologic (indicator 
dyes, antibiotics) [Berthiaume, 1998].
Medium c omponents Amount Physiologic 
al range
Purpose
Sodium chloride 6-8 g/L 5.55-6.14
g<L
Adjusts osmotic 
pressure
Inorganic salts 0.8-1 g/L NA Provide electrolyte 
balance similar to 
blood
Sodium bic atbonate 2-3 g/L 1.85-2.52 
g/L
Provide s buffe ring 
capacity, with 
appropriate COj 
level in the gas 
phase, maintains 
pH at 7.4
D-glucose 1 g/L 0.81-1.04
g^ L
Source of energy 
carbon
Amino acids 1 g/L NA Sources of nitrogen 
for protein 
synthesis
Vitamins 0.01 g/L NA Cofactois in 
various 
intracellular 
biochemical 
reactions
Phenol red 0.01 g/L NA Visual pH indicator
Serum (see fig.1.13) 1-20 Y*vfv NA
Provides cell 
growth, attachment 
factory hormones, 
carrier proteins
Growth factors, hormones 1-10
microg/L
NA Stimulate growth, 
functions
Antibiotics 1-50
microg/L
NA Prevent 
contamination by 
microorganisms
Table 1.1: Major components found in tissue-culture media [Palsson and Bhatia, 
2004].
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Typically, a synthetic basal medium is chosen to meet the environmental and 
nutritionals requirements of a given cell line. However, basal media formulations 
normally will not support cell growth alone, but must be further supplemented with 
animal serum.
1.4.2 Serum
Serum is a fraction of whole blood. Plasma is the non-cellular fraction of blood, 
whereas serum is the liquid that remains after plasma is allowed to clot. Sera are 
typically added to culture medium in a proportion of approximately 1 to 20 % by 
volume. Common tissue culture sera are newborn calf (NCS), fetal bovine (FBS), 
horse (equine), pig (porcine), and human. Fetal bovine serum (FBS) has been adopted 
as the standard supplement because of its rich content of growth factors and its low 
gamma globulin content [http://www.cellgro.com Mediatech, Inc. Cell Culture 
Reference Guide]. Historically, medium containing fetal bovine serum has been used 
for culture of a wide range of cell types.
As seen in table 1.2 [Palsson and Bhatia, 2004], sera are very complex 
supplements containing mostly proteins but also important growth factors, adhesion 
factors, minerals, lipids, enzymes and hormones that can be key to successful tissue 
culture.
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Constituent Eflectoncelh
Albumin, globulins, transferrin Carriers for fatty acids, iron, etc.
Fibronectin, fetuin Attachment factors
Alfa2-macroglobulin Inhibits proteases
Growth factors and growth hormones Promote cell proliferation
Hormones (e .g. insulin and corticosteroids) Stimulate uptake of glucose and amino acids; 
alter growth rate
Carbon and nitrogen sources Nutrients
Minerals and trace elements Essential for the activity of me talloenzymes
Inhibitors Inhibit cell proliferation
Table 1.2: Main constituents of serum [Palsson and Bhatia, 2004].
Despite the beneficial effects, the use of sera has some significant disadvantages, 
including batch-to-batch variability, the presence of adventitious agents, product 
availability, interference with detection of cell products, and potential regulatory 
hurdles. Moreover, sera contain a wide range of minor components that may 
potentially affect cell growth. These minor undefined components, including nutrients 
such as amino acids, nucleosides and sugars, are inherent to sera and may affect 
various parameters of particular importance [http://www.cellgro.com Mediatech, Inc. 
Cell Culture Reference Guide]. In order to minimize these variables there has been a 
move towards the use of serum-free media.
Removal of bovine serum from organ culture medium is necessary also because 
of the potential risk of infection. Bovine serum is the usual supplement in the medium 
for expanding human cells, however transmission of bovine diseases might be 
inevitable when such cells are introduced into the patient for tissue engineering 
applications. In addition, bovine serum proteins attach to the surface of the cells and 
the biomaterial. It is possible that transferring bovine serum proteins into patients 
elicits an unfavourable immune reaction [Yamamoto et al., 2003]. Nowadays there is 
both a moral and legal imperative (European Directive 86/609/EEC as amended by
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Directive 2003/65/EC) for scientists to use alternatives to animals in research 
wherever possible. To avoid all the above mentioned unfavourable possibilities, 
leading companies are supplying researchers with serum substitutes and serum-free 
media, which are used to support the maintenance and expansion of many cell types, 
including hematopoietic stem cells and other progenitor cells.
For instance, serum-free culture has been explored for human nasal epithelial cells 
(HUNEC) [Mattinger et al., 2002], human corneal endothelial cells [Bednarz et al., 
2001] but, most importantly, for rhesus monkey and human embryonic stem cells 
([Pei et al., 2003; Amit et al., 2003] respectively). A culture system for the growth 
and assay of human bone marrow stromal precursors under serum-deprived 
conditions has also been developed [Gronthos and Simmons, 1995]. As an alternative 
to serum-deprived conditions, human chondrocytes have been cultured in a medium 
supplemented with autologous serum, and then transplanted into the patient’s 
cartilage defects [Brittberg et al., 1994]. Moreover, the effects of human serum on the 
in vitro differentiation of human bone marrow fibroblasts into adipogenic and 
osteogenic cells have been investigated [Oreffo et al., 1997]. Human bone marrow 
derived MSCs have also been cultured in human and rabbit sera [Kuznestov et al., 
2000] or in autologous serum [Yamamoto et al., 2003] to test the hypothesis that 
these cells can be successfully expanded ex vivo without losing their potentiality for 
osteoblastic differentiation even in an FBS-free culture system.
All these studies represent important prerequisites for future investigations on the 
role of serum in the regulation of cell proliferation, differentiation and development.
1.4.3 Growth factors
To enhance cell proliferation, growth factors and other bioactive soluble 
macromolecules can be added directly to the growth medium or can be incorporated 
into the scaffold material. Growth factors play important regulatory roles in the 
control of the immune response, inflammatory reactions, cell proliferation and tumour 
growth [Yarden et al., 1991]. They can stimulate or inhibit cell division, 
differentiation, migration and apoptosis, and they are involved in the regulation of 
several cellular processes such as gene expression, DNA and protein synthesis, and 
autocrine and paracrine factor release.
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Some growth factors have demonstrated the ability to induce division of the 
endothelial cells and smooth muscle cells that represent the main cellular constituents 
of large blood vessels. These growth factors include:
a) basic fibroblast growth factor (bFGF) -  both endothelial and smooth 
muscle
b) vascular endothelial cell growth factor (VEGF) -  endothelial cells
c) platelet-derived growth factor (PDGF) - smooth muscle cells
d) epidermal growth factor (EGF) -  smooth muscle cells
e) endothelin-1 (ET-1) - smooth muscle cells
Each of these growth factors can interact with one another in an additive, 
cooperative, synergistic or antagonistic manner, and thus must be studied 
individually. For tissue engineering purposes, whether the cells are quiescent or 
activated, and whether they are in a two or three-dimensional culture environments, 
will influence the production of endogenous growth factor and consequently will also 
affect the response to exogenously applied bio-molecules.
1.4.4 Insoluble ECM adhesion molecules
The extracellular matrix (ECM) contains a number of proteins that contribute to 
both organizing the matrix and helping cells attach to it. Not surprisingly then, the 
composition and geometry of the ECM have both been shown to play a role in cell 
function. Due to the important effects of the ECM on cell behaviour, insoluble ECM 
molecules, such as fibronectin, laminin, or collagen, have been used to promote tissue 
regeneration in tissue engineering applications. These cue materials, together with the 
soluble factors such as growth factors or hormones normally added to the medium of 
culture, can be utilized to promote cell development and function [Gooch et al.,
1998].
Cell-ECM interactions can be controlled by modification of the solid substrate on 
which cells are grown. Polystyrene and other polymers normally employed in the 
preparation of tissue culture vessels can be improved just by coating the surface with 
ECM molecules such as collagen or fibronectin. Many tissue culture plates are 
currently treated with these molecules to improve cell binding.
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As already mentioned (see section 1.3.3), biomaterial scaffolds can also be treated 
with the RGD and other short peptide sequences derived from cell binding regions of 
ECM proteins in order to achieve biospecific cell adhesion [Gooch et al., 1998].
Culture surfaces modified with fibronectin are currently investigated for cell 
culture by several groups. Fibronectin, a large glycoprotein found in all vertebrates, 
was the first non-collagen ECM proteins to be well characterized [Alberts et al., 
1994]. Human fibronectin (HFN) sometimes serves as a general cell adhesion 
molecule through its central-binding domain RGD sequence. The apparent function 
of fibronectin is to mediate cell attachment by interacting with cell surface receptors 
and extracellular matrix components ([Hynes, 1985]; [Rouslahti, 1988]). HFN is not 
only used as a substrate to promote cell attachment; it is involved in many other 
cellular processes, including cellular migration during wound healing, tissue repair 
and development, embryogenesis, blood clotting, and haemostasis/thrombosis.
Also Matrigel, a solubilized basement membrane preparation commercially 
available, is currently used for several cell culture applications. According to the 
manufacturer’s (Becton-Dickinson Biosciences, Oxford, UK) specifications, ordinary 
matrigel contains (as a proportion of protein by weight) 56% laminin, 31% type IV 
collagen, 8% entactin, 5% heparan sulfate proteoglycans.
Both fibronectin and matrigel are used as substrates for growth and differentiation 
of different cell types.
1.4.5 The role of oxygen in cell culture
Metabolically active cells are also consuming and producing dissolved gases 
(oxygen and carbon dioxide). Cell viability and function are in fact dependent upon 
both nutrient supply and oxygenation. As a consequence, the in vitro growth 
characteristics of cells are subject to dissolved oxygen tension, among many other 
culture-related factors, such as the already described media formulation and growth 
factors supplementation [Parrinello et al., 2003].
Oxygen consumption can be a critical variable for certain cell types (for example 
hepatocytes consume five- to ten-fold more oxygen than other cells). Oxygen delivery 
in culture is different than oxygen delivery in vivo because of the lack of red blood 
cells (with haemoglobin) as oxygen carriers. Therefore, in culture, oxygen delivery is
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limited by two factors: 1) the relatively low solubility o f oxygen in media at body 
temperature (1.19 pM/mm Hg) and 2) transport of oxygen from gas phase to cell 
surface [Palsson and Bhatia, 2004].
Standard culture conditions use dissolved oxygen tension levels (20%-21%) that 
are hyper-physiologic for many cell types, including articular chondrocytes and bone- 
marrow derived MSCs, which are adapted to relatively low oxygen levels (< 10%) in 
vivo [Scott, 1992]. This suggests that excessive oxidative stress may limit the growth 
potential of cells under standard conditions. Indeed, it has been shown that MSCs 
cultured in low oxygen outgrow their high oxygen counterparts by at least 2-fold 
[Moussavi-Harami et al., 2004], suggesting that high oxygen levels are stressful to 
MSCs and limit their in vitro growth by inducing senescence. Culture-induced stress 
is probably an important factor affecting the in vitro growth of MSCs, and it is 
possible that preventing oxidative stress might help in overcoming this barrier. 
Lowering incubator oxygen levels may represent an effective and simple means to 
that end, but other modifications of standard conditions, such as the addition of 
antioxidants to the culture medium, might confer additional protection against 
oxidative damage. Moreover, even routine cell culture procedures such as initial cell 
isolation and trypsinization are potential sources of oxidative stress. Such occasional 
stress exposures might impact growth even in cultures exposed most of the time to 
low oxygen conditions.
The attenuation of growth imposed by culture-related stress seriously restricts cell 
yields and may have a negative impact on subsequent differentiation of MSCs and 
chondrocytes.
Recent studies [Moussavi-Harami et al., 2004] have proved that low oxygen 
culture is an effective means to control oxidative stress and to increase the 
proliferative potential of MSCs and chondrocytes destined for grafting procedures. 
Other investigations have demonstrated that a low oxygen atmosphere significantly 
affects rat marrow MSCs’ proliferation, differentiation and mobilization into the 
peripheral blood [Lennon et al., 2001; Rochefort et al., 2006;]. Hypoxic conditions 
have also proved to be necessary to maintain full pluripotency of human embryonic 
cells [Ezashi et al., 2005].
However, additional studies will be needed to determine what are likely to be 
diverse phenotypic effects of oxidative damage on human marrow-derived MSCs.
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1.5 The goals of the present thesis
The driver for this research stems from the ability to create viable three- 
dimensional alginate/hMSCs constructs and to define the optimal culture conditions 
where the cells display the ability to proliferate while retaining their original 
undifferentiated status and multipotentiality.
In order to accomplish this, the investigations of this research have been carried 
out at three levels.
Firstly, studies on the alginate matrix itself were conducted with the intention of 
optimising the carbodiimide coupling reaction between alginate and peptide, in order 
to enhance the efficiency of the derivatisation chemistry and to prepare a three- 
dimensional alginate matrix that permits cell adhesion and cell proliferation. In 
addition, NMR methods and amino acid analysis were performed to help 
characterising the resulting matrix and to quantify the degree of peptide attachment.
Secondly, the effects of some important culture parameters on MSCs’ viability, 
proliferation and metabolism were investigated in a two-dimensional culture 
environment (tissue culture plates). In particular, attention was focused on changing 
medium composition in respect of serum concentration and FGF-supplementation, on 
modifying the plastic surface of the vessels through coating with different 
biomolecules, and on testing different oxygen tensions.
Finally, the cells were combined with the GRGDY-modified alginate matrix and 
the optimal parameters identified in the two-dimensional environment were applied to 
the resulting three-dimensional constructs. Investigations were performed on the 
constructs in order to evaluate the cells ability to retain their initial viability and 
original undifferentiated status, and to determine the degree of cell proliferation.
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2. Materials and Methods
2.1 Human Mesenchymal Stem Cell culture In tissue 
culture vessels
2.1.1 Isolation of human mesenchymal stem cells from frozen 
bone marrow samples
The multipotent Mesenchymal Stem Cells (MSCs) used in this study were 
isolated from frozen human bone marrow samples received from the Department of 
Haematology, UCLH. The use of human clinical samples had been approved by the 
University College London Hospital Ethics of Human Research Committee (project 
reference number 03/0136). The mononuclear cells were isolated from frozen bone 
marrow samples stored in a liquid nitrogen container (Biostore 10) deploying a Ficoll 
gradient.
This procedure is described for a total volume of thawed diluted sample of 120 
mL (typically the amount of the original sample after thawing was around 125-150 
mL, the sample was diluted 1:2 and however only 120 mL of the total diluted sample 
was used).
First of all, 120 mL of the original thawed bone marrow sample was filtered 
through a 40pm nylon cell strainer (Falcon, Bibby Sterilin, Stone, UK). 100 mL of 
the resulting material was transferred in a 250 mL sterile bottle (Nalgene/Fisher) and 
was then rinsed with an equal volume (100 mL) of Dulbecco’s phosphate buffered 
saline without calcium and magnesium (PBS, Biowhittaker, Walkersville, MD, USA). 
6x20 mL aliquots of sterile Ficoll (density 1.077g/mL, Ficoll-Paque Plus, Stem Cell 
Technologies Inc., Vancouver BC) was poured into 6x50 mL centrifuge tubes 
(Coming, Acton, MA, USA) and 20 mL of the diluted bone marrow sample was then 
very slowly added to the edge of each tube such that the sample remained above the 
Ficoll surface. During this procedure the centrifuge tube was held at a sharp, slanted 
angle in order to increase the surface area on the top of the liquid and to create a clear 
phase separation between the Ficoll layer (at the bottom of the tube) and the sample 
(at the top of the Ficoll phase), avoiding mixing of the two layers.
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A 30 minutes centrifugation at 650g, room temperature (20°C), and with no brake 
applied (5 81 OR Centrifuge, Eppendorf AG, Hamburg, Germany) was performed in 
order to fractionate most of the red blood cells to the bottom of the tube, while 
maintaining the mononuclear cells at the interface of the Ficoll liquid. After 
centrifugation, the mononuclear cells were carefully removed from the tube without 
disturbing the Ficoll interface.
Approximately 5-6mL was collected (maximum of lOmL) from each tube and 
transferred into a new 50mL centrifuge tube. The cells were rinsed with 
approximately 40mL of PBS per tube and then centrifuged at 650g for 15 minutes, at 
room temperature (20°C), using a low brake setting. After discarding the 
supernatants, the cell pellets were gently resuspended and pooled together with a total 
growth medium volume of 12mL, and the cell suspension was equally divided into 3 
vented T150 flasks (Coming, 150cm ) already filled with 26mL complete growth 
medium (total volume within each flask was approximately 30mL). The flasks were 
then placed at 37°C in a 5% CO2 humidified incubator (HeraCelll50, Kendro 
Laboratory Products GmbH, Langenselbold, Germany or Galaxy S, RS Biotech 
Laboratory Equipment Ltd., Irvine, Scotland) for 2 days to allow the hMSCs to attach 
to the plastic surface. The spent medium containing non-adherent cells was then 
removed and replaced with fresh complete medium of culture. While waiting for the 
hMSCs to become visible (ca. 7 days) and ready for passaging (ca. 2-3 weeks), fresh 
complete growth medium was added every 4-5 days. After reaching approximately 
70-80% confluency, the cells were trypsinised, counted with an haemocytometer and 
split into the required number of new vented T75 or T 150 flasks in order to have an
"X 9initial cell seeding density (ICD) of 5x10 cells/cm (see sections 2.1.3 and 2.6.2). 
The flasks were labelled as passage 2 (p2) and incubated at 37°C in an atmosphere of 
5% CO2. When the resulting second passage cells were 70-80% confluent, they were 
either passaged again at the same ICD and labelled as passage 3 cells, or frozen in 
liquid nitrogen.
2.1.2 In vitro culture of human Mesenchymal Stem Cells
The in vitro expansion of hMSCs was performed in sterile, polystyrene T150 
tissue culture flasks (150cm2) (Coming Life Science, Coming, New York) with 30mL
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complete growth medium/ flask (0.2mL/cm2). The flasks were factory treated with a 
plasma charge, which introduces a hydrophobic, negatively charged surface. The 
cultures were maintained in a 5% CO2, 37°C humidified incubator and the cells were 
expanded in culture at 70-80% confluence (as described in section 2.1.3) and plated 
in new T150 flasks at the initial cell density of 5x103 cells/cm2 (7.5x105cells/flask). 
The culture medium was removed from the flasks and replaced with fresh and pre­
warmed (37°C) medium (30mL/flask=0.2mL/cm2) every 3-4 days of culture to 
provide the cells with the necessary nutrients and growth factors and to remove 
metabolic products.
Different culture conditions were compared and evaluated in this research, as 
described in section 2.1.5.
2.1.3 Cell expansion in tissue culture vessels
Human MSCs were harvested from their T150 tissue culture flasks with a 
trypsin/EDTA solution.
After removing the spent medium, each flask was rinsed with 20mL PBS without 
calcium and magnesium (O.lmL/cm ) (BioWhittaker) to remove residual serum 
proteins that reduce trypsin activity. Each flask was treated with 6mL (0.04mL/cm ) 
of 0.25% trypsin/0.02% EDTA (Sigma-Aldrich, LTD, Irvine, Ayrshire, UK). The 
enzymatic solution was spread over the whole growth surface and was left in action 
for 5-7 minutes at room temperature (20°C). The flasks were then gently tapped 
against the palm of the hand in order to completely detach the hMSCs from the 
surface of the culture vessel. Trypsin activity was then quenched with 12mL 
(0.08mL/cm ) of complete cell growth medium per flask. Since trypsin is a non­
specific protease that could permeate the cell membrane, the cells were never exposed 
to the trypsin solution for periods longer than 10 minutes. The cell suspensions from 
all individual flasks were combined together and gently mixed with a sterile pipet to 
ensure homogeneity of the final cell suspension. A 0.5mL volume sample was used 
for the determination of cell density with haemocytometer and for the cell viability 
assay with trypan blue dye (section 2.1.3, 2.6.2 and 2.6.3). The cell suspension was 
then centrifuged within a 50mL centrifuge tube at lOOg for 5 minutes. After 
discarding the supernatant, the cell pellet was resuspended with the necessary volume
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of complete cell growth medium. The resulting cell suspension was transferred within 
new T150 tissue culture flasks so that the initial seeding density ICD was 5xl03 
cells/cm2 (7.5x105 cells/flask). The volume of cell suspension within each flask was 
adjusted to a final value of 30mL (0.2mL/cm2) by addition of the necessary amount of 
complete growth medium, pre-warmed at 37°C. The flasks were incubated and re-fed 
with complete cell growth medium as previously described (section 2.1.2).
2.1.4 Creation of a working cell bank
In order to create a supply of low-passage cells for future experiments, a working 
cell bank of fourth passage (p4) hMSCs was created from cells isolated from a frozen 
bone marrow sample.
Five vented T150s of 80-90% confluent cells were harvested and trypsinised as 
described in section 2.1.3. The cells were treated with 6mL of 
0.25%trypsin/0.02%EDTA (Sigma) per flask until the cells had completely detached 
from the cell growth surface (approximately 5 minutes). Complete DMEM medium 
(12mL/flask) was added to quench trypsin activity and the resulting cell suspensions 
were removed from the flasks, pulled together and equally divided into two 50mL 
centrifuge tubes. A 0.5mL volume sample was taken from each tube and used for the 
determination of the cell density with haemocytometer and for the cell viability with 
trypan blue dye, as described in sections 2.6.2 and 2.6.3. The cell suspensions were 
centrifuged at 160g for 5 minutes. After discarding the supernatants, the two cell 
pellets were combined together and resuspended in 4mL of complete DMEM 
medium. Another cell count was performed after centrifugation to confirm the cell 
concentration and ensure that no significant cell loss had occurred during the 
centrifugation step.
3.6mL of complete DMEM medium were added to the resulting cell suspension. 
Finally 1.9mL (20%) of cryopreservation medium containing 75% fetal bovine serum 
(FBS, Biowhittaker) and 25% DMSO (Sigma) were slowly added to the cell 
suspension (final cell concentration = lxlO6 cells/mL). The total cell suspension 
(approximately 9.5mL) was equally aliquoted into 9 cryopreservation vials (Nalgene, 
lmL cell suspension/vial), which were then placed overnight in the -80°C freezer 
within a controlled rate freezer container (Nalgene TM Cryo 1°C Freezing Container,
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-l°C/min=rate of cooling) before transfer into liquid nitrogen (-196°C) for long-term 
storage.
2.1.5 Protocols of hMSCs culture using different basal media, 
different serum and fibroblast growth factor concentrations, 
different coatings and oxygen tensions
Taking into account the lack of a uniform approach for hMSC isolation and 
expansion between laboratories, various culture conditions were compared in this 
research with the purpose of first identifying an optimal laboratory protocol for 
hMSCs expansion with a view to later large-scale production, while maintaining their 
multipotency.
Several culture parameters, including the quality of fetal calf serum, basal 
medium, glucose concentration, bone marrow mononuclear cell plating density, 
hMSC passaging density, and surface characteristics of the tissue culture vessels are 
known to affect the final outcome [Sotiropoulou et al., 2006]. Also the use of basic 
fibroblast growth factor (FGF), the most common growth supplement in hMSC 
culture media, importantly influences cell proliferation and differentiation potential 
[Pitaru et al., 1993; Savion et al. 1996; Majors and Muschler, 1996].
In this study attention was focused on the following parameters:
• Basal cell growth medium
• Fetal bovine serum (FBS) concentration
• Surface coating of tissue culture vessels
• basic Fibroblast Growth Factor (bFGF) supplementation
• Oxygen tension
2.1.5.1 Basal growth medium
Two different growth media were compared for the in vitro expansion of hMSCs.
Complete MesenCult medium, obtained supplementing the basal MesenCult 
medium (Stem Cell Technologies Inc., Vancouver, British Columbia, Canada) with 
10% (v/v) Mesenchymal Stem Cell Stimulatory Supplement (Stem Cell Technologies
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Inc.), 100U penicillin/mL, lOOpL streptomycin/mL (both from BioWhittaker, 
Walkersville, MD, USA) and Ing/mL recombinant human fibroblast growth factor 
(rhFGF) (R&D Systems, Minneapolis Minnesota, USA); and low-glucose (1 g/L) 
Dulbecco’s Modified Eagles Medium DMEM (Biowhittaker), which was 
supplemented with the same reagents (Mesenchymal Stem Cell Stimulatory 
Supplement, penicillin, streptomycin and recombinant human fibroblast growth factor 
(rhFGF)) added in the same concentrations as for the MesenCult medium.
Fourth passage (p4) bone marrow-derived hMSCs were expanded in 12-well 
tissue culture plates with either complete MesenCult medium or complete DMEM 
medium, formulated as described above. In addition, these media were used for the 
cell expansion also in their serum-free formulation, or after addition of only 2% (v/v) 
serum. The Mesenchymal Stem Cell Stimulatory Supplement from StemCell 
Technologies Inc., which was found to consist only of Fetal Bovine Serum 
supplemented with 1-glutamine, was used for the serum-supplementation of both the 
MesenCult and the DMEM media. The cultures were maintained at 5% CO2, 37°C for 
a 12-day period. During the course of the culture, the plates were re-fed every 2-3 
days in order to provide the cells with the necessary nutrients and growth factors and 
to remove metabolic products. The cells were trypsinised at 4 different time-points 
during the culture for the evaluation of the cell density and viability, as measured 
with haemocytometer and trypan blue dye. This experiment was repeated twice, 
always with p4 MSCs; the results of these studies are discussed in section 4.3.
After a few preliminary studies, the basal low-glucose DMEM medium was 
supplemented with 10% (v/v) Fetal Bovine Serum (FBS) screened for hMSCs (Stem 
Cell Technologies Inc.), 2mM 1-glutamine, 100U penicillin/mL and lOOpL 
streptomycin/mL (both from BioWhittaker) and Ing/mL recombinant human 
fibroblast growth factor (rhFGF) (R&D Systems). This was the standard formulation 
for the DMEM medium, which was subsequently adopted for the expansion of the 
hMSCs used in this research, and it will be referred to as “complete DMEM” for the 
remainder of this thesis.
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2.1.5.2 Serum supplementation
2.1.5.2.1 Fetal Bovine Serum concentration
The standard 10% FBS-supplemented complete DMEM formulation was 
compared to DMEM growth medium equally supplemented with 1-glutamine, 
penicillin, streptomycin and recombinant human fibroblast growth factor, but 
supplemented with different (0%, 2% and 15%) FBS concentrations. The serum used 
in this research was fetal bovine serum (FBS) specifically selected by the 
manufacturer (Stem Cell Technologies) for optimal hMSCs growth.
The cells were plated in 24-well plates (ICD=5xl03 cells/cm2 or 9.5x104 
cells/well) and cultured with the different media formulations. The cells were 
harvested at different time-points over the 13-15 days culture period. At each time- 
point the cell density and viability were determined with haemocytometer and trypan 
blue (see sections 2.6.2 and 2.6.3.) and the cell metabolism was evaluated with the 
Nova Biomedical Bioprofile Analyzer (see section 2.6.5). The experiment was 
performed twice and the results obtained for the serum studies are presented in 
section 4.4.1.
2.1.5.2.2 Serum-free media experiment
A preliminary qualitative experiment was performed where hMSCs were cultured 
in different serum-free media, in order to see whether any of these formulations 
permitted, promoted or halted cell growth. The following commercially available 
serum-free media were tested:
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No. Medium M anufacturer Cat. no.
1 CD Hybrid0111 a 
Medium without L- 
glutamine
Gibco 11279-023
2 Stem Pro-34 SFM 
without L-glutamine 
without antibiotics
Gibco 10640-019
3 Protein free Hybridoma 
Medium PFHMII (IX)
Gibco 12040-051
4 Hybridoma-SFM 
serum-free Hybridoma 
Medium
BioWliittaker 12045-084
5 Ultraculture medium BioWhittaker BW12-725F
6 UltraDOMA 
Hybridoma serum-free 
growth Medium,
defined IX
BioWliittaker BW12-723B
7 Knockout D-MEM 
optimised D-MEM 
Medium for ES cells
Gibco 10829-018
8 Ex-cell 325 PF CHO 
scrum-free Medium, 
protein-free
SAFC
Biosciences
14340C
9 Ex-cell 302 CHO 
scrum-free Medium
SAFC
Biosciences
14324C
10 Ex-cell 620-HSF 
hybridoma serum-free 
Medium
SAFC
Bioscicnces
14621C
11 Ex-cell CD CHO 
serum-free Medium, 
chemically defined
SAFC
Biosciences
14361C
Table 2.1: Serum-free media investigated for the expansion of hMSCs in tissue 
culture flasks. Following the manufacturer’s suggestion, the Knockout D-MEM 
medium (medium number 7 on the table) was supplemented with 15% Knockout 
Serum Replacement (Gibco, Cat. No.=10828).
The cells used for this experiment were obtained from a third passage (p3) 
working cell bank. Cryopreservation vials of hMSCs were removed from liquid 
nitrogen storage and were thawed within a 37°C water-bath for exactly two minutes 
and then transferred to T25 tissue culture flaks (Coming, 25cm2). The cells were 
expanded at the standard culture conditions (complete DMEM medium, 5% CO2,
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37°C and 21% oxygen) for two passages before reaching the desired cell number. 
[The cell banking and passaging protocols are described in detail in section 2.1.4 and 
2.1.3 respectively.] The sequential adaptation protocol here described was then 
followed for each one of the 11 serum-free media under investigation and listed in 
table 2.1. Actively dividing, high (> 90%) viability cells were used. Sixth passage 
(p6) cells were inoculated at double the normal seeding density (10xl03 cells/cm2) in 
a 50:50 (v/v) mixture of traditional serum-supplemented DMEM : one of the serum- 
free media investigated. The cultures were monitored until the confluency reached 
approximately 80%. The cells were then sub-cultured into a 10:90 (v/v) mixture of 
serum-supplemented DMEM : serum-free medium. When 80% confluency was 
reached again the cells were sub-cultured into 100% serum-free medium. Two T25 
control flasks were maintained in the standard complete DMEM medium formulation 
throughout the whole experiment. At each expansion passage the cells were split in 
1:2 ratio without performing any cell count with haemocytometer, as the present was 
purely a preliminary exercise performed to obtain information on cell survival and to 
monitor significant cell morphology changes in the different serum-free culture media 
tested.
Light microscopy was used for the qualitative assessment of cell growth, 
proliferation and morphology. In particular, significant change in cell density and cell 
morphology were observed. These results are presented in section 4.4.2.
2.1.5.2.3 Surface coatings of tissue culture vessels
The effects of different surface coatings on the hMSCs proliferation and 
expansion potential were evaluated by comparing the culture within 24-well un­
coated tissue culture plates (353047, Falcon, Beckton Dickinson Labware Franklin 
Lakes, NJ, USA) with the culture of the same cells maintained in 24-well tissue 
culture plates coated by the supplier with either human fibronectin or with a thin 
Matrigel basement membrane matrix layer (Becton Dickinson Labware, Bedford, 
MA). The cells were seeded at an ICD of 5xl03 cells/cm2 (9.5x104 cells/well) and fed 
with lmL complete DMEM/well. The three different coating conditions described 
were also tested using rhFGF-free or serum-free DMEM formulations, or with 
DMEM medium supplemented with different serum concentrations. The cells were 
harvested at different time-points over the 13-15 days culture period. At each time-
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point the cell density and viability were determined with haemocytometer and trypan 
blue (see sections 2.6.2 and 2.6.3) and the cell metabolism was evaluated with the 
Nova Biomedical Bioprofile Analyzer (see section 2.6.5). The experiment was 
repeated twice and the results obtained for the coating studies are presented in chapter 
4.
2.1.5.2.4 Human recombinant Fibroblast Growth Factor 
supplementation
The standard formulation of the complete DMEM culture medium included 
supplementation with Ing/mL human recombinant basic Fibroblast Growth Factor 
(bFGF).
To investigate the effects of bFGF-supplementation on the growth potential of
' i  j
human MSCs, p4 hMSCs were plated at the usual ICD (5x10 cells/cm ) in non­
coated 24-well tissue culture plates and cultured for a 13-day period. The cells were 
expanded in low-glucose (lg/L) DMEM medium in standard culture conditions (10 % 
v/v FBS and 1 ng/mL bFGF supplementation). In addition, hMSCs were cultured in 
the plain basal (serum-free and bFGF-ffee) low-glucose DMEM medium, and in the 
same medium supplemented with increasing serum concentrations (2%, 10% or 
15%). For each serum concentration, both the bFGF-free and the bFGF-supplemented 
conditions were tested. As usual, the cells were re-fed every 2-3 days over the 13-day 
period of culture, thus ensuring the provision of nutrients and growth factors together 
with the removal of metabolic products. The cells were harvested as previously 
described (section 2.1.3) at day 3, day 7, day 10 and day 13 of culture, i.e. when the 
80% cell confluence was reached on the surface of the well plates. At each time-point 
the cells were harvested and assessed for cell count and cell viability as previously 
described (sections 2.6.2 and 2.6.3 respectively), and for each serum and bFGF 
condition a sample of the spent medium was recovered and assessed with the Nova 
Biomedical BioProfiler for the analysis of the cells metabolic activity, following the 
protocol elucidated in section 2.6.5.
The experiment was performed twice and the results obtained for the bFGF 
studies are presented in section 4.5.
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2.1.5.5 5 Dissolved oxygen tension
Where it is not otherwise specified, the humidified incubator for the culture of 
hMSCs was maintained at 5% CO2, 37°C and 21% O2. 21% oxygen levels are 
normally used in standard incubators and standard culture conditions, as they permit 
optimal growth of fibroblasts. However, MSCs live at relatively low oxygen levels in 
vivo [Grant and Smith, 1963; Ishiwaka and Ito, 1998; Harrison et al., 2002; Grigoryan 
et al., 2005], and the hyperoxic conditions employed in standard incubators can cause 
sufficient oxidative stress to induce premature senescence in MSCs, limiting their in 
vitro proliferation potential [Moussavi-Harami et al. 2004]. Modifying the oxygen 
tension is thought to have important effects on MSC growth and proliferation. For the 
purpose of evaluating the effects of oxygen tension on hMSCs proliferation rate and 
metabolism, the above-mentioned standard culture conditions were compared to low- 
oxygen (1% or 2%) and intermediate-oxygen (10%) culture conditions. The cells 
were cultured in 24-well plates and tested for cell proliferation and cell metabolism at 
different time-points in a similar way as for the previous culture conditions examined 
(sections 2.1.5.2, 2.1.5.3 and 2.1.5.4). Each experiment was performed twice and the 
results obtained for the studies on different oxygen tensions are presented in chapter 
4.
2.2. An alternative cell source: cell passaging protocol in tissue 
culture vessels for human Fibroblasts
The human foreskin fibroblasts used in this study (Karocell, Stockholm) were 
kindly provided by Dr. Stephen Minger, Wolfson Centre for Age-Releated Diseases, 
King’s College London. The cell growth medium was Iscove’s modified Dulbecco’s 
medium (IMDM) which had been supplemented by the manufacturer (Invitrogen, 
Paisley, UK) with 4mM glutamine and 25mM HEPES, and then further supplemented 
with 10% heat inactivated foetal bovine serum (Invitrogen, Paisley, UK) and 
lOOU/mL penicillin/streptomycin (BioWhittaker, Walkersville, MD).
As for hMSCs, the fibroblasts were cultured in tissue culture flasks specifically 
treated by the manufacturer in order to encourage cell attachment to the plastic 
surface. The cells were cultured with 30mL medium/T150 flask (0.2mL/cm2) and
74
were usually expanded at a 1:3 split ratio, following the trypsinisation procedure 
already described (see section 2; 1.3). Human fibroblasts were maintained in culture at 
37°C and 5%CC>2 in a humidified incubator.
2.3 Preparation of the alginate scaffold
The matrix used in this research for the three-dimensional studies with 
alginate/cells constructs consisted of sterile GRGDY-derivatised alginate. Alginate 
constructs have been extensively used in cell therapy and tissue engineering 
applications, mainly with secretory cells (e.g. islet cells) or transformed producer-cell 
lines that normally are expanded in suspension cultures [Read et al., 1999; Mullen et 
al, 2000; Tobias et al, 2001]. However, mesenchymal stem cells are anchorage- 
dependent cells that need to interact with a substrate or biomaterial to survive 
[Saltzman, 2000]. Alginate and other hydrogels are unable to specifically interact 
with mammalian cells, due to their hydrophilic nature [Smentana, 1993]. It was 
therefore necessary to chemically modify the alginate hydrogel by covalently binding 
the pentapeptide cell adhesion ligand glycine-arginine-glycine-aspartic acid-tyrosine 
(GRGDY) containing the specific RGD sequence, which has shown to promote 
cellular anchorage and interaction with hydrogels [Rowley et al., 1999; Chung et al., 
2002].
This section describes the preparation of alginate-GRGDY matrices. The 
preparation of alginate constructs including cells is described in section 2.5. A 
schematic representation of the standard alginate derivatisation method used in the 
present research is shown in figure 2.1.
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Fig.2.1: Schematic rqiresentation of the standard alginate denvatisahon procedure 
for the coupling of the GRGDY pentapeptide to sodium alginate.
2.3.1 Reconstitution of the sodium alginate matrix
Sodium alginate (please see section 1.3.4) was the scaffold material investigated 
in the present research.
The alginates used in this research were supplied as sterile freeze-dried products 
by NovaMatrix FMC BioPolymer AS, (Drammen, Norway). Different Pronova 
alginates were tested; the defining characteristics of these biomaterials, such as the 
guluronic acid content and molecular weight, were provided by the manufacturer (see 
table 3.2).
Vials of each sterile alginate were reconstituted as required with sterile filtered 
normal saline solution or MES/NaCl buffer, and mixed until visibly homogeneous 
prior the addition of the sterile filtered reactants for the derivatisation procedure (as 
described in section 2.3.2).
The normal saline solution used for the alginate reconstitution consisted of 0.9% 
w/v NaCl (Sigma) in cell culture grade water. Alternatively, the alginate was 
reconstituted in 0.1 M 2-(N-Morpholino)ethanesulfonic acid (MES) buffer (Lancaster, 
Morecambe, UK) with 0.3M NaCl.
Before adding the alginate, the pH of the normal saline and the pH of the 
MES/NaCl buffer were respectively adjusted to 7-7.4 and 6.5 with 0.1M NaOH 
obtained from 1M NaOH (Sigma) after 10-fold dilution. The alginate was prepared at 
a final concentration of 1% weight/volume (w/v), which was isotonic for subsequent 
addition of the cell suspension. At this concentration, the water-soluble alginate was 
completely dissolved and solubilised after overnight mixing at room temperature 
(20°C) on a platform roller (Roller Mixer SRT2, Bibby Stuart Scientific, Stone, UK).
2.3.2 Alginate derivatisation with GRGDY pentapeptide
Alginate hydrogels are able to discourage cell adhesion due to the hydrophilic 
nature of the polymer. In previous studies the attachment and proliferation of mouse 
skeletal myoblasts has been improved after incorporation of the pentapeptide 
GRGDY onto the polysaccharide chain of the alginate [Rowley et al., 1999; Rowley 
and Mooney, 2002]. In this research, sodium alginate was covalently modified
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utilizing aqueous carbodiimide chemistry in order to incorporate the pentapeptidic 
GRGDY sequence. The GRGDY pentapeptide was conjugated to the alginate’s 
carboxylic acid groups on the uronic acid units of the polymer backbone through the 
terminal amine of the peptide, as it is schematically represented in Figure 2.2.
A water-soluble carbodiimide, 1 -ethyl-(dimethylaminopropyl) carbodiimide 
(EDC), (Sigma-Aldrich Co., Ltd., Gillingham, Dorset, UK), was used to form amide 
linkages between amine containing molecules and the carboxylate moieties on the 
alginate polymer backbone. The amine-reactive O-acylisourea intermediate formed is 
prone to hydrolysis and thus will regenerate its carboxyl group, unless it encounters 
an amine. The co-reactant N-hydroxy-sulfosuccinimide (sulfo-NHS), (Pierce, 
Rockford, IL) was therefore added to stabilise the reactive EDC-intermediate against 
the competing hydrolysis reaction, raising the efficiency of amide bond formation. 
The amine-reactive intermediate was this way converted to a sulfo-NHS (N- 
hydroxysulfosuccinimide) ester, which then reacted with the amino terminus of the 
peptide. The EDC was converted to urea.
The peptide used in this research was supplied by two different suppliers, 
Neosystem Groupe SNPE, Strasbourg, France and Albachem, Edinburgh, and the 
whole procedure was performed in totally aseptic conditions, thus optimising the 
potential for the final derivatised product being sterile. A total of 12 derivatisation 
experiments, investigating different alginate types and alternative derivatisation 
procedures, were performed throughout the research.
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Fig. 2.2 : Overall reaction for the alginate derivatisation with GRGDY 
pentapeptide. Amide bond formation is mediated by the carbodiimide through the 
carboxyl group on the uronic acid units of the alginate and the N-terminal amine of 
the pentapeptide. Adapted from Rowley, 1999.
The reaction was carried out in a 50mL sterile tube (Bibby Sterilin Ltd, Stone, 
UK) on a platform roller (Roller Mixer SRT2, Bibby Stuart Scientific, Stone, UK) in 
the dark, to avoid potential denaturation of the reactants involved in the reaction.
Particular care was taken in maintaining the temperature constant at room 
temperature (approximately 20-22°C) throughout the whole alginate derivatisation 
procedure. This was necessary because the temperature can significantly affect the 
carbodiimide reaction by modifying the reaction rates, the molecular mixing and the 
diffusion of molecules across the dialysis membrane [Markusen, 2005]. First, the 
sulfo-NHS was added to the alginate solution and mixed for 5 minutes; the EDC 
carbodiimide was then added to the solution and allowed to react on the roller for 30 
minutes. Finally, the GRGDY pentapeptide was added to the tube and the resulting 
solution was mixed for a predetermined time period, typically 20 hours.
it
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2.3.2.1 Concentration of reactants
The concentration of reactants involved in the alginate derivatisation with 
GRGDY pentapeptide has been determined in previous studies [Rowley et al, 1999] 
based upon the efficiency of the peptide incorporation onto the uronic acid units of 
the alginate. These concentrations have been estimated for 1 mg of alginate to be 
38pg of sulfo-NHS, 67pg of EDC and 1 pig of pentapeptide.
The number of uronic acid units per mg of alginate is expected to vary according 
to the type of alginate and the alginate manufacturing and purification procedures 
employed. Unfortunately, the number of uronic acid units per mg of alginate has 
neither been determined in previous studies nor it is normally provided by alginate 
manufacturers. Moreover, in his studies Rowley used a radioactive label for 
measuring the amount of peptide incorporated into the alginate, which was not 
feasible to implement for this project. As a result, it was necessary to determine the 
concentration of reactants needed in this system. A series of range finding 
experiments has been previously performed in order to test several reactant 
concentrations for the carbodiimide reaction [Markusen, 2005]. In the present 
research, attention was focused on the use of highly purified alginate (Pronova 
SLG100), with high (approximately 148mPa-s) viscosity. In her studies [Markusen, 
2005] Markusen showed that 9X and 12X were optimal reactants concentrations to 
achieve successful peptide incorporation onto the Pronova SLG100 alginate polymer. 
These concentrations were multiple of those defined by Rowley [Rowley et al,
1999], more specifically 9X and 12X corresponded respectively to nine times and 
twelve times the reactants for lmg of alginate (please see table 2.2). The reactants 
used for the carbodiimide reaction (sulfo-NHS, EDC and GRGDY peptide) were 
individually weighed and dissolved in a small volume (500pL) of water for cell 
culture applications (WFI, BioWhittaker) to the desired concentrations. The dissolved 
reactants were then filtered through 13mm syringe filters (0.2pm pore size) and 
finally added to the 1% w/v alginate solution (typical alginate volumes were 3-12 
mL) in the reaction vessel as described in section 2.4.2. The sulfo-NHS and EDC 
were filtered using a low binding polytetrafluoroethylene (PTFE) membrane (Millex- 
LG, Millipore) whereas a low binding polyvinylidene fluoride (PVDF) membrane 
(Durapore, Millex-GV, MilliporeCorp., Bedford, Massachusetts, USA) was used for 
the filtration of the GRGDY peptide.
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Reactants’
ratio
EDC
concentration
(P€)
Sulfo-NHS
concentration
(Pg)
GRGDY
concentration
(P€)
IX
(Rowley’s)
67 38 1
9X 603 342 9
12X 804 456 12
Table 2.2: Ratios of the reactants concentrations as used by Rowley (1998) and in 
the present research (9X and 12X) for the alginate derivatisation procedure. The 
values are expressed per mg of alginate.
2.3.2.2 Dialysis
After completion of the 20-hour reaction, a dialysis cycle was performed in order 
to reduce the levels of residual cell-toxic reactants, such as EDC, leftover from the 
carbodiimide reaction. The alginate-GRGDY was therefore dialysed for 5 days in 
Reverse Osmosis (RO) purified water (MilliQ Synthesis A 10, Millipore, Molshein, 
France) filtered through a UV irradiated 0.22 pm filter (Acropak 500 capsule, Pall, 
Ann Arbor, Michigan) using gamma-irradiated dialysis cassettes (Slide-A-Lyzer, 
Pierce, Rockford, Illinois) with a molecular weight cut-off (MWCO) of 3.5 kDaltons. 
The alginate was injected into the pre-wetted dialysis cassettes using a 20mL Leur- 
lock syringe with a 21 gauge needle (Becton Dickinson UK Ltd., Cowley, UK). The 
dialysis process deployed 5 litres beakers (Azlon, bibby Sterilin Ltd., Stone, UK) 
filled with 5 litres of RO purified and filtered water. The water was constantly mixed 
at low speed (approximately 80-120 rpm) and was changed every 12 hours, and the 
whole procedure was performed avoiding direct light exposure, at 20°-22°C, within a 
laminar floor hood (LFH). All aseptic operations were conducted using sterilized 
equipment.
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2.3.2.3 Lyophilisation
During the 5-day dialysis cycle a significant influx of water into the dialysis 
cassette was observed. As a result, the final alginate-GRGDY appeared to be over­
diluted. It was therefore necessary to increase the resulting alginate concentration to 
reach the desired 1% w/v final concentration, in order to allow addition of the cell 
suspension. Previous solutions to this problem were investigated [Markusen, 2005] 
including the re-suspension of the cells in a very small volume of culture medium 
(e.g. lOOpL) before addition to the alginate, and the utilisation of solid polyethylene 
glycol (PEG) crystals (Sigma P-2139; Fluka Chemie no.94646) or Sterile Slide-A- 
Lyzer® concentrating solution (Pierce, identity of which was proprietary) to 
concentrate the alginate-GRGDY inside the dialysis cassette after completion of the 
dialysis process. However, these methods had important limitations, leading either to 
the formation of hydrogels with low strength and amorphous shape, or requiring 
excessive handling and non-aseptic manipulations. For this reason lyophilisation, 
which requires reduced aseptic manipulations, was adopted as the method for the 
concentration of the alginate-GRGDY, even though a long lyophilisation procedure 
(typically 2 days) was required in order to increase the alginate’s concentration to the 
desired 1% w/v final concentration required. After the 5-day dialysis procedure, the 
alginate-GRGDY was removed from the dialysis cassette using a 50mL Luer-Lok 
syringe with a 21 gauge needle (Becton Dickinson), while air was injected into the 
cassette to prevent damage to the dialysis membranes. The alginate-GRGDY was 
aliquoted into 75x25mm sterilised soda glass vials (Samco, LIG Supplies Ltd., 
March, UK) which were then covered with sterilised aluminium foil, loaded onto a 
tube rack and submerged in liquid nitrogen for 10 minutes. Particular care was taken 
during the freezing step in order to prevent entering of the nitrogen into the vials. The 
vials of frozen alginate were then placed onto the freeze drier chamber (Edwards 
Freeze Dryer) pre-cooled at -60°C. The aluminium foil was removed from the vials 
and the chamber was sealed with the cover containing a thin layer of vacuum grease 
(Dow Coming high vacuum grease, Dow Coming Corp, Midland, Michigan, USA). 
In order to prevent an increase in temperature above -60°C within the vials, the 
vacuum pump for the chamber was immediately turned on and set up at an initial 
vacuum of approximately 0.2-0.4 mbar. The lyophilisation was carried out for two 
days, after which the vacuum pressure had decreased to 0.6-0.8 mbar, indicating that
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the alginate was completely dry. The vacuum was then shut off and the chamber was 
slowly vented through a 0.2pm PTFE filter (Midisart, Sartorius AG, Goettingen, 
Germany). The vials were then removed from the chamber, covered with autoclaved 
aluminium foil, transferred to the laminar flow cabinet and covered with sterilised 
caps. The resulting freeze-dried alginate-GRGDY was either stored at -20°C in the 
dark until use, or immediately reconstituted and used for the preparation of 
cells/alginate-GRGDY three-dimensional constructs.
2.3.2.4 Alginate concentration with polyethylene Glycol (PEG) solution
Concentration of the alginate-GRGDY with PEG Slide-A-Lyzer concentrating 
solution (Pierce) was investigated as an alternative method to the lyophilisation 
procedure described in the previous section. This alternative concentration procedure 
was performed on a small amount of SLG100 alginate-GRGDY (9X reactants 10X 
peptide) that was left inside the dialysis cassette after completion of the 5-day dialysis 
cycle. The concentration of the resulting alginate-GRGDY solution was calculated by 
measuring the total volume inside the cassette and by weighing the cassette 
containing the alginate-GRGDY throughout the whole procedure. The cassette was 
placed in a sterile plastic bag containing the PEG solution and the weight was 
monitored at small intervals, making it possible to estimate when the concentration of 
the alginate-GRGDY had reached 1% w/v. The cassette was then removed from the 
PEG concentrating solution, and the alginate-GRGDY solution was extracted from 
the cassette with a 50 mL syringe fitted with a sterile 21 gauge needle. The resulting 
alginate-GRGDY solution was then either immediately used for the preparation of 
cells/alginate three-dimensional beads (as described in section 2.5.3), or frozen and 
stored at -20°C, covered with aluminium foil, for subsequent use (see flow chart in 
chapter 3).
2.3.2.5 Reconstitution of lyophilised alginate-GRGDY
After lyophilisation, the derivatised alginate was typically reconstituted in normal 
saline solution (0.9% NaCl in cell culture grade water), in order to achieve a final 1% 
w/v alginate concentration, which was isotonic for subsequent addition of the cell 
suspension. The extensive dialysis cycle (5 days) caused removal of the majority of
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the sodium ions and subsequently protonation of the carboxyl groups on the GRGDY- 
derivatised alginate polymers, converting the alginate into water-insoluble alginic 
acid (Doumeche, 2004). To help the dissolution of the resulting alginic acid, the 
necessary amount of 1M NaOH (Sigma) was added to the normal saline solution used 
for the alginate reconstitution. Typically 0.75-1.0mL of normal saline supplemented 
with 35-50pL of 1M NaOH were used to reconstitute each individual vial of the 
lyophilised alginate.
After reconstitution with normal saline solution the alginate-GRGDY solution 
was stored in the dark at +4°C until use.
2.4 Characterisation of the alginate matrix
Amino acid analysis and Nuclear Magnetic Resonance (NMR) were employed for 
the characterisation of the alginate matrix prepared as described in section 2.3. Mass 
Spectrometry and ultraviolet (UV)/visible spectroscopy were performed on the 
GRGDY peptide supplied by Albachem Limited in order to measure the amount of 
peptide added to the reaction vessel during the alginate derivatisation. These 
characterisation studies on the alginate matrix were carried out in collaboration with 
Emily Culme-Seymour (Department of Chemistry, UCL) and the results obtained are 
presented in chapter 3.
2.4.1 Quantification of amino acids in the alginate-GRGDY 
matrix
Amino acid analysis is a useful tool for analysing any amino acid containing 
compound, and provides a quantitative result of exactly how much of which amino 
acid is present. The diagram in Figure 2.3 describes how the analysis is carried out.
The intact protein is firstly hydrolysed with 6 M HC1 for 1 to 4 days at 110°C, 
producing a solution of the component amino acids. These amino acids are then 
separated by ion exchange chromatography: the amino acids are applied at pH 3 to a 
column made of sulfonated polystirene (a cation exchanger), onto which they all bind, 
and subsequently they are eluted off the column in sequence via increasing the pH.
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First off are the acidic amino acids (e.g. D), then neutral (e.g. G), then aromatic, due 
to additional hydrophobic interactions with the aromatic ring (e.g. Y), and finally 
basic (e.g. R). After being eluted off the column, each amino acid is visualised by 
reaction with ninhydrin: the adducts that are produced in the reaction coil can be 
detected by a spectrophotometer (^max = 570 nm), and ultimately quantified by 
comparison with a calibration mixture of amino acids.
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Figure 2.3: Schematic 
flow diagram of amino acid 
analyser, highlighting the 
ion-exchange 
chromatography and the 
ninhydrin detection.
(Picture sourced from
http://www,altabioscience.b
ham.ac.uk).
Light source 
at 440 and 540 nm
Amino acid analysis was employed in this project to evaluate the degree of the 
peptide attachment on the alginate polymeric chain after completion of the coupling 
reaction described in section 2.3. The analysis was performed by Alta Bioscience at 
the University of Birmingham. Unopened vials of sterile alginate-GRGDY from 
storage after lyophilisation were submitted for analysis.
2.4.2 Nuclear Magnetic Resonance (1H NMR)
Nuclear Magnetic Resonance (*H NMR) was performed to characterise the 
alginate matrix.
NMR is a procedure that, taking advantage of the magnetic properties of nuclei, 
allows for the identification of each atom and each functional group in a pure
85
molecule. It shows how many atoms of each type and what atom environments exist 
within the sample under analysis.
All the protons surrounding the five carbons on the ring of either the G- or M- 
unit in alginate are detectable by NMR spectroscopy. However, the signals from the 
protons on four of the carbons overlap largely, due to the similarities between their 
respective environments. The only signal that is visible derives from the anomeric 
protons on both of the units at position C-l. These are the only protons that are 
directly adjacent to two oxygen atoms, electronegative atoms that shift the signal 
from the anomeric proton slightly downfields, away from the bulk signal from the 
alginate, thus making the signal visible. The size of the shift of the anomeric protons 
depends on their environment regarding both the particular unit it is from, as well as 
the neighbouring unit. A proton on a G-unit positioned next to a M-unit will be in a 
different environment (and so a different shift) than a proton on a G-unit positioned 
next to another G-unit.
The block structure and molecular weights of a range of sodium alginates has 
previously been analysed via a range of techniques, resulting in information about the 
M-unit to G-unit ratio and the distribution of the uronic acid residues [Johnson et al, 
1997]. One major problem of the alginate is its high viscosity and large molecular 
weight, resulting in a broad NMR signal. Johnson and colleagues (1997) thus adapted 
a method to reduce the viscosity of the alginate before NMR analysis from the work 
of Haug et a l 1966 and Grasdalen et a l 1979, to produce a visibly more refined 
alginate signal.
The protocol utilised in the work presented here was adapted from the method 
described by Johnson et a l , 1997. Firstly, acid hydrolysis was performed on the 
alginate sample: the alginate was dissolved in distilled water and the pH was adjusted 
in two steps to the final value of 3.6 by dropwise addition of 1M HC1, followed by 
addition of 0.05M H2SO4. The hydrolysis was performed within an oil bath at 120°C 
under reflux. The solution was then cooled to room temperature prior to the freezing 
in liquid nitrogen, and the resulting material was lyophilised overnight.
*H NMR was performed on Pronova sodium alginate samples as follows: the 
alginate sample (approximately 12 mg) was dissolved in 2 mL of deuterated water 
(D2O) and filtered through cotton wool. The alginate solution was brought to 358°K 
within a NMR glass tube over a 15 minutes period, and the proton spectrum of the
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solution was recorded using a Brucker AMX 400 spectrometer (Bruken Spectrospin), 
with a 30° pulse sequence and with water suppression.
In order to determine the optimal NMR protocol, giving spectra with clear signals 
and allowing to gain accurate integral values of the alginate and tyrosine peaks, a 
series of experiments were performed with partially hydrolysed alginate and tyrosine. 
The same technique described above was performed on the alginate dissolved in 
deuterated water (D2O) after addition of a tyrosine solution in D2O. The 1H NMR 
spectrum was recorded as described above.
!H NMR was performed following the same procedure also on the alginate 
resulting after derivatisation with the GRGDY pentapeptide. In order to aid 
dissolution, deuterated sodium hydroxide (NaOD) was added to the alginate-GRGDY 
solution under Argon atmosphere. The material was then sonicated, heated and 
filtered through cotton wool and was then ready for the acquisition of the spectrum, 
which was recorded as described above.
2.4.3 Mass spectrometry (MS)
Mass Spectrometry (MS) is an analytical tool used for measuring the molecular 
mass of a sample. It is most generally used to find the composition of a physical 
sample by generating a mass spectrum representing the masses of sample 
components. MS can have many different applications, including amino acid 
sequencing and analysis of proteins, peptides and oligonucleotides. As such, it can be 
employed to obtain sequence confirmation or de novo characterisation of peptides, or 
to obtain accurate molecular weight measurement in order to determine the purity of a 
sample and to verify amino acid substitutions in the sample.
Structural information can be obtained by analysing the sample’s mass spectrum, 
which is measured by a mass spectrometer.
In this research Mass Spectrometry was performed to obtain information on the 
chemical structure and amino acid composition of the GRGDY peptide supplied by 
Albachem Limited. Mass spectra were obtained through the UCL Mass Spectrometry 
Department, and the results obtained are presented in section 3.3.1.1.
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2.5 Preparation of alginate/cells constructs
This section describes the preparation of the cells/matrix three-dimensional 
constructs. Alginate coupled with the GRGDY pentapeptide and prepared as 
described in section 2.3 was used as scaffold biomaterial.
The selected cells were harvested from their culture in tissue culture flasks and 
counted as described in sections 2.1.3 and 2.6.2 prior to the addition to the alginate 
matrix.
Non-derivatised alginate (alginate which had not been reacted with the GRGDY 
peptide) was used for the preparation of cells/non-derivatised alginate constructs 
serving as controls.
2.5.1 Preparation of the cell suspension for mixing with the 
alginate solution
The cells used for the preparation of three-dimensional constructs with the 
alginate-GRGDY matrix were harvested from their tissue culture flasks and 
trypsinised as described in section 2.1.3.
After trypsinisation, the cell suspensions from individual flasks were combined 
together in 50mL centrifuge tubes. A small sample was removed from the cell 
suspension and analysed with a haemocytometer for the determination of the cell 
density. The cells were then centrifuged at 100-160g for 5 minutes. After removal of 
the supernatant, the cell pellet was resuspended with cell growth medium to the 
desired concentration. At this stage of the procedure it was necessary to completely 
remove the trypsin/EDTA solution from the centrifuge tube, in order to prevent 
chelation of divalent ions such as calcium by residual EDTA present in the 
trypsinised cell suspension. Such chelation would have caused a reduction of the ratio 
of idivalent/monovalent ions, consequently resulting in the undesirable dissolution of 
the alginate hydrogel. When particularly small working volumes were used, a second 
centrifugation was performed in order to resuspend the cells in a larger volume (e.g. 
5-7mL) of culture medium to further dilute the residual trypsin/EDTA solution. After 
this second centrifugation step, the supernatant was removed and discarded and the
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cell pellet was finally resuspended in the required small volume of culture medium 
prior to being mixed into the matrix solution.
2.5.2 Cross-linking solution
A 1% w/v calcium chloride (Sigma) solution in normal saline solution was used 
to cross-link the alginate matrix during the fabrication of three-dimensional 
cells/alginate beads or sheets. 0.1M NaOH was used to adjust the pH of the CaCI2 
solution to 6.5-7. The resulting solution was sterile-filtered through a 0.22 pm 
cellulose acetate membrane (Nalgene) prior to use.
2.5.3 Preparation of alginate/cells beads
The selected cells were combined with the alginate matrix in three-dimensional 
spherical-shaped beads with a final diameter of approximately 2-2.5 mm. Typical 
combined matrix/cells working volumes were 0.2-1.2mL. The final matrix/cells beads 
consisted for 25% v/v of the resuspended cell pellet and the remaining 75% v/v was 
the matrix solution.
The fabrication of beads was preferred to the preparation of other three- 
dimensional constructs, such as tubes or sheets [Markusen, 2005]. The preparation of 
small spherical beads proved to be an easier and more rapid method to produce high 
numbers of multiple individual units usable for the evaluation of the cell growth and 
viability at micro-scale level. After trypsinisation the cells were homogeneously 
resuspended and mixed with the alginate to the final alginate concentration of 1 % w/v 
and final cell concentrations ranging from 2xl06 to lxlO7 viable cells/mL. The 
alginate/cells mixture was drawn into a lmL syringe and then very slowly syringed 
through a sterile 0.1mm diameter blunt needle. During this process small 
beads/droplets were dripped into the CaCk cross-linking solution. The beads were left 
in the cross-linking solution for 15-20 minutes and were then collected by pouring the 
CaCb cross-linking solution into a previously autoclaved metal strainer. The beads 
were then rinsed with culture medium within a Petri dish in order to reduce the 
residual CaCl2 levels. Finally the beads were carefully transferred into the microwells
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(1 bead/well) of 24-well ultra-low attachment plates (Costar, Coming Life Sciences, 
Coming, New York). The beads were cultured at required conditions (selected 
medium of culture, tissue culture plates, temperature and CO2), depending on the 
particular cell type under investigation and were re-fed every 3 to 4 days with fresh 
growth medium (lmL/well). Each alginate/cells beads experiment was repeated 
twice, and the results of these studies are described in chapter 5.
A schematic of the beads fabrication is shown in figure 2.4.
2.5.4 Preparation of alginate/cells disks
The preparation of three-dimensional alginate/hMSCs disks (or layers) was 
performed with the purpose of investigating the possible detrimental effects of the 
high molar concentration of the cross-linking solution on the cells after instantaneous 
immobilisation within the alginate matrix. The fabrication of alginate disks involves a 
two-step process, which makes it possible to de-couple the alginate preparation and 
the cell seeding. Firstly, the alginate is layered on top of Millipore Millicell 
transwells, which are placed in the wells of tissue culture plates pre-loaded with the 
CaCh solution. After formation of the alginate disks (approximately 1 hour), the cell 
suspension is added on top of the alginate layer and the cross-linking solution is 
replaced with growth medium. The preparation of alginate/cells disks is represented 
in figure 2.5.
Disks were prepared with either plain Pronova SLG100 alginate or SLG100 
alginate derivatised following the standard procedure (see section 2.3.2) with 9X 
reactants and 32X peptide (see table 2.1). Two different types of transwells were 
used: Millipore Millicell-PCF 3pm membrane, 12mm diameter (small sheets), 
cultured in 24-well ultra-low attachment tissue culture plates (Costar, Coming Life 
Sciences, Coming, New York), and Millipore Millicell-CM transwells 0.4pm 
membrane and 30mm diameter (big sheets), cultured in 6-well ultra-low attachment 
tissue culture plates (Costar, Coming).
lOOpL and 250pL of alginate were added to each well respectively. After 
trypsinisation, p5 hMSCs were counted with an haemocytometer as previously 
described (see section 2.6.2), resuspended in growth medium and seeded on top of the 
alginate layers within the transwells. Initial seeding densities were 5x104 cells/cm2
90
(corresponding to 9xl04 cells/transwell) for the small disks, and 3.3x104 cells/cm2 
(corresponding to 3.12xl05cells/transwell) for the bigger transwells. The resulting 
hMSCs/alginate disks were cultured at 37°C and 5% CO2 with 1 mL and 3 mL of 
complete DMEM respectively. The growth medium was replaced with fresh complete 
DMEM every 3-4 days. Each alginate/cells disks experiment was repeated twice, and 
the results obtained from these studies are presented in chapter 5.
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2.5.5 Release of cells from matrix using trisodium citrate 
solution
After incorporation of the cells in the alginate matrix and preparation of the three- 
dimensional constructs, release of the cells from the alginate hydrogel was necessary 
in order to be able to evaluate the alginate matrix for cell density and viability.
Trisodium citrate, a chelator of calcium ions, was used to reverse the cross-linking 
of the alginate molecules and dissociate the calcium ions from the alginate hydrogel 
[Read, 2001]. Previous studies have shown that the cell viability is not affected by 
cell exposure to a 0.1M trisodium citrate solution in complete DMEM [Markusen, 
2005]. Such a solution was therefore prepared for the dissociation of the cells/alginate 
constructs. The samples were incubated with the chelating solution for 10-15 minutes 
at room temperature and the resulting cells/alginate suspensions were thoroughly 
mixed to ensure homogeneous single cell suspension prior to the assessment of the 
cell density and viability with haemocytometer and trypan blue dye.
92
2.6 Methods of cells and matrix/cells constructs characterisation
2.6.1 Light microscopy for visualisation of cell morphology and 
cell growth
An inverted light microscope was used at 100-400X magnification for visualising 
and monitoring cell growth, both in tissue culture flasks, tissue culture plates and 
within three-dimensional alginate constructs. The microscopical observation allowed 
the evaluation of the cell morphology, to determine whether the cells were rounded, 
or elongated, spindle-shaped, and well networked together. The microscopical 
analysis was also used to determine the degree of confluency and to evaluate the 
presence of actively dividing cells, indicating cultures in exponential growth phase. 
Finally, the microscopic evaluation of the culture samples permitted to detect the 
presence of cellular debris, indicating cell death in the medium of culture.
The cells usually grow over time increasing in number and spreading throughout 
the plastic surface of the tissue culture vessel. Harvesting and trypsinisation of the 
cells was performed at 70-80% confluency in order to avoid formation of cell 
aggregates and to facilitate the detachment of single cells from the cell growth 
surface.
The colour of the spent medium was observed as an index of the healthy state of 
the cultures. The medium of culture appeared orange/red (basic) when healthy 
respiring cells released CO2 and metabolic waste products such as ammonium ions.
On the other hand, the medium of culture appeared red/purple when cell growth was 
poor and cell density low. Finally, a yellow (acidic) and turbid spent medium 
suggested the presence of eventual micro-organisms contaminating the culture.
2.6.2 Cell count with haemocytometer
A cell count with haemocytometer was performed to determine the density of the 
cell suspension at each passage. For this purpose, after trypsinization and quenching 
with complete medium, a small sample of the cell suspension (typically 0.5mL) was 
removed and diluted 1:2 with trypan blue dye (BioWhittaker, Walkersville, MD, 
USA). To improve the accuracy of the cell count the diluted cell suspension was 
gently pipetted until complete homogeneous mixing. Typically 20pL of sample were
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placed under a cover slip on the haemocytometer. The cells were counted in the grid 
that was etched onto the surface of the haemocytometer. The cell count was 
performed three times for each sample and the average value was used for the 
calculation. The total number of cells/mL was determined by multiplying the total 
cells counted in 10 squares by 1000 times the trypan blue dilution factor (2), as 
summarised in the equation:
Average number of cells in 10 squares x 1000 x Dilution factor (2) = Number of
cells/mL
The multiplication factor of 1000 was obtained from the volume of 1mm3 
contained in the counting grid (lOsquares x 1mm x 1mm x 0.1mm) and converted to 
mL (1mm = 0.00lmL) for the original sample.
The homogeneity of the cell suspension affected the accuracy of the cell count. 
Thorough pipetting was performed to ensure homogeneity of the cell suspension prior 
cell enumeration. However, the presence of occasional aggregates within the cell 
suspension may have led to lower results than actual numbers, as ultimately this 
procedure was dependent on the age of the culture, effective trypsinisation and the 
operator’s technique. In order to decrease statistical error due to small sample size, 
between 100-200 cells were normally counted over the 10 squares of the 
haemocytometer grid for each replicate.
2.6.3 Cell viability with trypan blue
The exclusion assay with trypan blue dye was performed for the assessment of the 
cell viability. This technique is one of the most common methods used to assess cell 
viability [Patterson, 1979]. Trypan blue is a small molecular weight dye that stains 
the cells in their cytoplasmic region. At each harvesting step during cell expansion, a 
0.5 mL sample of the cell suspension was removed after trypsinisation and quenching 
with complete medium, and then diluted 1:2 with trypan blue dye for the 
determination of cell viability. When the cell suspension was diluted with the dye, the 
live cells with an intact cell membrane excluded the dye (unstained, bright cells),
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whereas the dead cells with a permeable membrane allowed the dye to enter and 
colour the cells (stained, blue cells).
The efficacy of the assay is time-dependent, since after 15 minutes the dye can 
permeate live cells together with the dead ones [Veckeneer et al., 2001]. For this 
reason the cell count was always performed immediately after addition of the dye to 
the cell suspension. The viability of the cell suspension was determined by the 
equation:
Percentage of viable cells = (Number of live cells/Total number of cells)xl00
2.6.4 Calculation of cell growth rates
Cell growth typically exhibits a characteristic growth curve, as seen in figure 2.6. 
Cells progress through a consistent pattern comprising four main phases, including an 
initial lag phase, where the cells become accustomed to the new environment, a 
period of logarithmic growth in which the number of cells increases exponentially, a 
stationary phase (the plateau phase) in which the rate of cell proliferation slows down, 
and a final decline phase, characterised by cell death caused by depletion of essential 
nutrients or by the toxic metabolic by-products built-up in the culture medium.
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Fig. 2.6 : Growth phases of cells in culture [Palsson and Bhatia, 2004].
The cells were trypsinised and counted using a haemocytometer according the 
standard protocol described in section 2.6.2 in order to determine the initial and final 
cell densities (Xo and X).
The population doubling level (PDL) and the doubling time Td (hours) of the cells 
were then calculated as follows:
PDL = logio(X  / Xo) / logio(2)
Td = T / PDL,
where T (hours) is the total length of the culture.
For cells maintained in a closed system, such as the tissue culture flasks or plates 
used in this research, the cell growth can be described as:
dX / dt = pX
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which, integrating for the initial concentration X = Xo at t = 0 becomes:
X = Xo exp (pt).
When the cell population increases from Xo to 2Xo in the doubling time Td, the 
equation becomes:
2Xo = X 0 exp (pTd)
which can also be written in the following form:
Td = ln(2) / p (Doran, 1995; Butler, 2004).
The cells growth rate p (hours'1) was calculated using the following equation:
p = In (2) / Td (Doran, 1995; Butler, 2004).
which can also be expressed as follows:
p = 2.3* logio (X /X o )/T
The growth rate p, the PDL and the doubling time Td were calculated as described 
in this section for the characterisation of the hMSCs cultured in this research in 
monolayer, under the different culture conditions described in section 2.1.5. All these 
parameters were determined at selected time points over a total culture period of 13- 
15 days. In addition, in order to provide a more complete cell characterisation, the 
cell metabolism was evaluated from the spent medium recovered from the wells of 
the tissue culture plates. The spent medium was analysed with the Nova Biomedical 
Profile Analyzer, and the exact volume of the medium recovered at each time point 
was used as a correction factor for the calculation of the glucose consumption and 
lactate production (as described in section 2.6.5). The results obtained from the 
hMSCs growth and metabolic studies are presented in chapter 4.
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2.6.5 Nutrient and metabolite analysis with Nova Bioprofiler
The growth medium recovered at different time-points during cell culture was 
analysed, immediately after removal from the tissue culture plates, with the Nova 
Biomedical BioProfile 400 analyzer. Samples of growth medium were taken during 
the experiment and the glucose and lactate concentrations were measured afterwards 
with the BioProfiler’s sensors and used for the determination of glucose consumption, 
lactate production and specific glucose consumption rate. Only one sample per 
condition was taken and measured with the BioProfile analyzer for the metabolic 
analysis data sets presented in chapter 4.
2.6.5.1 Glucose and lactate biosensors in the Nova Biomedical BioProfiler
Potentiometric-based electrodes measure charged ions and have a sensing 
membrane that is selective to the ionic species being measured. They develop a 
voltage proportional to the concentration of the measured ionic activity. The basic 
amperometric electrode is the oxygen electrode, which consists of an oxygen- 
permeable membrane covering a platinum cathode. The Nova Biomedical 
BioProfiler’s glucose and lactate biosensors are amperometric electrodes that have 
immobilized enzymes in their membranes. They develop a current proportional to the 
substrate being measured, and can therefore be used to quantitate the metabolite 
concentration.
2.6.5.2 The glucose sensor and determination of glucose consumption
Glucose oxidase is bonded to a polymeric membrane substrate in the BioProfiler’s 
glucose sensor. The enzyme catalyses the oxidation of P-D-glucose to gluconic acid 
and hydrogen peroxide, as described in the reaction below:
Glucose + O2 + H2O -> gluconic acid + H2O2
glucose oxidase
Glucose diffuses from the sample through the membrane to the immobilized 
enzyme layer where oxidation occurs. The hydrogen peroxide produced is then 
oxidized at the platinum electrode.
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The platinum electrode, which is maintained at an applied voltage, detects the 
hydrogen peroxide produced:
H20 2^  0 2 + 2H++ 2e'
pt
The current generated is linearly related to the concentration of hydrogen 
peroxide [H20 2] and this is related to the concentration of glucose [Glu] in the 
sample:
[Glu] = J [H20 2] 
where J  is a constant set during calibration.
The measured current i is related to the concentration of glucose as follows:
i = KJC
where AT is a constant which includes electrode geometry, overall diffusion 
coefficients and reaction rates, and C is the glucose concentration.
M em brane
Glu
Glu
Glu
Im m obilized Glucose 
Oxidase
Electrode
Figure 2.7: Schematic representation of the glucose membrane in the Nova 
Biomedical Bioprofile 400 Analyzer. (Picture sourced from the Nova Biomedical 
BioProfile 400 instruction manual).
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Glucose is the primary energy source. The rate at which cells consume glucose 
during in vitro expansion can be used as an indication of cell proliferation [Ozturk et 
al.9 1997]..
Glucose concentration was measured using the Nova Bioprofiler at selected time- 
points just prior to trypsinisation. The specific glucose consumption rate GCR 
(g/cell/hour) was then determined using the following equation:
GCV
<-V -V T 2
Where Gc = glucose consumed during the selected culture period (g/L)
V — volume of growth medium analysed (L/cm )
'y
Xs = change in cell density for the culture length (hr/cells/cm )
T = total culture time (hours)
Xo = cell density at t = 0 
Xt = cell density at the time t
2.6.5.3 Lactate production
Lactate is produced during metabolism of glutamine. Together with glucose 
consumption, lactate production can be determined as an indication of the cell 
metabolism. The Nova Biomedical Profile Analyzer measures the lactate 
concentration based on the level of H2O2 produced during the enzymatic reaction 
between lactate and oxygen molecules in the presence of the lactate oxidase enzyme:
Lactate + O2 Pyruvate acid + H2O2
lactate oxidase
At a constant potential of 0.70 volts, electroactive H2O2 is oxidized at the surface 
of the platinum anode as follows:
H20 2 -> 2H+ + 0 2 + 2e'
pt
G C R  =
GCV
Xsds
 GcV_______
[A exp(kt) - A] t / 2
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The current generated by the flow of electrons at the surface of the platinum 
electrode is proportional to the lactate concentration of the sample.
The lactate concentration (g/L) was measured in the spent growth medium at 
selected time-points during culture with the Nova Biomedical Bioprofiler. The lactate 
values were then plotted over the desired culture period (expressed in days) and a 
linear curve was fit to the data.
2.6.6 Qualitative analysis of cell viability with fluorescence 
microscopy
The Live/Dead Viability/Cytotoxicity Assay (Molecular Probes, Inc, Eugene, 
Oregon, USA) was used to study and confirm the cell viability data obtained from the 
trypan blue dye exclusion assay. This qualitative assay utilises two fluorescent dyes 
to discriminate between live and dead cells, measuring recognized parameters of cell 
viability, intracellular esterase activity and plasma membrane integrity. Calcein-AM 
is a non-fluorescent cell-permeable substance (calcein acetoxy-methyl ester), which is 
intracellularly converted to the green fluorescent calcein by esterase activity in viable 
cells. The polyanionic calcein is well retained within live cells, producing an intense 
uniform green (excitation/emission approximately 495nm/515nm) fluorescence. 
Ethidium homodimer-1 (EthD-1), a red DNA dye non-permeable to viable cells, 
stains nucleic acids by intercalating between the base pairs. EthD-1 enters cells with 
damaged membranes and undergoes a forty times enhancement of its fluorescence on 
binding to nucleic acids, thereby producing a bright red (excitation/emission 
approximately 495nm/635nm) fluorescence in dead cells. This assay was performed 
on both cells cultured in monolayer and on three-dimensional cells/alginate beads.
For the assessment of cell viability in monolayer, the cells were cultured on sterile 
13mm diameter glass coverslips (BDH) placed within the transwells of 24-well tissue 
culture plates (ICD=5xl03 cells/cm2). The cells were washed with PBS (200 
pL/co verslip) prior to the assay, in order to remove or dilute serum esterase activity 
generally present in serum-supplemented growth media. Serum esterase activity could 
in fact cause some increase in extracellular fluorescence by hydrolyzing calcein AM.
The 2mM EthD-1 and the 4mM calcein-AM stock solutions were diluted with 
PBS to a 6.6pM and 3.2pM working solutions respectively. Each coverslip was
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treated with an equal amount ( 6 6 jliL )  of EthD-1 working solution, calcein-AM 
working solution and PBS, so that the final concentrations used were 2.2pM for the 
EthD-1 and 1.06pM for the calcein AM. The samples were incubated with the dyes 
for 30-40 minutes at 37°C. Using fine-tipped forceps, the coverslips were then 
carefully inverted and mounted on glass microscope slides (BDH). To prevent 
evaporation, the coverslips were sealed to the glass slides with clear fingernail polish, 
and were then visualised on a fluorescence microscope with optimal 
excitation/emission wavelengths of approx. 495/515nm for calcein AM and 
495/635nm for EthD-1.
To assess the cytotoxicity of the cells immobilised within alginate beads, each 
construct was thoroughly washed with PBS (300pL/bead) and then incubated with an 
equal amount (165pL) of EthD-1 working solution, calcein-AM working solution and 
PBS, so that the final concentrations used were 2.2pM for the EthD-1 and 1.06pM for 
the calcein AM. After 30-40 minutes incubation at 37°C, the beads were washed with 
PBS (300pL/bead) and carefully transferred on the cavities of microscope glass slides 
(Fisher, 1 bead/cavity). In order to prevent movement or loss of the beads, new 
untreated coverslips (Chance Propper Ltd, West Mids, England) were mounted and 
sealed with clear fingernail polish on top of the glass slides. The resulting samples 
were finally observed on the fluorescence microscope with excitation/emission 
wavelengths indicated above.
2.6.7 hMSCs multipotentiality with hMSCs Functional 
Identification Kit
The Human Mesenchymal Stem Cell Functional Identification Kit (R&D 
Systems, Inc, Minneapolis, USA) was used to measure the cells’ ability to 
differentiate into multiple mesenchymal lineages. hMSCs isolated from frozen bone 
marrow samples (as described in section 2.1.1) were cultured for 19-21 days under 
conditions that were favourable for adipogenic, chondrogenic, or osteogenic 
differentiation (section 2.6.7.1). The cells were then fixed and stained with specific 
antibodies included in the kit, normally used to define the mature phenotypes of
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adipocytes, chondrocytes and osteocytes (section 2.6.13). This experiment was 
performed twice, and the results for these studies are presented in chapter 4.
2.6.7.1 Lineage-specific differentiation
Initially, adipogenic/osteogenic basal medium was prepared by supplementing a  
Minimum Essential Medium (aMEM) (Gibco) with 10% Fetal Bovine Serum 
(Gibco) and 1% 100X Penicillin-Streptomycin-Glutamine (Gibco) [lOOU/mL 
Penicillin, 100|Jg/mL Streptomycin, 2mM L-glutamine].
Chondrogenic basal medium was prepared by supplementing DMEM/F12 
medium (Gibco) with 1% ITS supplement (R&D Systems) and 1% 100X Penicillin- 
Streptomycin-Glutamine (Gibco) [lOOU/mL Penicillin, lOOfJg/mL Streptomycin, 
2mM L-glutamine].
The cells were harvested and counted following the standard protocol previously 
described. For adipogenic and osteogenic differentiations, fourth passage (p4) the 
cells were resuspended in a  Minimum Essential Medium basal medium (0.5mL/well) 
and cultured until 80-90% confluent (approximately 2-3 days) on top of sterile 13mm 
diameter glass coverslips (BDH), within 24-well tissue culture plates, at
4 9 ^ 92.1x10 cells/cm and 4.2x10 cells/cm respectively. In order to avoid cell
detachment, which can occur during osteogenic differentiation, the cells undergoing 
osteogenic differentiation were seeded on coverslips which had been previously 
coated (24-30 hours at 37°C) with lpg/mL human fibronectin (R&D Systems). Once 
the cells had reached 80-90% confluence, the basal medium was replaced with 
aMEM supplemented respectively with 10X Adipogenic Supplement (1:100 dilution) 
and 10X Osteogenic Supplement (1:20 dilution). The cultures were maintained for 
19-21 days at 37°C and 5%C02 and re-fed every 3-4 days with aMEM freshly 
supplemented with the respective differentiation supplements.
For chondrogenic differentiation, six-eight 2.5x105 fourth passage (p4) cells 
aliquots were transferred to six-eight 15mL conical tubes. The tubes were centrifuged 
at 200g for 5 minutes at room temperature, the supernatant was removed from each 
tube and each pellet was resuspended with lmL of DMEM/F12 basal medium. The 
pellets were centrifuged a second time at 200g for 5 minutes at room temperature, the 
supernatants were discarded and the pellets were resuspended with 0.5mL of 
DMEM/F12 basal medium previously supplemented with 20X chondrogenic 
supplement (1:100 dilution). The samples were centrifuged again at 200g for 5
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minutes at room temperature and the resulting pellets were left in their tubes with the 
chondrogenic differentiation medium and incubated at 37°C and 5%CC>2. The caps of 
the tubes were left loose throughout the culture to allow gas exchange and the growth 
medium was replaced every 3-4 days with freshly supplemented chondrogenic 
differentiation medium.
After 19-21 days in lineage-specific culture conditions, both coverslips and pellets 
were washed with PBS and fixed with 4% paraformaldeyde (TAAB Laboratories, 
England, UK) in PBS (BioWhittaker) for 20 minutes at room temperature. Using a 
fine-tipped forceps, the coverslips for adipogenic and osteogenic differentiation were 
carefully removed from the tissue culture plates, inverted and mounted on polished 
glass microscope slides (BDH) and were then immediately processed for 
immunocytochemistry (see section 2.6.7.3). Whereas the pellets for chondrogenic 
differentiation were frozen in optimum cutting temperature O.C.T. freezing 
compound (BDH) and liquid nitrogen and stored at -80°C until processing (see 
section 2.6.7.2).
2.6.7.2 Cryosectioning of cell pellets for chondrogenesis
After fixation with 4% paraformaldeyde, the cell pellets were transferred from 
their tubes to 7 mm x 7 mm x 5 mm disposable vinyl plastic base moulds (Fisher) and 
embedded in optimum cutting temperature (O.C.T.) freezing compound (BDH). Each 
sample was frozen in liquid nitrogen to form a block that could be cryosectioned and 
kept at -80°C for long-term storage. The frozen pellets were cut into 5-7pm sections 
using standard cryosectioning methods (Cryostat Bright Otf Model, Serial no. 
95037/4676, Bright Instruments Co.).
The specimens were collected directly on clean SuperFrost Plus glass slides 
(VWR International, Leuven). Usually no more than three sections, each spaced well 
apart, were placed per slide. A circle was drawn with a liquid barrier marker pen 
(Dako) around each section on the slides in order to prevent reagent mixing between 
samples. The sections were left to air-dry at room temperature for 2-3 hours and the 
slides were then carefully wrapped in aluminium foil and store at -20°C overnight.
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2.6.7.3 Immunocytochemistry
Both the coverslips from adipogenesis and osteogenesis culture and the cryo- 
sections obtained from the cell pellets maintained in chondrogenic conditions were 
placed in a humidified chamber and processed for immunocytochemistry. Firstly, the 
samples were permeabilised and blocked with 0.3% Triton X-100, 1% BSA and 10% 
normal donkey serum in PBS in order to prevent non-specific binding. The blocking 
step was preformed at room temperature for 45 minutes. The samples were then 
incubated with the appropriate antibody working solution overnight at 2-8°C. The 
coverslips for adipogenic differentiation were treated with lpg/lOOpL goat anti­
mouse FABP-4. lpg/lOOpL mouse anti-human osteocalcin was used for coverslips 
cultured with osteogenic differentiation medium whereas the cell pellets for 
chondrogenic differentiation were incubated with lpg/lOOpL goat anti-human 
Aggrecan (all primary antibodies from R&D Systems). After overnight incubation, 
the samples were washed three times with PBS containing 1% BSA for 5 minutes. 
The samples were then incubated with the appropriate secondary antibody solution 
prepared in PBS containing 1% BSA. The incubation was maintained for 60 minutes 
at room temperature in the dark. Rhodamine Red-conjugated donkey anti-goat 
antibody (Jackson ImmunoResearch Lab. Inc., West Grove, PA, USA; 
Fluorophore/Protein absorbance ratio: A550/A280=0.71) was used for the reaction 
with adipo-induced coverslips and the chondro-induced pellets, whereas the 
coverslips that had been maintained in osteogenic differentiation medium were 
treated with Rhodamine Red-conjugated donkey anti-mouse antibody (Jackson 
ImmunoResearch Lab. Inc.; Fluorophore/Protein absorbance ratio: A570/A280=1.3). 
After incubation with the secondary antibodies, the samples were washed with 1% 
BSA in PBS for 5 minutes and then with distilled water. Using a fine-tipped forceps, 
the coverslips for adipogenic and osteogenic differentiation were carefully inverted 
and mounted on glass microscope slides. New untreated glass coverslips (Chance 
Propper Ltd, West Mids, England) were mounted on top of the cell sections obtained 
from the pellets for the chondrogenic differentiation. The resulting samples were then 
observed on the fluorescence microscope.
Negative controls were assessed in order to test for the specificity of the 
antibodies involved: three samples per each condition were tested following exactly 
the procedure described above but omitting the primary antibody incubation. These
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negative controls were instead incubated over-night with PBS containing 1% BSA 
and 10% normal donkey serum.
2.6.8 Cell apoptosis: Guava Nexin assay
Apoptosis, or programme cell death, is an important regulatory pathway of cell 
growth and proliferation. This phenomenon is characterised by intracellular processes 
that result in typical physiological changes, including: extemalisation of phosphatidyl 
serine (PS) to the cell surface, cleavage and degradation of specific cellular proteins, 
compaction and fragmentation of nuclear chromatin, and, at later stages, loss of 
membrane integrity [Kerr et a l , 1972; Wyllie, 1993].
A fluorescence-based assay was performed in order to measure apoptosis based 
upon the Guava EasyCyte system, a blue laser 96-well microcapillary flow cytometry 
instrument (Guava EasyCyte). This simple assay uses a combination of dyes to 
identify and distinguish apoptotic cells from dead cells and debris.
Annexin V is a calcium-dependent phospholipid binding protein with high affinity 
for phosphatidyl serine (PS) [van Heerde et al., 1995], a membrane component 
normally localised to the internal surface of the cell membrane. In early apoptotic 
cells, molecules of PS are translocated to the outer surface of the cell membrane 
where Annexin V can readily bind them [Fadok et a l , 1992; van Engeland et al., 
1996]. The Annexin V-PE provided with the Guava PCA-96 Nexin kit (Guava 
Technologies Inc. Hayward, CA; cat. no. 4500-0160) detects PS on the external 
membrane of apoptotic cells.
A cell-impermeant DNA intercalator, 7-aminoactinomycin (7-AAD), is the 
second dye included in the kit. This dye is excluded from live, healthy cells and early 
apoptotic cells, and is therefore used to monitor cell membrane permeability changes 
commonly observed later in apoptosis as well as in necrotic cells.
Three cell populations can be distinguished simultaneously in this assay: non- 
apoptotic Annexin V (-) and 7-AAD (-) cells, early apoptotic Annexin V (+) and 7- 
AAD (-) cells and late stage apoptotic and dead cells, which stain positively for both 
dyes.
Using both these dyes in a single assay not only allows the monitoring of cellular 
events leading to physiological changes typically involved in cell apoptosis, but also
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enables users to distinguish between cellular processes occurring at different stages of 
this phenomenon.
The cells were harvested and counted as previously described (section 2.1.3 and 
section 2.6.2). The cell suspension was equally divided in lmL capacity 
microcentrifuge tubes (Eppendorf), so that the final cell concentration was between 
lxlO4 and 5xl04 cells/tube. The tubes were centrifuged at 360g, +4°C for 5 minutes.
After complete removal of the supernatant, each cell pellet was resuspended in 
40pL IX Nexin buffer, obtained by diluting 10X Nexin Buffer with purified 
deionised water. 5pL Annexin V-PE and 5pL Nexin 7-AAD were added to each tube 
and the staining reactions were then incubated shielded from light for 20 minutes at 
+4°C. After incubation, each sample was diluted by addition of 150pL IX Nexin 
Buffer, so that both the Annexin V-PE and the Nexin 7-AAD concentrations in the 
final 200pL working solution were 2.5%. The resulting samples were transferred into 
individual wells of a 96-well microplate (Coming Incorporated, Costar, NY, USA) 
and were then immediately assessed on the Guava PCA-96 system using the 
ExpressPlus application software within CytoSoft.
The Nexin assay was performed on bFGF-ffee and bFGF-supplemented hMSCs 
cultured in different oxygen conditions, in order to evaluate the effects of both bFGF 
supplementation and oxygen tension on cell apoptosis. The results are described in 
section 4.8.3.
2.6.9 Statistical analysis
For the cell proliferation and cell viability analysis, three replicates for each 
condition were performed and assessed. The mean and standard error of the mean 
(S.E.) of the three measurements were calculated for each condition, whereby the 
standard error was given by the formula:
O'
Standard Eiror (S.E.) =
\ n
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where a  is the sample standard deviation (i.e. the sample based estimate of the 
standard deviation of the population), and n is the population size (number of 
replicates) of the sample.
The statistical significance of results was assessed using the single factor analysis 
of variance (one-way ANOVA) program from Microsoft Excel 2002. The single 
factor ANOVA analysis tool performed a simple analysis of variance, testing the 
hypothesis that the means from two or more samples were equal (drawn from 
populations with the same mean). Analysis of the groups of data that produced a p- 
value >0.05 indicated that the means were not statistically different (to the 95% 
confidence level); whereas a p-value <0.05 indicated one or more of the samples did 
not have the same mean.
2.7 MTT (3-(4,5-dimethylthiazol-2-y1)-2,5- 
diphenyltetrazolium bromide) assay
Several methods have been developed to study cell viability and proliferation in 
cell populations. The most common method for the determination of the growth and 
proliferation of anchorage-dependent cells involves harvesting of the cells with a 
0.25% trypsin/0.02% EDTA solution, followed by cell staining and cell enumeration 
using a haemocytometer and microscope (section 2.6.2 and 2.6.3). However, this cell 
count method may be considered time consuming, labour intensive and dependent on 
the operator’s technique. For this reason in this research an alternative method, the 
MTT assay, was investigated for the cell quantification.
This assay has been demonstrated as a sensitive, precise, rapid and reliable test 
method by many studies [Ferrera et al., 1993]. Moreover, results from MTT studies 
have shown a good correlation and consistency with direct cell counting and other in 
vitro proliferation assays [Zund et al. 1999; Markusen et al., 2006; Ciapetti et al., 
1993].
The MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) is a 
tetrazolium salt which is widely used to quantitate cell proliferation and cytotoxicity. 
The MTT Cell Proliferation assay has been developed based on the metabolic activity 
of viable cells. Because the original tetrazolium salt is reduced to a coloured, water-
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insoluble formazan product only by metabolically active cells, this assay detects 
viable cells exclusively. After it is solubilized, the formazan formed can easily and 
rapidly be quantitated in a conventional ELISA plate reader at 550-600 nm 
(maximum absorbance). Because this technique needs no additional cell washing or 
cell harvesting steps, the complete assay from the start of the microculture to data 
analysis in an ELISA plate reader can be performed in the same microplate. In 
addition, the ELISA plate reader is linked with a computer allowing rapid and 
automated data processing. In the present research, the whole assay was performed in 
a 96-well microplate format. This miniaturization allowed many samples to be 
analysed rapidly and simultaneously.
The MTT assay performed in this study was utilised for the quantification of both 
cells grown in adherent cultures in tissue culture vessels and of cells immobilised 
within three-dimensional alginate beads. The assay method used was adapted from 
Mosmann’s protocol (1983) Markusen’s revised version (2005).
The molecular structures of the MTT salt and its formazan product are shown in 
figure 2.8.
MTT Formazan
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CM}
Fig. 2.8 : Molecular structures of the dye precursor 3-(4,5-dimethylthiazol-2-yl)- 
2,5-diphenyltetrazolium bromide (MTT) and the purple formazan product formed 
upon reduction. (Picture adapted from biosynth chemistry and biology, available at 
http://www.biosvnth.com).
2.7.1 Cell standard curve
First of all, a cell standard curve was created from a serial dilution of the cell 
suspension. hMSCs were harvested with a 0.25% trypsin/0.02% EDTA solution as 
described in section 2.1.3. A small sample (500pL) of the cell suspension was used 
for the determination of the cell count using a haemocytometer, as described in
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section 2.6.2. After centrifugation and removal of the supernatant, the cell pellet was 
resuspended with Dulbecco’s phosphate buffered saline with lg/L D-glucose and 
36mg/L sodium pyruvate (DPBSG, Biowhittaker, Cambrex, Venders, Belgium) to a 
final concentration of 2xl06 viable cells/mL. A small aliquot of this cell suspension 
was used for an additional cell count after dilution with DPBSG, in order to confirm 
the cell concentration in the pellet sample. The cell suspension was serially diluted 
with DPBSG in a 96 well microplate; the final working volume in each well was 
lOOpL. The serial dilution was performed in duplicate with cell concentrations 
ranging from 0 to 20x104 viable cells/well (table 2.3). The MTT protocol was 
performed as described in section 2.7.4.
Volume of cell 
suspension (pL) Number of 
viable
cells/well
Volume of DPBSG
100 20x l04 0
75 15xl04 25
50 lOxlO4 50
25 5xl04 75
12 2.4xl04 88
The cells were 
diluted 1:12 with 
DPBSG and 
afiirther serial 
dilution was 
performed as 
follows
50 1.2x l04 50
30 0.72xl04 70
10 0.24xl04 90
control 0 100
Table 2.3: Serial dilution of the cell suspension for the MTT cell standard curve.
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2.7.2 Cell standard curve for hMSCs immobilised in three- 
dimensional alginate beads
Prior to the performance of the MTT assay on the cells/alginate beads, it was 
necessary to remove from the beads the residual culture medium containing phenol 
red that would interfere with the absorbance reading. For this reason, the beads were 
first transferred into a 10cm Petri dish (Sterilin, Bibby Sterilin, Stone, UK) and 
washed with DPBSG. After this washing step, the beads were removed from the Petri 
dish and placed into a 96-well microplate. In order to assess the linearity of each 
MTT assay, a serial dilution of beads was performed, as shown in table 2.4. The serial 
dilution was performed in duplicate with number of beads per well ranging from 0 
(for a background control) to 3. A cell standard curve was in this way created for 
hMSCs immobilised in the beads, since the number of cells/well would be a multiple 
of the number of beads. For the determination of the number of cells/well, additional 
beads were dissolved and used for the cell enumeration using a haemocytometer, as 
described in section 2.7.3. Afterwards, the final working volume in each well was 
equalised with DPBSG to a total volume of lOOpL/well, and the MTT assay was 
performed as described in section 2.7.4.
Num ber of beads 
per well
Volume of DPBSG 
(pL
Total (average) 
num ber of 
cells/well
0 100 control
1 100 IX
2 100 2X
3 100 3X
Table 2.4: Serial dilution of alginate/cells beads for the MTT assay standard 
curve. Additional beads were dissolved and used for the cell count with a 
haemocytometer, in order to determine the total number of cells/well for each 
experiment. In order to calculate the remaining total number of cells/well, the average 
number of cells/beads, denoted as IX, was multiplied by 2 (2X) and by 3 (3X).
I l l
2.7.3 Determination of cell concentration in alginate beads
For the determination of the cell concentration in the beads, 1-3 beads were 
dissolved for 15 minutes in a 0.3M trisodium citrate (Sigma) and 10X trypsin/EDTA 
in saline (BioWhittaker). Typically lOOpL citrate and 10pL trypsin/EDTA were used 
for each bead. The dissolved beads were then mixed and homogeneously resuspended 
into a single cell suspension. A small sample of the resulting cell suspension was used 
for the determination of the cell count with a haemocytometer (section 2.6.2) and for 
the assessment of the cell viability using the exclusion assay with trypan blue dye 
(section 2.6.3). The total volume of each sample was carefully monitored with a 
graduated pipette and the total cell concentration and the average cell concentration 
for each bead were subsequently calculated as follows:
Total cell concentration = (cell concentration/mL) x (total volume) 
Average cell concentration/bead = total cell concentration / number of beads
dissolved
The number of beads dissolved in each experiment varied depending upon the 
size of the bead and the original cell concentration in the bead.
2.7.4 MTT protocol
2.7.4.1 MTT incubation
A 5mg/mL MTT (Sigma) solution in Dulbeccos’s phosphate buffered saline with 
lg/L D-glucose and 36mg/L sodium pyruvate (DPBSG, Biowhittaker, Cambrex, 
Verviers, Belgium) was added to each sample well and left in action for 1-3 hours, at 
37°C in a humidified 5% CO2 incubator (HeraCelll50, Kendro Laboratory Products 
GmbH, Langenselbold, Germany or Galaxy S, RS Biotech Laboratory Equipment 
Ltd., Irvine, Scotland). Typically lOOjaL DPBS and lOpL MTT were added to each 
well. During incubation with the MTT solution the microplate was covered with 
plastic film in order to minimize evaporation. After diffusion into the cells, the water
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soluble yellow MTT salt was converted by the mitochondrial dehydrogenase enzyme 
of viable cells into an insoluble purple formazan product.
In the case of cells/alginate beads, it was necessary to add a 0.3 M trisodium 
citrate (Sigma) solution in distilled water (BioWhittaker) in order to dissolve the 
alginate within the beads. The citrate solution (40pL/well) was left in action at 37°C 
for an additional hour and the microplate was then centrifuged (5 81 OR, Eppendorf 
AG, Hamburg, Germany) at lOOg for 5 minutes. The supernatant was carefully 
removed from each well in order to eliminate any volume inconsistencies that may 
have arisen from the initial DPBSG or alginate beads, and to eliminate the majority of 
the alginate solution from the well. Mixing of the cell suspensions resulting from the 
dissolution with trisodium citrate was avoided in order to reduce loss of cells 
adhering to the inner surface of the pipette. Particular attention was also taken in 
removing the supernatant from the microplate wells after centrifugation, in order to 
ensure that the cell pellet at the bottom of the well was not disturbed during the 
procedure.
The hMSCs cultured in monolayer (without the alginate matrix) were incubated 
with the MTT solution following the same procedure, even though in this case the 
addition of the trisodium citrate solution was not necessary. An MTT procedure 
identical to the one outlined above for the cells/alginate beads was followed in order 
to mimic the contents of the residual alginate in the wells containing beads.
2.7.4.2 Solubilisation of the formazan product
After centrifugation and removal of the supernatant, the microplates were either 
immediately treated for the dissolution of the formazan product, or wrapped in foil 
and frozen at -80°C. The freezing step allowed to perform the procedure more 
conveniently in two separate steps. The frozen plates from each time point were 
usually thawed and completely processed (e.g. dissolved and read) on the same day. 
Microplates containing only cell pellets (and no cells/alginate beads) were treated 
immediately after centrifugation (or after the freezing-thawing step) with a solution of 
isopropanol (Sigma) containing 0.1N HC1 (Fluka), in order to dissolve the formazan 
product after permeabilisation of the cells.
Whilst the cells/alginate beads resulting from centrifugation (or from the freezing- 
thawing step) were reconstituted with DPBSG (50pL/bead) supplemented with 10X
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trypsin/EDTA in saline (20pL/bead), prior the addition of the isopropanol/HCl 
solution. Treatment with 10X trypsin/EDTA was necessary to release the single cells 
from the alginate-GRGDY matrix and to obtain a homogeneous cell suspension. After 
addition of 10X trypsin/EDTA in saline, the microplates were wrapped in plastic film 
and incubated at room temperature for approximately 30 minutes. The bead/s in each 
well sample was/were then thoroughly mixed with a micropipette to a final single cell 
suspension prior addition of the isopropanol/HCl solution.
The microplates were covered with plastic film in order to minimize evaporation 
and were incubated at room temperature with the isopropanol/HCl solution 
(100pL/well) for 20 minutes. The cell pellet in each well was then thoroughly mixed 
to maintain the homogeneity of the cell suspension and the microplates were 
subsequently incubated at room temperature for additional 20 minutes. Finally, the 
cell suspension in each well was mixed again just before reading the absorbance of 
the samples.
2.7.4.3 Analysis of data
After addition of the isopropanol/HCl solution, the 96 well microplates were read 
on a spectrophotometer (Packard Bioscience Spectracount™, Packard-Becker BV, 
Groningen, The Netherlands) using an absorbance value of 600nm.
In most cases when isopropanol is used to dissolve the formazan final product, the 
absorbance is measured at 570nm with background subtraction (reference 
wavelength) at 630nm [Mosmann, 1983; Wang, 2003; Yang, 2003]. Sometimes the 
data are read at 620nm [Carrier et al, 1999]. In the present research, the Packard 
Bioscience microplate spectrophotometer used did not contain a 570nm filter, 
therefore the reading was always performed at 600nm which was the closest filter 
available in the instrument. As previously demonstrated, the utilisation of a different 
wavelength did not affect the results of the MTT assay [Markusen, 2005].
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2.7.5 Interference of the three-dimensional alginate matrix with 
MTT absorbance
In this research the MTT assay was performed on three-dimensional beads 
containing only alginate (without cells), in order to evaluate the possible interference 
of the residual alginate with the final MTT results. For this purpose, beads consisting 
of complete MesenCult medium (25% v/v) and 1% w/v Pronova SLG100 alginate 
solution (75% v/v) were prepared as described in section 2.5.3, and then tested with 
the MTT assay according to the procedure that follows. For this experiment, a 96 well 
microplate was seeded with a constant cell concentration and an increasing number of 
“cell-free” alginate beads in each well. Typically 12pL of cell suspension were 
seeded in each individual well, corresponding to a cell concentration of 2.05x104 
cells/well. Table 2.5 shows the volumes of cell suspensions and of DPBGS and the 
number of alginate beads loaded to each well in the present experiment.
Volume of 
cell
suspension
(PL)
Cell
concentratio
n/well
Number of 
beads/well
Volume of 
DPBSG (pL
0 (control) 0 0 100
12 2.05xl04 0 88
12 2.05xl04 1 88
12 2.05xl04 2 88
12 2.05xl04 3 88
12 2.05xl04 4 88
Table 2.5: Volume of cell suspension, cell concentration, number of beads and 
volume of DPBSG loaded into each individual well of a 96 well microplate for the 
testing of the alginate interference with MTT absorbance. Each well was loaded with 
the same cell concentration and an increasing number of cell-free alginate beads.
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The microplates were incubated with the MTT solution and then immediately 
treated for the dissolution of the beads with trisodium citrate, according to the 
procedure outlined in section 2.7.4. No ffeezing-step was performed for the present 
experiment. These results are discussed in chapter 5.
2.7.6 Determination of hMSCs proliferation within alginate 
beads
In order to evaluate the hMSCs growth within three-dimensional alginate beads 
over a time course, the MTT assay was performed at different time-points over a 14- 
day culture period on cells entrapped within alginate beads. Concurrently, a serial 
dilution was performed in duplicate, with 0, 2, 4 and 6 beads per well to confirm the 
linear correlation between the number of cells/well and the number of beads tested. 
The beads were prepared with 25% v/v cell suspension and 75% v/v Pronova 
SLG 100 alginate-GRGDY.
In a similar study, the effects of the freezing-step were also evaluated by 
comparing the absorbance values obtained for plates frozen after MTT incubation 
with those measured for plates immediately processed for the dissolution of the 
formazan product. These results are discussed in chapter 5.
2.7.7 Interference of alginate in solution with MTT absorbance
The MTT assay was also performed on both hMSCs and rSMCs cultured in 
monolayer in the presence of alginate in solution, in order to evaluate the possible 
interference of the alginate in solution with the final MTT absorbance values. For this 
purpose, hMSCs or rSMCs were resuspended in complete growth medium and seeded 
on 96-well plates at the initial seeding density of 6xl03 cells/cm2. After 24 hours in 
culture, the medium was replaced from each well with the alginate solution. A serial 
dilution was performed in duplicate with alginate concentrations ranging from 0 to
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lmL/well. The culture was regularly evaluated microscopically for possible 
morphological changes, or eventual cell death, occurring over time.
The MTT assay was performed for both the rSMCs and hMSCs culture after 10 
days in culture, according to the procedure already described. These results are 
described in chapter 5.
The table below shows the cell concentration, the volumes of growth medium and 
of alginate in solution loaded into each individual well of a 96-well plate in the 
present experiment.
Cell
concentration
/cm2
Cell
concentration
/well
Volume of 
medium(jiL) 
/well
Volmne of 
alginate(pL)/ 
well
(Control)
6X103
1.14xl04
1000 0
6x10s 1.14xl04 990 10
6xl03 1.14xl04 980 20
6X103 1.14xl04 970 30
6x103 1.14xl04 960 40
6X103 1.14xl04 950 50
6x 103 1.14xl04 940 60
6x 103 1.14xl04 930 70
6x 103 1.14xl04 920 80
6x 103 1.14xl04 910 90
6X103 1.14xl04 900 100
6x 103 1.14xl04 500 500
6x 103 1.14xl04 0 1000
Table 2.6: Serial dilution performed into a 96 well microplate for the testing the 
interference of the alginate in solution with MTT absorbance. Each well was loaded 
with the same cell concentration and a solution with increasing concentration of the 
alginate in solution.
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3. The derivatisation and characterisation of the 
alginate derived-polymer for tissue engineering 
applications
This chapter focuses on the derivatisation of the alginate polymer with the Gly- 
Arg-Gly-Asp-Tyr (GRGDY) pentapeptide and on the characterisation of the resulting 
alginate-GRGDY, prior to its addition to the cells and its deployment as scaffold for 
the fabrication of tissue engineered constructs. The results obtained from the studies 
performed for the characterisation of these alginate constructs containing cells are 
presented in chapter 5.
3.1 Introduction
The aim of this research was the fabrication of alginate/cells constructs for future 
deployment in tissue engineering applications. Such tissue-engineered constructs 
could for instance be employed as living blood vessel substitutes for use in cardiac 
bypass surgery for coronary artery disease. Current methodologies using cells or 
veins or foreign materials for the treatment of these conditions are unsatisfactory 
[Edelman, 1999; Darling et al, 1972; Niklason et al, 1999]. As a result, there is a 
urgent need for alternatives, and tissue engineering was the approach investigated in 
this research.
The focus was on the use of a completely biological scaffold, one that would 
allow the fabrication of vascular grafts that are biocompatible and have adequate 
mechanical strength, durability and compliance comparable to the existing vessels 
[Nerem, 2000; Teebken and Haverich, 2002]. Because of their gentle gelling 
properties, alginates are widely used as materials for the encapsulation and 
immobilisation of a variety of cells in vitro [Fremond et al., 1993] and in vivo [Chang 
et al., 2001] and for several tissue engineering applications [Hauselmann et al., 1996; 
Atala et al., 1994]. Cross-linked alginate hydrogels are utilised in various biomedical 
applications [Draget et al., 1997] and recent studies suggest that different approaches 
can be used to control and manipulate the physical properties of these biomaterials in 
a way that permits the development of cell transplantation vehicles desirable for 
various biomedical applications [Kong et al., 2004; Kong et al., 2004]. In addition, in
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previous studies conducted with human cells, cell function and differentiation have 
been reported using alginate as a matrix [Rowley and Mooney, 2002; Wang et al, 
2003]. Furthermore, the alginate used in these studies (Pronova Biomedical, Oslo, 
Norway) has shown to support tissue and vascular ingrowth with minimal 
inflammatory response and capsule formation surrounding the implants when injected 
in the subcutaneous space of adult sheep [Halberstadt et al., 2002]. Given these 
advantages and encouraging results, alginate was the material of choice in this work.
Ultra-pure alginates, which contain only low levels of pyrogens, were used as 
scaffold materials for the preparation of alginate/cells constructs. In addition, in order 
to reduce potential contaminants (e.g. heavy metals and polyphenols) that could be 
present in the commercial biomaterial, dialysis was performed on the original alginate 
samples prior to its addition to the cell suspension.
In order to permit and improve cell binding to the biomaterial, the GRGDY 
peptide, containing the specific RGD cell adhesion sequence, was immobilised onto 
the alginate polymeric chain. The resulting alginate-GRGDY was then used to grow 
adherent cells (i.e. human mesenchymal stem cells and human foreskin fibroblasts).
The results obtained from the studies investigating the alginate derivatisation 
procedure with the GRGDY pentapeptide are presented in section 3.2, whereas the 
data obtained from the characterisation studies on the resulting alginate-GRGDY 
matrix are described in section 3.3.
3.2 Derivatisation of the alginate with the GRGDY 
pentapeptide
A detailed description of the protocols employed for the preparation of the 
derivatised alginate-GRGDY is given in section 2.3.2. The final derivatisation 
procedure adopted in the present research was the result of a series of optimisation 
studies conducted at the beginning of this research in collaboration with Julia 
Markusen [Markusen, 2005].
The first step for the derivatisation of the alginate was the 20-hour reaction 
incorporating the GRGDY pentapeptide on the alginate, resulting in the derivatised
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alginate, which displays the -GRGDY-COOH sequence bound to the carboxylic 
groups of the guluronic acid units recurring along the polymeric chain. Different 
alginate types (please see section 3.2.2.1) and reactants (EDC and sulfo-NHS) 
concentrations (section 3.2.2.2) were tested for the reaction. In addition, different 
peptide concentrations were investigated, as described in section 3.2.2.4. EDC, sulfo- 
NHS and the GRGDY peptide were all filtered through 0.2 pm filters prior to their 
addition to the reaction vessel, thus ensuring all the reagents were free from microbial 
contamination.
After completion of the coupling reaction a 5-day dialysis step was performed on 
the reaction mixture in order to remove the cell toxic reactants left over from the 
carbodiimide reaction (i.e. EDC and sulfo-NHS) and the heavy metals and 
polyphenols from the commercial alginate (please see section 3.2.3). The temperature 
was carefully monitored and maintained constant at 20-22°C during both the 
carbodiimide reaction and the dialysis cycle. Significant temperature changes would 
have otherwise affected the reaction, due to changes in reaction rates and molecular 
mixing, and the diffusion of molecules across the dialysis membrane. The whole 
procedure was conducted in the dark because the reactants are known to be light- 
sensitive.
The diagram presented in Figure 3.1 gives an overview of the derivatisation 
procedure employed for the attachment of the GRGDY peptide onto the alginate 
matrix. The different alginate types and the different reactants and peptide 
concentrations used in this work are shown, together with the alternative routes tested 
for the aseptic preparation of the final sterile alginate-GRGDY.
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Figure 3.1: Flow diagram representing a schematic of the alginate derivatisation with 
the GRGDY peptide. The diagram shows the different factors investigated and the 
alternative methods employed for the preparation of the final alginate-GRGDY 
product:
1 Performing 2-day lyophilisation followed by freezing step (procedure no.
i);
2 Avoiding freezing step after lyophilisation (procedure no. 2);
3 Performing polyethylene glycol (PEG) concentration as an alternative to
lyophilisation, followed by freezing step (procedure no. 3);
4 Avoiding freezing step after PEG concentration (procedure no. 4).
1 2 1
A summary of the different conditions tested during investigation on the coupling 
reaction (i.e., alginate types, l-ethyl-(dimethylaminopropyl) carbodiimide (EDC), N- 
hydroxy-sulfosuccinimide (sulfo-NHS) and GRGDY concentrations) is given in table 
3.1. The different procedural stages followed for each of these conditions during the 
derivatisation of the alginate matrix are also indicated in the table.
Alginate-
GRGDY
number
Alginate 
type (all 
supplied 
sterile by 
Pronova)
Cone.
reactants
(sulfo-
NHS,
EDC)*
Peptide 
cone, in 
reaction*
Dialysis Dialysis
length
Cone.
step
Freeze-
storage
(-20°C)
1
SLG100
9X
32X
Y-
irradiated
2 12X
cassettes,
0.2pm
filtered
5 days 2 days 
lyo.
Yes
3 SLG100
9X IX
water in 
LFH
4 SLM100
5 SLM20
6
SLG100 9X 10X
Y;
irradiated 
cassettes, 
0.2pm 
filtered 
water in 
LFH
5 days
2 days 
lyo.
Yes
7 No
8
SLG100 9X 10X
Y-
irradiated 
cassettes, 
0.2pm 
filtered 
water in 
LFH
5 days
PEG
conc.
Yes
9
(approx. 
3 hours) No
10 SLG100
9X
liquid
32X
Y-
irradiated 
cassettes, 
0.2pm 
filtered 
water in 
LFH
5 days 2 days 
lyo.
Yes
11 SLG20
EDC
Table 3.1: Derivatisation procedures performed in the present study for the 
incorporation of the GRGDY peptide in the alginate matrix. *1X reactants’ 
concentrations correspond to lmg of alginate containing 38 pg of sulfo-NHS, 67 pg 
of EDC and 1 pg of peptide, as defined by Rowley (1999). All reactants and peptide
1 2 2
were sterile filtered through a 0.2 pm filter prior to derivatisation. Alginates-GRGDY 
no. 1, no.2, no.6 and no. 10 (highlighted in yellow) were also assessed by means of 
amino acid analysis (data presented in table 3.3).
3.2.1 Effect of preservation of alginate-derived polymer with 
respect to biochemistry
The 5-day dialysis step was followed by the alternative concentration procedures 
listed below (please see diagram in figure 3.1):
1. Performing 2-day lyophilisation followed by freezing step (procedure no.
i);
2. Avoiding freezing step after lyophilisation (procedure no. 2);
3. Performing polyethylene glycol (PEG) concentration as an alternative to
lyophilisation, followed by freezing step (procedure no. 3);
4. Avoiding freezing step after PEG concentration (procedure no. 4).
The alginates resulting from these four different procedures were compared with 
respect to their effect on the gel strength during the preparation of alginate/cells beads 
and on cell behaviour. These results are described in chapter 5.
The following sections describe in more details the parameters investigated during 
the initial coupling reaction and subsequent dialysis and re-concentration steps of the 
derivatisation process.
3.2.2 The coupling reaction
The carbodiimide chemistry for the alginate derivatisation was performed 
according to the method reported by Rowley and colleagues [Rowley et al., 1999]. 
The H2N-GRGDY-COOH pentapeptide was incorporated onto the alginate through 
the carboxylic acid groups on the guluronic acid monomers of the polysaccharide 
chain, as already described in section 2.3.2 (please see figure 2.2 for the scheme of 
the reaction). The reaction involves the use of ethyl- 
(dimethylaminopropyl)carbodiimide (EDC) acting as a cross-linking agent and 
coupling the carboxyl groups on the polysaccharide to primary amines (through their 
N-terminal). The EDC first reacts with the alginate, by removing a proton from the
123
carboxyl acid groups on the uronic acid monomers. The resulting protonated EDC 
then reacts with the O' on the carboxylic acid group to form the intermediate (O- 
acylisourea), which then reacts with the sulfo-NHS to form a reactive sulfo-NHS 
ester. This then reacts with the N-terminal of the GRGDY pentapeptide, eliminating 
urea.
The reactants were added in a specific order, which was essential for the right 
reaction to result. The sulfo-NHS, followed by the EDC, had to be added to the 
alginate first, allowing enough time for them to disperse homogeneously throughout 
the alginate solution. This then ensured that the peptide reacted with an EDC 
molecule (according to the reaction shown in figure 2.2) immediately after addition to 
the reaction vessel. As a result, the probability that the unstable O-acylisourea 
intermediate would come straight into contact with a sulfo-NHS molecule was very 
high, thus immediately forming the amine-reactive sulfo-NHS ester.
3.2.2.1 Alginate formulation
The aim of this work was to produce a scaffold suitable for addition to the cell 
suspension and for the fabrication of alginate/cells constructs where cell viability was 
maintained over time. For this purpose, the sterility of the alginate-GRGDY resulting 
from the alginate derivatisation with the GRGDY peptide was an essential 
requirement.
Preliminary studies investigating various alginate types concluded that the use of 
sterile Pronova sodium alginate was the best way to ensure the preparation of a final 
sterile product, thus enabling it to be used for cell culture work [Markusen, 2005]. 
The use of a sterile alginate permits to by-pass any extra sterilisation step that would 
otherwise result necessary after the alginate itself has been derivatised. This reduces 
handling of the alginate-GRGDY and allows maintaining high sterility in the final 
product. As a result, the alginate used in this research was supplied by the 
manufacturer as sterile product (NovaMatrix FMC BioPolymer, Norway). For this 
reason it was not necessary to perform autoclaving, which would reduce the length of 
the alginate chain, the alginate viscosity and molecular weight [Leo et al., 1990; 
Vandenbossche and Remon, 1993; Zoro, 2005] and would denaturate the peptide, or 
filtration. Both these methods proved to be ineffective sterilisation techniques, hence 
the necessity and choice to use alginate supplied as sterile product.
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In the present study the use of different Pronova ultra-pure sodium alginates was 
investigated. Pronova’s alginate is available with either high guluronic acid (SLG) or 
high mannuronic acid (SLM) concentration, and with either high viscosity (SLG 100, 
SLM100) or low viscosity (SLG20, SLM20). Four alginate types (SLG100, SLG20, 
SLM 100 and SLM20) were investigated, and the products specifications for these 
alginates were provided by the manufacturer (please see table 3.2).
SLG20 SLG100 SLM20 SLM100
Apparent viscosity (mPA s) 20-100 >100 20-100 >100
Molecular weight (kDa) 75-180 160-250 75-180 160-250
PH 5.5-8.5
Guluronic acid (%) >60 Unknown
Mannuronic acid (%) Unknown >50
Protein (%) <0.3
Endotoxins (EU/gram) <100
Heavy metals (ppm) <40
Pb (ppm) <10
Hg (ppm) <1
Microbiological purity sterile
Table 3.2: Products specifications for Pronova SLG100, SLG20, SLM100 and 
SLM20 alginates (provided by the manufacturer, NovaMatrix FMC BioPolymer, 
Norway).
The alginate was dissolved in normal-saline solution (0.9% NaCl in water for cell 
culture applications, pH=7-7.4) or MES/NaCl buffer as described in section 2.3.1. 
Preliminary investigations had shown this was the best option since when alginate 
mixed with water for injection was used for the preparation of alginate/cells 
constructs, low cell viability and cell lysis due to the non-physiological conditions 
(e.g. low pH and osmolarity) were observed. In addition, reconstitution of the alginate
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with buffered saline solutions (e.g. PBS phosphate buffered saline without) caused 
precipitation of undesirable insoluble calcium phosphate after addition of the CaCl2 
cross-linking solution.
3.2.2.2 EDC and sulfo-NHS concentration employed in the 
coupling reaction
Different reactants (EDC and sulfo-NHS) concentrations were tested for the 
coupling of the GRGDY peptide onto alginate. The range of reactants’ concentrations 
used in this procedure (e.g. 9X and 12X) were multiples of the IX reactants’ 
concentrations described by Rowley (1999), where IX reactants correspond to lmg of 
alginate containing 38 pg of sulfo-NHS, 67 pg of EDC and 1 pg of peptide. 9X and 
12X were respectively 9 and 12 times the reactants’ concentration, as defined by 
Rowley (please see table 2.2). Range finding experiments conducted to optimise the 
alginate derivatisation procedure proved that 9X and 12X were the best reactants 
(EDC and sulfo-NHS) concentrations for the derivatisation of Pronova ultrapure 
SLG 100 alginate, permitting cell attachment and cell elongation after immobilisation 
of the cells within the three-dimensional alginate-GRGDY/cells constructs. Higher 
reactants concentrations (27X and 50X) led to the dissociation of the alginate beads 
within 24 hours (possibly because the higher incorporation of the pentapeptide onto 
the alginate prevented the binding of sufficient calcium ions, which is necessary to 
hold the beads in shape).
Amino acid analysis was performed to ascertain the degree of derivatisation on 
the alginate-GRGDY obtained from the coupling reaction involving either 9X or 12X 
reactants concentrations. The results of these studies are described in section 3.3.1.
3.2.2.3 Use of manufacturer-prepared EDC solution
1-Ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC) is a water-soluble 
derivative of carbodiimide, which catalyzes the formation of amide bonds between 
carboxylic acids and amines by activating carboxyl to form an O-urea derivative. This 
derivative then reacts readily with nucleophiles. Carbodiimide has been used in this 
work for the coupling reaction of the alginate with the GRGDY peptide as the water- 
soluble derivative EDC.HC1, as it is represented in figure 3.2.
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(ALGINATE)
HCI"
C H 5 C H 2 N  =  C = H — <CH2)3—f £ - C H 3
EDC I
CH3
Hf
H C f
U ♦CHjCH 2— NH— C = N— (CH2>2—N— CH^
CH3
q  unstable amine-reactive 
intermediate
pjm a Amino group 
N H ? R ?  (PEPTIDE)
O O H
il il I x CHa
RjC— N— R2 4  CHaCHjN— C— N— (C H ^  N
H H " CH3
ALGINATE-GRGDY UREA
Figure 3.2: The mechanism of the reaction of alginate with peptide, highlighting 
the role of the water-soluble 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC) 
as coupling agent. The schematic shows the carboxyl group (-COOH) of the 
guluronic acid units of the alginate polymer involved in the reaction. The amino 
group (-NH2) of the glycine (G) residue at the beginning of the GRGDY peptide 
sequence, which is the peptide’s group involved in the reaction, is also shown in the 
illustration above. Thus, Ri represents the alginate polymeric chain, whereas R2 
represents the peptide GRGDY sequence. EDC catalyses the formation of amide 
bonds between the alginate’s carboxylic acids and the peptide’s amino groups by 
activating carboxyl to form an urea derivative. Manufacturer-prepared EDC solution 
was tested as an alternative coupling agent, under the hypothesis that it would reduce 
the protonation of the peptide’s amino group thus increasing the efficiency of the 
reaction. (Picture sourced from Instructions EDC Pierce, available at 
http://www.piercenet.com).
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However, a manufacturer-prepared EDC solution was also tested as a possible 
better coupling agent for the incorporation of the GRGDY peptide on both SLG 100 
and SLG20 alginates. When EDC.HC1 is used in standard coupling reactions, the 
hydrochloride salt may protonate the terminal amino groups of the peptidic chain, 
thus reducing the efficiency of the coupling reaction. Addition of a base would 
therefore be necessary to avoid this protonation. The use of the manufacturer- 
prepared EDC solution (i.e. without hydrochloride salt crystals) was tested in order to 
see whether it would increase the efficiency of the coupling reaction, by reducing the 
protonation of the terminal amino group of the GRGDY peptide. The EDC solution 
was used to the same concentration of 9X EDC as in the previous experiments with 
solid EDC. It was filtered with the same filters used for the reactant in the solid form, 
and added to the reaction at exactly the same time-point in the derivatisation 
procedure.
Amino acid analysis was performed on the alginate-GRGDY after completion of 
the coupling reaction involving the manufacturer-prepared EDC solution, and these 
results are also described in section 3.3.1. The results for the analysis of alginate/cells 
beads obtained by using alginate-GRGDY derivatised with liquid EDC are presented 
in chapter 5.
3.2.2.4 Peptide source and concentration tested for the alginate 
derivatisation
The peptide used in this work was provided by two different suppliers. The 
GRGDY peptide supplied by Neosystem Groupe SNPE was used in the first 
preliminary experiments; when this was no longer available peptide supplied by 
Albachem Limited was used. The amount of the GRGDY peptide that was added to 
the alginate was varied between IX, 10X and 32X, where IX was lpg of peptide 
added per lmg of alginate [Rowley et al., 1999], and 10X and 32X were respectively 
ten and thirty-two times the peptide’s concentration per lmg of alginate. These 
investigations were performed to determine which was the lowest peptide 
concentration enabling incorporation of the GRGDY peptide on the alginate matrix 
prior to its use for the preparation of beads encapsulating cells.
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The GRGDY peptide sequence of the product originally supplied by the 
manufacturer was analysed with nuclear magnetic resonance and mass spectrometry, 
in order to obtain information on the chemical structure of the peptide, and to confirm 
it was supplied as a complete pentapeptide sequence from the manufacturer (please 
see section 3.3.3). After completion of the derivatisation reaction, the alginates 
coupled with the different peptide concentrations were mixed with the cell suspension 
and used for the preparation of alginate/cells constructs. The results obtained from 
these analyses are presented in chapter 5.
3.2.3 Dialysis step as purification method of the alginate- 
GRGDY
After completion of the 20-hour reaction it was necessary to remove from the 
reaction mixture the excess reagents and un-reacted peptide, which would otherwise 
bind to the cells and compete for binding sites with the alginate-GRGDY, since it is 
not bonded to any alginate. Removal of by-products toxic to the cells, such as urea, 
was also necessary. Gamma-irradiated Slide-A-Lyzer Dialysis Cassettes (Pierce, 
Rockford, Illinois) with a molecular weight cut-off (MWCO) of 3.5 kDaltons were 
used to ensure purification of the alginate-GRGDY by removal of the unwanted 
reactants. These devices effectively remove salts and small molecules less than 3,500 
daltons from solutions and are normally used for a wide range of applications, 
including low molecular-weight contaminant removal, buffer exchange, desalting, 
equilibrium dialysis, and concentration. The cassette membrane is composed of low- 
binding regenerated cellulose and features a hermetically sealed sample chamber to 
retain the sample. The dialysis cassette was hydrated in autoclaved reverse osmosis 
(RO) purified water (MilliQ Synthesis A 10, Millipore, Molshein, France) filtered 
through a UV irradiated 0.22 pm filter for 30 minutes prior addition of the alginate 
sample. The sample was then introduced into the cassette cavity by penetrating the 
self sealing port with a hypodermic needle attached to a syringe (please see schematic 
in figure 3.3). After removal of the needle, the gasket immediately resealed, ensuring 
that no sample was lost from the port of the cassette during dialysis.
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Figure 3.3: Schematic of the dialysis step for the alginate-GRGDY purification 
using Slide-A-Lyzer Dialysis Cassettes with 3.5 kDa MWCO membranes. (Picture 
sourced from http://www.piercenet.com).
1. The cassette cavity was filled 
with the alginate-GRGDY solution 
sample through one of the self sealing 
ports in the comer of the cassette.
2. The dialysis was carried out 
for 5 days, within autoclaved 
filtered RO purified water. 
Water changes were performed 
every 12 hours throughout the 
5-day dialysis cycle.
3. After competion of the dialysis, 
the dialysed alginate-GRGDY 
sample was withdrawn from the 
cassette with a sterile syringe and 
needle through the self sealing 
port.
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The dialysis was carried on for a minimum of 5 days, since preliminary 
investigations conducted at the beginning of this research concluded that 5 days was a 
suitable time necessary for completion of dialysis, as opposed, to a 2-day dialysis 
cycle. A shorter dialysis led to formation of alginate-GRGDY beads that were too 
weak and swelling within 24 hours after formation and addition of the medium of 
culture; the outer shell of the beads was still intact however the inner contents of the 
beads appeared to spill out due to the influx of water into the beads.
In order to maintain efficient dialysis all the way through the 5-day cycle, the 
dialysis water was changed every 12 hours, and was replaced with freshly autoclaved 
and filtered RO purified water. The whole procedure was performed within the 
laminar flow cabinet using previously autoclaved equipment, in order to ensure there 
was no build up of dialysed reactants in the water surrounding the reaction mixture. 
As a result, the whole dialysis step was performed in aseptic conditions, with the 
intention to remove the excess reactants and toxic by-products, while retaining the 
sterility of the alginate-GRGDY polymer, an essential prerequisite for its use in tissue 
engineering.
3.2.4 Concentration of derivatised alginate
The dialysis cycle resulted in the alginate-GRGDY being diluted due to influx of 
water into the dialysis cassette, i.e. following the concentration gradient. Since the 
resulting alginate-GRGDY was too diluted to form a strong scaffold, the material 
needed to be re-concentrated. Following the dialysis step, two different concentration 
methods, either lyophilisation or the use of a polyethylene glycol (PEG) solution, 
were investigated for the concentration of the alginate-GRGDY matrix. These 
different procedures, (procedures no. 1 and 2 and no. 3 and 4 respectively in the flow 
diagram in Figure 3.1) are described below.
3.2.4.1 Lyophilisation
After completion of dialysis, a lyophilisation step was performed in order to re­
concentrate the alginate-GRGDY, which had been diluted by the extensive dialysis. 
Particular care was taken during the lyophilisation procedure, in order to avoid phase
131
changes that could modify the pH and moisture content thus damaging the peptides. 
In early range-finding investigations performed at the beginning of this research a 
reduction of the alginate-GRGDY biological activity was observed when the 
lyophilisation was not performed properly, preventing cell elongation within the 
alginate-GRGDY/hMSCs three-dimensional constructs. These studies had shown that 
in order to maintain the stability of the peptide in the alginate hydrogels and the 
biological activity of the resulting derivatised alginate, it was necessary to perform a 
minimum 2-day lyophilisation cycle. In the subsequent experiments a 2-day 
lyophilisation step was performed on the derivatised alginate in aseptic conditions, in 
order to retaine the sterility of the final alginate-GRGDY product. As opposed to 
concentration with polyethylene glycol (PEG) solution, lyophilisation proved to be a 
more appropriate re-concentration method, requiring the least handling, and thus 
further ensuring the sterility of the final product. After completion of the 2-day 
lyophilisation cycle, the alginate-GRGDY was either frozen and stored at -20°C 
(procedure no.l), or it was immediately mixed with the cell suspension and directly 
used for the preparation of beads (procedure no.2 ).
3.2.4.2 Polyethylene glycol (PEG) concentration step
Concentration of the alginate with polyethylene glycol (PEG) was investigated as 
an alternative to the lyophilisation step in order to re-concentrate the alginate after 
dialysis. Preliminary investigations conducted at the beginning of this research had 
shown that freeze-drying the alginate-GRGDY may result in decreased biological 
activity, thus preventing cell binding to the matrix or compromising the cells capacity 
to elongate within the biomaterial. As a result, concentration of the alginate with the 
PEG solution was attempted as an alternative method to lyophilisation.
The use of solid PEG crystals was not considered because of cumbersome 
conditions. The use of the liquid Sterile Slide-A-Lyzer concentrating solution, which 
is supplied as a sterile product, was preferred. However, this procedure was 
problematic and required considerable handling of the sample, thus reducing the 
chances of maintaining sterility in the final alginate-GRGDY solution. The method 
involved suspending the dialysis cassette containing the dialysed sample solution in 
the sterile concentrating solution, and monitoring the weight over time. Frequent 
weighting of the alginate, while it was still within the dialysis cassette, was required.
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A measurement of the alginate weight was in fact taken every 10 minutes, in order to 
monitor carefully the changing volume and concentration of the alginate and to avoid 
an excessive loss of the alginate solution weight, which would result in the 
undesirable over-concentration of the alginate. In addition, it was difficult to perform 
the weighting under aseptic conditions, and ultimately the weight measurement for 
the alginate samples was not accurate. The graph in figure 3.4 shows the weight 
values of the dialysis cassette monitored throughout the re-concentration of the 
alginate-GRGDY with the concentrating solution.
Alginate w eight m onitored during re-concen tra tion  with PEG
solution
25
24.5 -
24 -
£  23.5 -
23 -
22.5 -
45
T im e (m inutes)
alginate weight
Figure 3.4: The weight of the dialysis cassette as monitored throughout the re­
concentration of the alginate-GRGDY with the PEG concentrating solution.
The graph indicates that the weight of the cassette was rapidly decreasing. Since a 
working volume of lmL was normally required for the preparation of the beads, and 
the volume of the alginate inside the cassette was visibly decreasing very quickly 
over time, the PEG re-concentration step was halted after 40 minutes. The volume of 
the resulting alginate solution was then measured with a sterile syringe and needle, 
mixed with the required volume of cell suspension and used for the preparation of the 
alginate/cells beads. The resulting alginate-GRGDY/cells constructs appeared to be 
considerably weaker than the constructs fabricated with lyophilised alginate, and 
started dissolving within few hours after formation and after addition of the growth 
medium (please see results in chapter 5).
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Thus, it can be concluded that the PEG concentration step did not prove to be an 
ideal method for the re-concentration of the alginate-GRGDY after dialysis. 
Lyophilisation was therefore preferred and was used in most of the following 
experiments.
3.2.5 Freezing/no freezing step
As shown in the diagram in figure 3.1, after completion of the whole 
derivatisation process, the lyophilised alginate-GRGDY was either frozen and stored 
at -20°C until use (procedure no.l in the diagram), or immediately reconstituted and 
mixed with the cell suspension for the preparation of alginate/cells beads (procedure 
no.2). Similarly, long-term storage at -20°C or immediate use for the constructs 
preparation and further analysis were investigated for the derivatised alginate 
prepared with the alternative procedure involving PEG-concentration step 
(procedures no.3 and no.4 respectively). The analysis of the different samples allowed 
for the investigation of the effects of freezing, low temperature storage and thawing 
on the gel strength and on cell behaviour and performance (i.e. cell adhesion, 
elongation, viability and proliferation) after immobilisation within the alginate- 
GRGDY matrix. These results are presented in chapter 5.
3.2.6 Sterility of alginate-GRGDY
For any biomaterial to be used as an implantable tissue engineered matrix in 
clinical applications, an essential requirement is for it to be non-toxic, biocompatible, 
non-immunogenic and pyrogen-free. For this reason Pharmacopea grade reactants 
(sulfo-NHS, EDC and GRGDY peptide) were used in the carbodiimide reaction and 
all these reagents were sterile filtered through 0.2pm 13mm syringe filters 
immediately prior to their use. This step ensured removal of microbes that would 
otherwise contaminate the alginate-GRGDY resulting from the derivatisation 
procedure.
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3.2.7 Reconstitution of the alginate-GRGDY
After completion of the derivatisation procedure, the resulting alginate-GRGDY 
was reconstituted by dissolution in normal saline solution (0.9% NaCl in water for 
injections, pH=7-7.4) supplemented with the necessary amount of 1M sodium 
hydroxide (NaOH), as it is described in section 2.3.2.5. The alginate was typically 
reconstituted to the desired 1% w/v final concentration, so that the solution was 
isotonic for subsequent addition to the cell suspension. The addition of NaOH was 
deemed necessary to allow the complete dissolution of the sterile Pronova derivatised 
alginate following 5-day dialysis cycle. The extensive dialysis with water had most 
probably removed the majority of the sodium ions along the alginate polysaccharide 
chain, thus permitting protonation of the carboxylic groups of the biomaterial. As a 
result, precipitation of alginic acid crystals was observed in the reaction vessel 
[Doumeche et al., 2004]. The addition of a base (i.e. NaOH) was necessary to 
solubilise the alginic acid precipitates
[www.fao.org/docrepAV6355E/w6355e04.htm], permitting complete dissolution of 
the alginate-GRGDY. The alginate-GRGDY solution was then mixed with the cell 
suspension for the preparation of the alginate/cells constructs; these results are also 
described in chapter 5.
3.2.8 CaCI2 solution as cross-linking agent
For the fabrication of alginate beads the alginate/cells mixture was syringed 
through a sterile 0 .1mm diameter blunt needle and then dripped into a calcium 
chloride (CaCh) solution, according to the method described in section 2.5.3. The 
resulting beads/droplets were left in the cross-linking solution for 15 minutes at room 
temperature and under agitation prior to being transferred into 24-well plates pre- 
loaded with the necessary amount of growth medium and to starting the culture.
The calcium chloride solution for the cross linking of the alginate was obtained by 
dissolving the calcium chloride (Pharmacopeia grade) in normal saline solution, as 
described in section 2.5.2. The dissolution in normal saline was preferred to the usage 
of water for cell culture applications or buffered phosphate saline solutions such as
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PBS, for the same reasons described previously for the alginate dissolution (please 
see section 2.3.1).
Typically a 1% w/v CaCh solution, corresponding to a concentration of 90mM, 
was used for the cross-linking of the alginate. However, it is recognised that the 
physiological CaCb concentration for cells is 1.8mM, considerably lower. The high 
molarity (90mM) of the CaCb solution used in this research may therefore be toxic 
for the cells, but was found to be necessary to effectively cross-link the alginate 
molecules. In fact, previous studies proved that the 1 % CaC^ solution is the lowest 
concentration able to reproducibly and effectively work as cross-linking agent 
[Markusen, 2005].
3.3 Characterisation of the alginate matrix
3.3.1 Characterisation of the alginate-GRGDY by amino acid 
analysis
Amino acid analysis was employed in this project as a method of deducing the 
degree of derivatisation on the alginate, since it could be used to directly measure the 
amount of peptide present in the alginate sample.
Approximately 10 mg samples of the alginate-GRGDY resulting from the 
derivatisation procedure were sent for amino acid analysis (Alta Bioscience, 
University of Birmingham) in order to ascertain the degree of peptide attachment onto 
the alginate polymeric chain. The analysis was performed according to the procedure 
described in section 2.4.1. All the samples analysed were SLG 100, whereas high M- 
unit (SLM100) or low viscosity (SLG20 and SLM20) alginates were derivatised and 
investigated mainly for the preparation of successful three-dimensional constructs 
with the cells (please see data presented in chapter 5).
The GRGDY sequence of the peptide used in the derivatisation of the alginate is 
shown in figure 3.5: a glycine (G) starts off the pentapeptide at the N-terminal side, 
and a tyrosine, Y (side chain = CH2-C6H4-OH) finishes the pentapeptide at the C- 
terminal side.
136
/
GLYCINE
«n
f GLYCINE
t ( Q
/ TYROSINE
ASPARTIC ACIDARGININE
(R) (D)
CH
Figure 3.5: Chemical formula of the GRGDY peptide sequence.
The amino acid analysis permitted the quantitative assessment of the four 
constituent amino acids glycine (G x 2 glycine residues for each of the pentapeptide 
sequence), arginine (R x 1 arginine for each of the penptapeptide sequence), aspartic 
acid (D x 1 aspartic acid for each of the pentapeptide sequence) and tyrosine (Y x 1 
tyrosine for each of the pentapeptide sequence) incorporated into the alginate after 
derivatisation. However, it was not possible to perform statistical analysis on the data 
obtained because only one measurement was taken from each sample. As a result, the 
comparison of the data can be characterised as indicative. Table 3.3 summarises all 
the amino acids data obtained from the analyses performed on approximately 10 mg 
samples of lyophilised SLG 100 alginate-GRGDY.
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Exp.
no.
alginate-GRGDY
num ber
ALGINATE REACTANTS PEPTIDE ASPARTIC
ACID(D)
nmole/mg
GLYCINE
(G)
nmole/mg
TYROSINE
(Y)
nmole/mg
ARGININE
(R)
iLmok/mg
TOT.
AA
nmole/
mg
Y/D Y/R
- . 0 0 0 0 0 0 0
1 1-Neosystem SUM 00 9X 32X 17.40 38.40 , 5.47 19.30 80.57 0.314 0.283
2 12X 18.30 41.40 5.45 19.60 84.75 0.298 0.278
■5 6 ct r*i nn OY LOX 7.700 16.900 3220 7.700 35.50 0.418 0.418
1-Albachem oULxiUU V A 32X 24.000 48.400 9.340 23.700 105.00 0.389 0.394
3 10 SLG100 9 X  (liq.EDC) 32X 12.000 21.800 1.470 11.100 46.40 0.122 0.132
Table 3.3: Amino acid analysis data: Hie amino acids resulting from hydrolysis of
the samples were separated by ion exchange chromatography, visualised by reaction 
with liiiihydiin and then quantified. Hie values of the four amino acids constituting 
the GRGDY peptide are expressed in n.mol/mg of alginate. Hie analysis was 
performed by Alta Bio science. University o f Birmingham.
A first amino acid analysis was performed on high G alginate derivatised with 
either 9X or 12X EDC and sulfo-NHS. The conditions employed for the 
derivatisation of these alginates are summarised in table 3.1, where these polymers 
are respectively designated as “alginate-GRGDY no .l” and “alginate-GRGDY no. 2”. 
The GRGDY peptide, which was supplied by Neosystem in this first experiment, was 
added at 32X concentration for the coupling reaction. Plain (non-derivatised) alginate 
SLG 100 was tested as negative control. As it is shown in table 3.3, no detectable 
amino acids were found in the plain alginate. On the other hand, all four component 
amino acids (G, R, D and Y) of the GRGDY pentapeptide were present in the alginate 
after derivatisation with either 9X (designated “alginate-GRGDY no. 1 - Neosystem” 
in table 3.3) or 12X reactants (designated “alginate-GRGDY no. 2” in table 3.3), 
indicating that a successful coupling reaction was achieved in both cases. In addition, 
no significant difference was observed in the amino acid content for the alginate- 
GRGDY coupled with either 9X or 12X reactants (EDC, sulfo-NHS) concentrations. 
9X reactants, 32X peptide were therefore deemed to be sufficient to achieve 
derivatisation of the Pronova SLG 100 alginate. As a result, 9X was maintained as the 
reactants concentration throughout all the subsequent experiments.
However, the most anomalous result observed in both cases was that the tyrosine 
level measured from this analysis was considerably lower than expected, since from 
the chemical structure of the GRGDY peptide (figure 3.5) the theoretical value 
expected for tyrosine is to be similar to the aspartic acid and arginine residues values 
(and therefore the Y/D and Y/R molar ratios are expected to be 1).
A lower concentration for the peptide was tested in a following experiment 
(indicated as experiment no. 2 in table 3.3): amino acid analysis was performed on 
alginate SLG100 derivatised with 9X reactants (EDC and sulfo-NHS) and 10X 
GRGDY peptide concentrations, (designated “alginate-GRGDY no. 6” in both table
3.1 and table 3.3) in order to see whether 10X was a sufficient peptide concentration 
to achieve successful coupling reaction. In the same experiment, the alginate SLG 100 
was coupled also with 9X reactants and with a higher (32X) GRGDY peptide 
concentration, and the amino acids levels were measured in the resulting alginate- 
GRGDY (designated “alginate-GRGDY no. 7” in table 3.1 and “alginate-GRGDY no. 
1 -  Albachem” in table 3.3), so that it was possible to have a direct comparison of the
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alginate derivatised with either 10X or with 32X of the GRGDY peptide. These data 
are also presented in table 3.3 (experiment no. 2).
The peptide used in this second experiment was supplied by a different 
manufacturer (Albachem), since the peptide from the previous supplier (Neosystem) 
was no longer available. Amino acid analysis data revealed that, regardless of the 
peptide concentration used, it was possible to achieve successful incorporation of the 
complete pentapetidic GRGDY sequence onto the alginate. As it is shown in table 
3.3, the four G, R, D and Y amino acids appeared to be present in all the alginate- 
GRGDY samples, indicating that peptide attachment was achieved also when the 
GRGDY peptide was used at a lower (10X) concentration. In addition, the amino acid 
levels measured for the alginate coupled with 10X peptide were 3 times lower than 
those measured for the same alginate derivatised with the higher (32X) peptide 
concentration, indicating direct proportionality between the amino acid levels and the 
amount of peptide used for the carbodiimide reaction.
Interestingly, the amino acid levels obtained in this experiment from the alginate 
coupled with the 32X peptide concentration were higher (average increase of 27.5% 
for the D, G and R amino acids) than those obtained for the previous experiment 
(experiment number 1 in table 3.3), where the same reactants (9X) and peptide (32X) 
concentrations were used. These differences could be attributed to the different 
peptide’s manufacturer, since the Neosystem peptide employed for the first 
experiment was no longer available, and the peptide supplied by Albachem Limited 
was used instead.
It is interesting to note that tyrosine level was considerably lower than the levels 
of the other amino acids, indicating that loss of tyrosine, as seen in the previous 
experiment, occurred again during the coupling reaction.
Finally, amino acid levels were assessed on SLG 100 alginate derivatised with the 
manufacturer-produced EDC in solution. The amino acid levels detected are also 
included in table 3.3 (experiment no. 3). 9X reactants and 32X GRGDY peptide 
(Albachem Limited) concentrations were used, since from all previous experiments 
these proved to be sufficient concentrations for the achievement of the peptide 
incorporation onto the alginate polymer. The resulting derivatised alginate is 
designated “alginate-GRGDY no. 10” in both table 3.1 and table 3.3.
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The four constituent amino acids of the pentapeptide sequence were all present, 
indicating that the coupling of the peptide was possible also with the use of the 
manufacturer-produced EDC in solution. However, lower amino acids levels were 
measured in comparison to the amino acid levels detected in the previous 
derivatisation experiments, where solid EDC.HC1 was used. A 2-fold decrease was 
observed for the amino acids aspartic acid (D), glycine (G) and arginine (R) in this 
experiment, indicating that the use of liquid EDC did not improve the efficiency of 
the coupling reaction. One reason that the EDC.HC1 worked better could be that it is a 
hydrochloride salt, and therefore in this form the EDC is already protonated when 
placed into the reaction mixture. This therefore permits the EDC to couple straight 
away to an activated carboxylic acid group on the alginate and form the O- 
acylisourea intermediate (as shown in the reaction represented in figure 3.2). Of note 
is that, as in the previous experiments, tyrosine level was always lower than the levels 
of the other amino acids, indicating that the use of liquid EDC did not prevent 
tyrosine loss.
From the amino acid analysis data described above, it can be concluded that 
successful incorporation of the GRGDY pentapeptide onto the SLG 100 alginate 
polysaccharide chain was achieved with 9X sulfo-NHS and solid EDC and with 32X 
peptide concentrations. However, in all cases a significant loss of tyrosine was 
observed, being 64 % the average tyrosine loss observed in all the derivatisation 
experiments performed. The coupling reaction was also achieved with 10X peptide 
concentration. Nevertheless, the amino acid levels measured for the 32X peptide 
reaction were higher, and it was assumed that a higher peptide concentration would 
have allowed better cell survival after immobilisation of the cells in the alginate/cells 
constructs. For this reason the 32X peptide reaction was overall preferred for the 
derivatisation of the alginate scaffold. Interestingly, the use of EDC.HC1 was 
associated with higher amino acids levels, as opposed to the use of the manufacturer- 
prepared EDC in solution; thus, EDC.HCL proved to be a better option, and was 
preferred in all subsequent derivatisation experiments.
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3.3.2 Characterisation of the alginate-GRGDY by nuclear 
magnetic resonance
Nuclear magnetic resonance (NMR) spectroscopy was performed on alginate- 
GRGDY samples in order to qualitatively assess the presence of the peptide 
incorporated in the derivatised alginate after completion of the coupling reaction. The 
amount of peptide attached during the derivatisation procedure can be deduced from 
integrating the signals of the alginate and the peptide detected in the final NMR 
spectra of an alginate-GRGDY sample solution.
NMR spectroscopy, exploiting the magnetic properties of nuclei and measuring 
their radio frequency, allows identification of individual atoms in a pure molecule 
(please see section 2.4.2 for a more details description of this technique). Tyrosine 
has a very distinctive NMR spectrum, due to the aromatic ring present in its side 
chain. The most important signals for these investigations are the signals at 8 6.8 ppm 
from the H in the meta position on the aromatic ring on the side chain, and at 8 7.1 
ppm from the H in the ortho position on the aromatic ring (slightly further downfield 
than the meta-H due to the proximity to the oxygen at the bottom of the aromatic 
ring). As a result, these two peaks at 8 6.8 ppm and 8 7.1 ppm should always be 
clearly readable in the typical NMR spectrum of the full H2N-GRGDY-COOH 
pentapeptide sequence.
In addition to these, in a NMR spectrum, the readable signal from the alginate 
manifests in 3 singlets at 8 4.4, 4.7 and 5.1 ppm. These are the signals from the 
anomeric protons present on both the M- and G-units repeating throughout alginate; 
in the alginate spectrum they tend to be shifted slightly downfield from the rest of the 
proton signals due to their proximity to oxygen atoms. Previous work by Penman and 
Sanderson (1972) identified the singlet at 8 5.1 ppm corresponding to the anomeric 
protons (H-l) on the guluronic acid residues throughout the alginate sample being 
analysed, and the singlet at 8 4.8 ppm corresponding to the anomeric protons on the 
mannuronic acid residues. Once both peaks are able to be distinguished, the integrals 
can be compared, and the G to M ratio in the alginate deduced. At concentrations that 
are convenient for !H NMR analysis, the alginate solution is too viscous and causes 
linear broadening in the spectrum [Johnson et al., 1997]. For this reason, a partial acid 
hydrolysis was carried out on the alginate to reduce its viscosity and thus sharpen the 
peaks visible in the spectra. The hydrolysis also makes the peak from the anomeric
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protons on the mannuronic acid residues clearly visible, thus allowing the G to M 
ratio to be deduced. The protocol followed for the alginate hydrolysis and the 
subsequent acquisition of the NMR signals is described in section 2.4.2.
A whole series of preliminary NMR investigations was performed, firstly on 
different samples of plain (i.e. non-derivatised) high G Pronova sodium alginate, and 
secondly on mixtures of differing and known amounts of non-derivatised alginate and 
tyrosine. This series of experiments was performed in order to optimise the NMR 
protocol, so that it was possible to obtain spectra with clear signals, and ultimately to 
gain accurate integral values of the alginate and tyrosine peaks. The best signals were 
obtained on partially hydrolysed samples recorded with water suppression, at high 
temperature and using a 30° pulse sequence (as described in section 2.4.2). This 
method was therefore adopted also for the following NMR investigations on the 
alginate-GRGDY samples.
Figure 3.6 shows one of the spectra recorded on partially hydrolysed plain 
SLG100 alginate (8.3 mg) in deuterated water (D2O) after addition of 0.01 mg of 
tyrosine. The most important NMR signals of the tyrosine residue, at 5 6.8 ppm from 
the H in the meta position on the aromatic ring on the side chain, and at 5 7.1 ppm 
from the H in the ortho position on the aromatic ring, are evident in this spectrum.
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Fig.3.6 : 1-Dimensional nuclear NMR spectrum for Pronova non-derivatised 
SLG100 alginate (8.3mg), after partial hydrolysis in D2O (2mL) and subsequent 
addition of 0.0lmg tyrosine. The peaks at 7.09 ppm and 6.9 ppm (highlighted by 
arrows), signalling the presence of the two unique proton chemical shifts on the 
tyrosine ring, are evident.
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Nuclear magnetic resonance was also performed on alginate SLM 100, derivatised 
with 9X reactants (EDC, sulfo-NHS) and IX GRGDY peptide. The alginate-GRGDY 
resulting from the derivatisation procedure was dissolved in a normal saline solution 
made up with deuterated water (i.e. deuterated normal saline solution) prior the 
registration of the spectrum. The high M alginate-GRGDY dissolved completely in 
such a solution, and the three singlets at 8 4.4 ppm, 4.7 ppm and 5.1 ppm originating 
from the resulting alginate solution were clearly visible in the final spectrum (please 
see figure 3.7). However, no tyrosine peaks at 5 6.9 ppm and 7.1 ppm could be 
detected in the spectrum.
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Figure 3.7: 1-Dimensional nuclear NMR spectrum obtained for the derivatised 
(9X reactants, IX peptide) SLM 100 alginate after dissolution in deuterated normal- 
saline solution. The three singlets at 5 = 4.4, 4.7 and 5.1 ppm originating from the 
alginate solution were clearly visible whereas no tyrosine peaks at 5 = 6.9 ppm and
7.1 ppm could be detected.
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Finally, NMR was performed on SLG 100 alginate-GRGDY samples, obtained 
from the coupling reaction with 9X reactants and 1 OX peptide. The high G alginate- 
GRGDY failed to dissolve well in either deuterated water (D2O) or in deuterated 
sodium hydroxide (NaOD), and the spectra recorded in these cases were both weak, 
with only very faint alginate signals visible. In addition, none of the tyrosine peaks at 
5 6.9 ppm and 7.1 ppm were present in these spectra. Unlike the SLM 100 alginate- 
GRGDY, the high G alginate derivatised with 10X peptide did not dissolve in 
deuterated normal-saline solution either, therefore indicating that it is not possible to 
employ the same NMR method for the analysis of high M and high G alginates. A 
possible reason for this is that the higher G-unit alginate is much harder to dissolve, 
due to the stronger conformation between many repeating G-units. NMR was 
therefore re-attempted on alginate SLG 100, 9X reactants, 10X peptide after addition 
of 60 pL of deuterated sodium hydroxide (NaOD) in a deuterated normal-saline 
solution. Complete alginate dissolution was achieved this time, however once again, 
no tyrosine peaks were detected (please see spectrum in figure 3.8).
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Fig.3.8: NMR spectrum recorded for Pronova SLG100 alginate coupled with 9X 
reactants (EDC and sulfo-NHS) and 10X GRGDY peptide, showing no detectable 
peaks for the tyrosine amino acid at 7.09 and 6.9 ppm. The spectrum was registered 
on the alginate-GRGDY after dissolution in deuterated normal-saline solution 
supplemented with deuterated sodium hydroxide.
In conclusion, no tyrosine peaks were detected when both derivatised SLG 100 
and SLM 100 alginates were analysed with nuclear magnetic resonance (NMR) 
spectroscopy, either because the peptide concentrations (IX  and 10X) used for the 
coupling reaction were too low, or because NMR was not sensitive enough to allow 
the detection of the tyrosine peaks in the alginate-GRGDY resulting from the 
derivatisation procedure. NMR can have a low sensitivity as millimolar 
concentrations of substrates can be detected via NMR, whereas it is rather difficult to 
detect less than 0.5 pM of a substance using this technique [Syrota and Jehenson, 
1991; Wishart, 2006]. Since the tyrosine value measured via amino acid analysis is 
considerably low, this implies that NMR might not be a sensitive enough method of 
detection for the tyrosine in the alginate-GRGDY samples. Increasing the magnet 
strength to 500 MHz was a possibility for enhanced detection, however all spectra 
had been previously recorded at 358°K, whereas it is undesirable to reach such high 
temperatures when using the Brucker 500. As a result, the amino acid analysis 
described above (section 3.3.1) proved to be a more suitable method for the 
characterisation of the coupling reaction. It can therefore be concluded that, for the 
purposes of this study (i.e. the evaluation of the peptide incorporation in the alginate 
matrix), the amino acid analysis is a much more useful and reliable technique, 
permitting the quantification of the GRGDY peptide attached to the alginate after 
completion of the coupling reaction.
3.3.3 Nuclear magnetic resonance (NMR) and mass 
spectroscopy (MS) for the analysis of the GRGDY peptide before 
use in the derivatisation of the alginate matrix
As it is described in section 3.3.1, the amino acid analysis provided surprising 
results concerning the amount of tyrosine present in the alginate-GRGDY resulting 
from the derivatisation procedure. For this reason, in order to obtain information on 
the complete chemical structure of the Gly-Arg-Gly-Asp-Tyr (GRGDY) peptide 
supplied by the manufacturer, nuclear magnetic resonance (NMR) and mass 
spectrometry (MS) were performed on the peptide prior to its use in the alginate 
derivatisation procedure.
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The signals at 5 6.8 ppm and 7.1 ppm, originating from the tyrosine residue, and 
therefore detectable in a typical NMR spectrum for the whole GRGDY pentapeptide 
sequence, have already been described in section 3.3.2.
As already described in section 2.4.3, mass spectrometry can be employed to 
obtain information on the peptidic composition of a given protein or peptide. A 
typical mass spectrum is an intensity versus m/z (mass-to-charge ratio) plot 
representing the chemical analysis of the sample. Hence, the mass spectrum of a 
sample is a pattern representing the distribution of components (atoms or molecules) 
by mass (more correctly mass-to-charge ratio) in a sample. The x-axis of a mass 
spectrum represents a relationship between the mass of a given ion and the number of 
elementary charges that it carries, and is written in m/z, denoting the quantity formed 
by dividing the mass of an ion by the unified atomic mass unit and by its charge 
number. The y-axis of a mass spectrum represents signal intensity of the ions.
The NMR spectrum performed on the GRGDY pentapeptide (Albachem) (figure 
3.9) shows the two distinct peaks at 5 6.8 ppm and 7.1 ppm, generating from the four 
aromatic protons on the side chain of tyrosine. Additionally, the mass spectrum 
performed on the same Albachem peptide (figure 3.10) showed a peak at m/z 567, 
corresponding to the correct molecular weight of the complete GRGDY pentapeptide.
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Fig. 3.9: 1-Dimensional nuclear magnetic resonance spectrum of the GRGDY 
peptide (Albachem) before use in the carbodiimide reaction for the alginate 
derivatisation. The two peaks at 5 = 6.8 ppm and 7.1 ppm (highlighted by arrows), 
originating from the four aromatic protons on the side chain of tyrosine, indicate that 
the peptide was a complete pentapeptide sequence.
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Fig.3.10: Mass spectrum of GRGDY peptide (Albachem) before use in the 
carbodiimide reaction for the alginate derivatisation. The peak at 567 m/z 
(highlighted by the first arrow), signalling the presence of the complete peptide, is 
evident. In addition, a signal at 386 m/z (highlighted by the second arrow), 
corresponding to the weight of the peptide minus the terminal tyrosine residue, is 
detectable.
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These data confirmed that the peptide was intact before starting the derivatisation 
reaction, and that all the amino acids, including the terminal tyrosine residue, were 
present in the original peptide supplied by the manufacturer. However, on the mass 
spectrum shown in figure 3.10 a peak at m/z 386, corresponding exactly to the weight 
of the peptide minus the end tyrosine, is also detectable. The amount of the shorter 
NH2-GRGD-COOH peptide, as indicated by integration of the MS spectrum, was 
small but still notable. A possible reason for the presence of this signal, is that the 
terminal tyrosine residue on the end of the pentapeptide is unusually reactive and is 
lost easily at some stage during the MS process. Alternatively, the presence of the 
peak might indicate that some oligopeptide of the shorter sequence NH2-GRGD- 
COOH was present in the original peptide sample supplied.
3.4 Conclusions and discussion
The aim of the work described in this chapter was to investigate the carbodiimide 
coupling reaction between the alginate and the GRGDY peptide, and to test different 
protocols and working conditions with the intention of optimising the derivatisation 
chemistry.
Nuclear magnetic resonance and mass spectrometry methods were used to achieve 
a better characterisation of the GRGDY peptide supplied by the different 
manufacturer, prior to its use in the coupling reaction with the alginate. In addition, 
nuclear magnetic resonance spectroscopy and amino acid analysis were used for 
measuring the degree of peptide attachment onto the alginate-GRGDY resulting from 
the derivatisation procedure.
In each of the derivatisation experiments attempted ultra-pure Pronova sodium 
alginate was used; however different viscosities and guluronic (G)-unit to mannuronic 
(M)-unit ratio alginates were evaluated. Attention was focused mainly on experiments 
with high viscosity and high guluronic acid content (SLG100) alginate, since it was 
known from the literature that alginates with a higher guluronic acid monomer 
content formed more stable and rigid gels [Wang et al. 2003; Martinsen et al., 1989; 
Constantidinis et al., 1999], Nevertheless, both high and low viscosity SLM alginates
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were selected for investigation alongside high and low viscosity SLG alginates in 
some of the studies performed for the optimisation of the derivatisation procedure. 
This was done with the intention to see what effect these alginates had on the gel 
formed. No differences between the alginate types were visible during the 
derivatisation reaction and dialysis, only very slight variation after the alginate- 
GRGDY had been lyophilised, with the low viscosity alginates (SLG20 and SLM20) 
looking slightly less viscous and weaker than the high molecular weight (SLG 100 and 
SLM10) alginates-GRGDY. However, differences were visible when making the 
three-dimensional alginate-GRGDY/cells constructs (please see data presented in 
chapter 5).
9X EDC and sulfo-NHS concentration, as defined by Rowley, proved to be 
sufficient for the incorporation of the GRGDY pentapeptide onto the alginate 
polysaccharide chain, as demonstrated by the amino acid analysis data.
Amino acid analysis was performed on SLG100 alginate-GRGDY derivatised 
with either solid EDC or with manufacturer-produced EDC in solution. The low 
levels of the four amino acids detected in the final SLG 100 derivatised alginate with 
EDC in solution indicated that the use of such EDC solution did not improve the 
efficiency of the coupling reaction. The amino acids levels measured after 
derivatisation with the EDC in solution were in fact half as much as the amino acids 
levels obtained from the previous derivatisation experiment with solid EDC, and 
similar to the reaction with solid EDC, the tyrosine level was lower than the other 
three amino acids levels.
In addition, following the 20-hour reaction, a 5-day dialysis cycle in aseptic 
conditions was performed to remove the cell toxic reactants left over from the 
carbodiimide reaction (EDC and sulfo-NHS) and of the heavy metals and 
polyphenols from the commercial alginate.
Lyophilisation, as opposed to the use of a polyethylene glycol (PEG) 
concentrating solution, resulted as the most successful method for re-concentrating 
the alginate after completion of the dialysis cycle. In the derivatisation method 
investigated in this work a 3-day lyophilisation step, necessitating the least handling, 
was carried out in aseptic conditions thus potentially permitting the preparation of a 
final sterile product.
The amino acids analysis data presented in this chapter proved that the 
carbodiimide coupling reaction between the high G Pronova sodium alginate and the
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GRGDY peptide was successful. As a result, the protocol adopted in the present 
research for the carbodiimide reaction and the whole alginate derivatisation procedure 
was successful.
Due to the surprisingly low tyrosine level that was detected through the amino 
acid analysis performed on the derivatised alginate, it was decided to conduct nuclear 
magnetic resonance and mass spectrometry on the GRGDY peptide prior to its 
addition to the reaction with the alginate, in order to verify the amino acidic 
composition of the original peptide. Both these techniques permitted to obtain 
sufficient information on the peptide sequence, showing that all the four amino acids 
of the GRGDY sequence were initially present and that the original product supplied 
by the manufacturer was indeed a complete pentapeptide sequence.
The nuclear magnetic resonance investigations into the alginate-GRGDY were 
not successful and NMR did not prove to be a suitable method to ascertain the 
attachment of the GRGDY peptide on the alginate. The main reason for this was that 
the tyrosine signals, which were being investigated in this technique, were too low in 
all the alginate-GRGDY samples prepared and tested to be detected in the NMR 
spectra.
As opposed to nuclear magnetic resonance, amino acid analysis permitted a more 
reliable quantification of the degree of the GRGDY peptide incorporation, showing 
that all four constituent amino acids were present in the derivatised alginate.
Even though the data from the amino acid analysis indicated that the GRGDY 
peptide had been successfully incorporated in the alginate after completion of the 
derivatisation procedure, in all the conditions investigated a significant loss of the 
terminal tyrosine residue (on average approximately 60%) from the alginate after 
derivatisation was observed. The low value of tyrosine present in all the alginate- 
GRGDY correlated with poor outcomes in later cell immobilisation experiments 
(please see data presented in chapter 5).
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4. Characterisation of human mesenchymal stem 
cells (hMSCs) growth kinetics and metabolic activity 
in monolayer culture
In order to understand and characterise the growth of cells encapsulated within 
alginate hydrogels, it was necessary to establish first their unencapsulated growth 
characteristics in tissue flasks. As a result, a whole series of experiments in tissue 
culture flasks were conducted with the purpose of investigating the cells growth 
kinetics during their in vitro expansion in such a culture environment. The aim of 
these studies was to identify the optimal condition of culture, allowing cell viability 
and promoting cell proliferation in monolayer. The intention was then to apply the 
optimal condition identified to the culture of the alginate/cells constructs obtained 
after immobilisation of the cells in the alginate matrix.
This chapter describes the investigations performed on cells cultured in a two- 
dimensional environment (tissue culture flasks and microwell plates), prior to the 
addition of the alginate matrix and the preparation of alginate/cells constructs. The 
studies performed on the constructs resulting after immobilisation of the cells in the 
alginate matrix are described in chapter 5.
4.1 Growth of human mesenchymal stem cells (hMSCs) in 
tissue culture plastic
The cells used in the monolayer studies described in this chapter were multipotent 
fibroblast-like plastic-adherent cells isolated directly from frozen bone marrow 
samples of adult patients, according to the density gradient protocol described in 
section 2.1.1. It is recognized that these bone marrow-derived cells most likely 
consist of an heterogeneous population, including small and rapidly self-renewing 
cells that have the highest multipotentiality, together with slowly replicating, large 
and more mature progenitor cells at different stages of their differentiation pathway 
[Tavassoli and Friedenstein, 1983; Lichtman, 1981; Allen et al., 1990]. However, as 
already mentioned (please see section 1.2.4.5), for simplicity they have been here
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termed “mesenchymal stem cells” (MSCs), this being the designation in use at the 
beginning of this study.
Several investigators have previously observed that there is a large number of 
variables and parameters that must be considered in expanding hMSCs for 
experimental and clinical purposes [Sekiya et al., 2002; Caplan, 2000; Phinney et al., 
1999]. Taken into consideration the lack of a uniform approach for MSCs isolation 
and expansion [Sotiropolou et al., 2005], in this research several of these variables 
and parameters were examined for the culture of these cells. The intention was to 
define an improved and optimal culture protocol for obtaining standardised 
preparations of hMSCs, while maintaining both their proliferative and multilineage 
capacities.
The cryo-preserved bone marrow samples used for the cells’ isolation were 
obtained from the Department of Haematology, University College London Hospital. 
The use of human clinical samples had been approved by the University College 
London Hospital Ethics of Human Research Committee (project reference number 
03/0136). Frozen working cell banks were produced in order to supply experimental 
material for this research. In addition, only cells below passage 7 were used, due to 
gradual decrease in growth rate and loss of multipotentiality of the hMSCs following 
serial passage in culture [Bruder et a l 1997; DiGirolamo et al., 1999].
The cells grown in tissue culture flasks and plates under the different culture 
parameters investigated were assessed according to their percent viability at each 
passage of culture, their growth kinetics, population doubling level (PDL), doubling 
time (Td, hours), specific cell growth rate (p, hours'1) and their specific glucose 
consumption rate (GCR, g/cell/hr). For the determination of these measurements, the 
cell concentration was obtained using a hemacytometer (please see section 2.6.2), 
whereas the exclusion assay with trypan blue dye (please see section 2.6.3) was 
performed to assess the cell viability. Finally, for the calculation of the specific 
glucose consumption rate, the glucose concentration in the medium of culture was 
determined using the Nova Biomedical BioProfile 400 analyzer (please see section 
2.6.5).
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4.2 Single cell cloning by serial dilution
Single cell cloning by serial dilution is widely used for the clonal isolation of 
hybridomas and other cell lines that are not attachment-dependent. However, it is also 
very useful for cloning attachment-dependent cells when the cell plating efficiency is 
very low, unknown or unpredictable. The technique is fast and easy; however, like for 
most clonal isolation methods, there is no guarantee that the colonies arise from 
single cells. As a result, re-cloning a second time is usually advised to increase the 
likelihood that the cells originated from a single cell. The working assumption is that 
a single cell gives rise to one visible colony of cells. Clones are normally detectable 
by microscopy after 4 to 5 days from plating and they should be ready to score after 7 
to 10 days, depending on the growth rate of the cells. The plates are checked for wells 
that contain just a single colony. These colonies can then be sub-cultured from the 
original well into larger culture vessels.
In this research human MSCs cloning was attempted by limiting dilution. In order 
to obtain single cell-derived, clonally expanded human MSCs, seventh passage (p7) 
bone marrow-derived cells were suspended in growth medium at a density of 
3.78x105cells/mL. Five microliters of the cell suspension were diluted with either 
75.6mL or 37.8mL of growth medium. Two hundred microliters of the diluted cell 
suspensions were plated in each well of a 96-well, flat-bottomed culture plate, so that 
each well was plated with 5 cells/well in the first plate and with 10 cells/well in the 
second plate. The following day all wells from the plates seeded with either 5 
cells/well or 10 cells/well were carefully evaluated microscopically over a 2-week 
period for the detection of single cells. The aim of this study was then to count the 
number of colonies that would form from a single cell after an incubation period. 
However, in both cases the cells failed to adhere to the plastic surface and to grow in 
monolayer. No discernible adherent spindle-shaped cells were observed and no cell 
colonies were detected. It was therefore not possible to achieve successful cell 
cloning by limiting dilution in expanded hMSCs derived from a frozen bone marrow 
sample.
As a result in all subsequent experiments, following the cell separation by 
discontinuous density gradient centrifugation with Ficoll, putative hMSCs were 
recovered from the mononuclear layer and were identified based on their ability and 
tendency to adhere in monolayer condition to the plastic surface of the culture
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vessels. Adherent cells were then enriched over increasing passage level by removing 
the non-adherent cells through medium refreshments. The resulting attachment- 
dependent, fibroblast-like cells were grown in tissue culture flasks and plates and 
were characterised under different culture conditions according to the methods 
described in section 2.6.
Isolation of bone marrow MSCs using the plastic adherent method was first 
described by Friedenstein et a l (1968), who noticed that the precursor cells obtained 
were growing in plastic cultureware forming colonies capable of giving rise to 
chondrocytes and osteoblasts. Since at present no unique phenotype has been 
identified that permits the reproducible isolation of MSC precursors, the isolation and 
characterization of stromal cell function still relies primarily on their ability to adhere 
to plastic and their expansion potential [Fibbe, 2002]. The majority of research groups 
continue to use this traditional method for isolating bone marrow MSCs 
[Haynesworth et al, 1992; Gronthos & Simmons, 1996; Pittenger et a l 1999; 
Prockop et a l 2001; Gronthos et a l 2003]. Thus, this was also the isolation method 
preferred in this research for obtaining MSCs preparations.
4.3 Influence of basal growth medium and Mesenchymal
Stem Cell Stimulatory Supplement on hMSCs monolayer 
culture: preliminary conclusions
It is known that specific cell lines can be grown in vitro in optimally formulated 
culture or nutrient media [Hanss and Moore, 1964; Fahey et al, 1966; Ham and 
McKeehan, 1979]. The growth of various mammalian cells in vitro has been achieved 
in several chemically defined media supplemented with various sera, preferably fetal 
calf or newborn calf serum and other incompletely defined growth factors. One 
distinct source of variability is therefore the choice of a culture medium with 
appropriate formulation. This is, among the others, an important in vitro condition, 
having direct influence on stem and progenitor cells expansion and maintenance in 
culture.
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The study described in this section aimed to expand in vitro MSCs from human 
frozen bone marrow by using two different growth media that are commercially 
available and widely used for the culture of these cells. Culture media tested were 
low-glucose (1 g/L) DMEM medium (BioWhittaker, Walkersville, MD, USA) and 
MesenCult medium (StemCell Technologies Inc., Vancouver, BC, Canada). The 
influence of these media in the culture system of bone marrow-derived MSCs has 
already been investigated in a previous study [Jager et a l 2003], but rather than 
analysing cell growth characteristics, this study focused on the impact that these 
culture solutions have on the cells’ osteoblastic differentiation.
In this research low-glucose DMEM and MesenCult medium formulations were 
used for the cell expansion in either their serum-free formulation, or after addition of 
either 2% or 10% (v/v) serum (full description of these media is given in section 
2.1.5.1). The Mesenchymal Stem Cell Stimulatory Supplement from StemCell 
Technologies Inc., consisting of Fetal Bovine Serum supplemented with L-glutamine, 
was used for the serum-supplementation of both media. Thus, this study compared the 
effects of the two selected growth media and the Mesenchymal Stem Cell Stimulatory 
Supplement on the proliferative capacity and the growth rate of hMSCs expanded in 
tissue culture vessels.
Fourth passage (p4) bone marrow-derived hMSCs were plated in non-coated 12 
well tissue culture plates (please see section 2.1.5.1). The culture was maintained for 
12 days and the cells were assessed for cell count and cell viability at four different 
time-points, according to the protocols described in section 2.6.2 and 2.6.3 
respectively. The growth rate (p), the population doubling level (PDL) and the 
doubling time (Td) were calculated as described in section 2.6.4.
The results obtained from this study are presented in figure 4.1, which shows the 
growth kinetics curves for all the conditions investigated, and in table 4.1, which 
presents the values of the population doubling level, the doubling time and the cell 
growth rate for each of these conditions.
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Fig. 4.1 : Cell growth for p4 human MSCs cultured in either non-supplemented 
MesenCult or DMEM media, or in these same media after addition of either 2% or 
10% (v/v) serum (Mesenchymal Stem Cell Stimulatory supplement) concentrations. 
Data are presented as means +/- s.e. of three independent measurements (please see 
section 2.6.9).
Table 4.1: Population Doubling Level (PDL), Doubling Time (Td) and cell 
growth rate (ji) values calculated for the hMSCs expanded in 3 different serum 
conditions for each of the two basal media under examination (MesenCult medium 
and low-glucose DMEM). The values are calculated from day 6 to day 9 of culture.
Growth conditions
^ (h o u rs '1)day6-day9 PDL Td(hours)
0%FBS, MSCCM 0.147 490.3 0.0014
2%FBS, MSCCM 0.233 309.5 0.0022
10%FBS, MSCCM 0.554 130.0 0.0053
0%FBS, CDMEM -0.415 -173.5 -0.0040
2%FBS, CDMEM 0.655 109.9 0.0063
10%FBS, CDMEM 1 72 0.0096
MesenCult medium seemed to have advantages in MSCs survival when cells were 
maintained in serum-free culture, resulting more effective than DMEM medium in 
impeding cell death. However, for both media, the serum-free culture was associated 
with significant cell death over time, and supplementation with the Mesenchymal 
Stem Cells Stimulatory Supplement appeared to be an essential requirement for cell 
survival and cell growth. Moreover, after addition of the serum-supplement, the 
DMEM medium clearly permitted better cell growth and higher cell density as 
compared to the MesenCult medium. After 12 days in 10% serum-supplemented
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culture cell densities were 12.5xl03 cells/cm2 in low-glucose DMEM and 8.25xl03 
cells/cm in MesenCult medium. In addition, for both media, stimulation of the cell 
proliferation was further enhanced by increasing the serum-supplement concentration 
(please see figure 4.1).
These data correlate well with the doubling time and growth rate values presented 
in table 4.1: regardless of the serum concentration, hMSCs expanded in DMEM 
medium displayed lower doubling times Td (hours) and higher cell growth rates p 
(hours A) than cells cultured in MesenCult medium. For both media, 10% serum- 
supplementation was associated with lower doubling times and higher cell growth 
rates than 2% serum-supplementation, confirming the dose-dependent positive effect 
of serum-supplementation on hMSCs growth and proliferation rate.
Cell viability was calculated with the trypan blue dye exclusion assay over the 12- 
day period of culture examined for all the conditions investigated. At the end of the 
culture, human MSCs expanded in serum-free condition retained approximately 70% 
cell viability for both the MesenCult and DMEM media (72.4% and 71.8% 
respectively). However, as expected, cell viability was considerably higher for both 
media in the culture samples supplemented with Mesenchymal Stem Cell Stimulatory 
Supplement (respectively 92.4% and 92.7% for the 2%-serum MesenCult and DMEM 
media, and 96.2% and 98.5% for the 10%-serum media). These data once again 
confirmed the need for serum-supplementation in the protocol to be developed for the 
culture of hMSCs, indicating that serum remains a critical factor for guaranteeing cell 
survival and cell growth.
Finally, cell morphology by means of light microscopy was also evaluated for all 
the different medium and serum conditions described. A difference in the number and 
density of spindle-shaped, fibroblast-like cells was already noticed after 6 days in 
culture, with the low-glucose DMEM medium giving more visible colonies and 
greater densities than the MesenCult medium. At the end of the 12-day culture period 
colonies of adherent cells with a fibroblast-like morphology appeared significantly 
more densely packed on culture plates with the low-glucose DMEM. The plates 
where the MesenCult medium was used did not present the same cell growth and cell 
density.
It can be concluded from these results that the usage of MesenCult medium did 
not lead to any advantage for the proliferation of human mesenchymal stem cells. 
Low-glucose DMEM medium, which is less expensive, was therefore chosen and
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adopted as the standard medium of culture for these cells in all the subsequent 
experiments. The formulation for the standard “complete DMEM” medium used in 
this research is given in section 2.1.5.1. These data correlate well also with other 
studies investigating the isolation and expansion of murine and human marrow- 
derived mesenchymal stem cells, where the first adherent fibroblast-like cell colonies 
were achieved only after 5 days in low-glucose DMEM culture [Meirelles and Nardi, 
2003; Pittenger et al., 1999; Lee et al., 2003]. In addition, this study confirmed the 
well documented significant positive effect of serum-supplementation on hMSCs 
survival and expansion in tissue culture plates, which is further discussed in the 
section below (section 4.4).
In all the subsequent studies, supplementation with the less expensive Fetal 
Bovine Serum (FBS) was preferred to the usage of the Mesenchymal Stem Cell 
Stimulatory Supplement, which was found to consist only of Fetal Bovine Serum 
supplemented with L-glutamine.
The effects of FBS-supplementation in the low-glucose DMEM culture medium 
for the in vitro expansion of hMSCs were further investigated in the following 
experiments.
4 A Studies on Fetal Bovine Serum
The data presented above demonstrated a significant positive effect of serum 
supplementation on hMSCs growth. The use of animal-derived serum for the large- 
scale expansion of cells to be used in cellular therapy is an interesting and well 
known subject. To this date, MSCs have been expanded in a culture medium 
supplemented with Fetal Calf Serum in most of the reported clinical trials 
[Sotiropoulou et al., 2006; Meuleman et al., 2006], and all current protocols for in 
vitro culture of hMSCs include Fetal Bovine Serum as nutritional supplement 
[Shahdadfar et al., 2005]. However, due to its inherent characteristics, serum is an 
undesirable additive to cells that are expanded for therapeutic purposes in humans 
(please see section 1.4.2). Because of undefined composition, risk of contaminations, 
cost factor and also animal welfare considerations concerning the production of sera, 
the switch to serum-free alternatives is promoted by regulatory authorities, industry 
and the research community in general [Falkner E. et al., 2004;
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http://www.aahr.asn.au/campaigns/fetal_calf_serum.html; “Australian Code of 
Practice for the care and use of animals for scientific purposes” 7th edition 2004 (1.8 
page 6); Even et al., 2006]. It follows that a serum-free medium, allowing the 
generation of an adequate number of pathogen-free MSCs, is urgently needed for 
clinical use. As already mentioned in section 1.4.2, the possibility of growing certain 
types of cells in serum-free formulations has been undertaken by several laboratories 
[Sato, 1975; Mattinger et al, 2002; Bednarz et al., 2001; Pei et al., 2003; Amit et al., 
2003]. However, in these studies replacement of serum with supplements of better 
defined composition was found to be not very successful for the growth of normal 
cells in conventional culture media. As a result, a number of fundamental questions 
relating to the feasibility of employing serum-free culture systems for the successful 
expansion of hMSCs are still unanswered.
Following the preliminary results described in the previous section, other studies 
were performed, focusing on investigating further the effects of different Fetal Bovine 
Serum (FBS) concentrations on hMSCs proliferation. Both the impacts of serum 
alone (section 4.4.1) and in combination with other culture parameters (section 4.5, 
4.6 and 4.8.2) on hMSCs behaviour in monolayer condition were investigated. Fetal 
Bovine Serum specifically selected by the manufacturer (Stem Cell Technologies 
Inc.) for optimal hMSCs growth was used for this purpose.
4.4.1 Effects of Fetal Bovine Serum (FBS) on hMSCs growth 
and metabolism in monolayer culture
To compare the effects of different serum concentrations on the proliferative 
capability of hMSCs, fourth passage (p4) bone marrow-derived hMSCs were 
established in parallel low-glucose DMEM cultures either with no serum or after 
supplementation with one of three different concentrations of FBS (2%, 10% and 
15% (v/v)). The cells were plated in non-coated 24-well microplates and grown for 13 
days. At day 3, 7, 10 and 13, the cells were harvested and enumerated with 
haemocytometer (as described in section 2.6.2) and the viable cells were identified 
and counted with trypan blue dye (as described in section 2.6.3). In addition, for each 
serum condition, the spent medium was recovered from the wells at each harvesting 
time-point. The recovered medium was then analysed with the Nova Biomedical
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BioProfiler for the assessment of the glucose and lactate concentrations (as per 
protocol described in section 2.6.5). Cell morphology was evaluated over the 13-day 
period of culture by means of light microscopy (as described in section 2.6.1).
The results obtained from this study are presented in figures 4.2, 4.3 and 4.4, and 
in tables 4.2 and 4.3.
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Fig. 4.2 : Effects of Fetal Bovine Serum on cell proliferation. Human MSCs were 
cultured in non-coated plates, with low-glucose DMEM medium supplemented with 
lng/ml bFGF. The low-glucose DMEM was either used with no serum 
supplementation or after addition of increasing (2%, 10% and 15%) serum 
concentrations (v/v). The line represents the cell growth curve for cells cultured 
in standard control conditions (“complete DMEM”, i.e. medium supplemented with 
10% FBS and Ing/mL bFGF). Data are presented as means +/- s.e. of three 
independent measurements (please see section 2.6.9).
As it is evident from figure 4.2, a significant difference in cell growth between 
media with high (10% and 15%), low (2%) serum concentrations and the serum-free 
medium condition was observed. 10% FBS- and 15% FBS-supplemented cells 
displayed very similar growth curves, the cell proliferation reaching a plateau at 
approximately 45x103 cells/cm2 after 7 days in culture in both cases. Also cells 
cultured in the presence of 2% serum displayed certain cell growth, and in this 
condition linear cell growth was maintained over the 13-day period examined.
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However, the cells plated in low serum concentration expanded only approximately 
4-fold (4.26) in 13 days, whereas the same number of cells plated in both the high 
serum concentrations expanded 9-fold (8.9 for 10%-serum cells and 8.72 for 15%- 
serum cells) over the same culture period. On the other hand, serum-free culture did 
not support cell proliferation, and resulted instead in a 1.5-fold decrease in cell 
growth over the 13-day period.
The analysis of the cultures at the inverted light microscope revealed no 
discernible morphological differences between cells expanded in high (10% or 15%) 
or low (2%) serum concentrations (data not shown). In all conditions, the cells were 
well elongated and showed a spindle-shaped, fibroblastoid morphology, indicating 
the appearance under the inverted microscope of a representative MSC culture.
The population doubling times and cell growth rates calculated (please see table 
4.2) correlated well with the growth kinetic curves described above, with the 10%- 
and 15%-serum cells displaying the highest growth rates, and the lower serum cells 
having significantly lower rates. There was virtually no difference between the 
doubling times Td (hours) and cell growth rates p (hours'1) for cells cultured in either 
10% or 15% serum concentrations.
Table 4.2: Population Doubling Level (PDL), Doubling Time (Td) and cell 
growth rate (p) values calculated for hMSCs expanded in all four different serum 
conditions tested during the first week of culture.
Growth conditions
p (hours’1)day0-day7 PDL Td(hours)
0%FBS -0.763 -220.33 -0.003
2%FBS 1.511 111.22 0.006
10%FBS 3.165 53.08 0.013
15%FBS 3.235 51.93 0.013
High cell viability (please see table 4.3) was retained over the 13-day culture 
period under examination for both cells maintained in serum-free (>92.29%) and cells 
grown in serum-supplemented (>94.14%) conditions. However, even though not 
statistically significant (p = 0.049, Anova single factor test), a slight decrease in 
viability was observed over time for the serum-free cells. As expected, the 10%- and
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15%-FBS cultures consistently yielded the highest cell viability values throughout the 
same period of culture (>96.58% and >95.29% respectively).
Table 4.3: Percent cell viability values obtained for hMSCs cultured in four 
different serum conditions (0 %, 2 %, 10 % and 15 % v/v). Cell viability was 
determined by means of the exclusion assay with trypan blue dye at four harvesting 
time-points during the 13-day period of culture under examination.
Growth conditions
0%FBS day viability average (%) std. err. (±%)
3 94.95 4.51
7 97.22 4.81
10 96.49 6.08
13 92.29 2.20
2%FBS day viability average std. err. (±%)
3 95.59 4.10
7 96.50 2.48
10 94.14 1.08
13 96.16 1.14
10%FBS day viability average std. err. (±%)
3 97.44 0.96
7 98.75 0.77
10 96.58 0.78
13 100.00 0.00
15%FBS day viability average std. err. (±%)
3 95.29 1.59
7 99.28 0.90
10 97.04 0.32
13 98.42 0.70
As shown by the metabolites analyses performed with the Nova Biomedical 
BioProfiler (please see figure 4.3), cells cultured in either serum-free or 2%-serum 
conditions were not metabolising any glucose or producing any lactate, and were 
therefore metabolically inactive. On the other hand, hMSCs cultured in the presence 
of either 10%- or 15%-serum were characterised by a more intense metabolic activity. 
These data correlate well with the growth kinetics data presented in figure 4.2 and 
described above.
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Effects of Fetal Bovine Serum on hMSCs glucose metabolism and 
lactate production
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Fig. 4.3: Glucose consumption and lactate production measured over the 13-day 
culture period for in vitro expanded hMSCs maintained under different Fetal Bovine 
Serum culture conditions.
The specific glucose consumption rate (g/cell/hour) was calculated according to 
the equation described in section 2.6.5.2. Interestingly, no significant difference in 
specific glucose consumption rate was observed for the different serum conditions up 
to 10 days in culture. However, 10% FBS-supplemented cells appeared to metabolise 
glucose at an increasing rate during the last 3 days of culture (please see figure 4.4).
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Fig. 4.4: Impact of different Fetal Bovine Serum concentrations on hMSCs 
specific glucose consumption rate during in vitro expansion in tissue culture plates.
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These results demonstrated that MSCs from human bone marrow can be 
successfully expanded in vitro in a low-glucose DMEM medium formulation 
enriched with 10 % Fetal Bovine Serum. The use of higher serum concentrations did 
not lead to evident benefits, whereas lower serum concentrations proved to be not 
equally successful and effective in promoting hMSCs proliferation.
4.4.2 Testing hMSCs growth under different serum-free media 
conditions
Given the numerous disadvantages associated with the usage of Fetal Bovine 
Serum in cell preparations to be used for clinical purposes (please see section 4.4 and 
section 1.4.2), another approach to avoid additives of animal origin in our culture 
system was investigated. A study was performed to compare the effects of eleven 
different serum-free formulations on in vitro expanded hMSCs (please see section 
2.1.5.2.2 for a detailed description of the study protocol). The commercially available 
serum-free media investigated in this experiment are listed in table 4.4. The 
composition of these media is not published, but it is understood that most of them do 
not contain animal derived components, some formulations containing only a very 
low amount of defined proteins.
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Table 4.4: Serum-free media investigated for the expansion of hMSCs in tissue 
culture flasks. Following the manufacturer’s suggestion, the Knockout D-MEM 
medium (medium number 7) was supplemented with 15% Knockout Serum 
Replacement (Gibco, Cat. No.=10828).
No. M edium M anufacturer Protein
free
Phenol red Animal
origin-free
O ptim ised for
1 CD Hybridoma 
Medium without L- 
glutamine
Gibco X no X Human, mouse, rat 
hybridomas, 
myelomas.
2 Stem Pro-34 SFM 
without L-glutamine 
without antibiotics
Gibco Human hematopoietic 
progenitor cells
3 Protein free 
Hybridoma Medium 
PFHM II ( IX)
Gibco X X X Human, mouse, rat 
hybridomas, 
myelomas
4 Hybridoma-SFM 
serum-free 
Hybridoma Medium
Bio Whittaker no X no Human, mouse, rat 
hybridomas, 
myelomas
5 Ultraculture medium BioWhittaker 3mg/mL no Most cell types
6 UltraDOMA 
Hybridoma serum- 
free growth Medium, 
defined IX
Bio Whittaker 30pg/mL no Murine, human and 
chimeric cell lines
7 Knockout D-MEM  
optimised D-MEM  
Medium for ES cells
Gibco Murine and human 
embryonic stem (ES) 
cells
8 Ex-cell 325 PF CHO 
serum-free Medium, 
protein-free
SAFC
Biosciences
X X Chinese Hamster 
Ovary (CHO) cells
9 Ex-cell 302 CHO 
serum-free Medium
SAFC
Biosciences
Transformed CHO 
cells
10 Ex-cell 620-HSF  
hybridoma serum-free 
Medium
SAFC
Biosciences
1 lm g/L Hybridoma and CHO
11 1-cell CD CHO serum- 
free Medium, 
chemically defined
SAFC
Biosciences
X CHO cells
These media formulations were compared with the standard low-glucose 
complete DMEM medium (formulated as described in section 2.1.5.1) for their use in 
serum-free cultivation of hMSCs. Low-glucose DMEM is routinely used for culturing 
human mesenchymal progenitor cells [Gotherstrom et al. 2003; Jager et a l, 2003; 
Romanov et al., 2003; Pittenger et al., 1999; Lee et al., 2003]. In addition, low 
glucose concentration in DMEM-based media has demonstrated to consistently 
support human bone marrow-derived MSCs growth [Sotiropolou et al., 2005]. A 
DMEM formulation, supplemented with FBS and appropriate additives, is generally 
the medium recommended also for expanding in vitro mouse embryonic stem cells
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[Robertson, 1987; Hogan et a l, 1994]. On the other hand, the media investigated in 
this study have been designed for cultivation of several cell types in serum-free 
conditions (please see table 4.4). The Knockout-DMEM medium, used without serum 
supplementation, for example, is a special basal medium formulated specifically to 
improve the morphology and performance of Embryonic Stem Cells. Interestingly, 
this medium has already been found to be superior for murine MSCs preparation in 
comparison with other commercially available media [de Camargo Bittencourt et al, 
2006].
In this experiment hMSC cultures were simply assessed by means of inverted 
light microscopy, as this was intended to be exclusively a qualitative and preliminary 
exercise, designed to evaluate the survival and growth of MSCs in serum-free 
conditions. The objective was to perform an initial rough screening, and to select 
among the media formulations investigated those ones, if there were any, allowing 
cell survival and proliferation, as compared to the standard 10% serum-supplemented 
complete DMEM medium.
Persuading cells to grow in serum-free condition is a process that usually involves 
gradual weaning. In this study, for each of the media listed in table 4.4, hMSCs were 
sub-cultured using the sequential adaptation protocol described in section 2.1.5.2.2. 
The cultures were examined at the inverted light microscope every 2-3 days during 
culture for the qualitative evaluation of cell proliferation and cell morphology. The 
visual evaluation of the cultures was intended as a simple procedure, providing a 
rapid method of assessing and predicting the quality of the cultures. Photographs 
using an inverted light microscope and a digital camera were taken at the end of the 
culture (data not shown).
During incubation in the 50:50 (v/v) mixture of the traditional serum- 
supplemented DMEM - : serum-free medium, a marked reduction in cell proliferation 
was observed. Under this condition, for media number 5, number 6 and number 7 the 
desired 80% confluence was reached after 17 days of culture, whilst all of the other 
serum-free cultures did not permit a similar cell growth. However, the cells were 
harvested at the same time even if  confluence was not reached in all media with the 
purpose to evaluate the more effective serum-free formulation for MSC expansion 
and for reduced culture period. Cell proliferation was further hampered during the 
following sub-culturing passage in the 10:90 (v/v) serum-supplemented - : serum-free
171
mixtures. This condition was unsuccessful for most of the serum-free media 
investigated, as in most cases cell proliferation was not observed. On the contrary, 
MSC cultures showed significant morphological abnormalities. The cells varied in 
size and shape, with noticeable granules in the cytoplasm, and debris was formed in 
the medium. After about 6-7 days in the majority of the cultures the granular cells 
began to be vacuolated, rounded and finally detached from the base of the flasks. 
However, cell survival and proliferation were noticed in three of the serum-free 
media under investigation. Medium number 5 [UltraCulture medium (BioWhittaker)], 
medium 6 [UltraDOMA Hybridoma serum-free medium, defined IX (BioWhittaker)] 
and medium 7 [Knockout DMEM optimised D-MEM medium for EScells lx, high 
glucose, with sodium -pyruvate, without L-glutamine (Gibco) supplemented with 
15% Knockout Serum Replacement] were the only media that enabled prolonged 
cultivation without serum-supplementation. Even though cell growth was worse than 
what observed in control (10% serum-supplemented) cultures, these three serum-free 
media did allow cell proliferation, and 70-80% confluence was seen in these 
conditions approximately eleven days after plating. Cell morphology evaluation by 
inverted light microscopy revealed in these cultures the presence of expanding 
adherent spindle-shaped fibroblastoid cells compatible with undifferentiated MSCs. 
In these three medium formulations, cell morphology was also very similar to that 
observed for the cells maintained in the control flasks (please see figures 4.5 and 4.6 
for representative examples of the different cell morphologies observed for hMSCs 
expanded in the Knockout D-MEM optimised medium from Gibco and the Ex-cell 
302 CHO serum-free medium from SAFC).
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Fig. 4.5: Morphology of hMSCs expanded in 10:90 (v/v) complete DMEM - : 
Knockout optimised D-MEM medium (formulated with high glucose, with sodium 
pyruvate, without L-glutamine, supplemented with 15% Knockout Serum 
Replacement and supplied by Gibco).
Fig. 4.6: Morphology of hMSCs expanded in 10: 90 (v/v) complete DMEM : Ex­
cell 302 CHO serum-free medium, protein free (SAFC Biosciences).
These preliminary results indicated that long-term culture of hMSCs without 
serum supplementation is possible in the UltraCulture, the UltraDOMA Hybridoma 
and the Knockout DMEM optimised media. This study therefore suggested that these 
media might represent a promising alternative for human MSCs culture in serum-free 
environment. However, due to time constraint it was not possible to characterise and
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verify the purity and homogeneity of the resulting MSCs in this study. It would then 
be necessary to investigate further the effects of these three media conditions on the 
MSCs growth kinetics, multipotentiality and metabolic activity. In future experiments 
both the hMSCs isolation from frozen bone marrow samples and their expansion in 
tissue flasks could be performed in each one of these three formulations in totally 
serum-free conditions. If successful cell isolation and expansion were then achieved 
in a reproducible way under any of these conditions, the characterization of the 
resulting cell population would confirm whether or not the purity, homogeneity and 
“sternness” of the cells are preserved. Growth rate and population time analyses, 
differentiation potential assay, flow cytometric analysis of specific surface antigens 
(for the determination of MSC markers, osteogenic precursor markers, etc.) could be 
performed to ascertain whether these media are truly suitable for the preparation of 
pure MSC populations without serum supplementation. If this is the case, deployment 
of these media will permit avoidance of serum in the hMSCs culture system, thus 
excluding any variability in medium composition and also minimising the risk of 
infection resulting from the supplementation with serum.
4.5 Influence of Fetal Bovine Serum (FBS) and basic 
Fibroblast Growth Factor (bFGF) on hMSCs 
proliferation and metabolic activity in monolayer 
culture
In addition to serum requirements, the combination of cytokines delivered to the 
cell microenvironment is one more key feature for any stem cell culture system. 
Maintenance of the concentrations of these cytokines and their associated receptors 
over time is also extremely important [Bianchi et a l, 2001; Locklin et al, 1999; 
Deasy. et a l, 2002]. Significant efforts have been made to define cytokine and 
growth factors supplementation strategies to control stem cell responses. The 
cytokine composition of the medium is particularly challenging to optimise in stem 
cell culture because multiple cell types compete for several cytokines that each 
influence stem cell fate directly or indirectly [Zandstra and Nagy, 2001].
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The addition of supplementary factors for the successful isolation and expansion 
of MSCs, and in particular the use of bFGF for proliferation enhancement, are 
currently objects of thorough studies [van den Bos et ah, 1997; Hori et ah, 2004; 
Solchaga et ah, 2005; Bianchi et ah, 2003]. Basic Fibroblast Growth Factor (bFGF) is 
undoubtedly the most common growth supplement in MSC culture media. bFGF- 
supplementation in MSC culture has already demonstrated to increase cell 
proliferation and affect their multilineage differentiation capacity [Sotiropolou et ah, 
2005]. Several studies have previously reported that in various culture systems bFGF 
acts as a potent mitogen for MSCs, whilst maintaining their differentiation potential 
and increasing at the same time their telomere length [Kotobuki et al., 2004; Bianchi 
et ah, 2003]. Other investigations suggest that bFGF addition in bone marrow stromal 
cells in vitro culture is associated with a higher osteogenic differentiation potential, as 
compared to cell samples maintained in the absence of the growth factor. This 
indicates that the growth factor might favour their osteogenic potential [Martin et ah, 
1997; Reyes and Verfaillie, 1999; Nagai et al, 1999].
Given the significant impact that growth factors addition has shown in stem cell 
culture systems, it was of interest to this research to better define the role of basic 
Fibroblast Growth Factor (bFGF) on MSCs proliferation potential and viability.
The aim of this experiment was to investigate the combined effects of Fetal 
Bovine Serum (FBS) and basic Fibroblast Growth Factor (bFGF) on hMSCs growth 
and metabolism in monolayer culture. For this purpose, fourth passage (p4) hMSCs 
were expanded in 24-well tissue culture plates in low-glucose DMEM medium 
formulated with increasing FBS and bFGF concentrations (see section 2.1.5.4 for a 
detailed protocol description). The cells were harvested and evaluated for cell density, 
viability and metabolism at different time-points over the 2 -weeks period examined.
The growth kinetics data obtained for all FBS and bFGF conditions are shown in 
the graph in figure 4.7.
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Combined effects of FBS and bFGF on hMSCs proliferation
60000 -I
50000 -
< 40000 -
y  30000 - 
if
Z  20000 - 
10000 -
Culture period (daysi
0%FBS,+FGF
0%FBS,noFGF
10%FBS,+FGF 15%FBS ,+F GF
1Q%FBS,noFGF 15%FBS,noFGF
Fig. 4.7: Effects of Fetal Bovine Serum (FBS) and basic Fibroblast Growth Factor 
(bFGF) on hMSCs proliferative capacity. Fourth passage (p4) human MSCs were 
plated in 24-well plates and cultured with growth medium with increasing serum and 
bFGF concentrations for up to 13 days. Data are presented as means +/- s.e. of three 
independent measurements (please see section 2.6.9).
It is evident from these data that medium supplementation with bFGF resulted in 
a significant positive effect on cell expansion in all the serum concentration 
conditions examined. In particular, cell death was observed over time (13-day culture 
period) in any case when hMSCs were maintained in serum-free DMEM medium. 
However, the presence of bFGF in this serum-free microenvironment significantly 
hampered cell death; bFGF-supplemented cultures exhibited only 1.5-fold decrease in 
cell proliferation over 13 days, as opposed to a marked 4.7-fold decrease in cell 
growth observed over the same time period for serum-free/ bFGF-free cultures. 
Addition of bFGF resulted essential particularly in serum-deprivation (2% FBS) 
condition, where cell proliferation resulted heavily compromised in the absence of the 
growth factor. Over the same time period (13-day culture period) bFGF-withdrawal 
resulted in 1.2 fold increase in cell growth, as opposed to a 4.2 fold increase 
calculated for bFGF-supplemented cells. Finally, bFGF-supplementation led to higher 
cell proliferation also in standard (10% FBS) and 15% FBS culture conditions. The 
growth factor had similar positive effect in these two higher serum conditions. After 
13 days in bFGF-supplemented medium culture, a 1.9-fold cell growth increase was 
measured for standard (i.e. 10%) serum cultures, and a 1.4-fold increase for cells
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supplemented with 15% serum, as compared to cells expanded in the absence of the 
growth factor.
It is interesting to note that there was also a good correlation between the growth 
kinetics data described above and the population doubling time and cell growth rate 
values determined (please see table 4.5). The lowest doubling times and highest cell 
growth rates were measured for 10 % and 15 % serum- and bFGF-supplemented 
cultures. The values calculated confirmed the positive influence of the growth factor 
on hMSCs proliferation.
Table 4.5: Population Doubling Level (PDL), Doubling Time (Td) and cell 
growth rate (p) values calculated for hMSCs expanded in all the different FBS and 
bFGF conditions under investigation during the first week of culture.
Growth conditions 
day0-day7 
0%FBS,+FGF 
2%FBS,+FGF 
10%FBS,+FGF 
15%FBS,+FGF
PDL
-0.763
1.511
3.165
3.235
Td(hours)
-220.33
111.22
53.08
51.93
^ (hours'1)
-0.003
0.006
0.013
0.013
0%FBS,noFGF -1.248 -134.62 -0.005
2%FBS,noFGF -0.046 -3629.01 0.000
10%FBS,noFGF 2.337 71.89 0.010
15%FBS,noFGF 2.337 71.89 0.010
The percent viability values for cells expanded in the absence of the growth factor 
are presented in table 4.6. The effects of bFGF on cell viability can be easily deduced 
by comparing these values with the viability data obtained for the same cells 
maintained in bFGF-supplemented DMEM medium (please see table 4.3). 
Supplementation with bFGF appears to have a significant positive effect on hMSCs 
viability particularly in serum-free culture. In the presence of serum, the positive 
effect of the growth factor on cell viability was much less evident, and was virtually 
void for 2  % serum cells.
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Table 4.6: Percent cell viability values obtained for hMSCs expanded in the 
absence of bFGF under different serum conditions. Data are shown for each 
harvesting time-point during the 13-day period o f culture evaluated.
Growth conditions
0%FBS,noFGF day viability average (%) std. err. (±%)
3 100.00 0
7 100.00 0
10 83.62 1.96
13 67.14 15.45
2%FBS,noFGF day viability average std. err. (±%)
3 100.00 0
7 93.17 2.21
10 84.39 9.54
13 96.63 3.45
10%FBS,noFGF day viability average std. err. (±%)
3 100.00 0
7 95.14 2.69
10 95.29 1.79
13 95.28 1.73
15%FBS,noFGF day viability average std. err. (±%)
3 99.09 1.58
7 97.69 1.27
10 96.13 1.58
13 95.26 0.75
The graph in figure 4.8 indicates the glucose depletion and lactate production 
measured in the spent medium recovered from the cultures over the 13-day period 
under examination. These data are given for hMSCs cultured in 10 % FBS- 
supplemented DMEM medium, either with or without Ing/mL bFGF. It is evident 
from the graph that in standard ( 1 0 % v/v) serum condition cell metabolism results 
favoured after addition of bFGF in the medium of culture.
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Effects of bFGF on hMSCs glucose metabolism and lactate 
production (10% FBS)
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Fig. 4.8: Influence of bFGF-supplementation on hMSCs metabolic activity. The 
graph indicates changing in glucose and lactate concentrations measured in the spent 
medium over time in culture.
As it is shown in figure 4.9, hMSCs maintained in bFGF-supplemented 
culture displayed a significant increase in glucose metabolism rate during the 
last 3 days o f culture, but there was almost no difference in specific glucose 
consumption rate up to 1 0  days in culture.
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Fig. 4.9: Impact of bFGF-supplementation on hMSCs specific glucose 
consumption rate.
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The results presented in this section suggested that supplementation of MSCs 
culture media with 1 ng/mL bFGF clearly affects cell proliferation, resulting in higher 
cell proliferation rates and higher cell densities within two weeks of culture. These 
data confirm results obtained by numerous other research groups indicating that FGF 
has the capacity to stimulate the life span and proliferation rate of human bone 
marrow stromal cells [Hankemeier et a l, 2005; Martin et a l, 1997] and MSCs 
[Sotiropolou et a l, 2005; Solchaga et al, 2005].
Microscopic investigation of the bFGF-supplemented cell cultures showed 
homogeneous, dense, elongated, spindle-shaped cells which were retaining unaltered 
their fibroblast-like morphology over subsequent expansion passages. This was in 
line with other studies showing that the characteristic fibroblast-like phenotype was 
retained for over 4 weeks when bFGF was added in bone marrow stromal cells’ 
culture systems [Hankemeier et a l, 2005; Martin et a l, 1997]. However, it must be 
noticed that other groups [Sotiropolou et al, 2005; Solchaga et al, 2005] have 
observed that bFGF-addition critically alters MSCs morphology and phenotype, 
resulting in cells that tend to shorten and lose their spindled shape over time, a 
phenomenon which was not seen in this research.
Finally, supplementation of bFGF in the DMEM culture medium did not limit the 
differentiation capacity of MSCs. Osteogenic, adipogenic and chondrogenic potential 
were retained after the cells were expanded over consecutive passages in bFGF- 
supplemented medium, as it is described in section 4.7. These results are consistent 
with previous investigations, which have also indicated that MSCs expanded in vitro 
with the growth factor retain their osteogenic and adipogenic potential throughout 
many mitotic division, while at the same time appear to be able to differentiate to 
chondrocytes in FGF-supplemented pellet cultures [Tsutsumi et al, 2001; van den 
Bos et a l, 1997; Solchaga et al, 2005; Bianchi et a l, 2003].
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4.6 Growth kinetics and metabolic activity of hMSCs
maintained in different culture vessel coatings under 
different serum conditions
The surface of the culture plates and their impact on cell expansion is an 
additional parameter investigated in this research. It is known that extracellular matrix 
(ECM) components interact with specific cell surface adhesion receptors and control 
various cellular functions, including differentiation, proliferation, migration and 
apoptosis [Magnusson and Mosher, 1998]. By regulating cell differentiation and 
function, cell-ECM interactions are thought to orchestrate tissue organization both 
during fetal development and throughout normal adult life [Darribere et al, 2000; 
Damsky, 1999]. The use of an ECM as a coating for tissue culture surfaces permits 
the development of culture systems mimicking closely in vivo conditions. Such in 
vitro models, which incorporate components of the in vivo environment, usually 
succeed in supporting normal cell culture and function. It follows from these 
considerations that the choice of ECM is an important component to consider when 
optimising in vitro systems for cell culture.
Previous studies have indicated that culture surface properties have significant 
impact on the behaviours of MSCs. For instance, enhanced cell attachment and 
spreading, together with a significant increase in the number o f adherent cells, were 
observed when hMSCs were cultured on fibronectin-coated dishes [Ogura et al, 
2004]. In other studies hMSCs growth rate and proliferative life span resulted 
markedly increased in tissue culture dishes coated with a basement membrane-like 
extracellular matrix with similar composition to that o f Matrigel [Matsubara et al, 
2004]. Results presented by other groups have suggested that Matrigel coating itself, 
used at an appropriate density, provides a favourable substrate that improves the 
efficiency o f MSC expansion and their neuronal differentiation [Qian and Saltzman, 
2004]. A short description of fibronectin’s properties and matrigel composition are 
given in section 1.4.4.
Since MSCs are known to be strongly affected by the properties of culture 
substrates [Fried et a l, 1996; Gronthos et a l, 2001], the possibility of improving the 
yield o f bone marrow-derived MSCs through culture surface modification was 
investigated.
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To compare the growth potential of hMSCs expanded in monolayer culture in 
different culture surfaces, fourth passage (p4) cells were incubated and maintained in 
either standard non-coated tissue plates or in plates coated by the supplier with either 
fibronectin or matrigel. For each of these coating conditions, DMEM medium with 
increasing serum concentrations (0 %, 2  % or 1 0 % v/v) was used (please see section 
2.1.5.2.3 for a detailed protocol description). The cultures were maintained for 13 
days. Cell proliferation, cell viability and cell growth rates were evaluated at day 3, 7, 
10 and 13 as previously described (please see sections 2.6.2, 2.6.3 and 2.6.4 
respectively). In addition, morphology of hMSCs was observed by phase-contrast 
microscopy, following the protocol presented in section 2.6.1. Finally, for each 
condition a sample of spent medium was recovered from the wells at all four time- 
points and was then analysed with the Nova Biomedical Bioprofiler for the 
measurement of glucose and lactate concentrations (please see section 2.6.5 for a 
description of this technique).
The growth curves obtained for all coatings conditions are represented 
respectively in figures 4.10 (10 % serum), 4.11 (2 % serum) and 4.12 (serum-free).
Effects of coatings on hMSCs proliferation (10% FB S, +bFGF)
60000
50000 -
< 40000 ■ 
£
% 30000 ■
« 20000
10000 -
10 12 140 2 4 6 8
Ciitrve period (days}
I — No Coatirq —<■— Ffcronectin Matrigel I
Fig. 4.10: 10% serum-supplemented hMSCs expanded in non-coated plates 
(control, ♦ ■' line), fibronectin-coated plates ( "  line) or matrigel-coated plates 
( line). Data are presented as means +/- s.e. of three independent measurements 
(please see section 2.6.9).
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Effects of coatings on hMSCs proliferation (2%FBS,+I>FGF)
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Fig. 4.11: 2% serum-supplemented hMSCs cultured in non-coated plates (control, 
— line), fibronectin-coated plates ( ■■» line) or matrigel-coated plates ( 
line). Data are presented as means +/- s.e. of three independent measurements (please 
see section 2.6.9).
Effects of Coatings on hMSCs proliferation (0%FBS,+bFGF)
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Fig. 4.12: Serum-free hMSCs cultured in non-coated plates (control, • line), 
fibronectin-coated plates ( line) or matrigel-coated plates ( line). Data are 
presented as means +/- s.e. of three independent measurements (please see section 
2.6.9).
In standard (10 % FBS) serum condition the growth kinetics curves exhibited a 
similar pattern for cells expanded in either non-coated or fibronectin-coated plates
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(please see graph in figure 4.10). In both these culture surfaces cell growth reached a 
plateau at approximately 44.5xl03 cells/cm2 after 1 week in culture. On the other 
hand, Matrigel coating did not permit a similar cell growth, as cell density measured 
at day 7 was only approximately 25.7xl03 cells/cm2 and did not increase significantly 
over the second week of culture.
When hMSCs were cultured in DMEM medium supplemented with 2% serum 
(figure 4.11), fibronectin-coated plates seemed to permit a slightly better cell 
proliferation as compared to non-coated plates. However, the difference was not 
statistically significant (p = 0.048, Anova single factor test), and the cells experienced 
a similar cell proliferation profile in both conditions (cell growth increase measured 
over 13 days in culture was 4.5-fold in fibronectin-coated plates and 4.3-fold in non- 
coated vessels). On the other hand, as opposed to fibronectin and non-coated plates, 
Matrigel-coated plates significantly limited cell expansion, as in this case only a 2.8- 
fold increase in cell growth was measured over the same time period.
Also in serum-free culture (figure 4.12) hMSCs expanded in either non-coated or 
fibronectin-coated plates exhibited similar growth kinetics, experiencing over the 13 
days of culture respectively a 1.5-fold and 1.9-fold decrease in cell growth. In 
agreement with what was seen for the serum-supplemented cultures, the reduction in 
cell proliferation was much more evident in the Matrigel-coated samples (5.5-fold 
decrease over the 13-day period).
From these data, it can be concluded that, regardless of the serum concentration in 
the culture system, there is no significant advantage in the use of fibronectin-coated 
plates as compared to the use of standard non-coated plates. Besides, evidence 
suggests that Matrigel-coating significantly inhibits cell proliferation in both serum- 
free and serum-supplemented samples.
The doubling time and cell growth rate values determined for hMSCs expanded in 
the different coating plates are shown in table 4.7. These values are in accordance 
with the growth kinetic data described above. Cells expanded in either non-coated or 
fibronectin-coated plates were characterised by the lowest doubling times and the 
highest cell growth rates, and these values were similar for these two coating 
conditions. Higher doubling time and lower cell growth rate values were observed for 
the Matrigel-coated samples, confirming the negative impact of Matrigel on hMSCs 
proliferation capacity. Well in accordance with the results presented in the previous
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sections, doubling time values decreased and cell growth rate values increased by 
increasing FBS concentration in the DMEM medium formulation.
Table 4.7: Population Doubling Level (PDL), Doubling Time (Td) and cell 
growth rate (p) values calculated for hMSCs expanded in all the different conditions 
under investigation from day 0 to day 7 of culture.
Growth conditions
day0-day7 PDL Td(hours) p (hours'1)
10%FBS,NC 3.165 53.08 0.0131
10%FBS,FN 3.154 53.27 0.0130
10%FBS, Matrigel 2.361 71.16 0.0097
2%FBS, NC 1.511 111.22 0.0062
2%FBS, FN 1.646 102.06 0.0068
2%FBS, Matrigel 0.640 262.67 0.0026
0%FBS,NC -0.763 -220.33 -0.0031
0%FBS,FN -0.347 -483.50 -0.0014
0%FBS,Matrigel -2.067 -81.26 -0.0085
Microscopic observation of the cultures revealed that in both the non-coating and 
fibronectin-coating conditions most of the cells attached to the vessel surface and 
exhibited a fibroblast-like spindle shape. Under these conditions the cells proliferated 
to form a uniform confluent cell monolayer every 3 to 4 days. hMSC attachment and 
spreading over the culture vessels’ surface were not observed in Matrigel-coated 
plates. Lower cell numbers were noticed in the samples expanded in Matrigel-coating 
as compared to non-coating and fibronectin-coating samples (please see figures 4.13, 
4.14 and 4.15).
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Fig. 4.13: Morphology o f  hM SCs expanded in non-coated plates in medium 
supplemented with 10% FBS.
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Fig.4.14: Morphology o f hM SCs expanded in fibronectin-coated plates in 
m edium  supplemented with 10% FBS.
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Fig. 4.15: Morphology of hMSCs expanded in Matrigel-coated plates in 10% 
FBS- supplemented medium.
Cell viability was assessed at each time-point for all serum and coating 
conditions. These data are presented in table 4.8. Regardless of the coating condition, 
10 % serum-supplementation permitted the highest cell viability, whilst serum 
deprivation significantly affected cell viability, particularly for cells cultured in 
fibronectin-coated or matrigel-coated plates. Overall, the culture within Matrigel- 
coated plates was associated with the lowest cell viability values. There was no 
significant difference between cell viability for non-coating and fibronectin-coating 
conditions, both in 10 % FBS- or 2 % FBS- supplemented media. On the other hand, 
the viability measured in serum-free culture was higher for cells expanded in non- 
coated plates than for cells grown in fibronectin-coated plates.
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Table 4.8: Percent cell viability values obtained for hMSCs expanded in all the 
different conditions tested at each harvesting time-point during the 13-day period of 
culture.
Growth conditions
10%FBS,NC day viability average std. err. (±%)
3 97.44 0.96
7 98.75 0.77
10 96.58 0.78
13 100 2.20
10%FBS,FN day viability average std. err. (±%)
3 97.38 1.97
7 99.06 0.04
10 98.67 0.37
13 99.26 0.50
10%FBS,Matrigel day viability average std. err. (±%)
3 97.68 1.40
7 98.57 1.15
10 96.42 0.51
13 95.70 1.15
2%FBS, NC day viability average std. err. (±%)
3 95.59 4.10
7 96.50 2.48
10 94.14 1.08
13 96.16 1.14
2%FBS, FN day viability average std. err. (±%)
3 99.32 1.18
7 97.77 1.63
10 97.14 1.46
13 95.28 2.44
2%FBS, Matrigel day viability average std. err. (±%)
3 100 0.00
7 100 0.00
10 94.35 2.37
13 87.80 3.26
0%FBS,NC day viability average std. err. (±%)
3 94.95 4.51
7 97.22 4.81
10 96.49 6.08
13 92.29 2.20
0%FBS,FN day viability average std. err. (±%)
3 98.72 2.22
7 94.89 0.41
10 95.37 4.24
13 85.61 2.91
0%FBS,Matrigel day viability average std. err. (±%)
3 98.25 3.04
7 100 0.00
10 84.85 26.24
13 51.98 16.85
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The metabolic activity data obtained confirmed the overall effects of the different 
culture plates surfaces on MSCs behaviour. These data are presented in figure 4.16 
(10 % serum), figure 4.17 (2 % serum) and figure 4.18 (serum-free). In standard (10 
%) serum condition, hMSCs expanded in traditional non coated-coated plates 
exhibited higher metabolic activity than cells maintained in fibronectin-coated or 
matrigel-coated plates. On the other hand, cells grown in serum-free cultures resulted 
metabolically inactive, and regardless of the surface conditions examined they 
resulted unable to consume any glucose or produce any lactate.
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Fig. 4.16: Effects of coatings on hMSCs metabolic activity. Cells were cultured in 
low-glucose DMEM medium supplemented with 10% (v/v) Fetal Bovine Serum 
(FBS) and 1 ng/mL basic Fibroblast Growth Factor (bFGF).
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Fig. 4.17: Effects of coatings on hMSCs metabolism. The cultures were 
maintained in low-glucose DMEM medium supplemented with 2% FBS and Ing/mL 
bFGF.
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Fig. 4.18: Effects of coatings on hMSCs metabolic activity. Cells were expanded 
in serum-free low-glucose DMEM medium supplemented with 1 ng/mL bFGF.
The specific glucose consumption rates (g/cell/hour) were calculated for each 
serum and coating conditions as it is described in section 2.6.4. The values obtained 
are presented in figure 4.19, 4.20 and 4.21. In the 10 % serum-supplemented culture
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samples a significant increase in GCR was observed during the last 3 days of culture 
only for hMSCs expanded in non-coated plates, whereas no significant increase in 
GCR was detected for cells expanded in fibronectin- or Matrigel-coated plates. 
Results for 2% serum or serum-free cells are more difficult to interpret (figure 4.19 
and figure 4.21).
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Fig. 4.19: Impact of coatings on 10% serum-supplemented hMSCs specific 
glucose consumption rate.
Effects of coating on Glucose Consumption 
Rate (2%FBS)
_  8.00E-10 
|  6.00E-10 - 
§ 4.00E-10 - 
a  2.00E-10 - 
a  0.00E+00 -- 
-2.00E-10 f|
-4.00E-10 - 
-6.00E-10 -1
NC FN Matrigel
Fig. 4.20: Effects of coatings on 2% serum-supplemented hMSCs specific glucose 
consumption rate.
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In conclusions, evaluation of different culture surfaces (i.e. standard non-coated, 
fibronectin-coated and Matrigel-coated plates) for hMSCs, revealed that, regardless 
of the serum concentration in the culture system, those based on Matrigel impeded 
cell growth, viability and metabolic activity. On the contrary, both standard non- 
coated and fibronectin-coated plates consistently supported hMSCs growth and 
metabolism.
4.7 Multipotentiality of human adult mesenchymal stem 
cells expanded in monolayer culture
For regeneration of human cartilage, bone and even osteochondral defects, 
different cell sources are being investigated. In general, stem and progenitor cells are 
preferable to final differentiated cells due to their proliferation and differentiation 
capacity [Caplan and Goldberg, 1999; Lemare et al., 1998]. In vitro, culture- 
expanded bone marrow-derived mesenchymal stem cells have indeed shown the 
capacity to differentiate into a number of mesenchymal lineages, including 
osteogenic, chondrogenic and adipogenic [Pittenger et al., 1999: Muraglia et al., 
2000; Jiang et a l, 2002]. MSCs’ ability to retain their multilineage differentiation
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potential for over a significant number of cell doublings in culture is what makes 
them so attractive for a broad range of tissue engineering applications [Reyes et al, 
2001]. In vivo, several studies in a variety of animal models have shown that hMSCs 
may be useful in the repair or regeneration of cartilage [Wakitani et al, 2002], 
damaged bone [Livingston et al, 2001; De Kok et al, 2003], tendon [Award, et al, 
2003] and meniscus [Murphy et al, 2003]. Other investigations have indicated that 
MSCs may result useful also for repair of skeletal muscle [Wakitani et al., 1995], 
while there has been also some evidence that hMSCs can also be induced to 
differentiate into neurons in vitro [Woodbury et a l, 2000].
The differentiation potential of MSCs into multiple mesenchymal lineages -  that 
is, bone, cartilage and adipose tissue -  is most commonly used as a functional 
criterium defining MSC precursor cells [Fibbe, 2002]. In order to assess their 
multipotency, fourth passage (p4) bone marrow-derived plastic adherent MSCs 
isolated from a sample of adult frozen bone marrow were tested with the “Human 
Mesenchymal Stem Cell Functional Identification Kit” (R&D Systems), which 
permits the identification of human bone marrow-derived stem cells 
(BMSCs)/mesenchymal stem cells (MSCs) based on their ability to differentiate into 
mature phenotypes of adipocytes, osteocytes and chondrocytes. Prior to the start of 
this study, the cells were expanded in vitro in “complete DMEM” medium, 
formulated as described in section 2.1.5.1, until the necessary numbers of cells was 
achieved. The typical morphology of the hMSCs expanded for this experiment and 
seen prior the switch to the differentiation media is shown in figure 4.28 a).
In order to assess their adipogenic potential, hMSCs were plated at a density of 
2 .1x l 0 4 cells/cm2 and were cultured with adipogenic medium, as it is described in 
section 2.6.7.1. Morphologic changes in the cells, as well as the formation of neutral 
lipid vacuoles, were noticeable 3 weeks after induction and were visualised by goat 
anti-mouse FABP-4 immuno-staining (figure 4.22 A, B). Adipogenic differentiation 
was not observed 21  days after induction in the negative control samples (not been 
treated with the same FABP-4 antibody (figure 4.22 C)).
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Fig. 4.22: Adipogenic differentiation of bone marrow-derived hMSCs. Monolayer 
MSCs were treated with adipogenic medium. After 21 days, the cells were fixed and 
immuno-stained for goat anti-mouse FABP-4. A y B  (positive staining) and C 
(negative control).
To investigate the osteogenic potential of the bone marrow-derived MSCs, the 
same cells were plated at a density of 4.2x103 cells/cm2 and were incubated under 
conditions appropriate for inducing differentiation for osteogenic lineage (please see 
section 2.6.7.1). When induced to differentiate under osteogenic conditions, the 
spindle shape of the bone marrow-derived cells flattened with increasing time of 
induction and formed mineralized matrix, as evidenced by microscopic evaluation. 
The osteocytes phenotype was shown after 21 days of induction by 
immunofluorescence staining for mouse anti-human osteocalcin antibody (figure 4.23 
A, B). Osteogenic differentiation, as determined by positive immunostaining for 
osteocalcin antibody, was achieved in all the osteogenic medium-treated samples 
tested with the osteocalcin antibody. The immunofluorescence assay performed on 
induced cells not treated with human osteocalcin (negative controls) stained negative 
for the antibody (figure 4.23 C).
195
A196
Fig. 4.23: A , B  (positive staining) and C (negative control): mouse anti-human 
Osteocalcin staining for hMSCs induced for 21 days with osteogenic medium.
Finally, the chondrogenic potential of the expanded bone marrow-derived cells 
was evaluated by culturing 2.5x105 cells under the pelleted micromass system in 
chondrogenic medium, as it is described in section 2.6.7.1. After 3 weeks of induction 
in the chondrogenic growth medium, the TGFp-treated micromasses displayed 
positive immuno-staining for the goat anti-human aggrecan antibody (figure 4.24 A, 
B). The positive immunohistochemical analysis performed 21 days after induction 
confirmed the cartilage phenotype of the tissue generated in vitro. On the contrary, 
differentiated micromasses untreated with the primary antibody (negative control 
cells) did not display positive immuno-staining (figure 4.24 C).
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Fig. 4.24: A, B (positive staining) and C (negative control): goat anti-human 
Aggrecan staining for hMSCs induced for 21 days with chondrogenic supplement.
This study confirmed that human bone marrow-derived MSCs, expanded under 
appropriate culture conditions, can be induced to differentiate in vitro toward the 
adipogenesis, osteogenesis and chondrogenesis pathways. Under these conditions, the 
cells showed the ability to successfully differentiate toward the three different 
lineages, as demonstrated by the positive staining for the specific antibodies provided 
with the “Human Mesenchymal Stem Cell Functional Identification kit”, defining the 
mature phenotypes of adipocytes, osteocytes and chondrocytes. As a result, it can be 
concluded that hMSCs originally isolated from a human frozen bone marrow sample 
retain their multipotentiality after 4 expansion passages in culture.
4.8 Dissolved oxygen tension (DOT) as an important 
parameter for hMSCs in vitro expansion
It is recognised that the dissolved oxygen tension (i.e. the exact oxygen level at 
the cells/medium interface) is lower than the oxygen level in the humidified gas 
mixture within the incubator. This is due to oxygen consumption by living cells. 
However, since to our knowledge there is no practical methodology that can be 
employed to measure the actual dissolved oxygen tension (DOT), we here make no
formal distinction between the two values, and refer to both simply as to “DOT” or 
“oxygen level”.
This parameter has been demonstrated to play an important role on the growth 
kinetics and functionality of a broad range of cell types grown in vitro, including rat 
marrow-derived MSCs [Lennon et a l, 2001], human articular chondrocytes [Martin 
et a l, 2004; Domm et al., 2004], human embryonic stem cells [Ezashi et al, 2005] 
and human MSCs [Moussavi-Harami et al, 2004; Rochefort et a l , 2006]. The 
importance of the oxygen levels in in vitro settings has already been elucidated in 
section 1.5.5. Due to the established significance of this parameter on cell behaviour, 
dissolved oxygen tension was thoroughly investigated in this research. Firstly, the 
effects of the oxygen level alone on hMSCs proliferation rate and metabolism were 
investigated (section 4.8.1). These studies were followed by experiments focusing on 
the combined effects of the DOT and FBS-supplementation (section 4.8.2), and the 
combined effects of the oxygen level and supplementation with bFGF (section 4.8.3). 
To ensure maintenance of the desired gas mixture and DOT, incubators with two air 
sensors, one for CO2 and the other O2, were used for all these studies.
4.8.1 Studies investigating hMSCs’ proliferation and metabolic 
activity under different dissolved oxygen tensions
This section describes the studies performed on hMSCs cultures maintained in 
standard serum (10 %-supplementation), bFGF (1 ng/mL-supplementation) and 
coating (traditional non-coated tissue culture plates) conditions, where focus was kept 
on varying the DOT value alone. A first experiment was conducted by growing 
hMSCs for a 13-day period in one or the other of the following dissolved oxygen 
tensions: 21  % (the typical ambient O2 level employed in most culture settings), 10  % 
or 2 % (please see table 4.9 for clarification on the terminology adopted in this 
research for defining the “ambient” and “hypoxic” conditions).
Table 4.9: Terminology adopted in this research to define the different oxygen 
levels investigated during in vitro expansion of hMSCs in monolayer culture.
2 0 0
Oxygen level 21  oxygen 6-10% oxygen 1 -2 % oxygen
Terminology 
adopted in this 
research
Ambient
(hyperoxic)
Normoxic Hypoxic
To understand the effect of relatively long-term, low DOT on hMSCs expansion, 
in a second study ambient oxygen (21  %) culture was compared with 6  % and 1 % 
DOT samples over a longer (21 days) time period. In order to characterize the growth 
kinetics and metabolic activity of hMSCs under the various oxygen regimes, sixth 
passage (p6 ) hMSCs were expanded in 24-well tissue culture plates that were 
maintained in culture at 37°C, 5% CO2 in air in three different humidified (>95%) 
incubators, each one set at one of the three selected DOTs for each experiment. All 
the cultures were performed in traditional complete DMEM medium, formulated as 
described in section 2.1.5.1. The cells were harvested and evaluated for cell density, 
viability and metabolism at different time-points over the culture period under 
examination.
In both studies, hMSCs grown at the 21 % standard DOT were characterised by 
the highest proliferation potential, as it is evident from the graphs in figure 4.25 and 
figure 4.26. On the other hand, cells maintained at lower oxygen regimes (10 %, and 
2 % in figure 4.25, 6  % and 1 % in figure 4.26) did not show a similar growth 
capacity.
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Effects of Oxygen tension on hMSCs proliferation
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Fig. 4.25: Effects of dissolved oxygen tension (DOT) on hMSCs proliferation. 
hMSCs were expanded in non-coated plates, in low-glucose DMEM medium 
supplemented with 10% FBS and lng/ml bFGF. The cells were incubated at 5%C02, 
37°C and either 21% DOT (standard culture condition, • line), or 10% DOT 
( ■ line), or 2% DOT ( line). Data are presented as means +/- s.e. of three
independent measurements (please see section 2.6.9).
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Fig. 4.26: Impact of dissolved oxygen tension (DOT) on hMSCs proliferation. 
hMSCs were cultured in non-coated plates, in low-glucose DMEM medium 
supplemented with 10% v/v FBS and lng/ml bFGF. The cells were incubated at 
5%C02, 37°C and either 21 % DOT (standard culture condition, —•— line), or 6 % 
DOT ( ■ line) or 1 % DOT ( line). Data are presented as means +/- s.e. of
three independent measurements (please see section 2.6.9).
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Even though higher cell proliferation was generally observed in the first 
experiment than in the second one for all conditions, in both studies the same rather 
weak but still negative effect of I0 W-O2 on cell expansion was noted. In both 
experiments a 1.05-fold reduction in cell growth was seen after 2 weeks in culture by 
reducing the DOT from ambient level to 10% or 6%, whereas hypoxic cultures were 
characterized in both studies by a 1.3-fold decrease in cell proliferation over the same 
time period. Overall, the pattern followed by the growth kinetics curves under the 
lower oxygen conditions was similar in the two studies, and indicated that reducing 
the dissolved oxygen tension in the attempt to approach the physiologic values and 
mimic the in vivo environment does not enhance the cells proliferative capacity.
These results correlate well with the population doubling time and the cell growth 
rate values obtained for both studies, and shown in table 4.10 and table 4.11.
Table 4.10: Population Doubling Level (PDL), Doubling Time (Td) and cell 
growth rate (p) values obtained for hMSCs expanded in the three dissolved oxygen 
tension conditions tested during the first week of culture.
Growth conditions
Day0-day7 PDL Td(hours) u(hours '1)
21%oxygen 3.01 55.79 0.012
10%oxygen 2.49 67.42 0.010
2%oxygen 2.34 71.89 0.009
Table 4.11: Population Doubling Level (PDL), Doubling Time (Td) and cell 
growth rate (p) values calculated for the hMSCs expanded in the three different 
oxygen conditions tested during the first week of culture.
Growth conditions
p (hours1)day0-day7 PDL Td(hours)
21 %oxygen 2.54 66.21 0.010
6%oxygen 2.36 71.30 0.010
1%oxygen 2.10 80.12 0.009
hMSCs expanded in the 21 % standard in vitro oxygen concentration were 
characterized by the lowest doubling time and the highest cell growth rate calculated 
during the first week of culture. On the other hand, the same cells expanded at the 
lower DOTs required longer times to double and proliferate. Even though this
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dissimilarity was small, particularly for the second experiment were the difference 
was not statistically significant (p value = 0.048, Anova single factor test; table 4.11), 
a trend was observed for which by reducing oxygen levels in the culture settings the 
doubling times increased and concordantly the cell growth rates decreased.
As it is evident from the data shown in both table 4.12 and table 4.13, cell 
viability was not significantly affected by decreasing the oxygen level in the culture 
environment. For all three the oxygen levels investigated, high cell viability (> 98.47) 
was retained after 13 days of in vitro expansion in the first experiment (please see 
table 4.12). In addition, only a slight decrease in cell viability was observed over time 
for cells maintained in culture for a longer time period in the second experiment 
(please see table 4.13), indicating no O2 effect on cell viability.
Table 4.12: Percent cell viability values calculated for the cells cultured in the 
three different dissolved oxygen tension conditions under investigation at each 
harvesting time-point during the 13-day period of culture examined.
Growth conditions
21%Oxygen day average viability std. err. (±%)
3 96.93 1.28
7 98.22 0.86
10 99.49 0.20
13 98.47 0.63
10%Oxygen day average viability std. err. (±%)
3 96.37 0.92
7 98.06 0.61
10 99.03 0.86
13 99.06 0.55
2%Oxygen day average viability std. err. (±%)
3 98.41 2.75
7 97.84 0.96
10 99.27 0.32
13 99.02 0.50
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Table 4.13: Percent cell viability values calculated for hMSCs cultured in the 
three different dissolved oxygen tension conditions tested at the beginning (day 3) 
and at the end (day 2 1 ) of the culture period.
G row th co n d itio n s
21% oxygen day av e rag e  viability std . err. (±%)
3 96.15 2.03
21 90.97 2.94
6% oxygen day av e rag e  viability std . . (±%)
3 96.83 0.25
21 92.01 1.51
1% oxygen day av e rag e  viability std . err. (±%)
3 96.63 2.94
21 90.67 2.71
hMSCs maintained in either ambient or low (1-10%) oxygen were essentially 
identical as viewed by phase contrast microscopy. Individual subcultured cells 
appearing as adherent, fibroblast-like healthy cells were similar to one another in 
morphology and size regardless of the oxygen condition (please see figures 4.27 and 
4.28).
Fig. 4.27: Morphology of hMSCs expanded in the traditional 21% Dissolved 
Oxygen Tension.
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Fig. 4.28: Morphology of hMSCs expanded in 2% Dissolved Oxygen Tension 
condition.
As it is shown in figure 4.29 and figure 4.30, in line with the positive effect of 
high DOT on cell proliferation rate and cell density, hMSCs expanded in the 
traditional 21  % oxygen condition were characterised by a more intense metabolic 
activity, as compared to cells maintained in lower oxygen conditions. Interestingly, in 
both studies the positive effect of DOT on cell metabolism appeared to be 
concentration-dependent, the metabolic activity was the lowest for cells maintained in 
hypoxic (2  % or 1% oxygen) conditions.
E f fe c t s  o f  o x y g e n  on  G l u c o s e  m e t a b o l i s m  
a n d  L a c t a t e  p r o d u c t i o n
1.2
5» 0.8
0.0
= 0.4
0.2
1010 14
Ti m e
2% oxygen- 
- *-2% oxygan-
21 %oxygtn*
21%oxyg«n- 10% oxygen-
Fig. 4.29: Impact of dissolved oxygen tension on hMSCs metabolic activity.
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Effects of Oxygen on hMSC Glucose metabolism and Lactate 
production
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Fig. 4.30: Effects of dissolved oxygen tension on hMSCs metabolic activity. The 
cells were cultured in either 21 % or 6  % or 1 % dissolved oxygen tensions for 21 
days.
Specific glucose consumption rate data are presented in figure 4.31 and figure 
4.32. Interestingly, cells expanded in the ambient (21%) oxygen condition seemed to 
be characterised by a significant increase in GCR (g/cell/hour) during the last 4 days 
in culture.
Effects of Oxygen on Glucose Consumption
Rate
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Fig. 4.31: Effects of dissolved oxygen tension on hMSCs specific glucose 
consumption rate.
207
Effects of oxygen on Glucose Consumption
Rate
6.00E-09
4.00E-09
|  2.00E-09 -
g 0.00E+00 -
3  -2.00E-09 0 10 15 20 25
O -4.00E-09 - O
-6.00E-09 
-8.00E-09 -
Time (days)
— 2 1 %o x y g e n  —■— 6% oxygen  1% oxygen
Fig. 4.32: Effects of dissolved oxygen tension on hMSCs specific glucose 
consumption rate. The cells were cultured in either 21% or 6% or 1% dissolved 
oxygen tensions for 21 days.
4.8.2 Combined effects of dissolved oxygen tension (DOT) and 
Fetal Bovine Serum (FBS) on hMSCs proliferation and metabolism
In order to evaluate the combined effects of high and low dissolved oxygen 
tension and FBS-supplementation during in vitro expansion, hMSCs were cultured in 
either complete DMEM or serum-free DMEM for two weeks under a humidified 
(>95%) atmosphere of the high (21%) or the low (1%) DOTs (5% CO2 in air). In 
addition to cell density, viability and metabolism analyses, the cell samples were 
assessed by means of the Live/Dead Viability/Cytotoxicity assay with calcein 
AM/ethidium homodymer described in section 2.6.6. This two-colour fluorescence 
cell viability technique was used to measure intracellular esterase activity and plasma 
membrane integrity as indicators of cell viability.
The growth kinetics curves obtained from this study are presented in figure 4.33. 
In line with the results observed in the studies presented in the previous sections 
(sections 4.3, 4.4 and 4.6), hMSCs proliferative capacity was significantly enhanced 
by culture in FBS-supplemented medium. Regardless of the dissolved O2 tension 
maintained over the 14-day period of culture, serum-free culture did not allow cell 
growth. In addition, and in accordance with the results shown above (section 4.8.1),
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2-week (short-term) exposure of serum-supplemented hMSCs to 1 % oxygen was 
associated with a similar diminished proliferation potential, being 1.2-fold the 
decrease in cell growth measured as compared with growth of cells expanded in 
ambient oxygen level.
Effects of FBS and Oxygen tension on hMSCs 
proliferation
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Fig. 4.33: Effects of dissolved oxygen tension (DOT) on hMSCs proliferation in 
serum-free and 10% serum culture conditions. hMSCs were cultured in non-coated 
plates, in low-glucose DMEM medium supplemented with lng/ml bFGF. The cells 
were incubated in 5%C02, 37°C incubators with 21%02 level (10%serum standard 
culture condition = ■» line; serum-free condition = —■— line) or 1 % 0 2  level 
(10%serum or serum-free = and lines respectively). Data are presented as 
means +/- s.e. of three independent measurements (please see section 2.6.9).
These data were confirmed by the cell viability measurements obtained with the 
trypan blue dye exclusion assay and presented in table 4.14. High cell viability 
(>91%) was maintained over the 2-week period in serum-supplemented cultures, 
whereas serum-deprivation resulted in important cell death over time. Interestingly, 
this phenomenon was particularly evident and significant for serum-free cells 
expanded in hypoxic (1% O2 ) condition, for which cell viability measured 14 days 
after plating was reduced to 55%.
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Table 4.14: Cell viability values calculated for hMSCs cultured in all the different 
conditions tested at each harvesting time-point during the 13-day period of culture 
examined.
Growth conditions
21%oxygen,
+FBS day average viability std. err. (±%)
3 92.74 1.68
7 94.10 3.10
10 98.05 20.32
14 92.30 5.69
21%oxygen,
noFBS day average viability std. err. (±%)
3 90.37 4.20
7 90.48 16.50
10 66.35 19.20
14 82.93 1.84
1%oxygen,
+FBS day average viability std. err. (±%)
3 88.00 5.43
7 94.11 3.43
10 99.23 57.24
14 91.75 20.39
1%oxygen,
noFBS day average viability std. err. (±%)
3 77.07 1.98
7 73.82 16.14
10 25.00 33.06
14 55.56 18.86
Cell proliferation was determined for this study also by means of the MTT Cell 
Proliferation assay described in section 2.7, which confirmed the cell count/viability 
data obtained with hemacytometer and trypan blue dye exclusion assay described 
above. These data are shown in figure 4.34. The highest formazan absorbance values 
(index of mitochondria activity observable only for living and functional cells) were 
measured for serum-supplemented cells. FBS permitted significant cell growth over 
time, particularly in ambient oxygen level: the increase in absorbance readings 
measured from the first (day 2) and the last measurements (day 13) was 2.9-fold for 
cells expanded in traditional (2 1  %) oxygen settings, and 2 .6 -fold for cell expansion 
performed in hypoxic (1 %) condition.
Also the ambient (21 %) dissolved O2 tension seemed to have a positive influence 
on cell proliferation, and this effect was particularly noticeable and significant during 
the second week of culture. Absorbance readings taken from high oxygen cultures at
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day 9 and day 13 were in fact approximately 1.3-fold higher than the measurements 
detected for 1 % oxygen cells.
MTT assay : effec ts of FBS and Oxygen ten sion  on hM SCs 
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Fig. 4.34: Cell metabolic activity measured by means of the MTT Cell 
Proliferation assay. Data are presented as means +/- s.e. of three independent 
measurements.
Cell proliferation data were also confirmed in this study by the evaluation of the 
hMSCs culture with both phase contrast microscope and Live/Dead cytotoxicity 
assay. Photographs at the phase contrast and the confocal microscopes were taken at 
day 6  of culture. Cells expanded in 10% serum-supplemented growth medium at 21% 
O2 level appeared as healthy adherent, spindle-shaped cells at phase contrast 
microscopy analysis (please see figure 4.35 a). After treatment with the calcein 
AM/ethydium homodimer dyes provided with the Live/Dead Viability/Cytotoxicity 
assay, these same cell samples revealed at the confocal microscope the presence of 
intact, elongated cells displaying intense green fluorescence along their entire length 
(figure 4.35 c). No red fluorescence from ethidium homodimer could be detected in 
any serum-supplemented ambient oxygen cells, indicating that under these conditions 
hMSCs retain their membrane integrity.
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Figure 4.35: Photographs taken for cells maintained at 21% DOT, with or without 
serum. The photographs were taken at day 6 o f  culture with the phase contrast 
microscope (A and B) and with the confocal microscopes (C and D) after treatment 
with the calcein AM/ethydium homodimer dyes.
A) 21% oxygen, +FBS, day 6, phase contrast microscope; B) 21% oxygen, no FBS, 
day 6, phase contrast microscope; C) 21% oxygen, +FBS, day 6, confocal 
microscope; D) 21% oxygen, no FBS, day 6, confocal microscope.
Similar healthy morphology and intense green fluorescence were observed for 
serum-supplemented cells grown in hypoxic (1% oxygen) condition. However, in this 
case viable cells were visible in lower numbers, while a weak red fluorescence was 
noticeable at the confocal microscopy analysis (please see figure 4.36 c). These 
results indicate that hypoxia might be associated with cytotoxicity, a phenomenon 
that has already been observed for hepatocytes [Khan and O ’Brien, 1995].
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Figure 4.36: Photographs taken for cells maintained at 1% DOT, with or without 
serum. The photographs were taken taken at day 6 o f  culture with the phase contrast 
microscope (A and B) and with the confocal microscopes (C and D) after treatment 
with the calcein AM/ethydium homodimer dyes.
A) 1% oxygen, +FBS, day 6, phase contrast microscope; B) 1% oxygen, no FBS, 
day 6, phase contrast microscope; C) 1% oxygen, +FBS, day 6, confocal microscope; 
D) 1% oxygen, no FBS, day 6, confocal microscope.
In marked contrast, in all serum-free samples examined only very few adherent 
and elongated cells were visible at inverted light microscope (figure 4.35 b and figure
4.36 b), m ost o f  the cells having been removed with medium refreshments after 
detachment from the culture surface. Green calcein fluorescence was absent from all 
serum-free samples, confirming very low cell viability, in this culture condition 
(please see figure 4.35 d and figure 4.36 d). Diffuse red fluorescence o f low intensity 
was noticed in the cultures maintained in serum-free and hypoxic condition (figure
4.36 d), revealing damaged plasma membranes in these cell samples.
213
The doubling time and cell growth rate values determined for hMSCs expanded in 
high and low oxygen with or without serum are shown in table 4.15. These values are 
in accordance with the growth kinetic data described above and with the results 
described in the previous sections. In standard serum-supplemented cultures, 21 % 
DOT cells displayed lower doubling time and higher cell growth rate values than cells 
cultured in hypoxic condition. The lack of cell growth in serum-free culture was 
confirmed by the (negative) doubling time and cell growth rate values (please see 
table 4.15).
Table 4.15: Population Doubling Level (PDL), Doubling Time (Td) and cell 
growth rate (p) values calculated for the cells expanded in all the different conditions 
tested during the first 1 0  days of culture.
Growth conditions
Day0-day10 PDL Td(hours) p hours '1)
21 %oxygen,+FBS 2.898 82.81 0.0084
21%oxygen,-FBS -2.017 -118.97 -0.0058
1%oxygen,+FBS 2.537 94.59 0.0073
1%oxygen,-FBS -3.892 -61.67 -0.0112
In 10% serum-supplemented samples, high DOT seemed to permit a slightly more 
intense metabolic activity as compared to low DOT (figure 4.37). However, in serum- 
free condition hMSCs appeared to be metabolically inactive, regardless of the oxygen 
level employed during in vitro cell expansion (figure 4.38).
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Fig. 4.37: Effects of dissolved oxygen tension on hMSCs metabolic activity. Cells 
were cultured in either 21 % or 1 % dissolved oxygen tension in FBS-supplemented 
low-glucose DMEM medium.
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Fig. 4.38: Effects of dissolved oxygen tension on hMSCs metabolic activity. Cells 
were cultured in either 2 1 % or 1% dissolved oxygen tensions in serum-free low- 
glucose DMEM medium.
According to the data presented in figure 4.39, there appeared to be no significant 
difference in specific glucose consumption rate (g/cell/hour) for hMSCs cultured for 
up to 10 days in the different FBS and oxygen conditions. However, cells expanded in 
serum-supplemented medium at the ambient (2 1 %) oxygen experienced a significant 
increase in GCR over the last 4 days in culture, whereas cells maintained in hypoxic 
conditions in serum-free DMEM medium appeared to be characterised by a 
significant decrease in GCR over the same culture period (dayl 0-day 14).
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Fig. 4.39: Effects of dissolved oxygen tension and FBS-supplementation on 
hMSCs specific glucose consumption rate.
4.8.3 Combined effects of dissolved oxygen tension (DOT) and 
basic fibroblast growth factor (bFGF) on hMSCs proliferation and 
metabolism
Given the positive impact that bFGF had demonstrated on hMSCs proliferative 
capacity in the previous investigations (please see results presented in section 4.5), 
the combined effects of dissolved oxygen tension and bFGF-supplementation were 
also evaluated.
For this purpose, hMSCs were cultured in either complete (bFGF-supplemented) 
DMEM or in the same DMEM medium formulated without bFGF. The cultures were 
maintained for two weeks in two separate incubators (>95% humidity, 5% CO2 in 
air), one equipped with ambient (21%) and the other with low (1%) DOT. Growth 
kinetics, cell doubling time and viability were assessed as for the previous 
experiments. In addition, in this study mitochondrial activity and cell apoptosis were 
determined with the Guava Nexin assay, following the protocol described in section 
2.6.8. This technique was performed in order to identify and distinguish in our 
samples apoptotic cells from dead cells and debris.
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Once again, the high DOT maintained during in vitro expansion supported 
hMSCs growth more efficiently than the low oxygen, as it is evident from the growth 
kinetics curves presented in figure 4.40. This effect was observed for both bFGF- 
supplemented and bFGF-free culture conditions, for which increase in cell 
proliferation measured 13 days after plating was respectively 1.3 and 1.4-fold.
Interestingly, bFGF-supplementation was associated with significantly increased 
cell proliferation over the 13 days of culture for both cells expanded in ambient 
oxygen (1.33-fold increase) or in the hypoxic condition (1.4-fold increase). These 
data were in accordance with the bFGF results presented previously (section 4.5), and 
confirmed the key role played by the growth factor in the hMSCs in vitro 
proliferation.
Effec ts  o f  bFGF a n d  O x y g e n  t e n s i o n  o n  h M S C s  
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Fig. 4.40: Growth kinetics curves obtained for hMSCs maintained for a 13-day 
period under different dissolved oxygen tension (DOT) conditions, with either bFGF- 
supplemented or bFGF-free growth medium. hMSCs were cultured in non-coated 
plates, in low-glucose DMEM medium supplemented with 10 % Fetal Bovine Serum. 
The cells were maintained in 5% C 02, 37°C incubators with either 21 % 0 2 level 
(with bFGF, standard culture condition, represented by the •  line; bFGF-free 
condition, represented by the "  line) or 1% 0 2 level (with or without bFGF, 
line and line respectively). Data are presented as means +/- s.e. of three 
independent measurements (please see section 2.6.9).
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The population doubling and growth rate values obtained from this investigation 
confirmed the positive effect of the basic Fibroblast Growth Factor. bFGF- 
supplementation allowed the cells to double faster both in high and low oxygen 
regimes, as demonstrated by the Td values shown in table 4.16. The effect of the 
growth factor was particularly important in ambient oxygen condition. In accordance 
with the data described in the previous sections (4.8.1 and 4.8.2), the lowest doubling 
time and highest cell growth rate values were measured for cells grown at the 
standard 21 % DOT in complete DMEM medium after bFGF-supplementation. 
Interestingly, even though doubling times were lower for cells in ambient oxygen, 
there appeared not to be a significant difference in cell growth rates for bFGF- 
deprived cells grown in either ambient or hypoxic conditions.
Table 4.16: Population Doubling Level (PDL), Doubling Time (Td) and cell 
growth rate (p) values calculated for hMSCs expanded in all the different conditions 
tested from day 3 to day 6  of culture.
Growth conditions
Day0-day10 PDL Td(hours) H (hours'1)
21 %oxygen,+FGF 2.799 85.7 0.008
21%oxygen,-FGF 1.350 177.8 0.004
1 %oxygen,+FGF 2.127 112.8 0.006
1%oxygen,-FGF 1.506 159.3 0.004
The combined effects of the DOT and bFGF-supplementation on cell viability 
were also analysed. Cell viability was assessed as usual using the trypan blue dye 
exclusion assay, according to the protocol described in section 2.6.3. High cell 
viability was maintained over the 13-day period of culture for all the three different 
oxygen conditions tested (please see table 4.17). As in all the studies described above 
(section 4.8.1 and 4.8.2), regardless of DOT, the cells did not experience any 
dramatic loss in cell viability over time. In addition, cell viability was not affected by 
supplementation of the growth medium with bFGF, as the percentage of viable 
hMSCs was over 90.05 % for all culture conditions, regardless of bFGF- 
supplementation. These results confirmed that even though bFGF may promote 
considerably hMSCs viability in serum-free cultures (please see results described in 
tables 4.3 and 4.6), this effect is not so relevant for cells expanded in serum- 
supplemented DMEM.
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Table 4.17: Percent cell viability values calculated for hMSCs cultured in all the 
different conditions tested at the beginning (day 3) and at the end (day 13) of the 
culture period.
Growth conditions 
21%oxygen,
+FGF day
3
13
average viability
89.67
92.42
std. err. (±%) 
3.45 
2.49
21 %oxygen,
noFGF day average viability std. err. (±%)
3 91.43 3.09
13 94.22 1.01
1%oxygen,
+FGF day average viability std. err. (±%)
3 82.92 3.45
13 90.05 2.39
1%oxygen,
noFGF day average viability std. err. (±%)
3 92.09 8.60
13 92.33 2.71
At the end of the 13-day culture period under examination the Nexin assay, which 
is based upon the Guava EasyCyte system, was performed in order to investigate the 
effects of both DOT and bFGF-supplementation on hMSCs’ apoptosis. The protocol 
for the Guava Nexin assay is described in detail in section 2.6.8, and the results from 
this analysis are presented in table 4.18. It must be noted that no significant difference 
was detected with this technique in percentages of viable cells for all oxygen and 
bFGF conditions, and high cell viability (>97%) was observed in all conditions over 
the 13-day period of culture examined (please see table 4.18). In the same way, 
similar percentages of early apoptotic (0.2-0.4%) and late apoptotic (1.1-1.4%) cells 
were measured for all cell samples, regardless of the dissolved oxygen tension in 
culture settings or the bFGF presence in the growth medium. These data 
demonstrated that, even though hMSCs incubated under hypoxia had decreased rates 
of proliferation, there was no increase in apoptosis for these samples. The results 
were consistent with previous reports [Salim et al., 2004, Hung et al., 2007] but not 
with other publisehd studies [e.g. Fink et al., 2004; Lennon et al. 2001]. The 
conflicting results may in part be explained by the variation in the DOT, the duration 
of hypoxic culture and the system used in each study to control the oxygen level 
[Hung et al., 2007].
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Table 4.18: Influence of dissolved oxygen tension and bFGF-supplementation on 
hMSCs viable, early apoptotic and late apoptotic cell populations, as obtained with 
the Nexin cell apoptosis assay performed on the Guava EasyCyte system. Data are 
presented for measurements taken at the end of the 13-day culture period.
Growth
conditions
Average
viable
cells
Standard
error
Average
early
apoptotic
cells
Standard
error
Average
late
apoptotic
cells
Standard
error
21%oxygen,
+FGF
21%oxygen,
noFG
F
1%oxygen,
+FGF
1%oxygen,
+FGF
97.00 0.523 0.35 0.159 1.36 0.184
97.11 0.137 0.37 0.053 1.10 0.094
97.98 0.554 0.22 0.106 1.19 0.486
97.78 0.205 0.28 0.059 1.17 0.225
As it is shown in figure 4.42, cells expanded in the absence of bFGF appeared to 
be unable to metabolise any glucose or produce any lactate, and this metabolic 
inactivity was observed for both cell samples expanded in high or low DOTs. On the 
other hand, bFGF-supplementation seemed to permit a slightly higher metabolic 
activity, and in this case cells maintained in high DOT seemed to be more 
metabolically active than cells expanded in hypoxic conditions (figure 4.41).
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Effects of oxygen on glucose metabolism and 
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F ig. 4 .41: Effects of dissolved oxygen tension on hMSCs metabolic activity. The 
cells were cultured in either 21 % or 1 % dissolved oxygen tensions in bFGF- 
supplemented low-glucose DMEM medium.
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F ig . 4 .42: Effects of dissolved oxygen tension on hMSCs metabolic activity. Cells 
were cultured in either 21 % or 1 % dissolved oxygen tensions in bFGF-free low- 
glucose DMEM medium.
The specific glucose consumption rate data are presented in figure 4.43. These 
data are quite difficult to interpret. However, it can be noted that cells expanded in 
hypoxic condition, in bFGF-free medium appeared to be characterised by an increase 
in GCR from day6  to day 10 in culture, whereas GCR for these cells seemed to
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decrease during the last 4 days in culture. No significant difference in GCR was 
observed instead for the cells maintained in all other culture conditions investigated in 
this experiment.
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Fig. 4.43: Effects of dissolved oxygen tension and bFGF-supplementation on 
hMSCs specific glucose consumption rate.
4.8.4 Preparation of hMSCs working cell banks at 21% and 1% 
oxygen levels
The aim of this study was to compare the expansion and behaviour of human 
mesenchymal stem cells maintained in monolayer culture under two different 
dissolved oxygen tensions (i.e. 21 % and 1 %). In order to do so, after cell isolation 
from the same bone marrow sample by discontinuous density gradient centrifugation, 
two hMSC cultures were performed in parallel in T75 flasks that were maintained 
throughout the whole experiment in the two different DOTs selected. The standard 
low-glucose “complete DMEM” formulation was used for the cell expansion for both 
the oxygen cultures. Once a sufficient number of cells was reached within the T75 
flasks, two separate working cell banks were prepared for each of the two different 
DOT conditions under investigation. The resulting cells were transferred and
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maintained in liquid nitrogen (-196°C) for long-term storage, in order to supply 
material for future studies investigating further the effects of DOT on MSCs 
proliferation and function in culture. The protocols followed for the cell isolation and 
the creation of the working cell banks are described in sections 2.1.1 and 2.1.4 
respectively.
After cell isolation from the same bone marrow source, successful hMSCs 
expansion was achieved in both oxygen levels. In both conditions the cells started to 
adhere to the plastic surface of the tissue culture vessels and began to elongate within 
48 hours after plating. Cell proliferation occurring in both oxygen conditions was 
comparable and equally slow, and the desired 80 % confluence was reached in 
parallel in the two culture systems. In both oxygen conditions the primary culture 
cells reached the desired confluence 22 days after plating. In both cases, second 
passage (p2 ) cells were again approximately 80 % confluent and ready for 
trypsinisation after 11 days in culture. 2 1 % oxygen and 1% oxygen-cells displayed 
similar cell growth rates (p) values (0 .0 0 2 2  and 0 .0 0 2 1  hours' 1 respectively) and 
doubling time (Td) values (318.3 and 329.9 hours respectively). Both oxygen cell 
types displayed also similar morphology, as assessed by the microscopic evaluation 
of the culture samples. In both cases, the cells appeared to have a spindle-shape 
fibroblast-like morphology, characteristic of healthy bone marrow-derived MSCs 
(data not shown).
Despite the extremely high doubling time values measured, the microscopic 
evaluation of the samples, performed every other day during the whole culture period, 
revealed over time the presence of healthy, elongated spindle-like cells adhering to 
the plastic surface of the tissue flasks. In addition, successful cell expansion leading 
to cell numbers sufficient for the preparation of a working cell bank was achieved in 
both oxygen conditions. In conclusion, no discemable differences were noticed in the 
cell behaviour during this expansion procedure, indicating that oxygen level does not 
affect hMSCs proliferation capability and cell morphology in primary culture.
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4.9 Conclusions on MSCs monolayer culture studies
The increasing number of clinical protocols using hMSCs underscores the need 
for serum supplements other than Fetal Bovine Serum [Shahdadfar et al., 2005]. As a 
result, supplementation of the cell culture medium with FBS was one of the principal 
parameters investigated in this study. In conclusions, this research substantiated the 
significant positive influence of FBS in promoting cell proliferation rate for MSCs 
derived from human bone marrow samples. Serum, which delivers important 
nutrients, proteins and growth factors to the culture system (please see section 1.5.2), 
resulted essential for cell survival and long-term cell expansion in in vitro monolayer 
conditions. Importantly, the 10 % v/v serum concentration traditionally employed in 
standard culture protocols, resulted the most appropriate for yielding highest cell 
densities and allowing hMSCs metabolic activity.
Preliminary studies were also conducted to define the optimal basal growth 
medium for hMSCs expansion, and low-glucose DMEM was chosen against the more 
expensive MesenCult medium because of its advantages in terms of number of cells
'X 9generated after 12 days in serum-supplemented culture (12.5x10 cells/cm versus
"X 98.25x10 cells/cm counted in 10% serum-supplemented cultures).
Several serum-free media have also been investigated in a preliminary qualitative 
study whereby media effects were observed purely by means of inverted light 
microscopy. Interestingly, among all the formulations examined, UltraCulture 
(BioWhittaker), UltraDOMA Hybridoma (BioWhittaker) and Knockout D-MEM 
(Gibco) optimised media permitted survival and proliferation of attachment- 
dependent fibroblast-like cells resembling pure MSCs. Future studies could be 
performed to characterise the cell samples grown in these medium formulations and 
to prove whether these cultures retain all the unique and desirable features 
characteristic of unadulterated authentic stem cells.
The cytokines released in the MSCs’ microenvironment appears to be an 
additional essential factor for proper development. Among all growth factors, 
Fibroblast Growth Factor, which is known to be an effective mitogen for a variety of 
cells of mesenchymal or neuroectodermal origin in vitro [Basilico and Moscatelli, 
1992; Scherping et al, 1997], demonstrated to play a key role in promoting hMSCs 
proliferation and activity. bFGF appeared to be able to significantly obstruct cell 
death in serum-free cell samples. In addition, in the standard 10% serum-
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supplemented cultures, after 13 days, bFGF-addition resulted in a 1.9-fold increase in 
cell growth as compared to cells expanded in bFGF absence. Interestingly, the most 
remarkable positive influence of bFGF was observed in low (2%) serum 
concentration samples, for which the growth factor permitted a 4.2-fold cell growth 
increase over 13 days, as opposed to the 1.2-fold increase measured over the same 
time period for bFGF-free cells.
Also the culture surface properties investigated in this research were demonstrated 
to have a significant influence on hMSCs behaviour. Matrigel proved not to be a 
favourable coating surface for cell growth, leading to both significant cell death over 
time and metabolic inactivity. Its negative effect was noticed regardless of the serum 
concentration used for the medium supplementation. Moreover, the use of 
fibronectin-coated plates did not reveal any particular advantage as compared to the 
traditional non-coated plates frequently employed for tissue culture. Similar growth 
kinetics were observed for cells grown in fibronectin-coated or non-coated vessels in 
all serum conditions, and a similar increase in cell density (approximately 9-fold 
increase for 10% serum condition and 4.5-fold increase for 2% serum samples) was 
observed over 13 days in culture for both culture surfaces. Cell morphology and cell 
viability were also similar under these two coating conditions.
Finally, in this research several investigations were performed in order to 
elucidate the impact of oxygen levels on hMSCs expansion potential and metabolic 
activity. It has already been envisaged that among all tissue environmental factors 
affecting MSCs functionality and differentiation, perhaps the most important is 
oxygen level [Salim, 2004]. However, to date, studies focusing on mesenchymal stem 
cells responses to hypoxia have been inconclusive [Lennon et al, 2001; Ma et al,
2001]. Since in the bone marrow environment oxygen level is low, and normally 
ranging from 5.7 % to 7.1 % (40-50 mmHg) [Ishikawa and Ito, 1988; Grant and 
Smith, 1963; Harrison et al, 2002], it was decided to test whether hypoxia can 
enhance proliferation and growth potential of MSCs isolated from human bone 
marrow samples. In conclusion, the results of these studies clearly demonstrated that 
the exposure of hMSCs to high (21%) dissolved oxygen tension (maintained by 
exposure to 5 %CC>2 in air) during in vitro expansion is beneficial for cell growth. On 
the other hand, exposure to low DOT during culture did not significantly improve the 
cells proliferation capacity. However, no significant treatment effect by DOT was 
found in the percentages of viable cells.
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Overall, the best results, yielding highest cell growth kinetics (average 38.9xl04 
cells/cm counted after 13-14 days in culture), highest cell viabilities (average 
96.08% +/-3.01% over 2-week culture), and lowest doubling times (average 58.36 
hours calculated from day 0 to day 7) were derived from the combined use of the high 
DOT and serum-/bFGF-supplemented low-glucose DMEM medium and non-coated 
culture vessels. It was also demonstrated that hMSCs expanded for four subsequent 
passages in monolayer culture under these conditions appeared to retain their 
undifferentiated state and their ability to differentiate toward the phenotypes of fully 
mature adipocytes, osteocytes and chondrocytes.
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5. Characterisation of alginate/cells constructs
Following the studies establishing the growth kinetics of unencapsulated cells 
expanded in tissue flasks and microwell plates (described in chapter 4), interest was 
focused on investigating the growth of cells within alginate hydrogels. The optimal 
conditions of culture identified in monolayer, allowing cell viability and promoting 
cell proliferation, were employed for the growth of the alginate/cells constructs 
resulting after immobilisation of the cells in the alginate matrix. This chapter 
describes the results obtained from the characterisation of these constructs.
5.1 Alginate-GRGDY as scaffold for cell growth
The ultimate research goal was the fabrication of alginate/hMSCs constructs 
suitable for use in the clinic. In order to do so, a cell adhesion site was first 
incorporated onto the alginate molecules to create a scaffold able to encourage cell 
adhesion and proliferation (please see results presented in chapter 3).
Sodium alginate is often used as a material for the encapsulation and 
immobilisation of a variety of cells for different applications, since, subject to 
diffusion limitations, cells can maintain viability within cross-linked alginate gels 
[Trivedi et al., 2001; Park and Chang, 2000]. However, mammalian cells cannot 
interact with unmodified alginate gels [Smentana, 1993]; thus, the alginate surface 
chemistry is often modified to improve cellular functions (i.e. cell adhesion, 
spreading, migration and differentiation functions) [Saltzman, 2000]. Following 
incorporation of the RGD ligand sequence, alginate scaffolds encapsulating calvarial 
osteoblasts [Alsberg et al, 2001], pre-adypocytes [Halberstadt et al., 2002] and 
fibroblasts [Marler et al., 2000] have shown encouraging results in in vivo studies. In 
addition, in vitro studies have shown that alginate covalently modified with the 
GRGDY pentapeptide has the potential to promote mouse skeletal myoblasts 
attachment and proliferation [Rowley et al., 1999]. More recently it has also been 
demonstrated that human MSCs have the ability to adhere, elongate and retain high 
viability within alginate-GRGDY beads [Markusen et al., 2006]. However, in these 
studies no hMSCs proliferation has been observed within these matrices.
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Thus, studies were conducted in this research to investigate further the effects of 
non-derivatised alginate and alginate-GRGDY on cell behaviour and performance 
following the fabrication of constructs incorporating cells.
5.2 Culture and characterisation of cells in alginate 
constructs
Several experiments were performed in order to evaluate cell behaviour and 
performance after immobilisation within either plain alginate or alginate-GRGDY 2- 
2.5 mm diameter beads. In addition to the bone marrow-derived hMSCs employed in 
the monolayer studies, human foreskin fibroblasts were also used for the fabrication 
of alginate/cells constructs. The fibroblasts (Karocell, Stockholm) were kindly 
provided by Dr. Stephen Minger, Wolfson Centre for Age-Releated Diseases, King’s 
College London. Following mixing of the alginate matrix with the cell suspension, 
gel beads were produced by extrusion of alginate/cells droplets into the CaCl2 cross- 
linking solution. The beads were cultured in 24-well non-coated plates in “complete 
low-glucose DMEM” (as defined in section 2.1.5.1) in a humidified 37°C incubator at 
21% DOT, 5% CO2 (i.e. the optimal culture conditions identified in the monolayer 
studies). Following digestion with a trisodium citrate solution (please see section 
2.5.5), the cell suspension was analysed at selected time-points with haemocytometer 
(please see section 2 .6 .2 ) and trypan blue exclusion dye assay (please see section 
2.6.3) for the determination of cell count and cell viability. In some cases cell 
viability was confirmed by means of the calcein AM/ethidium homodimer assay 
(please see section 2.6.6 for full description of the methodology). hMSCs behaviour 
and functionality were also examined after seeding the cells on the surface of alginate 
disks (layers), which were maintained under the same culture conditions and were 
characterised using the same techniques employed for the beads.
Scaffold-cells interactions were also analysed in order to assess the biological 
activity of the alginate matrices. In particular, eventual changes in the cell 
morphology, evaluated by way of light microscopy were observed. Cells remaining 
rounded and spherical indicated that no interaction with the biomaterial was 
occurring, whereas elongated cells would have indicated association with the matrix.
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Cell studies were performed also to simultaneously establish the alginate 
derivatisation procedure, since different Pronova ultra-pure alginates (i.e. high and 
low G-subunits contents and high and low viscosity) were used for the preparation of 
the constructs. Alginates resulting from the coupling reaction with 9X reactants 
(EDC, sulfo-NHS) and different GRGDY peptide concentrations (1-32X) according 
to alternative derivatisation procedures were investigated.
Finally, the MTT assay (described in section 2.7) was employed in few 
preliminary studies as an additional method for the evaluation of cell proliferation 
within alginate/hMSCs beads.
5.3 High and low G-content and high and low viscosity 
alginates for the fabrication of hMSCs-containing beads
During beads fabrication, the gelation of the alginate takes place due to interchain
94-chelation of the Ca ions of the cross-linking solution with blocks of guluronic acid 
(G) residues between two different polysaccharide chains [Grant et al., 1973; 
Smidsrod and Skjak-Braek, 1990; Rowley et a l, 1999]. The divalent Ca2+ cations 
cooperatively bind between the G-blocks of adjacent alginate chains, creating ionic 
interchain bridges which cause gelling of aqueous solutions. Mannuronic acid (M) 
blocks and alternating MG blocks do not participate in gel cross-linking [Smidsrod 
and Skjak-Braek, 1990; Draget et al., 1994; Wang et al., 1993]. As a result, the cross- 
linking density and thus mechanical strength of the network depend on the ratio of 
guluronic/mannuronic acid residues, the length of the guluronic acid residues, the
94-molecular weight (MW) of the polymer, and the Ca ion concentration at the time of 
gelation [Martinsen et al., 1989; Drury and Mooney, 2003; Kong et al., 2004a; Kong 
et a l, 2004b; Wong M., et al, 2001]. High guluronic alginates have long been 
advocated for use in encapsulated cell systems [Colton, 1996], due to their strength 
and stability. In addition, rat bone marrow cells have shown to be able to adhere and 
proliferate on high G-content unmodified alginate hydrogel discs [Wang et al., 2003]. 
However, other groups have shown that unmodified high G alginates have also the 
ability to inhibit normal cell growth and overall metabolic activity [Stabler et al.,
2002]. On the other hand, high-G alginates chemically modified with RGD-
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containing peptides demonstrated to permit mouse skeletal myoblasts adhesion and to 
promote higher proliferation rates than lower G-content substrates [Rowley and 
Mooney, 2002].
Moreover, recent studies have indicated that high MW alginates are associated 
with low cell viability, due to the high shear forces required to mix cells with these 
(high viscosity) solutions [Kong et al., 2003]. However, these polymers are normally 
preferred for use in encapsulated cell systems because of their gel-forming ability, 
while low MW alginates tend to form brittle hydrogels [Colton, 1996; Weber et al.,
2002]. Interestingly, alginates that maintain the required mechanical rigidity and 
allow at the same time higher cell viability have been recently created by combining 
low MW alginate molecules with a small fraction of high MW alginate [Kong et al.,
2003].
Given these interesting and sometimes contradictory findings, it was of interest to 
see whether the alginate composition and viscosity, together with the GRGDY 
peptide incorporation procedure, had any different effect in terms of both alginate-cell 
interactions (i.e. alginate biological activity) and bead strength and stability.
As a result, initial studies with hMSCs were performed using high G-subunits 
high viscosity (SLG100) alginate and high M-subunits high and low viscosities 
(SLM100 and SLM20) alginates. Each of these biomaterials was used either in its 
plain (i.e. non derivatised) form or after completion of the standard derivatisation 
method described in section 2.3. In particular, for the derivatisation procedure these 
alginates were coupled with 9X EDC and sulfo-NHS and IX GRGDY peptide (i.e. 
alginate 3, 4 and 5 in table 3.1). Alginate beads were made with 25% v/v fourth 
passage (p4) hMSCs resuspended in “complete DMEM” medium to a final 
concentration of 1x10 cells/mL in each of the alginate solutions under investigation.
Interestingly, the high mannuronic acid content (M) alginates did not prove to be 
ideal biomaterials for cell immobilisation, as both the SLM100 and SLM20 beads 
completely dissolved within 24 hours from cross-linking. This is in line with the well- 
documented structural integrity of high guluronic acid (G) content alginates, which 
develop stiffer, more porous gels that maintain their integrity for longer periods of 
time, as opposed to alginates rich in mannuronic acid (M) [Stabler et al., 2002]. Thus, 
following complete dissolution, the SLM100 and SLM20 beads were discarded, while 
the culture of the SLG100 alginate beads was carried on over a 2-week period. The 
scaffold was evaluated immediately after cross-linking (day 0 ) and at two additional
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time-points during culture (i.e. day 4 and day 7) for cell density and viability, using a 
haemocytometer and trypan blue. In addition, the culture of the beads was monitored 
and evaluated by means of light microscopy, and photographs were taken four days 
after beads preparation (please see figure 5.1 A and B). No cell adhesion was 
observed on both control alginate or alginate-GRGDY beads. In both alginate types 
the cells remained rounded and failed to elongate and acquire their typical spindle- 
shaped morphology.
Fig. 5.1 A and B: hMSCs immobilised within SLG100 alginate-GRGDY beads. 
The alginate was derivatised with 9X reactants and IX peptide, and after 
lyophilisation it was frozen at -20°C. The alginate-GRGDY was then thawed and 
mixed with the cell suspension for beads preparation (i.e. standard derivatisation
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protocol). The photographs were taken at the inverted light microscope 4 days after 
beads fabrication. The arrows indicate some of the cells failing to adhere to the 
alginate-GRGDY matrix.
High cell viability was measured immediately after cross-linking for both the 
control (average 90.37±1.6%) and the derivatised SLG100 (average 92.18±3.1%) 
alginates. However, a significantly decrease in cell viability was observed over time 
for all bead samples, and values as low as 8±1% and 9±2% were measured after 1 
week of culture for the non derivatised matrix and the alginate-GRGDY respectively. 
Viability measurements were not taken after this time-point, as the data suggested 
that, regardless of the alginate condition (i.e. uncoupled alginate or alginate- 
GRGDY), neither cell elongation nor cell growth were occurring within the beads. 
The cell density of the hMSCs immobilised in the alginate-GRGDY beads decreased 
from 2.12-2.5 xlO4 to 1.3-1.4 x 104 cells /bead during the first 4 days in culture, and 
further down to 0.5-0.7 x 104 cells /bead during the subsequent three days (day4- 
day7). Similar cell densities were measured for the beads created with the non- 
derivatised alginate (data not shown). These results indicate that, despite the positive 
results shown by other groups [Rowley et al., 1999; Markusen, 2005], SLG100 
alginate-GRGDY did not encourage cell attachment in the hMSCs-containing beads 
created in this research.
However, it must be noted that, due to time constraints, no amino acid analysis 
was performed on this SLG100 alginate, which was made with a lower (i.e. IX) 
peptide concentration as compared to the alginate-GRGDY that was analysed for 
amino acid levels (i.e. 10-32X peptide). Therefore it could be excluded that the IX 
peptide concentration was too low to allow successful incorporation of the GRGDY 
sequence onto the alginate biomaterial. In addition, the hMSCs used for the 
fabrication of the constructs in this experiment were not characterised by the expected 
cell growth rates and kinetics in the control monolayer condition either. Thus, the 
cells themselves might have been associated with low cell proliferation capacity 
independently of the alginate matrix. Therefore the cell source employed in this 
particular experiment could not be excluded as possible additional cause to the poor 
cellular functions observed within the beads. As a result, the biological activity of the 
SLG100 alginate and its appropriateness as a scaffold material for cell immobilisation
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was investigated further in additional studies, which are described in the following 
sections.
Nevertheless, in accordance with other groups findings [Stabler et al, 2002], this 
study confirmed that the chemical composition of the alginate has a significant effect 
on its physical properties and suggested that high-G content alginates should be 
preferred over the high-M content polymers for their gelling properties and their 
strength and stability. As a result, SLG100, which permitted the fabrication of 
stronger and more stable beads, was chosen and adopted as the preferred alginate 
biomaterial for all subsequent matrix/cells constructs studies.
5.4 Fabrication of alginate-GRGDY/hMSCs beads using 
alginate modified according to different derivatisation 
procedures
The aim of this study was to test the effects of SLG100 alginates prepared 
according to different derivatisation procedures (alginates 6 , 7, 8 , 9 in table 3.1) on 
both the cell behaviour after immobilisation and the mechanical properties of the 
resulting constructs. The coupling reaction for all of these alginates was performed 
using exactly the same reactants concentrations (i.e. 9X reactants and 10X peptide) 
under the same working conditions (20-hour reaction at T=20-22°C, under constant 
mixing on a platform roller, in the dark). However, after completion of the 
carbodiimide reaction and the 5-day dialysis cycle, alternative methods (i.e. 
lyophilisation with or without freezing step, PEG concentration with or without 
freezing step) were used for the purification and the concentration steps, as described 
in section 3.2 (please see figure 3.1).
Fourth passage (p4) hMSCs (25% v/v) were mixed with each of the four alginate
n
solutions to a final concentration of 1x10 cells/mL, and the resulting alginate/cell 
mixtures were treated with CaCl2 for gel cross-linking and beads fabrication.
Particular care was taken on the cell choice, with respect of their proliferation 
potential in the control monolayer culture, and only hMSCs associated with high 
growth rate (0.012 hours-1) and low doubling time (55.79 hours) were used for the 
fabrication of the beads. This permitted a more accurate comparison of the cell
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performance in monolayer condition (tissue flasks) and within alginate-GRGDY 
beads.
No significant differences were noted among all bead samples in terms of gel 
stiffness and mechanical behaviour. Stable and rigid constructs were obtained for all 
alginate conditions, and all beads held regular structure and shape over the 1 0 -day 
period examined. However, despite the structural integrity and stability, no cell 
attachment and elongation within the alginate polymers were observed (please see 
photograph in figure 5.2). Regardless of the derivatisation procedure employed for 
the fabrication of the alginate matrix, hMSCs demonstrated to be unable to adhere to 
and elongate within the alginate-GRGDY biomaterial.
In addition, a significant drop in cell viability, comparable to that observed for the 
control constructs (i.e. beads prepared with non derivatised-alginate) was measured 
over time (please see table 5.1 and photograph in figure 5.3). The cell density values 
measured for hMSCs immobilised in the alginate-GRGDY beads also decreased 
consistently over time, similarly to what was seen for cells immobilised in the control 
(i.e. non derivatised) alginate (please see table 5.1).
Thus, no discemable differences were observed between the non derivatised 
alginate and all the alginate-GRGDY types investigated.
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Beads conditions
day Viability
average
Cells/beads
Control
(non derivatised) 
alginate
0 91.4+0.9% 2.70-2.91 x104
4 55.9+2.6% 1.67-1.69x104
7 8.5+1.2% 0.82-0.91 x104
Standard
protocol
(no.1)
0 92.18+2.9% 2.95-3.09x104
4 62.3+1.3% 1.70-1.2x104
7 7.2+0% 0.90-0.97x104
Protocol no.2 0 89.7+1.6% 2.7-2.93x104
4 57.1+2.8% 41.50-1 9x104
7 7.9+1.3% 0.60-0.75x104
Protocol
no.3
0 90.2+0% 3.0-1:3x104
4 52.8+5.7% 1.6-0.9x104
7 9.1+3.1% 0.8-0.95x104
Protocol
no.4
0 93.2+0.3% 2.80-2.93x104
4 64.2+3.2% 1.57-1.81 x104
7 6.9+3.4% 0.63-0.71 x104
Table 5.1: Percent cell viability and cell concentration values obtained for 
hMSCs immobilised in non-derivatised alginate (control beads) and alginates 
modified with the GRGDY peptide according to different derivatisation protocols. All 
alginates were coupled with 9X sulfo-NHS and EDC and with 10X peptide 
concentrations (the resulting derivatised alginates are designated as “alginate- 
GRGDY number 6 ”, “number 7”, “number 8 ” and “number 9” respectively in table 
3.1) Data are shown for each harvesting time-point during the first week of culture.
Interestingly, amino acid analysis data revealed that the GRGDY peptide was 
successfully incorporated onto the alginate after completion of the derivatisation 
procedure according to the standard protocol (procedure no. 1 in figure 3.1). This 
alginate (final alginate-GRGDY number 6  in table 3.1) contained all the four 
constituent amino acids of the GRGDY sequence, as it appears from the results 
shown in table 3.3 (final alginate-GRGDY number 6 ). However, as already 
mentioned in section 3.3.1, a significant tyrosine loss was also detected in these 
samples. Ultimately, it can be hypothesised that this phenomenon was responsible for 
the low biological activity of the alginate-GRGDY, resulting in lack of matrix-cells
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interactions and cell death over time. Amino acid analysis was not performed on the 
other alginate-GRGDY types resulting from the alternative derivatisation procedures 
(i.e. alginates numbers 7, 8 , 9 in table 3.1) due to time constraints. Hence, such 
analyses will need to be performed in future in order to investigate further the effects 
of the different derivatisation protocols on the peptide attachment. This measure will 
permit to determine whether the alternative steps involved in the derivatisation 
process (e.g. freezing for long-term storage, lyophilisation and PEG concentration) 
ultimately affect the efficiency of the coupling reaction and, subsequently the 
cellularity of the final alginate-GRGDY/hMSCs constructs.
Fig. 5.2: hMSCs immobilised within SLG100 alginate-GRGDY beads. The 
alginate was derivatised with 9X reactants and 10X peptide, according to the standard 
derivatisation protocol described in section 2.3.2. The photographs were taken at the 
inverted light microscope after 5 days in culture. The arrows indicate some of the 
cells failing to adhere to the alginate-GRGDY matrix.
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Fig. 5.3: Fluorescence photograph obtained for hMSCs immobilised within 
SLG100 alginate-GRGDY beads stained with calcein AM/ethidium homodimer for 
the qualitative evaluation of cell viability. The alginate was derivatised with 9X 
reactants and 10X peptide prior to the beads preparation. The resulting alginate- 
GRGDY was mixed with the cell suspension and used for beads preparation 
following the lyophilisation and freezing steps (i.e. standard derivatisation 
procedure). The photograph was taken at the confocal microscope 5 days after beads 
fabrication. The intense red fluorescence originates from the Ethidium homodimer-1 
bound to the cellular DNA after permeation of the damaged cell membranes.
5.5 Alginate-GRGDY/fibroblasts beads
In place of hMSCs, human foreskin fibroblasts were used in this study for the 
preparation of alginate beads, in order to see whether different cell types exhibit 
different adhesion properties, and whether the GRGDY ligand may favour fibroblast 
attachment and functionality as opposed to what was observed in this research for 
hMSCs.
Several in vitro studies have already indicated that fibroblasts can be successfully 
encapsulated in alginate beads to be employed in different therapeutic applications 
[Peirone et al., 1998; Schwinger et al, 2002; Keshaw et al, 2004; Ueng et al, 2000].
In this study SLG100 alginate coupled with 9X reactants and 10X peptide 
according to the standard derivatisation protocol (alginate-GRGDY no. 6  in table 3.1) 
was mixed with the cell suspension (lxlO 7 cells/mL) and the resulting matrix-cells 
mixture (25% v/v of cells) was gelled into 2-2.5 mm diameter beads following the
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previously described (please see section 2.5.3) cross-linking treatment in 90 mM 
CaCl2. Sixth passage (p6 ) fibroblasts were used in this study, and a culture in T25 
tissue flasks was run in parallel in order to have a direct comparison with cell 
performance in the monolayer condition. Control beads were simultaneously 
fabricated with non-derivatised SLG100 alginate and were assessed in parallel with 
the alginate-GRGDY constructs. As in the previous experiments, cell morphology 
and alginate biological activity were evaluated by means of light microscopy, and cell 
densities and viabilities were assessed with haemocytometer and trypan blue dye 
exclusion assay respectively following cell release with trisodium citrate solution.
Both control (i.e. non derivatised) alginate and alginate coupled with the GRGDY 
peptide formed stable gel beads, which retained a defined regular shape over the 1 0 - 
day period tested. However, similarly to what was observed in the previous 
experiment for the hMSCs, the fibroblasts failed to interact with both the unmodified 
polymer and the alginate-GRGDY, and could not elongate and acquire their 
characteristic spindle-shaped morphology (please see photographs in figure 5.4 A and 
B). Moreover, while the cells were proliferating extensively in tissue flasks (growth 
rate = 0.014 hours-1, doubling time = 49.8 hours), no cell proliferation was observed 
within the beads. Cell viability data indicated significant cell death over time, both for 
the control beads and the alginate-GRGDY constructs (please see table 5.2). The 
cells, having failed to adhere to the alginate scaffold, completely dissociated from the 
matrix as small spherical entities floating in the growth medium within 48 hours from 
cross-linking.
Light microscopy also revealed that in these constructs the cells tended to position 
in close proximity to the outer surface of the matrix/cells beads. This inhomogeneous 
cell distribution may have been caused by the particular method employed for the 
beads fabrication in this research. It has already been reported that the diffusion- 
setting method for the gelation of the alginate with CaCl2 results in an 
inhomogeneous alginate distribution within the gels [Skjak-Braek et al, 1989]. In 
general, it is well documented that a very rapid and irreversible binding reaction of 
multivalent cations is typical for alginates; a direct mixing of these two components 
therefore rarely produces homogeneous gels [Draget et al., 2005] (please see section 
6.4 for a more detailed description of this phenomenon).
Ultimately, a similar poor cellular behaviour within the alginate-GRGDY beads 
was therefore observed for the hMSCs and the fibroblasts, as both cell types appeared
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to be unable to interact with the biomaterial and to spread out as spindle-shaped 
elongated healthy cells within the alginate beads.
As mentioned in the previous section, amino acid analysis was performed on the 
alginate used here for the preparation of the beads (alginate number 6  in table 3.1), 
revealing the presence of a complete GRGDY sequence attached to the polymer, yet 
with a very low tyrosine level (please see alginate-GRGDY number 6  in table 3.3 for 
the amino acid content data). Thus, the most probable cause for the lack of alginate- 
cells interactions observed in these studies was the significant loss of the final 
tyrosine residue of the GRGDY sequence, which, according to the amino acid 
analysis data, was being cleaved off (at some stage) during the derivatisation 
procedure. This event probably determined the poor results in terms of cellularity 
described in this research for the studies performed on the alginate/cells beads. 
However, despite the lack of cell adhesion and proliferation, it must be noted that 
constructs fabricated with SLG100 alginate retained good mechanical properties (i.e. 
considerable stiffness, structural integrity and stability) over the 10 -day week period 
of culture under examination.
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Beads conditions
Day Viability
average
Cells/bead
Control
(non
derivatised)
alginate
0 94.4+1.3
%
2.46-2.78x104.
4 65.7+1.6
%
1.52-1.61x104
7 9+2.1% 0.92-0.98x104
SLG100
alginate-
GRGDY
0 92.67+3.
4%
2.65-2.91 x104
4 67.0+0.3
%
1.59-1.64x104
7 11.3+1% 0.92-0.99x104
Table 5.2: Percent cell viability and cell concentration values obtained for human 
foreskin fibroblasts immobilised in non-derivatised alginate (control beads) and in 
alginate modified with the GRGDY peptide according to the standard derivatisation 
procedure. 9X sulfo-NHS and EDC and 10X peptide were used for the coupling 
reaction (the resulting derivatised alginate is designated as “alginate-GRGDY no. 6 ” 
in table 3.1). Data are shown for each harvesting time-point during the first week of 
culture.
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Fig. 5.4 A and B : Human foreskin fibroblasts immobilised within SLG100 
alginate-GRGDY beads. The alginate was derivatised with 9X reactants and 10X 
GRGDY peptide according to the standard derivatisation procedure described in 
section 2.3.2. The photograph was taken at the inverted light microscope 6  days after 
beads fabrication. The small spherical morphology indicates that the cells were 
unable to adhere to the alginate-GRGDY matrix within the beads.
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5.6 Additional studies on alginate-GRGDY for the 
immobilisation of fibroblasts
Additional studies were performed in order to investigate further the possibility 
for the alginate-GRGDY (fabricated according to the standard derivatisation 
procedure described in this research) to act as a suitable substrate for cell viability and 
growth.
Thus, SLG100 alginate coupled with the same (i.e. 9X) EDC and sulfo-NHS 
concentrations as in the previous experiments, but with a higher (i.e. 32X) peptide 
concentration, was used for the fabrication of the constructs (alginate no. 1 in table 
3.1).
Frozen vials of this alginate-GRGDY were thawed and reconstituted with normal 
saline solution as described in section 2.3.2.5. The resulting alginate solution was 
mixed with fifth passage (p5) human foreskin fibroblasts in suspension (lxlO 7 
cells/mL) and the alginate-GRGDY/fibroblast mixture (25% v/v of cells) was then 
used for the fabrication of the constructs. Fibroblasts were also simultaneously 
expanded in monolayer culture, and were also grown within non-derivatised alginate 
beads acting as control.
The expectation was that the higher peptide concentration (32X) used in this 
experiment, which had already led to the incorporation of higher amino acid levels 
onto the alginate chain (please see data for alginate designated as “alginate-GRGDY 
no. 1-Albachem” in table 3.3), would have resulted in cell adhesion and cell 
proliferation within the constructs. However, once again neither cell attachment nor 
cell elongation were observed in the alginate-GRGDY beads (please see photograph 
in figure 5.5). As for all the experiments described above (sections 5.3, 5.4 and 5.5), 
significant loss of cell viability was observed over time (please see photograph in 
figure 5.6). The percentage of detectable viable cells at day 7 of culture was in fact 
only 10.4±0.9% and 9.07+3.4% for the control beads and the derivatised alginate 
constructs respectively. Concurrently, cell numbers calculated after dissolution of 
both bead types with trisodium citrate decreased considerably over time, dropping 
from initial values in the 2.15-2.79xl04 cells/bead range (day 0) to merely 0.49-
0.76x104 cells/bead at day 7.
Thus, the use of alginate coupled with higher peptide concentrations did not 
improve the biological activity of the resulting polymer hydrogels. According to the
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amino acid analysis data (please see section 3.3.1), also in this case a significant loss 
of tyrosine was occurring during the derivatisation process. Hence, the negative 
results in terms of cell performance consistently observed after cell immobilisation 
corroborate the hypothesis of the correlation between tyrosine loss and lack of cell 
adhesion, and ultimately lack of cell survival, within the alginate-GRGDY beads.
Fig. 5.5 : Human foreskin fibroblasts immobilised in SLG100, 9X reactants, 32X 
GRGDY peptide alginate-GRGDY. The photograph was taken at the inverted light 
microscope 5 days after beads fabrication. Small, spherical cells failing to adhere to 
the scaffold and to elongate are clearly visible within the bead.
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Fig. 5.6: Fluorescence photograph obtained for human foreskin fibroblasts 
immobilised within SLG100 alginate-GRGDY beads stained with calcein 
AM/ethidium homodimer for the qualitative evaluation of cell viability. The alginate 
was derivatised with 9X reactants and 32X peptide prior to the beads preparation. The 
resulting alginate-GRGDY was mixed with the cell suspension and used for beads 
preparation following the lyophilisation and freezing steps (i.e. standard 
derivatisation procedure). The photograph was taken at the confocal microscope 5 
days after beads fabrication. The intense red fluorescence originates from the 
Ethidium homodimer-1 bound to the cellular DNA after permeation of the damaged 
cell membranes.
5.7 HMSCs immobilised in alginate-GRGDY disks
Given the lack of cell attachment observed for both hMSCs and human foreskin 
fibroblasts after immobilisation within alginate-GRGDY beads, it was decided to 
investigate hMSCs performance and functions after seeding the cells on top of 
alginate-GRGDY disks (or layers).
Despite the project’s aim to immobilise the cells within the alginate hydrogels in a 
one-step process, alginate disks were fabricated to de-couple the cell seeding step 
from the alginate scaffold formation, in order to investigate the possible detrimental 
effects of high molar concentration of the cross-linking solution. During the beads 
preparation procedure the cells were immediately mixed with the alginate and the 
resulting suspension was then syringed into the CaCI2 cross-linking solution (please
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see schematic representation in figure 5.7). Thus, the final alginate/cells beads were 
instantaneously formed within the cross-linking solution.
However, the 1 % CaC^ solution used (corresponding to 90mM) was hypertonic, 
being 1.8mM the physiological CaC^ concentration for cell maintenance and growth,
i.e. level in DMEM medium (BioWhittaker Product Catalog, 2001). During cell 
immobilisation in alginate beads the cells are exposed to the calcium chloride solution 
for prolonged time periods. This procedure can, in principle, cause unwanted and 
uncontrolled physiological effects. In addition, only recently attachment-dependent 
cells have been reported to be successfully immobilised within alginate beads, whilst 
alginate encapsulation systems are in most cases employed only for cell therapy 
applications involving the use of suspension adapted cells. Even Rowley’s and 
Mooney’s studies had been performed by constructing alginate layers and then 
seeding on the surface with cells [Rowley, 1999].
Given the potential harmful effect of the cross-linking solution on the overall cell 
performance, and given that no cell adhesion was observed from the cell 
immobilisation studies with alginate-GRGDY beads (described in the sections 5.3 
and 5.6 above), experiments were conducted by pre-forming the alginate-GRGDY 
matrices as layers in the bottom of a microwell, and then seeding the cells separately 
onto the surface of the alginate (please see section 2.5.4 for a full description of the 
method employed for disks preparation). This procedure made it possible to de­
couple the alginate preparation and the cell seeding steps, and therefore to test the 
detrimental effects of the cross-linking solution on cell behaviour. A schematic 
representing the different procedures for beads and disks fabrication is given in figure 
5.7.
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Fig. 5.7 : Schematic of the cross-linking procedures for the preparation of 
alginate/cells beads (A) and layers (B). Figure A adapted from Draget et al. 2005.
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Sixth passage (p6 ) human MSCs and SLG100 Pronova alginate derivatised 
following the standard derivatisation procedure with 9X EDC and sulfo-NHS and 
32X peptide (designated as “alginate-GRGDY number 1” in table 3.1) were used in 
this experiments for the disks preparation (3.3x104cells/cm2- 5xl04cells/cm2). The 
cells were also immobilised directly into alginate-GRGDY beads (average 2.52x104 
cells/bead) for a direct comparison. Alginate-GRGDY disks and beads were 
constructed as described in sections 2.5.4 and section 2.5.3 respectively. After 
formation, the alginate layers were rinsed thoroughly of excess CaCl2 prior to the 
addition of the cells. A monolayer culture in 24-well tissue culture plates was 
performed in parallel, and alginate/cells layers and beads were created also with non- 
derivatised SLG100 alginate for control. Light microscopy was used to evaluate 
matrix-cells interactions, cell attachment to the surface of the alginate disks and cell 
morphology. The cells were released from the matrix with trisodium citrate solution 
(please see section 2.5.5) and were evaluated for cell density and viability with 
haemocytometer and trypan blue (please see sections 2.6.2 and 2.6.3). While the cells 
in monolayer culture were characterised by high proliferation potential (cell growth 
rate = 0.014 hours-1) and low doubling time (50.86 hours), cell growth was not 
observed after seeding on the surface of the alginate-GRGDY disks. The cells did not 
attach to the alginate-GRGDY layers and could not spread out to acquire their typical 
fibroblast-like appearance. Virtually no difference was observed among cellularity 
within the beads and cell behaviour on the surface of the hydrogel disks, and in both 
construct types the alginate-GRGDY matrix did not support cell adhesion and 
elongation (please see photographs in figures 5.8 and 5.9).
Thus, it can be concluded that the lack of cell response that was seen for both the 
alginate/hMSCs beads and disks was most likely due to the alginate-GRGDY 
biological inactivity, rather than to the harmful treatment with the high molarity 
cross-linking agent during the beads fabrication procedure. Since the alginate- 
GRGDY was characterised by a considerable loss of the tyrosine residue, it cannot be 
excluded that this phenomenon was the major cause responsible for the lack of cell 
attachment, cell elongation and, ultimately, cell proliferation observed for both the 
alginate beads and disks. According to this hypothesis, tyrosine loss probably altered 
the chemical conformation of the GRGDY sequence, ultimately preventing cell 
attachment. Thus, the hMSCs, which are strongly anchorage dependent, could not 
attach to the alginate matrix of both beads and disks simply because the polymer,
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having lost the tyrosine residue, could not provide cell adhesion sites. However, other 
possibilities cannot be excluded, since there are several other parameters that may 
affect the beads fabrication procedure, and thus the cell adhesion properties of the 
resulting scaffold. It is known that the gelation process, which occurs when divalent 
cations take part in the interchain binding between G-blocks, depends on both the 
alginate and gelling ion concentrations [Martinsen et al., 1989]. Thus, future studies 
could be performed investigating cell immobilisation within alginate beads made with
04-different Ca concentrations, or by using different length exposures to the cross- 
linking solution. Furthermore, it is true that for the immobilisation of living cells 
calcium has become the primary choice as a gel-inducing agent. However, alginate
04-forms gels with most di- and multivalent cations. While monovalent cations and Mg
04- 0 Iions do not induce gelation [Sutherland, 1991], ions like Ba and Sr produce
04- 0 Istronger alginate gels than Ca [Clark and Ross-Murphy, 1987]. Like Ca , these 
ions are considered to be sufficiently biocompatible for applications involving 
immobilisation of living cells [Smidsrod and Skjak-Braek, 1990], Moreover, as 
compared to Ca2+, they have a higher affinity for alginate [Smidsrod, 1974], and 
consequently are associated with higher gel stability [Clark and Ross-Murphy, 1987]. 
As a result, the use of alternative gelling cations, such as Ba or Sr , could be 
investigated. Ultimately, further studies are needed to elucidate whether the lack of 
cell adhesion to the alginate beads and disks was caused in both matrices by the 
tyrosine loss and subsequent biological inactivity of the alginate-GRGDY matrix, or 
by other mechanisms.
248
249
Fig 5.8 A, B  and C: hMSCs immobilised within alginate-GRGDY beads. The 
alginate polymer was coupled with 9X EDC and sulfo-NHS and 32X GRGDY 
peptide, and was derivatised according to the standard protocol described in section
2.3.2. The photographs were taken at the inverted light microscope 4 days after the 
fabrication of the constructs. It is evident from the photographs that the cells were 
unable to adhere to the alginate-GRGDY and to elongate within the beads. The 
arrows indicate some of these cells.
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Fig 5.9 A and B: hMSCs seeded on top of alginate-GRGDY disks. The alginate 
polymer was coupled with 9X EDC and sulfo-NHS and 32X GRGDY peptide, and 
was derivatised according to the standard protocol described in section 2.3.2. The 
photographs were taken at the inverted light microscope 4 days after the fabrication 
of the constructs. The arrows indicate big cells failing to attach to the alginate- 
GRGDY layers.
5.8 MTT assay: analysis of cell proliferation within 
alginate matrices
Experiments were performed using the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5- 
diphenyltetrazolium bromide) assay for the determination of viable cell numbers 
within the alginate matrix. The MTT Cell Proliferation assay is a rapid colorimetric 
method, which is commonly used for the quantitative assessment of cellular survival 
and proliferation, based on the metabolic activity of viable cells (please see section 
2.7 for a more detailed description of the MTT technique). Only active mitochondria 
of live cells can cleave the tetrazolium ring of the MTT compound. The absorbance 
subsequently measured for the blue formazan product generated from the MTT dye is 
linearly related to the quantity of viable cells added per well. Thus, the assay can be 
used to detect the cell proliferation rate and conversely, when metabolic events lead 
to apoptosis or necrosis, the reduction in cell viability [Mosmann, 1983; Ferrera et al., 
1993; Ciapetti et al., 1992].
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5.8.1 Comparison of cell numbers derived from MTT 
absorbance readings and from haemocytometer
In order to confirm the linearity of the MTT assay, a series of cell standard curves 
were created from individual cell suspensions using T150 (150 cm2) flasks. Seventh 
passage (p7) human MSCs were harvested from tissue flasks and brought in cell 
suspension in Dulbecco’s phosphate buffered saline with lg/L D-glucose and 36mg/L 
sodium pyruvate (DPBSG, Bio Whittaker), following the method described in section
2.1.3. The resulting cell suspension was serially diluted with DPBSG and seeded in a 
96-well tissue culture plate as it is described in section 2.7.1. The MTT assay was 
then performed on the resulting samples as described in section 2.7, and the 
absorbance was measured at 600nm on a spectrophotometer (please see section 
2.7.4.3).
The cell standard curves obtained for the T150 flasks were plotted according to 
the cell density (cell number/mL) measured simultaneously by haemocytometer 
count. Figure 5.10 shows one of the typical standard curves obtained from this 
analysis. The curve indicates that the MTT absorbance readings detected with the 
spectrophotometer correlated very closely to the cell concentration measured with the 
haemocytometer. This study confirmed that by following the MTT assay protocol 
described in section 2.7 it was possible to establish a linear relationship between the 
formazan absorbance readings and the cell concentration within the samples. This 
relationship was established for a cell suspension of hMSCs from tissue flask cultures 
harvested at day 4 of culture.
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MTT assay on hMSCs in monolayer
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Fig.5.10: MTT absorbance values at 600 nm detected from human MSCs (p7) 
cultured in monolayer.
In this research the MTT assay was used to confirm the decrease of cell viability 
observed for cells encapsulated within the alginate beads.
Indeed, the MTT assay has already been used in previous studies for the 
determination of the status of several cell types in different alginate matrices [Barralet 
et a l, 2005; Lawson et a l, 2004; Markusen et a l, 2006; Rokstad et al, 2005; Mahler 
et a l, 2003; Khattak et al, 2006; Khattak et a l, 2006; Zhang et al, 2005]. In this 
research, the technique was used at a preliminary stage, hence, prior to perform the 
assay on the matrix/cells beads, experiments were performed to confirm that the 
alginate biomaterial does not interfere with the absorbance readings measured and 
does not affect the validity of the results. In addition, only beads fabricated with non- 
derivatised alginate were tested for cell viability in the MTT experiments.
5.8.2 MTT cell proliferation assay on hMSCs expanded in 
monolayer condition in the presence of increasing concentrations 
of alginate in solution
The aim of this study was to test any potential interference of the alginate 
biomaterial on the MTT absorbance readings measured during determination of cell 
viability for hMSCs expanded as a monolayer.
253
ProNova non-derivatised SLG100 alginate was used for this purpose. Sixth 
passage (p6 ) hMSCs cells were resuspended in complete DMEM, and seeded onto 
24-well microplates in monolayer condition (6xl03cells/cm2) according to the usual 
plating protocol (please see section 2.1.2). 24 hours after plating, the medium of 
culture was removed from the wells and replaced with alginate in solution (1% w/v), 
which was serially diluted in complete DMEM medium. The cells were maintained in 
culture in the resulting alginate/DMEM solutions (alginate final concentration 
ranging from 0 to 100% v/v) for 10 days, with alginate/DMEM refreshments 
performed every 2-3 days. The MTT assay was performed on the resulting cell 
samples at the end of the culture period (day 1 0 ), following the protocol described in 
section 2.7.8.
The absorbance readings obtained for the microwell samples were plotted 
according to the alginate solution concentration in the DMEM medium. The data 
obtained from this analysis are shown in figure 5.11.
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Fig. 5.11: MTT absorbance values obtained for hMSCs in microwell (6xl03cells/cm2) 
after 1 0  days in culture in the presence of an increasing concentration of alginate in 
solution (0, 1, 2, 3, 4, 5, 6 , 7, 8 , 9, 10, 50 and 100 v/v %).
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As it is evident in the graph, the alginate solution did not affect the MTT 
absorbance readings detected with the spectrophotometer up to a 50% v/v 
concentration. Whilst no significant difference was observed between the absorbance 
readings measured for cells expanded in the alginate solutions with concentration 
ranging from 0% to 50% v/v, a significant decrease in the absorbance value was 
observed for hMSCs expanded in the complete (100% v/v) alginate solution. These 
results indicate that the cells experienced a dramatic drop in cell viability following a 
10-day culture in the alginate solution. As it is shown in the graph, cells that had been 
completely deprived of the DMEM medium of culture over the 10-day period, and 
had been grown instead in the complete alginate solution, retained no cell viability. 
The absorbance readings measured for these DMEM-deprived cells were in fact 
comparable to those measured for the blank (i.e. complete DMEM medium only) 
microwells.
According to these data, hMSCs can be cultured in monolayer condition in the 
presence of alginate solution with a concentration up to 50% v/v, without 
experiencing cell death due to the presence of the alginate polymer.
5.8.3 MTT cell proliferation assay on hMSCs expanded in 
monolayer culture in the presence of an increasing number of cell- 
free alginate beads
Experiments were also performed using cell-free alginate beads to test whether 
the presence of the alginate polymer, after cross-linking treatment and gelling into 
hydrogel beads, had any effect on the absorbance values measured for samples of 
hMSCs expanded in monolayer culture.
Pronova non-derivatised SLG100 alginate and sixth passage (p6 ) hMSCs were 
used in these studies. The cells were harvested from T150 flasks and resuspended in 
Dulbecco’s phosphate buffered saline with 1 g/L D-glucose and 36 mg/L sodium 
pyruvate (DPBSG, Bio Whittaker). The cell suspension was seeded into two 96-well 
plates (2.05x104 cells/well) as it is described in section 2.7.6 and an increasing 
number o f cell-free alginate beads (0, 1, 2, 3 and 4) were added to the microwells in 
culture. The culture was performed under the optimal conditions identified in the 
monolayer studies (please see results from chapter 4) and was maintained for a 10- 
day period. The MTT cell proliferation assay was performed at the end of the culture
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period (day 10), following the protocol described in section 2.7. The MTT solution 
was left in incubation at 37°C for one 1 hour and the absorbance values were read on 
the spectrophotometer at 600nm within 1 hour from isopropanol/HCl addition, 
following the standard MTT assay protocol, as described in section 2.7.4.3.
The results are presented in figure 5.12.
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Fig. 5.12: MTT absorbance values measured at 600 nm for hMSCs expanded in 
monolayer condition (2.05x104 cells/well) in the presence of an increasing number of 
non-derivatised alginate beads. The assay was performed 10 days after plating.
It is apparent from this graph that there was no significant difference in the 
absorbance values detected for hMSCs expanded in monolayer in the presence of an 
increasing number of cell-free alginate beads. Thus, the presence of the alginate 
biomaterial in the assay does not interfere with the absorbance readings for the period 
examined. As a result, it can be concluded that short-term culture of hMSCs 
microwell samples in the presence of alginate gel beads is possible without 
experiencing a subsequent change in absorbance readings and in the cell proliferation 
potential.
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5.8.3.1 MTT cell proliferation assay on hMSCs immobilised in 
alginate beads
The MTT assay was then used to measure cell proliferation potential for hMSCs 
immobilised in Pronova SLG100 alginate beads (average 4.47x103 cells/bead). The 
constructs were fabricated according to the usual protocol (please see section 2.5.3) 
and were maintained in culture over a 14-day period. The microwells were seeded 
with an increasing number of beads (0, 2, 4 and 6) and were cultured under the 
optimal culture conditions identified from the monolayer studies described in chapter 
4. At selected time-points (dayl, day 4, day 7 and day 14) cell proliferation within the 
beads was assessed by means of the MTT assay. These data are presented in figure 
5.13.
MTT absorbance values for hMSCs encapsulated in non- 
derivatised alginate beads
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Fig. 5.13: MTT absorbance readings measured at 4 different time-points (day 1, 
day 4, day 8, day 14) for an increasing number of alginate/hMSCs beads (average 
4xl03 cells/bead). The constructs were maintained in the culture conditions that in the 
extensive monolayer studies presented in chapter 4 were associated with the highest 
growth kinetics and cell viability data.
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The graph in figure 5.13 indicates that there was a good linear relationship 
between the number of beads evaluated and the formazan absorbance readings 
measured with the spectrophotometer. This relationship was established for constructs 
cultured over a 4-day period. The absorbance measurements taken at the additional 
time-points (day 8 and day 14) indicate that the cells were characterised by a 
significant decrease in cell viability after immobilisation within the alginate bead 
matrices. In conclusions, the MTT assay data confirmed the lack of cell proliferation 
experienced by hMSCs immobilised within non-derivatised alginate beads. 
Ultimately, the absorbance readings measured with the MTT assay appeared to be 
consistent with the cell density and cell viability measurements obtained with the 
haemocytometer and the trypan blue exclusion dye assay. In principle, this proves 
that the MTT cell proliferation assay can be used in future studies as a reliable 
method for the quantitative assessment of the proliferation and mitochondrial 
metabolic activity of viable cells encapsulated in alginate-GRGDY constructs.
5.9 Conclusions and discussion
The advantages of using the RGD containing alginate matrices as scaffold 
materials to promote cell attachment and growth have already been shown by 
different authors [Rowley et al., 1999; Markusen et al., 2006; Halberstadt et al., 
2002; Alsberg et al., 2001]. Thus, several experiments were performed in order to 
investigate cell behaviour and performance after immobilisation within alginate- 
GRGDY matrices. Both hMSCs and fibroblasts were analysed for this purpose.
It is known that the mechanical strength and compression modulus of alginate 
hydrogels are strictly related to the ratios of G to M subunits, as well as to the lengths 
of G blocks [Smidsor and Skjak-Braek, 1990]. In addition, recent evidence suggests 
that the alginate viscosity may have significant impact on the viability of 
encapsulated cells [Kong et al., 2003]. As a result, it was interest of this research to 
evaluate the effects of alginates with different chemical compositions and viscosities 
on cell behaviour and mechanical integrity during the fabrication of alginate-cells 
beads. High mannuronic acid (M) content alginates (i.e. alginate SLM100 and 
SLM20) proved not to be ideal biomaterials for cell immobilisation and beads 
preparation. The constructs created with these alginates appeared to be weak and
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fragile, and quickly dissolved after treatment with the cross-linking solution. On the 
other hand, the use of high guluronic acid (G) content alginates permitted the 
fabrication of stronger beads, which retained their structural integrity over time. 
These results are well in accordance with previous studies indicating that alginate 
containing the highest percent of guluronic acid is the most mechanically stable 
[Wong et a l, 2001] and that the strength of the network depends on the overall 
fraction of G units [Smidsor and Skjak-Braek, 1990; Martinsen et al., 1989; Stabler et 
al, 2 0 0 2 ].
Moreover, regardless of the peptide concentration used for the coupling reaction 
(i.e. 10X or 32X), both hMSCs and fibroblasts in SLG100 alginate beads did not 
interact with the biomaterial and did not elongate to acquire their characteristic 
spindle-shaped morphology. The initial cell viability within the constructs was high 
(>92.18%±2.9%) but no cell proliferation was observed over time. A similar lack of 
cell adhesion and cell growth was also seen after seeding the cells on the surface of 
alginate-GRGDY disks. Ultimately, additional studies are needed to clarify the 
mechanisms responsible for the lack of cell attachment in the modified alginate 
matrices.
Finally, preliminary studies proved that the MTT assay can be used as a reliable 
method for the quantification of metabolically active cells within the alginate matrix. 
The assay proved not to be adversely affected by the presence of the alginate polymer 
itself within the samples, and MTT data revealed lack of cell proliferation after 
immobilisation within non-derivatised alginate constructs. These results are in 
accordance with the cell proliferation data obtained with the haemocytometer 
measurements presented in sections 5.3-5.6 . However, further studies including the 
assessment of positive control samples (i.e. alginate/cells beads characterised by good 
proliferation kinetics from haemocytometer data) will need to be conducted to 
confirm the consistency and thus the validity of the MTT data presented in this 
research.
In conclusions, in this research it was not possible to obtain immobilised cells, 
which were associating with the matrix once the GRGDY peptide motif was 
incorporated into the alginate polymer. These findings are inconsistent with previous 
studies indicating that, after incorporation of RGD-containing sequences, alginate 
matrices are able to promote adhesion, proliferation and differentiation of different 
cell types, including mouse skeletal myoblasts [Rowley et al, 1999; Rowley et al,
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2002]. In particular, previous studies have shown that also adult hMSCs can be 
encapsulated in alginate beads with a substantially retained viability (>80%), and that 
the GRGDY peptide encourages hMSCs attachment and elongation within the three- 
dimensional matrix [Markusen et a l 2006].
The lack of cell adhesion and functions within alginate-GRGDY matrices 
observed in this research may have been caused by the loss of the final tyrosine 
residue from the GRGDY peptide sequence bound to the alginate polymeric chain 
(please see amino acid analysis data presented in chapter 3). The detachment of the 
tyrosine residue may have caused a significant stereochemical change in the overall 
three-dimensional configuration of the resulting alginate-GRGDY. This may have 
caused a rearrangement of the charge distribution along the polymeric chain of the 
modified matrix. Since the polyelectrolyte nature of the alginate molecule is also an 
important parameter for its function [Draget et a l, 2005], the altered stereochemistry 
and conformational properties of the resulting scaffold may ultimately have been 
responsible for obstructing and preventing cell adhesion to the biomaterial. Thus, the 
chemistry and structural configuration of the adhesion ligand chosen for the covalent 
coupling to alginate hydrogels seems to play a critical role in the specific adhesion 
properties of the resulting matrix.
Overall, further optimisation of the alginate derivatisation process is required to 
achieve the appropriate adhesion properties for optimal cell binding, and more work 
is required to design a practical and reproducible system for hMSCs immobilisation.
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6. Conclusions
6.1 The goal of this thesis
The final goal of this research was the fabrication of functional tissue-engineered 
constructs suitable for clinical use. For this purpose, selected cell types were mixed 
with a natural water-soluble polymer and, following gelling of the polymer by addition 
of a cross-linking agent, the resulting polymer/cells mixture was processed into 
homogeneous gel beads.
This approach may for example be applicable for the fabrication of blood vessel 
substitutes that can potentially be employed for the treatment of blood vessels diseases 
(e.g. coronary artery disease and atherosclerosis), thus addressing a noteworthy 
clinical need (please see section 1 .1 .6 ).
Essential requirements for the fabrication of any functional tissue-engineered 
substitute are structural uniformity and homogeneous cell distribution. In the specific 
case of living blood vessels, in order to resemble the cell elements that compose the 
media and adventitia layers (i.e. smooth muscle cells and fibroblasts respectively), 
the cells must be able to elongate and spread out within the scaffold, thus giving rise 
to flattened cell layers lining the surface of the graft, so that it can ultimately acquire 
a normal vessel-like appearance.
In particular, this research project was focused on investigating both alginate 
hydrogels and hMSCs respectively as the matrix and the cell source to be used for 
the fabrication of functional matrix/cells constructs.
6.2 The alginate biopolymer
In first instance, it was intended to devise a process for producing a scaffold 
suitable for addition to the cell suspension and, ultimately, for the fabrication of
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functional scaffold/cells constructs where cell adhesion was encouraged and cell 
viability maintained over time.
Sodium alginate, which has a major use in tissue engineering applications [Atala 
et a l, 1994; Hauselmann et al, 1996], was the natural polymer selected among all 
other biomaterials for the fabrication of the constructs. Alginate is relatively 
biocompatible and approved by the Food and Drug Administration (FDA) for human 
use as wound dressing material [Atala, 2004]. Because of their gentle gelling 
properties, low toxicity, abundance in source and low price alginates are widely used 
for cell encapsulation in vitro and in vivo and for several tissue engineering 
applications [Drury and Mooney, 2003; Rowley and Mooney, 2002; Kuo and Ma, 
2001]. However, it must be noted that the hydrophilic nature of the alginate normally 
discourages protein adhesion and cell attachment [Smentana, 1993; West et al,
1997]. As a result, in applications that require some anchorage-dependent cell 
cultures (the majority of mammalian cell types, e.g. mesenchymal stem cells and 
smooth muscle cells), alginate hydrogels have been chemically modified to 
covalently attach cell adhesion molecules [Rowley et a l , 1999; Alsberg et al, 2001; 
Markusen et a l, 2006]. In this research, studies were performed on the biomaterial 
itself, whereby the alginate was chemically modified using aqueous carbodiimide 
chemistry with a protein containing the Arg-Gly-Asp (RGD) attachment site, a 
sequence known to promote cell attachment [Ruoslahti, 1996]. The alginate 
biomaterial modified by addition of RGD-containing peptides has already 
demonstrated to permit and support adhesion and proliferation for several cell types, 
including endothelial cells, preadipocytes, fibroblasts and skeletal myoblasts 
[Rowley et al, 1999; Greene et al, 2000; Loebsack et a l, 2001]. In this research the 
alginate was covalently modified to attach the RGD adhesion ligand according to the 
method described by Rowley and colleagues (1999), which was modified with 
respect to the reactants (i.e. EDC and sulfo-NHS) concentrations. The GRGDY 
pentapeptide was chosen as the RGD-containing sequence to mimic cell adhesion 
proteins and promote cell adhesion on the alginate scaffold.
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6.2.1 Derivatisation of the alginate polymer
Several conditions were investigated in order to optimise the derivatisation of the 
alginate, and the degree of peptide attachment in the resulting biomaterial was 
examined and assessed by means of nuclear magnetic resonance (NMR) and amino 
acid analysis. The material employed in this research was supplied in sterile form 
with negligible endotoxin level (< 100 EU/gram) [www.novamatrix.biz]. Thus, the 
alginate did not require autoclaving or filtration, which in previous studies 
[Markusen, 2005] proved to be ineffective techniques for the sterilisation of the 
alginate biomaterial. Autoclaving would have been particularly undesirable because 
it would reduce the alginate viscosity and molecular weight [Leo, 1990; 
Vandenbossche and Remon, 1993] and would denaturate the GRGDY peptide.
High (> 100 mPa-s) and low (20-100 mPa-s) viscosities alginates, with different 
guluronic and mannuronic acid compositions (i.e. either high G alginates with > 60 
% guluronic acid content, or high M alginates with > 50 % mannuronic acid content) 
were investigated. No major dissimilarities were identified among these biomaterials 
during the derivatisation reaction and the subsequent dialysis step. However, after 
reconstitution and derivatisation with the GRGDY peptide, low viscosity (SLG20 
and SLM20) alginates appeared to be slightly more heterogeneous and less viscous 
than the high molecular weight (SLG100 and SLM100) products.
Based on the results from previous range-findings studies [Markusen, 2005], it 
was decided to perform investigations focusing on the use of 9X-12X reactants 
(EDC and sulfo-NHS) and 1X-32X GRGDY peptide concentrations. These 
concentrations were multiples of the IX reactants concentrations described by 
Rowley (1999), where IX reactants correspond to lm g of alginate containing 38 pg 
of sulfo-NHS, 67 pg of EDC and 1 pg of peptide. 9X, 12X and 32X were 
respectively 9, 12 and 32 times the reactants concentration, as defined by Rowley. 
9X EDC and sulfo-NHS and 32X peptide proved to be sufficient concentrations for 
the incorporation of the pentapeptide onto the alginate polysaccharide chain. Amino 
acid analysis data revealed that alginate-GRGDY samples prepared in this condition 
did contain all the constituent amino acid residues of the pentapeptide sequence (i.e. 
G, R, D and Y). It follows that higher level of reactants were required in this 
research for the polymer-GRGDY covalent binding, as compared to what was
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observed by Rowley in his work. This discrepancy may be explained by the 
variation in the reactants that have been used in each study. Rowley tested alginates 
supplied by different manufacturers in his investigations, but he also used the same 
ProNova Biopolymers high G content sodium alginate that was used in this research. 
It must be noted that ProNova polymers are manufactured in compliance with US 
FDA (Food and Drug Administration) guidelines for current GMP (Good 
Manufacturing Practice) practice (Code of Federal Regulations, Title 21, Part 210 
and 211), and adhere to the most stringent standards [www.novamatrix.biz]. These 
products are developed through use of validated analytical methods and automated 
manufacturing processes. Under these circumstances variability of results should be 
an exception. However, the GRGDY peptide and the other reactants used in this 
research have been provided by different manufacturers, as compared to the products 
used by Rowley and colleagues, and also by Markusen in most of her studies. These 
variations, together with batch to batch variability, cannot be excluded as possible 
cause to the different reactants concentrations required to achieve successful 
polymer-GRGDY binding through the carbodiimide chemistry reaction described.
Following the dialysis cycle, it was necessary to re-concentrate the alginate- 
GRGDY, which had been extensively diluted due to the influx of water into the 
dialysis cassette. The results presented in this research revealed that lyophilisation, 
as opposed to the use of a polyethylene glycol (PEG) solution, is more appropriate 
for re-concentrating the alginate after the dialysis cycle. Previous studies [Markusen, 
2005] had shown that a 2 -day lyophilisation cycle was sufficient for re-concentrating 
the alginate, whilst retaining the stability of the peptide in the alginate hydrogels and 
the biological activity of the resulting alginate-GRGDY. These results were 
confirmed by the amino acid analysis data presented in this thesis, which showed 
successful incorporation of the peptide sequence onto the alginate following a 2 -day 
lyophilisation cycle.
6.2.2 Alginate-GRGDY characterisation
Nuclear magnetic resonance (NMR) was performed on the alginate-GRGDY 
samples as a qualitative measure to assess the incorporation of the GRGDY peptide
264
in the alginate biomaterial. However, this technique did not prove to be a suitable 
method to ascertain the attachment of the peptide onto the alginate. The signals at 5 
6 .8  ppm and 7.1 ppm, typically originating from a tyrosine residue, were not 
detected when both derivatised SLG100 (coupled with 10X peptide) and SLM100 
(coupled with IX peptide) alginates were analysed with NMR spectroscopy. It can 
therefore be concluded that this technique is probably not sensitive enough to allow 
the detection of the tyrosine peaks in the alginate-GRGDY samples. NMR has in 
fact very low sensitivity and only millimolar concentrations of substrates (lower 
limit of detection = 1-5 pM) can be detected with this methodology [Syrota and 
Jehenson, 1991; Wishart, 2006], while amino acid analysis data revealed that the 
level of tyrosine was indeed very low (i.e. < 9.3n.mole/mg) in the alginate samples 
resulting from the derivatisation procedure. This might explain why NMR failed to 
detect the tyrosine residue and, ultimately, to measure the degree of peptide attached 
to the alginate polymer.
As opposed to NMR, amino acid analysis allowed for a more reliable 
quantification of the degree of peptide incorporated in the polysaccharide chain of 
the SLG100 alginate. Amino acid analysis data demonstrated that all four 
component amino acids (G, R, D and Y) of the GRGDY pentapeptide were present 
in the alginate coupled with either 9X or 12X EDC and sulfo-NHS and either 32X or 
10X peptide. These data indicated that a successful polymer-GRGDY coupling 
reaction was achieved under these conditions. No significant difference was 
observed in the amino acid content for the alginate-GRGDY coupled with either 9X 
or 12X EDC and sulfo-NHS concentrations. As a result, 9X was the concentration 
maintained for these reactants throughout all the subsequent experiments. It is also 
interesting to note that there seemed to be a direct proportionality between the 
peptide concentration used in the carbodiimide chemistry reaction and the amino 
acid levels measured following the derivatisation procedure. However, even though 
successful incorporation of the GRGDY peptide was achieved, the amino acid 
analysis also revealed that a significant (approximately 60 %) loss of the final 
tyrosine residue was occurring during derivatisation in all the SLG100 alginate 
samples. This phenomenon will require future investigations.
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Markusen [Markusen, 2005 and 2006] did not measure the amino acid levels in 
her final alginate-GRGDY, thus one can only assume that her alginate-GRGDY 
contained an intact sequence (complete of tyrosine) from the positive results she 
obtained from her cell adhesion studies. On the other hand Rowley did quantify the 
GRGDY ligand incorporated onto the alginate by labelling it with a radioactive tag 
( I), and saw no tyrosine loss. It was rather unexpected to observe in this research
a consistent tyrosine loss from the alginate-GRGDY samples. This was indeed 
surprising, especially considering that the same derivatisation procedure described 
by both Rowley and Markusen was followed, but neither Rowley nor Markusen 
did observe a similar phenomenon in their studies. Possible causes for these 
discrepancies are difficult to speculate. As already mentioned, the divergent results 
may perhaps be attributed to different manufacturers and batch to batch 
variabilities. In particular, the amount of EDC present in the reaction is known to 
have a dramatic effect on peptide incorporation efficiency [Rowley et al, 1999]; 
thus, even a small difference in the concentration of EDC appearing in the reaction 
vessel may have been responsible for such different outcomes. In addition, EDC- 
mediated cross-linking of the alginate with diamines is known to be affected by 
both the pH and the NaCl concentration of the reaction medium [Rowley et al, 
1999], therefore the divergent results may also be attributed to possible changes of 
these parameters, which in this research have not been monitored throughout the 
whole derivatisation procedure.
6.3 Characterisation of human mesenchymal stem cells 
expanded in monolayer culture
Primarily studies using multipotent fibroblast-like plastic-adherent cells isolated 
from frozen bone marrow samples of adult patients were performed. These cells 
were recovered from the bone marrow according to a well-established density 
gradient protocol [Friedenstein et al, 1968]. It is acknowledged that these cells 
represent a heterogeneous population, which includes a variety of progenitor cells at 
different stages of their differentiation pathways [Tavassoli et al. 1983; Lichtman, 
1981; Allen et a l, 1990; Bianco et al, 2001]. As a result, Horwitz et a l  (2005) have
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recently proposed to term this cell population as “mesenchymal stromal cells”, 
which is a more general and, thus, more appropriate definition. However, these cells 
are here defined as “mesenchymal stem cells” (MSCs), as this was the accepted and 
popularised term at the beginning of this research, when stem cells were more 
generally defined as cells having the ability to self-renew and, under proper culture 
conditions, the potential to differentiate into a variety of cell and tissue types (i.e. 
including tissues other than those originating in the mesodermal germ layer) [Quarto 
et a l, 1998; Pereira et al., 1995; Caplan, 1991; Lalan et al, 2001; Stock and 
Vacanti, 2001].
Prior to the cell immobilisation in the alginate matrix, studies were performed to 
identify the optimal conditions for cell expansion in monolayer culture.
Despite the need for vast number of hMSCs as therapeutic means, there is only 
limited information on the optimisation of culture conditions required for their large- 
scale production for clinical applications [Bianco et a l, 2001; Tuan et al, 2002; 
Sotiropolou et al, 2005]. Nevertheless, Athersys has recently licensed a noteworthy 
invention for providing a substantially homogeneous stem cell population of non- 
embryonic origin that can be maintained in culture in the undifferentiated state or 
can be differentiated to form cells of multiple tissue types. In their patent, the 
methods of isolation and culture, as well as therapeutic uses for the isolated cells are 
described [Furcht et al, 2005]. However, one must remember that the scale-up of a 
MSCs reservoir that can be available for “off-the-shelf’ use implies the utilisation of 
allogeneic cells. In this case, significant issues of host rejection, disease transmission 
and ethical disquiet need to be overcome.
Although the long-term goal remains the production of a sufficient number of 
safe cells that can be ready in advance of need, a more realistic short-term goal is to 
develop an optimised protocol for the MSCs in vitro expansion. As a result, several 
variables were investigated in this research to improve the hMSCs expansion 
protocol in monolayer condition. In particular, attention was focused on changing 
medium composition in respect of serum concentration and FGF-supplementation, 
on modifying the plastic surface of the culture vessels through coating with different 
biomolecules, and on testing different oxygen tensions. Following measurements 
taken with a haemocytometer and the Nova Biomedical BioProfile 400 analyser, the 
monolayer cell samples were assessed according to their growth kinetics, their
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doubling time, cell growth rate and their specific glucose consumption rate. In 
addition, cell percent viability was assessed at each expansion passage by means of 
the trypan blue dye exclusion assay.
6.3.1 Basal growth medium formulation
The choice of an appropriate medium formulation is an important in vitro 
condition, having direct influence on stem and progenitor cells expansion and 
maintenance in culture [Sotiropolou et al, 2005; Robertson, 1987; Hogan et al, 
1994]. Preliminary studies were conducted in order to evaluate two different 
commercially available basal medium formulations toward their proliferation 
promoting capacity on hMSCs in vitro. Following direct comparison with the more 
expensive MesenCult medium (StemCell Technologies Inc.), low-glucose DMEM 
medium (BioWhittaker) demonstrated to permit better cell growth and higher cell 
densities, and was therefore preferred in all subsequent experiments for hMSCs 
expansion.
Most basal cell media cannot support the growth of mammalian cells by 
themselves. As a result, it is a common practice to supplement cell culture media 
with animal sera [Shah, 1995]. Serum additives are typically provided by fetal 
bovine serum (FBS), which is capable of supporting the growth of a variety of cell 
types. The availability and ease of storage of FBS [Barnes and Sato, 1980], together 
with its rich content of growth factors and nutrients for proliferation and 
differentiation [Lambert and Birch, 1985; Palsson and Bhatia, 2004], have led to its 
adoption as the standard medium supplement. However, the use of animal-derived 
sera in tissue culture systems is a practice that raises ethical, scientific and safety 
concerns [Even et al, 2006]. Serum is an ill-defined mixture, containing by-products 
like bacterial endotoxins and contaminants such as viruses, prions and mycoplasma 
[Merten, 1999; Falkner, 2004], which ultimately impair the use of culture-derived 
products. Given its undefined composition, batch to batch variability, which may 
seriously affect experimental data, is also normally associated to serum use [Morris 
and Warburton, 1975]. In addition, FBS is harvested from bovine foetuses taken 
from pregnant cows, and it is estimated that between 44 and 144 heads of cattle must 
be slaughtered to obtain only one litre of FBS [Hodgson, 1991]. This consideration
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has obviously captured the attention of several animal welfare associations, which 
believe that researchers have a moral and legal obligation to replace animals with 
alternatives when they are available [AAIIR
http://www.aahr.asn.au/camnaigns/fetal calf serum.html; “Australian Code of 
Practice for the care and use of animals for scientific purposes” 2004]. Given the 
recognized controversy that is currently surrounding the use of animal-derived 
serum for proliferation enhancement during in vitro cell culture [Falkner et al., 2004; 
Even et a l, 2006; www.focusonaltematives.org.uk], interest of this work was to 
investigate the possibility for hMSCs expansion in serum-free culture settings. 
Extensive studies were performed to investigate the effects of fetal bovine serum on 
hMSCs proliferative capacity and metabolic activity. The data obtained from these 
investigations revealed that 10  % serum-supplementation resulted necessary to 
achieve good cell growth, high cell viability and to retain cellular metabolic activity. 
However, three commercially available serum-free formulations (i.e. UltraCulture 
and UltraDOMA Hybridoma optimised media, both from BioWhittaker, and the 
Knockout DMEM medium from Gibco) also showed interesting and encouraging 
preliminary data, resulting capable of permitting long-term culture of hMSCs in 
serum-free environment.
In addition to serum requirements, bFGF has also demonstrated to have a 
significant impact in stem cell culture [Kotobuki et a l, 2004; Bianchi et al, 2003; 
Martin et a l, 1997; Reyes and Verfaillie, 1999; Nagai et al, 1999]. As a result, the 
effects of bFGF-supplementation on hMSCs proliferation potential and viability 
were also investigated. In line with previous data [Sotiropolou et a l, 2005; Kotobuki 
et a l, 2004; Bianchi et al, 2003] the data presented in this research revealed that 
bFGF-supplementation significantly improves and favours cell expansion and 
proliferation. Addition of 1 ng/mL bFGF was associated with higher cell 
proliferation rates, higher cell densities and lower doubling times, as compared to 
the values observed for cells maintained in bFGF-free growth medium. What is 
particularly interesting is that the growth factor seemed to favour considerably 
hMSCs expansion also in serum-deprivation (2% FBS) condition, where cell 
proliferation resulted heavily compromised in the absence of the growth factor. 
Moreover, the presence of bFGF in serum-free microenvironment also significantly 
hampered cell death. These findings suggest that bFGF-supplementation may well
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represent an essential additive for those culture systems that are being developed to 
avoid FBS use for cell in vitro expansion.
6.3.2 Different coating conditions for the culture vessels
Previous studies have shown that the behaviour of mesenchymal stem cells is 
also significantly affected by the culture surface properties employed in their in vitro 
settings [Ogura et al., 2004; Matsubara et al., 2004; Qian and Saltzman, 2004]. In 
line with these considerations, the culture surface of the vessels employed in this 
study demonstrated to have a considerable impact on hMSCs expansion. Among the 
different coatings tested, Matrigel seemed to significantly hamper cell growth, cell 
viability and metabolic activity. On the other hand, the use of fibronectin-coated 
plates did not have such a negative effect, but did not lead to any advantage as 
opposed to the use of the traditional non-coated vessels either. Both non-coated and 
fibronectin-coated plates consistently supported hMSCs proliferation and metabolic 
activity, and these coatings effects were observed regardless of the serum 
concentration used for the medium supplementation.
These findings are rather unexpected, given that fibronectin contains the RGD 
cell adhesive site [Ruoslahti and Pierschbacher, 1986; Magnusson and Mosher,
1998], a peptide sequence with well-documented cell adhesion properties. Indeed 
fibronectin has been shown to support attachment of different cell types both in vitro 
[Prajapati et al, 1996; Ejim et al., 1993] and in vivo [Whitworth et al., 1995; Sethi et 
al., 2002], In addition, enhanced cell adhesion and spreading have been previously 
observed for hMSCs expanded in fibronectin-coated dishes [Ogura et al., 2004]. 
However, other investigators have also seen no difference in MSCs growth on 
surfaces coated with either fibronectin or the polystyrene control [Qian and 
Saltzman, 2004]. Similarly to what Qian observed in his studies, this research also 
revealed that the typical morphology of undifferentiated MSCs was retained on both 
fibronectin-coated and non-coated surfaces. The inconsistency of the data presented 
by different groups is not easy to explain. Indeed the expectation would have been 
that the RGD sequence contained in the fibronectin coating would have favoured 
cell attachment, whereas this research (and Qian’s group) shows that hMSCs 
adhesion occurred at the same extent in the fibronectin-coated and the traditional 
non-coated plates. However, given their complexity, cell-cell and cell-matrix
270
interactions are still unclear, and virtually nothing is known of the interactions 
between stromal precursor cells and the extracellular matrix in vivo [Gronthos et al, 
2001]. That stromal precursors possess a high binding affinity to the extracellular 
matrix components commonly found in the reticular marrow (e.g. fibronectin, 
collagen I, collagen III) is a reality. However, it is also true that the attachment of 
cells to various glycoproteins may depend on their original location and their stage 
of cellular differentiation [Gronthos et al, 2001]. Because the cell population 
investigated in this research most likely comprised mesenchymal stromal cells at 
different stages of their differentiation pathway, and because the exact location of 
these cells in the marrow spaces is still a matter of conjecture [Gronthos et al, 
2 0 0 1 ], this may perhaps justify more easily the differential binding affinity to 
fibronectin that is observed by different investigators.
6.3.3 Dissolved oxygen tension (DOT)
Dissolved oxygen tension (DOT), which is known to have a profound influence 
on the growth potential and functionality of different cell lines [Lennon et a l, 2001; 
Martin et a l, 2004; Domm et a l, 2004; Ezashi et a l, 2005; Moussavi-Harami et al, 
2004; Rochefort et al., 2006], was an additional parameter investigated in this 
research for hMSCs in vitro expansion. The ambient 21 % O2 traditionally employed 
in most culture environments was compared with lower oxygen levels, ranging from 
1 % to 10 % O2. The results presented in this thesis revealed a positive effect of the 
high (21 %) DOT on cell proliferation rate and cell density. hMSCs grown at the 21 
% standard oxygen DOT were characterised by the highest proliferation potential 
and the lowest doubling time; on the other hand, cells maintained at lower oxygen 
regimes ( 1 0  %, 6  %, 2 % and 1 %) did not demonstrate a similar growth capacity. 
However, it must be noted that no oxygen effect on cell viability was observed in 
this research. In addition, no evident changes in cell morphology were seen among 
cells expanded in all the different oxygen regimes investigated (i.e. 1%, 2 %, 6 %, 
10% and 21%). One hypothesis that can be drawn as to why no oxygen effect on cell 
viability was seen is that the cells might have been able to quickly adapt to the 
change of environment and the different oxygen levels applied to the incubators 
settings. The cells were in fact transferred to the lower oxygen levels after 
incubation in the ambient (i.e. 2 1 %) O2 condition, and were maintained under the
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different low oxygen regimes selected only for the limited culture period under 
investigation (i.e. 2 weeks). This might explain why a significant oxygen effect was 
seen mostly on cell proliferation capacity and growth rate, while no significant 
changes in cell viability and morphology were observed as a result of the short-term 
hypoxic treatments. To date, studies focusing on the MSC responses to hypoxia have 
been inconclusive [Lennon et al, 2001; Mackay et a l, 1998; Wang et al, 2005], and 
the mixed results reported for MSCs proliferation and differentiation under hypoxia 
highlight the need for further studies elucidating the pathways involved in hypoxic 
processes for these cells [Ma et al, 2001; Malladi et al, 2006].
6.3.4 Optimal culture conditions identified for hMSCs growth in 
monolayer
The extensive monolayer studies performed in this research permitted to identify 
the optimal culture conditions for hMSCs, allowing cell viability and promoting cell 
proliferation during in vitro expansion in tissue culture microwell plates. Overall, the 
combined use of 10 % (v/v) serum- / 1 ng/mL bFGF-supplemented low-glucose 
DMEM medium and non-coated culture vessels in high (21 %) oxygen tension was 
associated with the highest cell growth kinetics (average 38.9x104 cells/cm2 counted 
after 13-14 days in culture), highest cell viabilities (average 96.08% +/-3.01% over 
2-week culture), and lowest doubling times (average 58.36 hours calculated from 
day 0 to day 7). In addition, hMSCs expanded for four subsequent passages in 
monolayer culture under these conditions proved to retain their undifferentiated state 
and their differentiation potential. Fourth passage (p4) hMSCs induced for 21 days 
with adipogenic, osteogenic and chondrogenic differentiation media demonstrated 
the ability to respectively differentiate to the phenotypes of adipocytes, osteocytes 
and chondrocytes.
6.4 Matrix/cells constructs
The overall objective of this research was the fabrication of functional tissue- 
engineered constructs with the potential to be employed in therapeutic applications. 
Following studies focusing first on the alginate matrix itself and then on the cell
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expansion in monolayer culture, investigations were therefore performed on the 
fabrication of alginate/cells beads and disks. By utilising the capability of the 
alginate to form a gel-like structure, alginate/cells constructs were prepared, and the 
optimal parameters identified in monolayer condition were applied to the culture of 
these constructs.
In order to ensure the functionality of a tissue engineered construct whereby 
attachment-dependent cells are employed, the cell elements must in the first place 
effectively interact with the polymer scaffold, which must therefore possess good 
cell adhesion properties. Cell elongation and alignment are also essential 
requirements in the specific case of smooth muscle cells and fibroblasts immobilised 
within constructs intended as human blood vessel replacements. Thus, the 
preparation of a natural matrix covalently modified with the GRGDY peptide 
(containing the well-known RGD adhesive site) has been investigated in this 
research ultimately to create a guidance scaffold, one that would have encouraged 
cell attachment and elongation after processing of the matrix/cells suspension into 
gel beads. However, the studies performed on the constructs demonstrated that, after 
immobilisation within the alginate matrix, both hMSCs and human foreskin 
fibroblasts failed to adhere to the alginate-GRGDY polymer. Light microscopy 
revealed that the cells appeared to be small and rounded, and cell attachment was not 
observed even several days after plating. Histological staining confirmed that the 
cells resulted unable to spread and elongate within the biomaterial and could not 
acquire their characteristic spindle-shaped morphology. Lack of cell proliferation 
and significant cell death were also observed over time for all cell types within 
constructs prepared with either the unmodified or the derivatised alginates.
In several cases light microscopy also revealed that the cells tended to position in 
close proximity to the outer surface of the matrix/cells beads. This inhomogeneous 
cell distribution may have been caused by the intrinsic structural inhomogeneity of 
the alginate beads, which is a result of the rapid and virtually irreversible gelling 
mechanism taking place during the process of beads fabrication. It has in fact been 
reported that gels made by the diffusion-setting method utilised also in this research 
(please see section 2.5.3 for the full description of the method) often exhibit a 
polymer concentration gradient within the gel bead, due to the fast gelation rate with 
CaCl2 [Skjak-Braek et al., 1989; Draget et al., 2005; Thu et al., 2000; Melvik and 
Domish, 2004]. The rapid gelling kinetics of this methodology cause an
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inhomogeneous distribution of the alginate, the highest concentration being at the 
surface and gradually decreasing towards the centre of the gel [Draget et al., 2005]. 
This result has been explained by the fact that the diffusion of gelling ions create a 
sharp gelling zone that moves from the surface toward the centre of the gel. The 
activity of the alginate (and of the gelling ion) equals zero in this zone, and alginate 
molecules diffuse from the internal, non-gelled part of the gelling body toward the 
zero-activity region [Skjak-Braek et al., 1989]. It is important to note that structural 
uniformity in scaffolds to be used for tissue engineering applications is necessary to 
ensure uniform porosity in all areas of the gel, thus permitting homogeneous cell 
distribution and, ultimately, uniform tissue formation [Kuo and Ma, 2001]. Thus, the 
particular gelling mechanism described above may explain why heterogeneous cell 
distribution was observed in the alginate beads fabricated in this research. 
Importantly, for tissue engineered scaffolds a homogeneous structure is desirable not 
only for uniform cell distribution, but also for well-controlled material properties. 
This is because the mechanical properties of the matrix result more consistent 
throughout the gel and between samples if the structure is homogeneous [Kuo and 
Ma, 2001].
Despite the lack of cell adhesion and cell proliferation within the alginate- 
GRGDY constructs, these studies also demonstrated that, among all the alginate types 
evaluated, high G high viscosity (SLG100) alginate was the most appropriate for the 
fabrication of rigid and stable gel beads. Alginate polymers with many repeating G- 
units are in fact normally more rigid and inflexible, and tend to form gels at rather 
specific concentrations of cations, as compared to alginate chains of repeating M- 
units, which form a softer gel over a wider range of conditions 
[http://www.cybercolloids.net/library/alginate/structure.php]. It has in fact been 
shown that a polymer of repeating G-units forms stiffer intra-molecular H-bonding 
[http://www.lsbu.ac.uk/water/hyalg.html]. Thus, the difference in strength of bonding 
between two subsequent uronic units results in the desirability of higher G-unit- 
containing alginates for use when culturing with cells. High purity and high G-unit 
alginate has in fact shown to retain 27% of its initial strength after 12 days in culture, 
compared to the high M-unit alginate, which loses its strength quicker [Wang et al., 
2003].
Ultimately, in this research alginate hydrogels covalently modified with the 
GRGDY peptide did not encourage cell attachment and elongation. This data are not
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in line with previous studies where cell attachment was observed in constructs 
prepared with alginates chemically modified with RGD-containing sequences 
[Rowley et a l, 1999; Alsberg et a l , 2001; Halberstadt et a l, 2002; Marler et al, 
2000; Alsberg et a l, 2002; Markusen et al, 2006]. In addition, importantly, the 
method described by Rowley and Mooney for the preparation of alginates modified 
through the covalent bonding of synthetic peptides containing the well-known RGD 
attachment ligand is now also protected by a US patent [Mooney et al, 2003].
It can be hypothesised that the tyrosine loss consistently observed in this work 
was responsible for the lack of cell adhesion and ultimately cell survival and 
proliferation within the alginate scaffold. The missing tyrosine may have changed 
the structural conformation of the remaining peptide, thus affecting cell adhesion 
and resulting in the cells not binding to the normally well-recognised RGD 
attachment site. According to this hypothesis, the low value of tyrosine present in all 
the alginate-GRGDY samples analysed does account for as to why none of the cells 
successfully attached, after immobilisation within the derivatised alginate. If this is 
true, it will be particularly interesting to understand why tyrosine is lost during the 
derivatisation procedure, and at which stage of the process this loss occurs.
Different hypothesis can be drawn as to why this phenomenon was observed in 
all the alginate samples. Firstly, it must be noted that the significant tyrosine loss 
observed cannot be accounted for by the acid hydrolysis reaction during the amino 
acid analysis since, unlike other amino acids, tyrosine is not affected by the acid 
hydrolysis [www.altabioscience.bham.ac.uk/services/amacid/].
A second possibility could have been that an endopeptidase was present in the 
alginate, which could be cleaving the tyrosine off during the 20-hour reaction. If 
this were the case, the tyrosine would then be lost during the dialysis and therefore 
would not be present in the final alginate-GRGDY sample, thus confirming the 
results seen in the amino acid analysis. However, the ProNova alginate used in this 
research was supplied by the manufacturer as a sterile product, and the level of 
endotoxins in each vial of the original product is stated to be less than 1 0 0  
EU/gram [www.novamatrix.biz], corresponding to a quality for the purified 
polymer that exceeds FDA specifications for implantable polymers [Prokop and 
Wang, 1997]. Thus, one can conclude that also this second possibility is quite 
unlikely.
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A reaction occurring between the tyrosine side chain and the coupling reactants 
could have been another possibility. The activation of tyrosine on the phenol ring 
(HO-C6H5) for example could cause subsequent cleavage from the rest of the 
peptide. However, due to the high stability of the amide bond, this possibility is 
also considered to be unlikely.
In conclusion, neither of the above causes is very likely, and further work is 
needed to understand the mechanisms leading to tyrosine loss. This will probably 
permit in future to reproduce a derivatisation procedure that allows incorporation 
of normal tyrosine levels onto the alginate, thus ultimately permitting the 
fabrication of functional alginate-GRGDY scaffolds able to encourage cell 
attachment.
Interestingly, NovaMatrix has recently developed a new high quality, ultrapure 
peptide-coupled alginate, which is protected by a US patent licensed from the 
University of Michigan. The Novatach GRGDSP-coupled alginate is a trial 
product that could result particularly useful in cell therapy and tissue engineering 
applications where cell-to-matrix interaction is beneficial [www.novamatrix.biz]. 
Thus, to use this product for the development of an alginate scaffold with optimal 
cell adhesion properties is an interesting alternative that can be investigated in 
future studies.
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6.5 Conclusions
The investigations carried out in this research revealed some interesting 
findings in relation to the in vitro expansion of adult mesenchymal stem cells and 
their association with an alginate scaffold for tissue engineering applications.
• A procedure already described and employed for the derivatisation of 
the alginate matrix with the GRGDY cell adhesion sequence has been here 
reproduced, and some of the parameters involved have been further investigated in 
the attempt to optimise the process. Successful incorporation of the peptide onto 
the alginate polyaccharide chain was achieved under the conditions employed. 
However, some additional complexities, mainly the loss of the final tyrosine 
residue from the GRGDY sequence bound to the alginate, have been identified as 
critical in this process, and will need to be explored in future studies.
• Amino acid analysis has proven to be a useful and appropriate 
technique to ascertain the amount of peptide incorporated in the alginate 
biomaterial, and may be employed in future to elucidate the mechanisms 
underlying the tyrosine loss phenomenon.
• The effects of changes in several culture parameters on the in vitro 
hMSCs expansion as a monolayer have been used to establish their optimal growth 
conditions, associated with the highest cell growth rates and viabilities, the lowest 
doubling times, and maintenance of undifferentiated state and multipotentiality 
over time. These conditions can be applied to the culture of alginate/hMSCs 
constructs to promote cell proliferation once cell adhesion to the matrix will be 
achieved.
• Despite not promoting cell attachment after derivatisation with the 
GRGDY cell adhesion sequence, high G high viscosity alginate proved to be an 
appropriate biomaterial for the fabrication of rigid and stable gel constructs.
In conclusions, there are many questions that remain to be answered and that 
will require more work in future. Nevertheless, the findings observed in this 
research are of interest to the field of tissue engineering, as they highlight some of 
the fundamental complexities encountered when attempting the long-term in vitro 
expansion of hMSCs and the design of a practical cell immobilisation system to be 
implanted in vivo.
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7 Recommendations for future work
7.1 Additional parameters to be considered for 
optimisation of the alginate derivatisation procedure
The work conducted in this research allowed for the optimisation of the 
procedure developed to introduce the cell attachment GRGDY peptide sequence 
onto the alginate polysaccharide chain. However, in order to further improve the 
derivatisation protocol, other conditions affecting the outcome of the coupling 
reaction will need to be investigated in future studies. These include the pH and 
osmolality of the alginate-GRGDY, which should be measured at every stage of 
the reaction to ensure that they are maintained at a physiological level relative to 
the extracellular matrix. In particular, it is well known that degradation of the 
alginate is a function of pH [Draget et al., 2005]. In addition, the pH of the 
reaction medium has also been reported to affect cross-linking of alginate 
mediated by the EDC with diamines [Rowley et al., 1999], and it has been proved 
that for optimal peptide incorporation in this system a neutral pH is indeed 
necessary [Rowley, 1999]. Thus, this parameter should be monitored carefully 
during the coupling reaction.
The light exposure of the reactants is an additional parameter that can 
potentially affect the efficiency of the derivatisation procedure. As a result, light 
exposure could also be carefully controlled and reduced to a minimum throughout 
the whole derivatisation process, in order to ensure maintenance of the stability of 
all the reactants and to avoid the peptide denaturation.
Future studies could also be performed to verify and adjust the viscosity of the 
reconstituted alginate-GRGDY, which is directly related to the molecular weight 
o f the alginate [Smidsrod and Haug, 1972; Mackie et a l, 1980], and ultimately 
reflects the polymer chain stiffness and its gelling properties [Draget et al., 2005].
It is also necessary to consider that any biomaterial to be implanted as a 
scaffold in tissue engineering applications should be biocompatible, non-toxic, and 
pyrogen-free. The derivatisation procedure employed in this research for the 
preparation of the alginate-GRGDY matrix was conducted in aseptic conditions. 
Sterile reagents and autoclaved equipment were used for both the initial coupling
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reaction and the subsequent dialysis and lyophilisation cycles. However, this 
process needs to be further improved with respect to the sterility conditions, and a 
method involving the least handling of both the reagents and materials used should 
be developed. The alginate and all o f the reactants could be tested for sterility at 
each stage of the process so that every component and every process step could be 
tested to see if  contamination is introduced. Endotoxins tests, together with 
polymerase chain reaction (PCR) for mycoplasma screening and detection could 
be performed for this purpose. This would ensure the preparation of a final 
alginate-GRGDY product that is sterile and therefore suitable for in vivo 
applications in the clinic.
One of the main drawbacks observed for all alginate-GRGDY samples after 
completion of the coupling reaction was a significant loss of the tyrosine residue at 
the end the GRGDY sequence. Furthermore, results obtained from the studies 
performed on the alginate/cells constructs revealed that both hMSCs and human 
foreskin fibroblasts failed to adhere to the alginate-GRGDY matrix.
As already mentioned, tyrosine loss might have been responsible for the lack of 
alginate-cells interactions. In particular, the missing tyrosine may have caused a 
conformational change in the structure of the remaining peptide associated to the 
alginate, and this may have ultimately impaired cell attachment. Thus, the loss of 
tyrosine may be associated with biological inactivity o f the alginate-GRGDY matrix.
In order to better elucidate the causes of tyrosine loss more amino acid analysis 
will need to be performed on alginate samples harvested at different time points 
during the coupling reaction. This will make it possible to understand why, and at 
what stage of the reaction the tyrosine loss occurs. Alternatively, two-dimensional 
or three-dimensional liquid chromatography techniques, using ion exchange and 
size exclusion chromatography as initial separation techniques and coupled to 
electrospray ionisation mass spectrometry, could be used. These methods have 
been previously used to analyse complex peptide mixtures [Langrock et al, 2006]. 
These techniques would also allow the effective direct measurement of the amino 
acid levels eliminating the need for the spectrophotometric detection.
Another strategy that could be considered in the future is the utilisation of a 
different adhesion peptide sequence for the covalent modification of the alginate
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polymer, one with a chemical conformation that perhaps could permit better 
recognition of the RGD ligand and would therefore facilitate the matrix-cells 
interactions. For instance, for improved cell functionality and viability, 
NovaMatrix has recently introduced a new peptide-coupled alginate, the Novatach 
GRGDSP-coupled alginate. This product is particularly indicated to facilitate and 
promote the scaffold/cells interaction and has therefore major utility in 
formulations where cell-to-matrix interaction is beneficial [www.novamatrix.biz].
Ultimately, understanding the reason why tyrosine loss was observed during 
the derivatisation procedure described in this research will probably permit to 
avoid the occurrence of this phenomenon in future.
7.2 human Mesenchymal Stem Cells (hMSCs) 
characterisation
One of the great challenges facing mesenchymal stem biology is the 
development of a simple and reproducible method to identify and recover from 
bone marrow samples a pure hMSC population [Horwitz, 2002; Sotiropoulou et 
al., 2005]. Given the heterogeneous composition of the bone marrow stromal 
microenvironment, it is necessary to remove from the unfractionated bone marrow 
cell population those accessory cells that do not meet clearly defined “stem 
criteria” (i.e. long-term self-renewal capacity and the ability to differentiate in vivo 
into specific, multiple cell types) [Wang et al, 1990; McIntyre and Bjomson, 
1986]. However, since there is no universal antigenic definition of MSCs and there 
is no universal assay, the approach to isolation and purification still varies widely 
from different research groups and investigators [Horwitz, 2002].
The progenitor cells described and investigated in this research have been 
recovered from bone marrow samples by isolation of the mononuclear fraction of 
marrow cells through density gradient centrifugation, followed by their tendency 
to adhere to the plastic surface of the culture vessels, according to the protocol 
described by Friedenstein and colleagues [Friedenstein et al., 1968]. The resulting 
heterogeneous cell population comprises several progenitors at different stages of 
their differentiation pathways. In line with these considerations, it is acknowledged
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that future studies are needed to verily and confirm the purity and “sternness” (i.e. 
self-renewal capacity and multilineage differentiation) of these cells. To this end, 
several approaches can be followed.
The colony-forming-unit-fibroblast (CFU-F) assay has been used by several 
groups as indicative of the numbers of marrow-derived stromal cells in test 
populations [Owen et al, 1987; Perkins and Fleischman, 1990]. However, it is 
clear that this assay does not, on its own, directly detect self-renewal potential or 
multilineage capacity [Zandstra and Nagy, 2001].
Although there are no universally accepted antigenic determinants for 
mesenchymal stem cells [Horwitz et al, 2002] and opinions seem still to differ 
[De Bari et a l, 2006], a series of markers defining the phenotype of mesenchymal 
stem and progenitor cells have been recently agreed upon [Tyndall et al, 2007]. 
Mesenchymal stem cells are known to express the antigens CD 105 and CD73 
reactive respectively with the monoclonal antibodies SH2 and SH3-SH4. These 
CD antigens have been explored as important antigenic determinants in the 
identification of these cells [Haynesworth, 1992; Barry et al, 2001]. Pittenger has 
reported that CD29, CD44 and CD90 are also important determinant [Pittenger et 
al, 1999], while Gronthos and Simmons described STRO-1 antibody that also 
seems to identify an immature population of mesenchymal cells [Gronthos et al, 
1998; Simmons et al, 1991]. Thus, flow cytometry could be performed for the 
characterisation of hMSCs by immunophenotyping. As the panel of antibody 
markers for monitoring the hMSCs profile of antigen expression grows and 
develops, this technique will result more and more useful for the identification of 
these cells.
In addition, karyotype analysis, performed to monitor the genetic stability of a 
cell culture [Rutzky et al, 1980], can be employed to analyse the physical 
structure of hMSCs genome and visualise their chromosomes. The resulting 
chromosome mapping would permit to understand whether the cells show 
significant chromosome abnormalities or, on the contrary, retain a normal 
karyotype.
Furthermore, differentiation potential assays similar to the one employed in 
this research should be performed to demonstrate that the cells retain the 
multilineage potential that is a key attribute of mesenchymal stem cells 
functionality.
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Ultimately, what is probably required is to combine these (and possibly others) 
assays to better determine the biological properties of hMSCs and to confirm their 
identity. This measure may facilitate all current efforts to optimise the production 
of authentic marrow-derived progenitor stem cells that possess the “stem criteria” 
defined above, and that may therefore demonstrate a real potential for a variety of 
clinical applications.
7.3 Strategies to be considered for the fabrication of 
functional alginate/cells constructs
The results presented in this research showed that both hMSCs and human 
foreskin fibroblasts were not able to adhere to and elongate within the alginate 
matrix. The expectation would have been that the cells would have elongated 
along the pores of the alginate hydrogel containing the GRGDY peptide. It is 
possible that the pore size of the alginate-GRGDY matrix may have been too small 
or restrictive. It has in fact been previously suggested that alginate used in the 
physical form of a hydrogel contains small pore size that does not allow cell 
movement [Eiselt, 2000].
Zmora and colleagues found that the morphology of rat hepatocytes seeded in 
macroporous high G alginate scaffolds (pore diameter ranging from 110±30pm to 
210±80pm) was either elongated or spherical based upon the pore microstructure 
[Zmora, 2002]. The different pore microstructures were created by freezing the 
alginate matrix and examining the structure using a scanning electron microscope. 
The freezing regimen can in fact have a critical effect on the polymer pore 
microstructure [Lin and Yeh, 2004; Zmora et al., 2002], and the effects of freezing 
rate on the morphology of scaffolds for tissue engineering applications have been 
reported in many works [Mohan and Nair, 2005; Kang et al, 1999]. Hydrogels 
that are used for tissue engineering should have pores within the inter-molecular 
network large enough to provide sufficient space for cell growth and extracellular 
matrix production [Kang et al, 1999]. Uniform pore size and distribution are 
necessary also to permit diffusion of growth factors and nutrients to the 
surrounding cells and to ensure removal of metabolic wastes from the system [Kuo
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and Ma, 2001; Kang et a l, 1999]. Thus, the porosity, pore structure and pore size 
distribution, which are directly related to the scaffold diffusion properties, are 
particularly important for cell growth and nutrient supply of cells [Melvik and 
Domish, 2004; Mohan and Nair, 2005]. Since this issue has not been addressed in 
this research, the alginate pore size and microstructure could be examined in future 
studies. Numerous methods and materials have been continuously developed for 
preparing porous materials for cell scaffolding [Laurencin et al., 1996; Liu and 
Kodama, 1992; Whang and Healy, 2001]. Interconnecting macroporous scaffolds 
with >90% porosity can typically be processed from alginate gels under mild 
conditions using lyophilisation (freeze-drying) [Klock et al, 1997] or carbon- 
dioxide foaming [Eiselt et a l, 2000] techniques [Velema and Kaplan, 2006]. 
Macroporous alginate beads have for instance been fabricated by incorporating gas 
pockets within the alginate beads, stabilising the gas bubbles with surfactants such 
as BSA or Pluronic (F68 or F I08), and subsequently removing the gas [Eiselt et 
al, 2000].
This work also revealed that, after immobilisation within the alginate 
biopolymer, in several samples the majority of the cells tended to locate on or near 
the outer surface of the matrix/cells beads. This inhomogeneity was probably 
caused by the particular gelation process taking place during beads formation. It 
has in fact been reported that alginate gels formed by diffusion of cross-linking 
ions into the alginate solution result in a polymer concentration gradient within the 
gel beads [Melvik and Domish, 2004; Skjak-Braek et al, 1989; Thu et al, 2000]. 
However, the gel formation process may be carefully controlled. In particular, 
bead homogeneity results to be dependent upon the way in which the gelling ions 
are added in the system. For instance, it has been shown that slower gelation 
systems generate more uniform and mechanically stronger gels than faster gelation 
systems [Martinsen et al, 1989; Skjak-Braek et al, 1989] and that slowing the 
gelation rate can lead to more uniform and mechanically stronger hydrogels [Kuo 
and Ma, 2001]. Thus, the use of slow-gelling ions systems can be investigated in 
future studies in order to produce more homogenous alginate/cells beads. A similar 
approach has already been followed for example by Kuo and colleagues, who 
reported the fabrication of structurally uniform gels for tissue engineering
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applications with the use of calcium carbonate-GDL (D-glucono-5-lattone) and 
calcium carbonate-GDL-calcium sulfate systems [Kuo and Ma, 2001].
Finally, the beads size is an additional parameter that can be taken into 
consideration when preparing alginate beads in future investigations. The 
fabrication of smaller diameter constructs offers several advantages, including 
better transportation of nutrient and oxygen [Chicheportiche and Reach, 1988], and 
higher mechanical strength [Sugiura S., et a l, 2005]. This approach has already 
been successfully followed in several microencapsulating alginate systems, for 
which the use of 185 pm diameter microcapsules has also given much less severe 
pericapsular reactions than those induced by standard size microcapsules [Halle’ et 
al, 1994; Robitaille et al, 1999]. A critical diameter of approximately 400-500 
pm is indeed the preferred device geometry for cell immobilisation from a 
biocompatibility, functional and technological point of view [Hunkeler, 2001; 
Orive et al, 2003]. Thus, to ensure both a better nutrient and oxygen supply to 
encapsulated cells and the fabrication of biocompatible constructs, future studies 
could investigate novel approaches for the preparation of smaller diameter beads. 
Alginate constructs as small as 300pm diameter beads for example could be 
fabricated by use of an electrostatic potential droplet generator. In such a system 
the beads size can be regulated by the following parameters: the droplet generator 
needle diameter, the electrostatic potential, the flow-rate of the cell-gel suspension 
and the distance between the needle and the gelling bath [Orive et a l, 2003; Klokk 
and Melvik, 2002]. Thus, by adjusting these parameters in a droplet generator 
system alginate/cells beads with appropriate size can be fabricated.
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